
<html lang="en"     class="pb-page"  data-request-id="68c788f8-0b04-4caa-af5c-7eecb1d6468f"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.5b01312;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2015.58.issue-23;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer" /></meta><meta name="dc.Creator" content="Helen E.  Colley" /></meta><meta name="dc.Creator" content="Munitta  Muthana" /></meta><meta name="dc.Creator" content="Sarah J.  Danson" /></meta><meta name="dc.Creator" content="Lucinda V.  Jackson" /></meta><meta name="dc.Creator" content="Matthew L.  Brett" /></meta><meta name="dc.Creator" content="Joanne  Harrison" /></meta><meta name="dc.Creator" content="Sean F.  Coole" /></meta><meta name="dc.Creator" content="Daniel P.  Mason" /></meta><meta name="dc.Creator" content="Luke R.  Jennings" /></meta><meta name="dc.Creator" content="Melanie  Wong" /></meta><meta name="dc.Creator" content="Vamshi  Tulasi" /></meta><meta name="dc.Creator" content="Dennis  Norman" /></meta><meta name="dc.Creator" content="Peter M.  Lockey" /></meta><meta name="dc.Creator" content="Lynne  Williams" /></meta><meta name="dc.Creator" content="Alexander G.  Dossetter" /></meta><meta name="dc.Creator" content="Edward J.  Griffen" /></meta><meta name="dc.Creator" content="Mark J.  Thompson" /></meta><meta name="dc.Description" content="A number of indole-3-glyoxylamides have previously been reported as tubulin polymerization inhibitors, although none has yet been successfully developed clinically. We report here a new series of r..." /></meta><meta name="Description" content="A number of indole-3-glyoxylamides have previously been reported as tubulin polymerization inhibitors, although none has yet been successfully developed clinically. We report here a new series of r..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 1, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01312" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01312" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01312" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01312" /></link>
        
    
    

<title>An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01312" /></meta><meta property="og:title" content="An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0001.jpeg" /></meta><meta property="og:description" content="A number of indole-3-glyoxylamides have previously been reported as tubulin polymerization inhibitors, although none has yet been successfully developed clinically. We report here a new series of related compounds, modified according to a strategy of reducing aromatic ring count and introducing a greater degree of saturation, which retain potent tubulin polymerization activity but with a distinct SAR from previously documented libraries. A subset of active compounds from the reported series is shown to interact with tubulin at the colchicine binding site, disrupt the cellular microtubule network, and exert a cytotoxic effect against multiple cancer cell lines. Two compounds demonstrated significant tumor growth inhibition in a mouse xenograft model of head and neck cancer, a type of the disease which often proves resistant to chemotherapy, supporting further development of the current series as potential new therapeutics." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01312"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01312">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01312&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01312&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01312&amp;href=/doi/10.1021/acs.jmedchem.5b01312" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 9309-9333</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01136" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01329" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Helen+E.++Colley">Helen E. Colley</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Munitta++Muthana">Munitta Muthana</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sarah+J.++Danson">Sarah J. Danson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lucinda+V.++Jackson">Lucinda V. Jackson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+L.++Brett">Matthew L. Brett</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joanne++Harrison">Joanne Harrison</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sean+F.++Coole">Sean F. Coole</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+P.++Mason">Daniel P. Mason</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Luke+R.++Jennings">Luke R. Jennings</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Melanie++Wong">Melanie Wong</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vamshi++Tulasi">Vamshi Tulasi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dennis++Norman">Dennis Norman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter+M.++Lockey">Peter M. Lockey</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lynne++Williams">Lynne Williams</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexander+G.++Dossetter">Alexander G. Dossetter</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Edward+J.++Griffen">Edward J. Griffen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+J.++Thompson">Mark J. Thompson</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">School of Clinical Dentistry, University of Sheffield, 19 Claremont Crescent, Sheffield S10 2TA, U.K.</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Oncology, The University of Sheffield, Medical School, Beech Hill Road, Sheffield S10 2RX, U.K.</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Academic Unit of Clinical Oncology and Sheffield Experimental Medicine Centre, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, U.K.</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Department of Chemistry, University of Sheffield, Brook Hill, Sheffield S3 7HF, U.K.</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">⊥</span> <span class="aff-text">Charles River, 8−9 Spire Green Centre, Harlow, Harlow, Essex CM19 5TR, U.K.</span></div><div class="aff-info" id="aff6"><span class="aff-symbol">#</span> <span class="aff-text">MedChemica Limited, Ebenezer House, Ryecroft, Newcastle-Under-Lyme, Staffordshire ST5 2BE, U.K.</span></div><div class="corresp-info"><strong>*</strong>For M.J.T.: phone +44 (0)114 222 9364; E-mail: <a href="/cdn-cgi/l/email-protection#2a470440045e4245475a5945446a59424f4c4c434f464e044b49045f41"><span class="__cf_email__" data-cfemail="8de0a3e7a3f9e5e2e0fdfee2e3cdfee5e8ebebe4e8e1e9a3eceea3f8e6">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For H.E.C.: phone +44 (0)114 271 7966; E-mail: <a href="/cdn-cgi/l/email-protection#3a5214595556565f437a49525f5c5c535f565e145b59144f51"><span class="__cf_email__" data-cfemail="4a2264292526262f330a39222f2c2c232f262e642b29643f21">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01312&amp;href=/doi/10.1021%2Facs.jmedchem.5b01312" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 9309–9333</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 18, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>25 August 2015</li><li><span class="item_label"><b>Published</b> online</span>1 December 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01312" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01312</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by text">with CC-BY<a href="/page/policy/authorchoice_ccby_termsofuse.html" title="License">license</a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01312"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4606</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">36</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01312" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Helen&quot;,&quot;last_name&quot;:&quot;E. Colley&quot;},{&quot;first_name&quot;:&quot;Munitta&quot;,&quot;last_name&quot;:&quot;Muthana&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;J. Danson&quot;},{&quot;first_name&quot;:&quot;Lucinda&quot;,&quot;last_name&quot;:&quot;V. Jackson&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;L. Brett&quot;},{&quot;first_name&quot;:&quot;Joanne&quot;,&quot;last_name&quot;:&quot;Harrison&quot;},{&quot;first_name&quot;:&quot;Sean&quot;,&quot;last_name&quot;:&quot;F. Coole&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;P. Mason&quot;},{&quot;first_name&quot;:&quot;Luke&quot;,&quot;last_name&quot;:&quot;R. Jennings&quot;},{&quot;first_name&quot;:&quot;Melanie&quot;,&quot;last_name&quot;:&quot;Wong&quot;},{&quot;first_name&quot;:&quot;Vamshi&quot;,&quot;last_name&quot;:&quot;Tulasi&quot;},{&quot;first_name&quot;:&quot;Dennis&quot;,&quot;last_name&quot;:&quot;Norman&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;M. Lockey&quot;},{&quot;first_name&quot;:&quot;Lynne&quot;,&quot;last_name&quot;:&quot;Williams&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;G. Dossetter&quot;},{&quot;first_name&quot;:&quot;Edward&quot;,&quot;last_name&quot;:&quot;J. Griffen&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;J. Thompson&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;9309-9333&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01312&quot;},&quot;abstract&quot;:&quot;A number of indole-3-glyoxylamides have previously been reported as tubulin polymerization inhibitors, although none has yet been successfully developed clinically. We report here a new series of related compounds, modified according to a strategy of reducing aromatic ring count and introducing a greater degree of saturation, which retain potent tubulin polymerization activity but with a distinct SAR from previously documented libraries. A subset of active compounds from the reported series is shown to interact with tubulin at the colchicine binding site, disrupt the cellular microtubule network, and exert a cytotoxic effect against multiple cancer cell lines. Two compounds demonstrated significant tumor growth inhibition in a mouse xenograft model of head and neck cancer, a type of the disease which often proves resistant to chemotherapy, supporting further development of the current series as potential new therapeutics.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01312&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01312" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01312&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01312" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01312&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01312" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01312&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01312&amp;href=/doi/10.1021/acs.jmedchem.5b01312" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01312" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01312" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01312%26sid%3Dliteratum%253Aachs%26pmid%3D26580420%26genre%3Darticle%26aulast%3DColley%26date%3D2015%26atitle%3DAn%2BOrally%2BBioavailable%252C%2BIndole-3-glyoxylamide%2BBased%2BSeries%2Bof%2BTubulin%2BPolymerization%2BInhibitors%2BShowing%2BTumor%2BGrowth%2BInhibition%2Bin%2Ba%2BMouse%2BXenograft%2BModel%2Bof%2BHead%2Band%2BNeck%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D23%26spage%3D9309%26epage%3D9333%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291137" title="Lipids">Lipids</a>,</li><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=291862" title="Indoles">Indoles</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292349" title="Alkyls">Alkyls</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/jmcmar.2015.58.issue-23/20151210/jmcmar.2015.58.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A number of indole-3-glyoxylamides have previously been reported as tubulin polymerization inhibitors, although none has yet been successfully developed clinically. We report here a new series of related compounds, modified according to a strategy of reducing aromatic ring count and introducing a greater degree of saturation, which retain potent tubulin polymerization activity but with a distinct SAR from previously documented libraries. A subset of active compounds from the reported series is shown to interact with tubulin at the colchicine binding site, disrupt the cellular microtubule network, and exert a cytotoxic effect against multiple cancer cell lines. Two compounds demonstrated significant tumor growth inhibition in a mouse xenograft model of head and neck cancer, a type of the disease which often proves resistant to chemotherapy, supporting further development of the current series as potential new therapeutics.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18485" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18485" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Microtubule-targeting agents (MTAs) are a major class of cancer chemotherapeutic drugs<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> that have enjoyed decades of clinical success in the treatment of a wide range of cancers. These agents bind to heterodimers of α- and β-tubulin, the building blocks of cellular microtubules, and in doing so interfere with normal microtubule dynamics. Depending on their exact binding site, MTAs can stabilize or destabilize microtubules, but in either event, disruption of normal function results and ultimately leads to apoptosis. The precise mechanism of action of MTAs used in the clinic is still incompletely understood, and as such continues to be investigated and debated.<a onclick="showRef(event, 'ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6">(3-6)</a> Although it had long been assumed that MTAs are effective against cancers solely through interruption of mitosis, on which their effect is certainly important,<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> more recent evidence points toward a multifaceted mode of action arising from interaction with microtubules throughout the cell cycle.<a onclick="showRef(event, 'ref7 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref7 ref9 ref10 ref11">(7, 9-11)</a></div><div class="NLM_p">Despite the advances in treatment MTAs have undoubtedly offered, existing agents suffer from some significant drawbacks<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> which often compromise clinical efficacy and can lead to treatment failure. Drug resistance (either innate or acquired) is a serious problem,<a onclick="showRef(event, 'ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16">(13-16)</a> and adverse toxicities such as peripheral neuropathy<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> (PN) can prove dose-limiting, indicative of a narrow therapeutic window.</div><div class="NLM_p">The search for novel agents in the class has therefore been intensive<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> and whereas the more recent approvals, such as vinflunine,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> eribulin,<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22-24)</a> ixabepilone,<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a> and the antibody–drug conjugate trastuzumab emtansine,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> have proven beneficial for a limited number of indications, not all clinical studies have demonstrated improved efficacy, and classical MTA-associated adverse reactions,<a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(28-30)</a> including PN,<a onclick="showRef(event, 'ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33">(31-33)</a> are still encountered with these newer agents. It is worth noting that eribulin in particular has shown evidence of an improved safety profile and promise for wider application<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> although drug resistance has also been encountered with this agent.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Overall, in spite of some welcome benefits, the newer MTAs have seemingly failed to displace their older counterparts to a significant degree, at least to date. Alhough they are expected to gain broader use in the future, it remains an important goal for the field to develop novel agents which can demonstrate the same broad spectrum of efficacy as the more established drugs while offering significant progress in overcoming resistance and minimizing unmanageable toxicity.</div><div class="NLM_p">To this end, many novel small-molecule MTAs have been reported in recent years,<a onclick="showRef(event, 'ref36 ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38 ref39">(36-39)</a> some with promising preclinical or early clinical data, although the challenge of demonstrating superior clinical performance over existing agents is considerable. Nonetheless, such compounds include indibulin <b>1</b> and rosabulin <b>2</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), two experimental drugs with high structural similarity for which a novel tubulin binding site has been claimed.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40, 41)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of glyoxylamide-based tubulin polymerization inhibitors that have progressed to clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Little has been published regarding <b>2</b>, and its development appears to have been abandoned following phase I clinical trials.<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41, 42)</a> Compound <b>1</b> showed in vivo efficacy and early evidence of improved therapeutic window,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> suggested to be a consequence of it targeting a novel binding site on tubulin.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> It has persisted in phase I clinical development for a number of years, with the primary issue apparently being low exposure,<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44, 45)</a> in turn likely due to its poor aqueous solubility. Although both <b>1</b> and <b>2</b> have encountered problems in the clinic, the fact remains that they were promising preclinical agents, and the issues subsequently encountered for <b>1</b> do not seem insurmountable.</div><div class="NLM_p">In the light of an intriguing report<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> suggesting indole-3-glyoxylamides unsubstituted at N1 can still make effective tubulin polymerization inhibitors, we supposed that exploring modifications of <b>1</b> and <b>2</b> at this locus would be a viable starting point for the development of new potential MTAs. The initial focus of the present work was replacement of the <i>p</i>-chlorobenzyl group of <b>1</b>, aiming first to improve aqueous solubility through the dual strategy of reducing aromatic ring count and increasing saturation. The benefits in terms of compound developability of both minimizing the number of aromatic rings<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and increasing the count of <i>sp</i><sup>3</sup> carbon atoms<a onclick="showRef(event, 'ref48 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50">(48-50)</a> are gaining appreciation as a result of several studies supporting such rationale over recent years. Solubility prediction by either direct calculation or matched molecular pair analysis (MMPA) is shown to justify such an approach in the present context.</div><div class="NLM_p">Tubulin polymerization inhibitors identified during this study were first applied in models of head and neck cancer (HNC), a disease in which existing MTAs have shown promise for improved treatment outcomes if the common problems of toxicity and drug resistance can be overcome.<a onclick="showRef(event, 'ref51 ref52 ref53 ref54 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53 ref54 ref55 ref56">(51-56)</a></div><div class="NLM_p last">HNC is the sixth most common cancer worldwide and is of particular concern due to rising incidence over the past two decades. Treatment is often some combination of surgery, radiotherapy, and chemotherapy, but overall survival rates have not significantly improved in many years and response rates to typical first-line chemotherapy regimens, usually a combination of 5-FU and cisplatin, are problematically low (around 30%).<a onclick="showRef(event, 'ref51 ref57'); return false;" href="javascript:void(0);" class="ref ref51 ref57">(51, 57)</a> More recently, targeted therapies have been introduced<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> in an effort to improve treatment of HNC, most notably the EGFR-targeted monoclonal antibody cetuximab, which was approved in 2008 for use in locally advanced or metastatic/recurrent HNC. Other targeted therapies remain under investigation in HNC, including antiangiogenic agents, PI3K/Akt/mTor inhibitors, and p53 gene replacement therapy.<a onclick="showRef(event, 'ref58 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref58 ref59 ref60">(58-60)</a> Whereas such targeted approaches have certainly benefited some patients, their overall impact on HNC treatment has been mixed,<a onclick="showRef(event, 'ref59 ref60 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref59 ref60 ref61 ref62">(59-62)</a> and personalized or combination therapy will likely prove necessary to maximize clinical success of these targeted drugs;<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60, 61)</a> thus, more effective general first-line chemotherapy treatments are still much needed. Given the limited but promising data on the potential of MTAs in HNC, appropriate disease models therefore represent a useful context for the testing and development of new agents in the class.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00512" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00512" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Solubility Prediction Studies</h3><div class="NLM_p last">To test our initial assumptions regarding modifications to <b>1</b>, directly calculated solubilities were determined for some of the first-generation analogues planned initially and detailed in the SAR study below (<b>5</b>–<b>13</b>, <b>17</b>, <b>18</b>, <b>32</b>, and <b>33</b>; <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Direct calculation of aqeuous solubility is known to represent a considerable challenge, although several methods now exist with accuracy to well within an order of magnitude for most small molecules.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> The compounds specified above were evaluated by the method of Tetko et al.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> using the web-based ALOGPS 2.1 program,<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> which estimated at least an order of magnitude improvement in solubility over <b>1</b> in each case (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Table S11</a>). Given such direct prediction of solubility is acknowledged as a difficult problem, an alternative method was applied to further validate our proposed structural modifications to <b>1</b>. A matched pairs approach was employed that has previously shown promise in providing guidance when seeking to optimize molecular properties.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> The database of solubility transformations curated by MedChemica<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> was used to give an historical view of how different chemical changes have influenced measured solubility in order to set reasonable bounds on what effects should be expected. The chemical changes were identified using a matched pair finding approach combining that of Hussein and Rea<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> with that of Warner et al.,<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> which captures both the group being changed and essentially<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> the local chemical environment around the change. The data associated with each chemical change in its local environment was then recalled from the database and the recovered values used to construct a solubility network (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S16</a> and accompanying legend). Results of the matched pair analysis were in agreement with those from direct calculation above, predicting at least an order of magnitude increase in solubility for analogues of <b>1</b> replacing the <i>p</i>-chlorobenzyl group with simple aliphatic substituents. Addition of a methoxy-group to the pyridine ring, as was ultimately found necessary to recover activity, was predicted to cause a small compromise in solubility although these analogues (<b>8</b>–<b>10</b>; <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) were still expected to be much more soluble than <b>1</b>.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">Glyoxylamides derived from <i>N</i>-substituted indoles <b>4</b> were prepared using a straightforward two-step, one-pot procedure essentially as described previously (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>a).<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> However, for derivatization of intermediates <b>67</b> containing modifications at indole positions 4–7, this approach was surprisingly found to be unsuitable, in contrast to earlier examples where similar substrates unsubstituted at N1 (i.e., R<sup>1</sup> = H) gave the expected products, albeit in reduced yields.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> In the present study, when compounds of general structure <b>67</b> were reacted as outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>a (with or without heating to 50 °C in the first step to promote reaction with oxalyl chloride); no significant formation of the expected indole-3-glyoxylamide products was observed as evidenced by HPLC or LC-MS, yet little of the starting indoles remained, suggesting degradation of these starting materials had occurred. Addition of DIPEA to the first step of the process, reaction with oxalyl chloride, to prevent strongly acidic conditions from developing only appeared to suppress reaction of the indole derivative with the latter. Thus, an alternative route was employed (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>b) via glyoxylate ester intermediates <b>67</b>, formed using a Friedel–Crafts reaction with methyl chlorooxoacetate. This transformation has been shown effective with the less reactive azaindole derivatives,<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> as also proved the case in our hands, and was easily adapted for substituted indoles with acceptable yields. The resulting ester intermediates were then readily converted into the desired glyoxylamides via direct amidation catalyzed by 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD).<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0011.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Routes to the Indole-3-glyoxylamide Screening Libraries, Using Either (a) a One-Pot Procedure, or (b) a Two-Step Route Suitable for Modified Indoles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaH, R<sup>1</sup>-X, DMF or THF, 6–83%; (b) (i) oxalyl chloride, THF, 3 h, (ii) R<sup>2</sup>-NH<sub>2</sub>, DIPEA, DMAP (catalytic), THF, 18 h, 20–78%; (c) methyl chlorooxoacetate, AlCl<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 7–86%; (d) R<sup>2</sup>-NH<sub>2</sub>, 30 mol % TBD, toluene, 85 °C, 18 h, 5–58%. For the sake of clarity, individual structures of <b>4a</b>–<b>i</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Table S8</a>) and modified indoles <b>66a</b>–<b>l</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Table S9</a>) and their <i>N</i>-alkylated derivatives <b>67a</b>–<b>o</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Table S10</a>) are provided in the Supporting Information.</p></p></figure><div class="NLM_p">Some <i>N</i>-substituted indole derivatives not accessible through direct <i>N</i>-alkylation were also required, and these were approached by various other methods as appropriate (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). 1-Cyclopentylindole <b>4j</b> was prepared by reaction with cyclopentylboronic acid using conditions reported for preparation of the cyclopropyl derivative from the requisite boronic acid.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Ring-opening of isobutene oxide by indole anion<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> followed by <i>O</i>-methylation furnished intermediate <b>4k</b>. Tertiary alkyl derivatives <b>4l</b> and <b>4m</b> were accessed by <i>O</i>-alkylation of <b>72</b>, which in turn was synthesized in three steps from indole <b>3</b> utilizing methodology already reported for some substituted indole starting materials.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Finally, <b>4n</b> was prepared by an aza-Michael reaction between indole and methyl acrylate.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Glyoxylamide synthesis from these additional intermediates <b>4j</b>–<b>n</b> was performed according to the general method outlined above (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>a).</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0012.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of <i>N</i>-Substituted Indole Intermediates Accessed via Other Routes<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) cyclopentylboronic acid, NaHMDS, 10 mol % Cu(OAc)<sub>2</sub>, DMAP, toluene, 95 °C, 18 h, 34%; (b) isobutene oxide, NaH, DMF, 24 h, 74%; (c) MeI, NaH, THF, 24 h, 52%; (d) ethyl 2-bromopropionate, NaH, DMF, 40 °C, 18 h, 74%; (e) LDA, MeI, THF, −78 °C → rt, 18 h, 86%; (f) LiAlH<sub>4</sub>, THF, −78 °C → rt, 18 h, 78%; (g) MeI, NaH, THF, 3 h, 79% (<b>4l</b>) or ethyl bromoacetate, NaH, DMF, 20 h, 29% (<b>4m</b>); (h) methyl acrylate, 50 mol % DBU, MeCN, 50 °C, 12 h, 43%.</p></p></figure><div class="NLM_p">Variation of the glyoxylamide N-substituent R<sup>2</sup> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) was mostly achieved through the use of commercially available starting materials, although some such analogues required in-house synthesis of the amine precursors, R<sup>2</sup>-NH<sub>2</sub> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Nucleophilic aromatic substitution of 2-chloro-5-nitropyridine <b>73</b> with alkoxides followed by hydrogenolysis of the nitro-group<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> provided easy access to intermediates <b>77</b>–<b>79</b> for use in glyoxylamide syntheses. A small number of analogues exchanging the indole core for indolizine, as found in model compound <b>2</b>, were also evaluated. 3-Alkylindolizines <b>85</b>–<b>87</b> were prepared from 2-bromopyridine in two steps by a known route<a onclick="showRef(event, 'ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref79 ref80">(79, 80)</a> comprising Sonogashira cross-coupling followed by a copper(I)-mediated cyclization. For the most part, this sequence proceeded smoothly, with the exception of intermediate <b>84</b>, whose synthesis proved surprisingly challenging. Sonogashira reaction between 2-bromopyridine <b>80</b> and pent-4-yn-1-ol readily afforded alcohol <b>83</b>, but initial attempts at <i>O</i>-methylation in THF were unsuccessful, giving none of the desired product and seemingly resulting in intramolecular reaction between the generated alkoxide and the alkyne (data not shown). Attempts to convert <b>83</b> into 3-(2-hydroxyethyl)indolizine resulted in similar mixtures with no formation of the expected product. Methylation under modified conditions in DMF at 0 °C did provide a low yield of <b>84</b>, but its isolation from the product mixture formed was not straightforward so these shortcomings inspired an alternative approach whereby pent-4-yn-1-ol was first methylated to give 5-methoxypent-1-yne. Because this intermediate is somewhat volatile (lit.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> bp 107–115 °C), the crude material was used without extensive purification and reacted with 2-bromopyridine under the usual conditions (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). This completed an alternative route to <b>84</b>, which although still low-yielding, proved operationally simpler and more amenable to scale than the earlier method. Once in hand, the 3-alkylindolizine intermediates <b>84</b>–<b>86</b> were successfully elaborated into the desired glyoxylamides by the same two-step, one-pot procedure used for the majority of the indole derivatives (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>a).</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0013.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of 5-Aminopyridines with Varied 2-Alkoxy Substituents<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) R<sup>5</sup>-OH, NaH, <sup><i>i</i></sup>PrOH or DMF or THF, 44–65%; (b) H<sub>2</sub>, Pd-C, MeOH, 62–95%.</p></p></figure><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0014.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Analogues Replacing the Indole System with an Indolizine Core<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) R<sup>1</sup>CH<sub>2</sub>C≡CH, 2 mol % PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, 4 mol % PPh<sub>3</sub>, 4 mol % CuI, TEA, 18 h, 63–78%; (b) MeI, NaH, DMF, 0 °C, 3.5 h, 27%; (c) CuCl, DMA/TEA (7:1), 130 °C, 31–55%; (d) (i) oxalyl chloride, THF, 0 °C, 3 h, (ii) R<sup>2</sup>-NH<sub>2</sub>, DIPEA, DMAP, THF, 18 h, 20–66%.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Primary Screening and Elucidation of SAR</h3><div class="NLM_p">Test compounds were first assessed for cytotoxicity against FaDu, an EGFR inhibitor insensitive<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> HNC cell line derived from squamous cell carcinoma of the pharynx. Screens consisted of a 72 h end point MTT assay, and LC<sub>50</sub> values were determined for compounds showing cytotoxic activity at or below 10 μM. Analogues of <b>1</b> replacing the <i>p</i>-chlorobenzyl group at N1 with various simple alkyl groups showed a loss of cytotoxic activity (compounds <b>5</b>–<b>7</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>); however, introduction of a methoxy-group adjacent to the pyridine ring nitrogen rescued activity (<b>8</b>–<b>10</b>), and switching the positions of these structural features, as in analogues <b>11</b>–<b>13</b>, was found to result in a further order of magnitude improvement in potency.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1.  Cytotoxic Potencies of First-Generation Compounds in the Present Library<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0015.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0016.gif" alt="" id="GRAPHIC-d1997e1097-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">An expanded form of this Table, including yields, is included in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Table S1</a>).</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Reported mean and SEM values represent the results of at least three independent experiments.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Compound <b>1</b> was sourced commercially.</p></div></div><div></div></div><div class="NLM_p">The foregoing results inspired synthesis of a wider range of analogues to investigate the SAR with respect to variation of both R<sup>1</sup> and R<sup>2</sup>. First, systematic changes to the R<sup>2</sup> group revealed some clear trends in activity (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Removal of the pyridyl nitrogen (N to CH; <b>14</b> and <b>15</b>) resulted in a modest compromise to cytotoxic potency of no more than a 3-fold change, whereas in contrast, the inactivity of <b>16</b> indicated the <i>p</i>-methoxy group is essential for activity. Introduction of a second ring nitrogen at the <i>meta</i>-position of the aromatic group (pyrimidines <b>17</b> and <b>18</b>) showed the same modest reduction in potency as the aniline compounds, whereas introduction of a second ring nitrogen at the <i>ortho</i>-position (pyridazine <b>19</b>) proved highly detrimental to activity. A change of <i>p</i>-methoxy to ethoxy was tolerated with a 2-fold increase in LC<sub>50</sub> (compound <b>20</b>), whereas introduction of a second methoxy-substituent, as in <b>21</b>, was not. Replacement of the <i>p</i>-methoxy group with either trifluoromethoxy or trifluoromethyl was found severely detrimental to cytotoxic activity (compare <b>22</b> and <b>23</b> with <b>14</b> and <b>15</b>, and <b>24</b> and <b>25</b> with <b>12</b> and <b>13</b>, respectively). Exchanging the pyridine ring of <b>12</b> for a five-membered heterocycle, in analogous fashion to compound <b>2</b>, also proved unproductive. In sum, although the R<sup>2</sup> variations explored at this stage did not lead to improvement in cytotoxic potency in any case, a number of changes were identified that are tolerated without seriously compromising activity.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Cytotoxicity Data for Second-Generation Analogues Designed to Interrogate SAR at R<sup>2</sup> Position of the Parent Structure<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0017.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">An expanded form of this Table, including yields, is included in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Table S2</a>).</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Reported mean and SEM values represent the results of at least three independent experiments (except <b>24</b>, <i>n</i> = 2).</p></div></div><div></div></div><div class="NLM_p">In contrast, variation of the R<sup>1</sup> group did lead to the sought-after improvement in cytotoxic potency (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Changing the isopropyl group of <b>12</b> to <i>sec</i>-butyl slightly improved activity, although cyclopentyl <b>29</b> or isobutyl <b>30</b> substituents resulted in a 4-fold drop-off. Exchanging the oxygen atom in the 2-methoxyethyl substituent of <b>13</b> for a methylene group, as in <i>n</i>-butyl analogue <b>31</b>, caused no change in potency, indicating that the shape, rather than polarity, of this R<sup>1</sup> group is the major determinant of activity. Another change to <b>13</b>, introducing an additional methyl group α- to indole N1, resulted in the most potent compound in the series, <b>32</b>, with an LC<sub>50</sub> against FaDu of 12 nM. Other analogues of <b>13</b>, with a ring bridging the side chain oxygen atom, differed markedly in activity. Tetrahydrofuran compound <b>33</b> was essentially as potent as its parent, whereas oxetane analogue <b>34</b> was unexpectedly compromised by more than an order of magnitude. Introducing a tertiary center β- to N1, as in <i>gem</i>-dimethyl compound <b>35</b>, was not tolerated at all. Taken together, cytotoxicity data for this set of analogues are suggestive of a common binding pocket for the R<sup>1</sup> side chain. Although simple, linear R<sup>1</sup> chains give rise to some of the most potent compounds, a degree of further substitution is tolerable or even beneficial, whereas too much substitution severely compromises or abolishes the observed activity.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Cytotoxicity Data for Second-Generation Analogues Designed to Interrogate SAR at R<sup>1</sup> Position of the Parent Structure<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0018.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">An expanded form of this Table, including yields, is included in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Table S3</a>).</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Reported mean and SEM values represent the results of at least three independent experiments.</p></div></div><div></div></div><div class="NLM_p">The final set of compounds prepared for initial SAR studies focused on variation at indole positions 4–7 (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). These analogues <b>36</b>–<b>51</b> retained the core structure of compounds <b>12</b> or <b>13</b> (except for <b>39</b>, R<sup>2</sup> = 4-methoxyphenyl) with systematically varied modifications at C4 to C7: chloro- or methoxy-substitution, or a switch to an azaindole (i.e., ring CH to N). The majority of these changes were not tolerated and abolished cytotoxic activity, which was particularly unexpected in the case of azaindoles <b>47</b>–<b>49</b> given such a small structural change. For analogues introducing an additional group, only chloro-substitution at C4 or C6 gave any retention of activity, albeit with at least a 20-fold increase in LC<sub>50</sub>. The single useful modification identified in this series was a change from indole to 7-azaindole, with <b>50</b> and <b>51</b> showing similar potency to their parent compounds, <b>12</b> and <b>13</b>, respectively.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Synthesis and Evaluation of Further Analogues, Modified at Indole Positions 4–7<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0019.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0020.gif" alt="" id="GRAPHIC-d1997e1391-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">An expanded form of this Table, including yields, is included in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Table S4</a>).</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">Reported mean and SEM values represent the results of at least three independent experiments.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">Compounds <b>37</b> and <b>39</b> were synthesized according to <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>a, in turn meaning intermediate <b>68b</b> was not synthesized.</p></div><div class="footnote" id="t4fn4"><sup>Table d</sup><p class="last">The R<sup>2</sup> group in <b>39</b> is 4-methoxyphenyl, not 2-methoxy-5-pyridyl as in all the other examples.</p></div></div><div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Evaluation and Early Optimization of in Vitro PK Properties</h3><div class="NLM_p">A selection of the most promising compounds was screened for solubility, microsomal stability, and Caco-2 permeability in an initial effort to identify likely ADME liabilities. Aqueous solubility thresholds for <b>12</b>, <b>13</b>, and <b>32</b> were estimated to be in the region of 10 μM by HPLC (cf. <b>1</b>, ≤ 1 μM) although reproducibility was difficult, thought to be due to approaching the detection limit by UV, such that these measurements were not considered reliable. Results from dynamic light scattering (DLS) experiments (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S6</a> and accompanying text) were more supportive of a solubility threshold of 10 μM or higher for several compounds, including thresholds of at least 20, 80, and 40 μM, respectively, for <b>12</b>, <b>13</b>, and <b>32</b>. Taken together, it appeared as anticipated that considerable improvement had already been realized over <b>1</b>, which in contrast was seen to form large aggregates at 10 μM by DLS with some evidence for aggregate formation at 1 μM (markedly raised count rate).</div><div class="NLM_p">Caco-2 permeability data (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>) for selected compounds were predictive of good intestinal absorption, i.e. <i>P</i><sub>app</sub> (A → B) > 10 × 10<sup>–6</sup> cm s<sup>–1</sup>, with no evidence of active efflux (<i>P</i><sub>app</sub> ratio <2). Mouse microsomal half-lives, estimated by extrapolation from 30 min assay end point values (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Table S6</a>), did prove a concern, however, indicating rapid clearance would likely be an issue in vivo. Metabolism was previously identified<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> as a possible contributing factor to the suboptimal pharmacokinetics of <b>1</b>, making this issue all the more important to address in the present series of related compounds.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Assessment and Preliminary Optimization of Selected in Vitro PK Properties</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0021.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last">An expanded form of this Table, including yields, is included in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Table S5</a>).</p></div><div class="footnote" id="t5fn2"><sup>Table b</sup><p class="last">Reported mean and SEM values represent the results of at least three independent experiments.</p></div><div class="footnote" id="t5fn3"><sup>Table c</sup><p class="last"><i>P</i><sub>app</sub> values are quoted as ×10<sup>6</sup> cm <sup>–1</sup>; values quoted are the mean of two independent experiments, which were in good agreement in every case.</p></div><div class="footnote" id="t5fn4"><sup>Table d</sup><p class="last"><i>P</i><sub>app</sub> ratio = <i>P</i><sub>app</sub> (B → A)/<i>P</i><sub>app</sub> (A → B).</p></div><div class="footnote" id="t5fn5"><sup>Table e</sup><p class="last">Recovery was <50% in the Caco-2 assay with <b>59</b>, indicating potential issues with solubility or binding to cellular proteins/lipids under the assay conditions, which may reduce the accuracy of the result.</p></div></div><div></div></div><div class="NLM_p">A further selection of analogues was subsequently designed and synthesized in an attempt to address the shortcomings with respect to metabolic stability. It had not been possible to extract conclusive trends from the first round of data, although the R<sup>1</sup> group did appear to influence stability (noting <i>t</i><sub>1/2</sub> order <b>32</b> > <b>13</b> > <b>12</b>); thus, exchange of the indole for an indolizine core heterocycle, replacing the C–N bond linking the R<sup>1</sup> substituent with a C–C bond, was attempted but unfortunately did not prove advantageous. Indolizine analogues <b>53</b> and <b>54</b> proved equally as metabolically unstable as their indole counterparts <b>12</b> and <b>13</b>, if not more so, and also suffered from a small but notable drop-off in cytotoxic potency. Alternatively, introducing a tertiary center α- to N1, as in <b>57</b>, did not offer any improvement either.</div><div class="NLM_p">In contrast, adding extra bulk to the methoxy-substituent of the R<sup>2</sup> group to block metabolism at this site greatly improved stability, conferring an order of magnitude increase in half-life without adversely compromising cytotoxic potency (compare <b>59</b> with <b>13</b>). However, adding further substitution at this site did negatively affect activity (compare <i>tert</i>-butyl derivative <b>60</b>). A related modification to the methoxy-group in the R<sup>1</sup> substituent resulted in modest stabilization (comparing <b>56</b> with <b>13</b>), but in this case the penalty in cytotoxic activity was too severe to consider it a useful change.</div><div class="NLM_p last">Matched pair analysis for prediction of solubility, as described above, anticipated a modest but acceptable compromise for representative compounds introducing more bulky hydrophobic groups in an attempt to block metabolism (<b>56</b>, <b>57</b>, <b>60</b>; Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S17</a>). These predictions were indeed reflected in the DLS measurements referred to earlier (Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S6</a>). Other analogues prepared specifically with the aim of improving solubility included <b>61</b>, <b>63</b>, and <b>65</b>, and although all three compounds appeared fully soluble up to 200 μM by DLS (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S6a,b</a>), introduction of the carboxylic acid group abolished cytotoxicity in every case.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Targeting of Tubulin</h3><div class="NLM_p">A subset of cytotoxic compounds from the initial SAR study was evaluated further to confirm their presumed mode-of-action, inhibition of tubulin polymerization (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). GTP-promoted microtubule assembly from purified porcine brain tubulin was followed by measuring changes in optical density (OD<sub>340</sub>) of the solution over a period of 60 min following initiation of reaction, according to a well-established protocol.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Increasing concentrations of <b>12</b>, <b>32</b>, <b>33</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>a), <b>51</b>, <b>57</b>, and <b>59</b> were found to suppress the polymerization reaction in a dose-dependent manner. Assay end point values, expressed relative to vehicle control, were considered indicative of extent of reaction, and a secondary plot of these results against inhibitor concentration permitted derivation of IC<sub>50</sub> values (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>b; full dose–response plots for all six compounds, and colchicine used as a positive control, are included in the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S1</a>). In contrast, compounds <b>11</b> and <b>13</b> unexpectedly showed no inhibition in the polymerization assay, alongside <b>1</b>, for which such a result has already been reported<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S2</a>). Earlier work<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> on <b>1</b> suggested it does not inhibit the polymerization of post-translationally modified tubulin (acetylated on Lys40 of the α-subunit) from mature animal brain, such as would be expected in a commercially sourced preparation, and an unmodified sample derived from infant animal brain is required to see inhibition. This observation, among others, led the authors to conclude the compound binds to an unprecedented site in the vicinity of Lys40 of α-tubulin. The apparent inactivity of <b>1</b> in the present tubulin polymerization assays was therefore anticipated, but similar results for <b>11</b> and <b>13</b> seemed unusual given the positive results for closely related analogues.</div><figure id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Tubulin polymerization time-course plots following changes in OD<sub>340</sub> of reaction mixtures in the presence of increasing concentrations of <b>33</b> (blue lines) compared to vehicle control (red line). (b) Secondary plots of reaction end point data allow determination of IC<sub>50</sub> for inhibition of tubulin polymerization by <b>33</b> and other compounds as indicated. Data from multiple experiments was plotted as individual data points, as shown, and fit globally. (c) Competition for tubulin binding between [<sup>3</sup>H]-colchicine (at 0.1 μM) and vincristine, docetaxel, or podophyllotoxin shows only the latter competes with binding at the colchicine site, as expected. (d) The same six compounds listed in (b) above all compete for binding at the colchicine site with IC<sub>50</sub> values as shown, with representative results graphed for <b>32</b>, <b>51</b>, <b>57</b>, and podophyllotoxin (positive control).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To investigate further, the above set of compounds, together with <b>10</b>, <b>23</b>, <b>50</b>, and <b>57</b>, was tested in an alternative tubulin polymerization assay which relies on the fluorescence of DAPI when incorporated into growing microtubules,<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> as opposed to detecting polymer growth through changes in OD<sub>340</sub>. Under these conditions, inhibition was now observed for all library compounds, including <b>11</b> and <b>13</b> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figures S2,S3</a>). Where results were obtained in both assays, there was qualitative evidence for agreement between the relative IC<sub>50</sub> values (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S4</a>), although the very small sample size precludes any firm evidence of a correlation. Similarly, the trend in potencies obtained in both polymerization assays (particularly the fluorescence-based method, with the larger number of compounds screened) is in good general agreement with that seen earlier in cellular cytotoxicity activities, suggesting interaction with tubulin was a major factor leading to the observed toxic phenotype (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S5</a> and accompanying legend). It is worth noting that although <b>1</b> did not show inhibition of tubulin polymerization in the absorbance-based assay, as stated above, there was some evidence of activity using the fluorescence-based method (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S2</a>), although results between experiments were inconsistent. It is thus not possible to reach a conclusion either way regarding inhibition by <b>1</b>, although it seemed plausible to suggest that obtaining a clear result was compromised by the poor solubility of the compound. To investigate this possibility further and assess whether the initial results for <b>11</b> and <b>13</b> described above might likewise be linked to solubility issues, DLS experiments were carrried out to look for evidence of aggregation over a concentration range relevant to the inhibition assays (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S6a,b</a>). Extensive aggregation was seen for <b>1</b> at 10 μM, forming particles of approximately 1 μm in diameter, with some evidence for aggregate formation at 1 μM as already noted above. In contrast, most compounds evaluated from the present library showed no obvious evidence of aggregation at 10 μM, which was true of the subset evaluated in both the tubulin polymerization assays and the DLS screen (<b>11</b>–<b>13</b>, <b>32</b>, <b>33</b>, <b>53</b>, <b>57</b>, and <b>59</b>). It seems apparent that <b>11</b> and <b>13</b> are not appreciably different in solubility to other representative library members which did display tubulin polymerization inhibition in both assays, suggesting the observed inactivity of the former in the OD<sub>340</sub>-based assay is due to an as yet unknown property of these compounds (because both seem fully soluble over the concentration range used). In contrast, the DLS results lend support to the idea that, in the case of <b>1</b>, poor compound solubility may indeed interfere with the reliability of these assay readouts.</div><div class="NLM_p">Having gained evidence that compounds from the current series do interact directly with tubulin, it was considered important to elucidate their binding site. There are three well-characterized binding domains on tubulin, the colchicine, <i>Vinca</i> alkaloid, and taxane binding sites, all located on the β-subunit, and most (but not all) established MTAs bind at or close to one of them. Taxane domain ligands are known to act as microtubule stabilizers, whereas drug binding to the <i>Vinca</i> alkaloid or colchicine sites destabilizes microtubules. Given that actives from the current series inhibit tubulin polymerization, binding at either the colchicine or <i>Vinca</i> domains was anticipated. Evaluation of test compounds at all sites was probed by competition with tritium-labeled standards (colchicine, vinblastine, or paclitaxel), looking for dose-dependent displacement of radioactivity from the protein with increasing test compound concentration. The same set of compounds evaluated in the tubulin polymerization assays was screened for binding. Results at the colchicine site proved the most conclusive, with the assay first validated using competition of [<sup>3</sup>H]-colchicine with podophyllotoxin, a known binder at this site<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>c). As expected, no competition with [<sup>3</sup>H]-colchicine was observed with either vincristine or docetaxel. All test compounds gave positive results, with selected IC<sub>50</sub> values presented in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>d together with dose–response plots for <b>32</b>, <b>51</b>, and <b>57</b> (see Supporting Information for dose–response plots for all compounds, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S7</a>). Good correlation between FaDu cytotoxicity (LC<sub>50</sub> values) and IC<sub>50</sub> for competition with [<sup>3</sup>H]-colchicine seems apparent (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S8</a>), although as applies to the polymerization assay results above, a firm conclusion cannot be drawn from existing data given the small sample size. Evaluation of <b>1</b> again proved problematic (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S9</a>): a partial competition curve was obtained up to a point where binding leveled off, suggesting a solubility threshold could have been reached. It is informative to consider this result in the light of previous data<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> reporting that [<sup>3</sup>H]-<b>1</b> was readily displaced from tubulin by excess colchicine, whereas in the reciprocal experiment, [<sup>3</sup>H]-colchicine binding was only partially competed by excess <b>1</b>. Considering all aspects together, these results could be interpreted to mean that <b>1</b> binds to the colchicine site with good affinity but its poor solubility hinders accurate assessment of this binding, especially where the compound must be present in excess. It remains to be said that binding of <b>1</b> to the colchicine site is necessarily assessed independently of that at the other proposed site on the α-subunit, suggesting the compound could be a dual site binder to tubulin.</div><div class="NLM_p">In our experience, evaluation of the same 12 library compounds as above at the <i>Vinca</i> alkaloid and taxane binding sites proved unexpectedly difficult (for a more detailed analysis, see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figures S10–S12</a> and accompanying legends). Briefly, at the <i>Vinca</i> site, docetaxel was found to complete with [<sup>3</sup>H]-vinblastine binding just as well as vincristine, whereas at the taxane site, vincristine competed with [<sup>3</sup>H]-paclitaxel binding with an IC<sub>50</sub> only 2-fold higher than that for docetaxel (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S10</a>). These observations limited the confidence with which clear results could be drawn from the data; however, none of the compounds showed any obvious evidence of binding at the taxane domain in agreement with their activity as inhibitors, rather than promoters, of tubulin polymerization. At the <i>Vinca</i> site, some (but not all) of the test compounds displayed IC<sub>50</sub> values close to that of vincristine, suggesting the intriguing possibility that these members of the library are capable of binding tubulin at both the colchicine and <i>Vinca</i> alkaloid domains (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S12</a>); however, given the difficulties encountered with the assay this can only be considered a preliminary finding, deserving further investigation in due course.</div><div class="NLM_p">In sum, a small set of compounds from the cytotoxicity-led SAR study was found to inhibit tubulin polymerization through binding at the colchicine site, with good general agreement between potency in both assays and the earlier LC<sub>50</sub> data. Attention was next focused on whether the expected phenotype for destabilization of microtubules is seen at the cellular level.</div><div class="NLM_p">To visualize the effect of <b>32</b>, <b>33</b>, and <b>59</b> on the microtubule network, FaDu cells were treated with two concentrations of each compound for 24 h then fixed and stained for α-tubulin and DNA (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Concentrations were chosen corresponding to approximately 1× and 5× the cytotoxic LC<sub>50</sub> (72 h end point); after exposure for 24 h, the majority of the cell population will be in mitotic arrest at the higher of these concentrations (as discussed later; see <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>).</div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Representative images of fixed FaDu cells stained for α-tubulin (green) and DNA (blue) after treatment as indicated for 24 h. Control cells (DMSO-treated) show a well-structured microtubule network and are dividing normally, with mitotic cells in anaphase (center) and prophase (left) clearly visible in the upper-left panel. In contrast, cells treated with active tubulin polymerization inhibitors showed multiple mitotic defects, most notably formation of multipolar spindles, and compound <b>59</b> appeared especially destructive to the microtubule network at high concentration. Images in all panels are to the same scale. An enlarged version of these images is provided in the Supporting Information for improved clarity (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S13</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Exposure of FaDu cells to increasing concentrations of the compounds indicated, for 24 h, caused dose-dependent cell cycle arrest in the G<sub>2</sub>/M phase; for comparisons, ns = <i>P</i> > 0.05, ** = <i>P</i> < 0.01, *** = <i>P</i> < 0.001. (b) Representative histograms for the three concentrations of <b>57</b> (cell count versus DNA staining intensity) showing the clear shift in cell cycle distribution upon compound treatment; DMSO control (not shown) was essentially identical to the 0.5 × LC<sub>50</sub> (green) plot. (c) A more detailed dose–response analysis for compounds <b>33</b> and <b>59</b> provided EC<sub>50</sub> values for the observed mitotic arrest.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">All three compounds proved able to induce mitotic spindle defects at low concentration, and in particular, several cells with multipolar spindles were seen with <b>33</b> and <b>59</b>. It is also clear that a high concentration of each compound caused extensive damage to the microtubule network. Comparison of the images suggests there may be some differences in the cellular phenotype produced by each compound, perhaps indicating subtle variation in their precise mode of action. This observation could form the basis of future investigations to understand the effects of compounds from this series in cells in more detail. In the present context though, it is clear that the three compounds tested caused obvious defects in the microtubule network of FaDu cells at concentrations consistent with the cytotoxic potencies determined earlier. Because the compounds have also been shown to interact directly with purified tubulin, these results do appear to confirm engagement of the same target in cells as the basis of their cytotoxic action.</div><div class="NLM_p">A small set of the most potent compounds was also assessed by flow cytometry for their effect on the cell cycle distribution of proliferating FaDu cells (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). As can be seen clearly, all compounds induced accumulation of the majority of the population at G<sub>2</sub>/M phase after 24 h exposure. Using multiple concentrations of <b>33</b> and <b>59</b> allowed dose–response curves to be plotted and EC<sub>50</sub> values derived for this mitotic arrest, and these values are approximately 5-fold or 2-fold higher, respectively, than the LC<sub>50</sub> values for cytotoxicity (72 h end point). This does suggest mitotic arrest as the primary cause of cell death in the latter assays, although a direct comparison at equivalent end points is not possible because all cells are dead by 72 h (compromising analysis by flow cytometry), whereas meaningful LC<sub>50</sub> values cannot be obtained at 24 h (because viability is only partially reduced by this stage, typically by only 40–50% even at the top of the dose–response concentration range). It appears that G<sub>2</sub>/M accumulation results relatively soon after treatment, within the first 18–24 h, and a prolonged period of cell cycle arrest is entered, as is typical with MTAs,<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> before ultimate cell death, which is not extensive until around 48 h (data not shown).</div><div class="NLM_p last">Thus, it was established that representative compounds from the current series cause disruption of the cellular microtubule network and induce cell cycle arrest in mitosis, consistent with their tubulin polymerization inhibition properties.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Evaluation in Other Cell Models</h3><div class="NLM_p">It was also considered important to evaluate some of the most potent compounds more widely, including cell lines representing other cancer types. The additional lines used were SCC-4 (squamous cell carcinoma of the tongue), SK-MEL-28 (malignant melanoma), SH-SY5Y (neuroblastoma), and MES-SA (uterus sarcoma). A multidrug-resistant derivative of the latter, MES-SA/Dx5, was also used because it is known to express very high levels of P-glycoprotein (P-gp).<a onclick="showRef(event, 'ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref88 ref89">(88, 89)</a> When used in combination, these two lines therefore represent a useful tool to evaluate the propensity of test compounds for efflux-mediated resistance.</div><div class="NLM_p">Screening against the additional cell lines was carried out with a selection of six compounds (<b>13</b>, <b>32</b>, <b>33</b>, <b>51</b>, <b>57</b>, and <b>59</b>), spanning an order of magnitude range of LC<sub>50</sub> from the FaDu screen (12–137 nM), alongside <b>1</b> for comparison (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). The observed cytotoxic activities, together with the trend in potency, remained very similar across all lines (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>a; see also Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S14</a>). The multidrug-resistant cell line MES-SA/Dx5 showed significant cross-resistance to vinblastine, paclitaxel, and colchicine as expected, but not to <b>1</b> or the present test compounds (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>b), suggesting the latter are not substrates for efflux by P-gp. Further support for this assumption is provided by the bidirectional Caco-2 assay results discussed above (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Efflux can also occur by the Caco-2 cell line and may be mediated by any of multiple transporters including P-gp, BCRP/ABCG2, MRP1, and MRP2.<a onclick="showRef(event, 'ref90 ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref90 ref91 ref92">(90-92)</a> Hence, the fact an efflux ratio of less than 2 was observed for <b>12</b>, <b>13</b>, <b>17</b>, <b>32</b>, <b>33</b>, and <b>59</b> suggests these compounds are not good substrates for any of the transporters characterized in Caco-2.</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0007.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Distribution of cytotoxicity LC<sub>50</sub> values for the compounds indicated across a range of cell lines representing different cancer types. (b) Ratio of LC<sub>50</sub> values for various compounds between the multidrug-resistant cell line MES-SA/Dx5 and its parent line, MES-SA. Varying degrees of resistance are seen to vinblastine, paclitaxel, and colchicine but not to <b>1</b> or a selection of members from the present series. The cytotoxicity data used in making both these graphs are tabulated in full (mean, SEM, n) in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Table S7a,b</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The present series of compounds appears to possess general cytotoxic activity against cancer cell lines and does not seem susceptible to active efflux based on results from two cell lines expressing transporter proteins commonly associated with multidrug resistance.</div><div class="NLM_p">A further priority was to evaluate selected compounds from the series in a suitable 3D cell culture model. Whereas 2D (monolayer) culture provides a convenient platform for initial screening experiments, it is not a representative model of a clinical tumor; thus, 3D cell culture models are increasingly being developed and applied to better assess the potential for in vivo activity of preclinical compounds.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> The simplest such 3D model is the multicellular tumor spheroid (MCTS), a valuable screening tool which may be formed from either a single cell type or cocultured cells.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> The FaDu cell line employed for primary screening in this study readily forms monocultured MCTS,<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> permitting the effect of compounds <b>32</b>, <b>33</b>, and <b>59</b> on these spheroids to be monitored in a time- and dose-dependent fashion (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). FaDu MCTS are an established and well-characterized model of HNC solid tumors that have been widely employed.<a onclick="showRef(event, 'ref94 ref95 ref96'); return false;" href="javascript:void(0);" class="ref ref94 ref95 ref96">(94-96)</a></div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0008.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect of compounds <b>32</b>, <b>33</b>, and <b>59</b> on multicellular tumor spheroids (MCTS) formed from the FaDu cell line. (a) Images captured at 0, 2, 4, and 7 days postdosing demonstrate ongoing toxicity toward treated MCTS, whereas untreated controls show continued growth over the same time period; scale bar (lower left panel) 500 μm. (b) Images of MCTS treated with increasing concentrations of <b>59</b> captured 7 days postdosing, with enhanced brightness to emphasize the fragmentation of spheroids which is induced in a dose-dependent manner; scale bar (leftmost panel) 500 μm. (c) Time-course plots of average volume at selected concentrations of <b>59</b> again show dose-dependent toxicity toward FaDu MCTS. (d) Representative dose–response plots at end point (7 days postdosing) allow EC<sub>50</sub> determination for spheroid disruption; values derived from these data are 39 nM (<b>32</b>), 77 nM (<b>33</b>), and 113 nM (<b>59</b>). (e) Comparison of 3D cytotoxic potencies (mean ± SEM) with values from 2D (monolayer) screening reported earlier (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An effect on normal spheroid growth was not evident until 2–3 days after dosing, but from this point onward, an ongoing dispersion of cells from the spheroid was seen (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>a), assumed to be due to the cytotoxic effect of the compounds inducing progressive cell death. As shown for <b>59</b> (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>b), the extent of this effect was dose-dependent at the experiment end point (7 days post dosing), and size measurements taken at regular intervals allowed time-course plots of spheroid volume to be made (also for <b>59</b>; <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>c). This revealed that at concentrations high enough to ultimately reduce the spheroid volume (>0.1 μM), it takes several days before the toxic effect of the compound is sufficient to outweigh new cell growth, emphasizing the requirement for continued drug exposure in vivo. Measurements taken at the 7 day end point over a range of concentrations allowed dose–response plots to be constructed for all three test compounds and EC<sub>50</sub> values for spheroid disruption to be derived (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>d). Combined results from two such independent experiments were compared with the 2D cytotoxic potencies determined earlier (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>e).</div><div class="NLM_p last">Compounds <b>32</b> and <b>59</b> demonstrated good agreement between duplicate experiments, with a 3D potency approximately 3- or 2-fold higher, respectively, than the requisite result in 2D culture. In contrast, more variation was seen in 3D experiments with <b>33</b> for reasons which were not immediately clear, but 3D results were nonetheless well within an order of magnitude of those seen in 2D. Hence, all three compounds did show efficacy in the 3D MCTS model at concentrations similar to those observed in the earlier FaDu monolayer screens, without any prohibitive dropoff in activity. There is certainly scope for higher-content screening using MCTS which could be exploited in the future as part of more detailed mode-of-action studies, but for the purposes of the current work, it was satisfactory to note successful translation of activity to a 3D model for representative compounds in the existing series.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Mouse Xenograft Study</h3><div class="NLM_p">Two compounds, <b>33</b> and <b>59</b>, were selected for a preliminary in vivo efficacy study in a mouse model of HNC using xenografts of the FaDu cell line. In addition to the positive results for both in the FaDu MCTS model described above, these compounds were chosen because they were the only candidates with both LC<sub>50</sub> < 100 nM from the primary cytotoxicity screen and a microsomal half-life of at least 30 min. Given concerns over the still suboptimal solubility of the series, oral dosing was chosen since earlier data suggested moderate to good absorption by this route (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Mice with established xenografts were dosed once daily for a period of 10 days as shown (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>), and a significant inhibition of tumor growth was seen initially in all treatment groups.</div><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0009.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compounds <b>33</b> and <b>59</b> were administered by oral gavage at the doses indicated, once daily for 10 days (gray arrowheads), and produced a significant reduction in tumor growth relative to the control group. This effect was statistically significant (<i>P</i> < 0.05) in all treatment groups at days 3, 6, and 9, and significant at the <i>P</i> < 0.0001 level at day 6 in all cases. Only <b>33</b> exerted a sustained effect beyond the dosing period (<i>P</i> < 0.01 at days 13 and 15). Detailed plots of tumor volume, body weight, and survival for each treatment group, including results with vinblastine as a comparator/control drug, are presented in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S15</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">An unexpected feature of the results is the apparent partial recovery in tumor volume before the end of the dosing period (comparing measurements between days 6 and 9), although numerical analysis revealed this difference is only statistically significant in the group receiving <b>59</b> at 10 mg/kg. There are a number of possible explanations for this observation, and particularly in the absence of accompanying pharmacokinetic data, any interpretation would be speculative at best. The FaDu cell line does overexpress BCRP/ABCG2,<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> so even though there is no reason to assume acquired resistance is developing to the current test compounds, the above results do emphasize the importance that the potential for new drugs to activate mechanisms of resistance be appropriately investigated at an early stage of development. On a more encouraging note, treatment with <b>33</b> appeared to result in poor tumor growth even after administration had ceased.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27338" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27338" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A library of modified indole-3-glyoxylamides has been reported, capable of inhibiting tubulin polymerization and displaying cancer cell cytotoxicity with a well-defined SAR. Furthemore, two compounds from the series displayed evidence for efficacy in a mouse xenograft model of HNC. This study builds on previous work by others which has already established a range of compounds of the indole-3-glyoxylamide class, such as <b>1</b> and <b>2</b>, as promising tubulin polymerization inhibitors. Other members of the class have been investigated preclinically,<a onclick="showRef(event, 'ref97 ref98 ref99'); return false;" href="javascript:void(0);" class="ref ref97 ref98 ref99">(97-99)</a> including <b>88</b>–<b>91</b> (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>) arising from an SAR study<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> published shortly after the disclosure of <b>1</b>, with both <b>90</b> and <b>91</b> reportedly demonstrating in vivo activity.</div><figure id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0010.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Some other indole-3-glyoxylamides with reported in vitro or in vivo antitumor activity. Note <b>88</b> is the indole analogue of <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Given the apparent failure of <b>2</b> in the clinic, and the difficulties encountered in attempting to develop <b>1</b>, we hypothesized as the basis of the present work that the physicochemical and PK properties of such compounds might be improved by removing the benzylic group at N1 common to existing compounds in the class and replacing it with aliphatic substituents. This current study details first steps in such a direction, establishing that compounds modified thus are capable of retaining potent activity, albeit with a subtly different but distinct SAR suggestive of changes in binding pose. The desired improvement in solubility as compared to <b>1</b> looks to have been realized successfully.</div><div class="NLM_p last">Although the reported library has been established as a workable hit series, further optimization of PK properties is evidently necessary, although the present results suggest this is achievable. A better-defined SAR, aspects of which remain unexplored, is ideally necessary to help inform this undertaking. A more detailed understanding of the compounds’ mode of action at the cellular level is also important, especially to interrogate and direct improvement of their selectivity for the desired target, tubulin. In the context of the MTA drug class, selectivity is a critical consideration given that a narrow therapeutic window remains arguably the most significant drawback of the existing agents in clinical use. Compounds with superior therapeutic window are urgently required, and evidence for such was probably the most appealing aspect of preclinical data for <b>1</b>. Efforts to assess and optimize the therapeutic window must therefore be a priority in the identification and development of potential new MTAs likely to be of clinical value, arising either from this series or elsewhere.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88407" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88407" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> General Procedures</h4><div class="NLM_p">Reactions were run under an inert atmosphere of N<sub>2</sub> unless stated otherwise. Anhydrous solvents were obtained from an in-house “Grubbs” system and stored under N<sub>2</sub> until use. All other solvents and reagents were obtained from commercial sources and used as supplied. NMR spectra were recorded at the frequencies listed, and <sup>13</sup>C NMR spectra were recorded with complete proton decoupling. <i>J</i> values are reported in Hz. Melting points were determined using a Gallenkamp melting point apparatus in capillary tubes and are uncorrected. Analytical HPLC was carried out using a C<sub>18</sub> 5 μm column (4.6 mm × 250 mm) and a gradient of 5–100% MeCN/water over 20 or 25 min (holding at 100% for 5 min), with UV detection at 254 nm and a flow rate 1.0 mL min<sup>–1</sup>. Purity of all screening compounds was determined to be >95% by HPLC; a tabulated list of purities is included in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Supporting Information</a>. Where required, preparative HPLC was performed using a C<sub>18</sub> 5 μm column (19 mm × 250 mm) with UV detection at 254 nm and a flow rate between 15–20 mL min<sup>–1</sup>, using a gradient specified in each case. Dynamic light scattering measurements were carried out using the Malvern Instruments Zetasizer Nano ZS system, equipped with a 4 mW He–Ne laser at 633 nm, as described.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> To our knowledge, the compound series presented here is free of obvious interference motifs (“PAINS”), and the presence of a well-defined SAR (with respect to both tubulin interaction and cytotoxicity) provides good evidence against nonspecific modes of action.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></div><div id="sec4_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23"> 2-Isopropoxyethyl 4-Methylbenzenesulfonate (Precursor to <b>4e</b>)</h5><div class="NLM_p last">2-Isopropoxyethanol (1.15 mL, 1.05 g, 10 mmol) and triethylamine (1.53 mL, 1.11 g, 11 mmol) were dissolved in anhydrous CH<sub>2</sub>Cl<sub>2</sub> and the solution cooled to 0 °C before addition of <i>p</i>-toluenesulfonyl chloride (2.10 g, 11 mmol). The mixture was stirred at 0 °C for 30 min then at rt overnight. The reaction was quenched by addition of satd NH<sub>4</sub>Cl then diluted with water and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 20 mL). The combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to give a colorless oil which was purified by flash chromatography on silica gel, eluted with 1:1 CH<sub>2</sub>Cl<sub>2</sub>/hexane → CH<sub>2</sub>Cl<sub>2</sub> → 1:4 EtOAc/CH<sub>2</sub>Cl<sub>2</sub>, affording the title compound as colorless oil (1.46 g, 57%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 7.78 (d, 2H, <i>J</i> = 8.0), 7.48 (d, 2H, <i>J</i> = 8.0), 4.08 (t, 2H, <i>J</i> = 4.5), 3.52–3.45 (m, 3H), 2.40 (s, 3H), 1.00 (d, 6H, <i>J</i> = 6.0). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 145.3, 133.8, 130.6, 128.1, 71.4, 70.9, 65.5, 22.3, 21.5. <i>m</i>/<i>z</i> (ES) 281 ([M + Na]<sup>+</sup>). HRMS, found 281.0817 (C<sub>12</sub>H<sub>18</sub>NaO<sub>4</sub>S requires 281.0824).</div></div><div id="sec4_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> 1-Methoxypropan-2-yl 4-Methylbenzenesulfonate (Precursor to <b>4g</b>)</h5><div class="NLM_p last">1-Methoxypropan-2-ol (4.9 mL, 4.5 g, 50 mmol) was dissolved in anhydrous THF (250 mL) then the solution cooled to 0 °C. Sodium hydride (60% dispersion in mineral oil, 2.3 g, 58 mmol) was added portionwise over 10 min, followed 5 min later by the addition of <i>p</i>-toluenesulfonyl chloride (11.0 g, 58 mmol) and DMAP (50 mg). After 30 min at 0 °C, the mixture was warmed to 40 °C and maintained at this temperature for 24 h. The reaction was quenched by addition of satd NH<sub>4</sub>Cl then the mixture evaporated under vacuum. The residue was partitioned between Et<sub>2</sub>O and water, the layers separated, and the aqueous phase extracted again with Et<sub>2</sub>O. The combined organic extracts were washed with water then brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated, yielding a thick, yellow oil. Purification by flash column chromatography on silica gel, eluted with 50 → 75 → 100% CH<sub>2</sub>Cl<sub>2</sub>/hexane then 1% MeOH/CH<sub>2</sub>Cl<sub>2</sub>, afforded the title compound as a yellow oil (7.3 g, 60%) which was stored at −20 °C until further use. δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 7.79 (d, 2H, <i>J</i> = 8.0), 7.47 (d, 2H, <i>J</i> = 8.0), 4.66 (ddd, 1H, <i>J</i> = 3.5, 6.0, 12.5), 3.37–3.27 (m, 2H), 3.13 (s, 3H), 2.42 (s, 3H), 1.14 (d, 3H, <i>J</i> = 6.0). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 145.1, 134.2, 130.4, 128.0, 78.8, 74.3, 58.7, 21.5, 17.4. <i>m</i>/<i>z</i> (ES) 245 ([M + H]<sup>+</sup>). HRMS, found 245.0845 (C<sub>11</sub>H<sub>17</sub>O<sub>4</sub>S requires 245.0848).</div></div><div id="sec4_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> Oxetan-2-ylmethyl 4-Methylbenzenesulfonate (precursor to <b>4o</b>)</h5><div class="NLM_p last">A stirred solution of oxetane-2-methanol (0.95 g, 10.8 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) was cooled to 0 °C then triethylamine (1.65 mL, 1.20 g, 11.8 mmol) and <i>p</i>-toluenesulfonyl chloride (2.26 g, 11.8 mmol) were added successively, followed by a small amount of DMAP. The mixture was maintained at 4 °C overnight then poured into water, extracted, and the layers separated. The aqueous layer was extracted with additional CH<sub>2</sub>Cl<sub>2</sub> then the combined organic solutions washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated, giving a pale-yellow oil. Flash column chromatography, eluted with 15 → 30 → 45% EtOAc/hexane, afforded the title compound as a crystalline white solid (2.11 g, 81%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 7.84 (d, 2H, <i>J</i> = 8.0), 7.37 (d, 2H, <i>J</i> = 8.0), 4.98–4.91 (m, 1H), 4.66–4.59 (m, 1H), 4.56–4.49 (m, 1H), 4.17 (d, 2H, <i>J</i> = 4.0), 2.78–2.67 (m, 1H), 2.64–2.53 (m, 1H), 2.47 (s, 3H). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 144.9, 132.9, 129.9, 128.0, 78.6, 72.0, 69.0, 23.4, 21.7. <i>m</i>/<i>z</i> (ES) 243 ([M + H]<sup>+</sup>). HRMS, found 243.0694 (C<sub>11</sub>H<sub>15</sub>O<sub>4</sub>S requires 243.0691); mp 55–58 °C (lit.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> 58–59 °C).</div></div></div><div id="sec4_1_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Typical Procedure for Synthesis of <i>N</i>-Alkyl Intermediates <b>4a</b>–<b>i</b>, <b>4o</b>, and <b>67a</b>–<b>o</b></h4><div class="NLM_p">Indole, or the relevant indole derivative, was dissolved in anhydrous DMF (or THF if specified) at a concentration between 0.25–0.5 M, then the solution cooled to 0 °C. Alkylating agent (1.2 equiv unless stated otherwise) was added, then sodium hydride (60% dispersion in mineral oil, 1.2 equiv) was added in small portions over a period of 10–15 min. Once addition was complete, the reaction mixture was stirred at 0 °C for 30 min then continued at rt (unless stated otherwise) for a duration specified in each case. The reaction was quenched by cautious, dropwise addition of water or satd NH<sub>4</sub>Cl, then evaporated to dryness. The residue was partitioned between EtOAc or Et<sub>2</sub>O and water and extracted, then the aqueous layer extracted with a second portion of organic solvent. The combined extracts were washed three times with water, once with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to afford the crude product which was purified by flash column chromatography on silica gel as indicated for each case, then dried and stored at −20 °C until further use.</div><div id="sec4_1_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> 1-Ethyl-1<i>H</i>-indole <b>4a</b></h5><div class="NLM_p last">Prepared from indole (1.17 g, 10 mmol) and bromoethane (1.35 mL, 1.97 g, 18 mmol), reacting overnight at 30 °C. Column eluent 5 → 10 → 20% CH<sub>2</sub>Cl<sub>2</sub>/hexane. Product obtained as a colorless oil (1.12 g, 77%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 7.55 (d, 1H, <i>J</i> = 8.0), 7.46 (dd, 1H, <i>J</i> = 0.5, 8.0), 7.38 (d, 1H, <i>J</i> = 3.0), 7.14 (dt, 1H, <i>J</i> = 1.0, 7.0), 7.02 (dt, 1H, <i>J</i> = 1.0, 7.0), 6.43 (dd, 1H, <i>J</i> = 0.5, 3.0), 4.19 (q, 2H, <i>J</i> = 7.0), 1.35 (t, 3H, <i>J</i> = 7.0). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 135.8, 128.6, 128.3, 121.4, 120.9, 119.2, 110.1, 100.9, 40.7, 15.9; <i>m</i>/<i>z</i> (ES) 146 ([M + H]<sup>+</sup>). HRMS, found 146.0970 (C<sub>10</sub>H<sub>12</sub>N requires 146.0970). HPLC purity 98.4%.</div></div><div id="sec4_1_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> 1-Isopropyl-1<i>H</i>-indole <b>4b</b></h5><div class="NLM_p last">Prepared from indole (2.93 g, 25 mmol) and 2-iodopropane (3.0 mL, 5.1 g, 30 mmol), reacting at rt for 90 min. Column eluent 5 → 10 → 20% CH<sub>2</sub>Cl<sub>2</sub>/hexane. Product obtained as a colorless oil (1.67 g, 42%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 7.55 (d, 1H, <i>J</i> = 7.5), 7.51–7.46 (m, 2H), 7.15–7.10 (m, 1H), 7.01 (t, 1H, <i>J</i> = 7.5), 6.45 (d, 1H, <i>J</i> = 3.0), 4.74 (septet, 1H, <i>J</i> = 6.5), 1.45 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 135.6, 128.6, 125.0, 121.3, 120.9, 119.3, 110.2, 101.2, 46.8, 23.0. <i>m</i>/<i>z</i> (ES) 160 ([M + H]<sup>+</sup>). HRMS, found 160.1120 (C<sub>11</sub>H<sub>14</sub>N requires 160.1126). HPLC purity 99.5%.</div></div><div id="sec4_1_1_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> 1-(2-Methoxyethyl)-1<i>H</i>-indole <b>4c</b></h5><div class="NLM_p last">Prepared from indole (2.34 g, 20 mmol) and 2-bromoethyl methyl ether (2.26 mL, 3.34 g, 24 mmol), reacting at rt for 30 min. Column eluent 20 → 30 → 40 → 60% CH<sub>2</sub>Cl<sub>2</sub>/hexane. Title compound is a viscous, pale-yellow oil (2.90 g, 83%). δ<sub>H</sub> (250 MHz, DMSO-<i>d</i><sub>6</sub>) 7.58–7.45 (m, 2H), 7.34 (d, 1H, <i>J</i> = 3.0), 7.17–7.09 (m, 1H), 7.06–6.98 (m, 1H), 6.42 (dd, 1H, <i>J</i> = 0.5, 3.0), 4.32 (t, 2H, <i>J</i> = 5.0), 3.64 (t, 2H, <i>J</i> = 5.0), 3.21 (s, 3H). δ<sub>C</sub> (62.8 MHz, DMSO-<i>d</i><sub>6</sub>) 136.4, 129.4, 128.6, 121.4, 120.8, 119.3, 110.3, 101.0, 71.5, 58.5, 45.8. <i>m</i>/<i>z</i> (ES) 176 ([M + H]<sup>+</sup>). HRMS, found 176.1077 (C<sub>11</sub>H<sub>14</sub>NO requires 176.1075). HPLC purity 99.4%.</div></div><div id="sec4_1_1_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 1-Butyl-1<i>H</i>-indole <b>4d</b></h5><div class="NLM_p last">Prepared from indole (1.17 g, 10 mmol) and 1-bromobutane (1.29 mL, 1.64 g, 12 mmol), reacting at rt for 30 min. Column eluent 5 → 10 → 20% CH<sub>2</sub>Cl<sub>2</sub>/hexane. Product obtained as a pale-yellow oil (1.43 g, 83%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 7.70 (dt, 1H, <i>J</i> = 1.0, 8.0), 7.42 (dd, 1H, <i>J</i> = 0.5, 8.0), 7.30–7.25 (m, 1H), 7.19–7.14 (m, 2H), 6.55 (dd, 1H, <i>J</i> = 0.5, 3.0), 4.18 (t, 2H, <i>J</i> = 7.0), 1.92–1.84 (m, 2H), 1.41 (sextet, 2H, <i>J</i> = 7.5), 1.03 (t, 3H, <i>J</i> = 7.5). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 136.0, 128.6, 127.8, 121.3, 121.0, 119.2, 109.4, 100.9, 46.2, 32.4, 20.2, 13.8. <i>m</i>/<i>z</i> (ES) 174 ([M + H]<sup>+</sup>). HRMS, found 174.1276 (C<sub>12</sub>H<sub>16</sub>N requires 174.1283). HPLC purity 99.9%.</div></div><div id="sec4_1_1_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> 1-(2-Isopropoxyethyl)-1<i>H</i>-indole <b>4e</b></h5><div class="NLM_p last">Prepared from indole (469 mg, 4 mmol) and 2-isopropoxyethyl-4-methylbenzenesulfonate (1.14 g, 4.4 mmol) in THF, reacting at rt overnight. Column eluent 50 → 60 → 100% toluene/hexane. Title compound obtained as a yellow oil (387 mg, 50%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 7.55 (d, 1H, <i>J</i> = 8.0), 7.49 (d, 1H, <i>J</i> = 8.0), 7.36 (d, 1H, <i>J</i> = 3.0), 7.12 (t, 1H, <i>J</i> = 8.0), 6.99 (t, 1H, <i>J</i> = 8.0), 6.42 (d, 1H, <i>J</i> = 3.0), 4.29 (t, 2H, <i>J</i> = 5.5), 3.68 (t, 2H, <i>J</i> = 5.5), 3.48 (septet, 1H, <i>J</i> = 6.0), 1.00 (d, 6H, <i>J</i> = 6.0). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 136.3, 129.5, 128.5, 121.3, 120.8, 119.3, 110.3, 100.8, 71.4, 66.9, 46.4, 22.4. <i>m</i>/<i>z</i> (ES) 204 ([M + H]<sup>+</sup>). HRMS, found 204.1385 (C<sub>13</sub>H<sub>18</sub>NO requires 204.1388).</div></div><div id="sec4_1_1_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 1-<i>sec</i>-Butyl-1<i>H</i>-indole <b>4f</b></h5><div class="NLM_p last">Prepared from indole (2.34 g, 20 mmol) and 2-iodobutane (2.76 mL, 4.42 g, 24 mmol), reacting at rt for 6 h. Column eluent 5 → 10 → 20% CH<sub>2</sub>Cl<sub>2</sub>/hexane. Product obtained as a thick, colorless oil (0.20 g, 6%). δ<sub>H</sub> (250 MHz, DMSO-<i>d</i><sub>6</sub>) 7.56–7.47 (m, 2H), 7.44 (d, 1H, <i>J</i> = 3.0), 7.14–7.06 (m, 1H), 7.03–6.95 (m, 1H), 6.46 (d, 1H, <i>J</i> = 3.0), 4.49 (sextet, 1H, <i>J</i> = 7.0), 1.92–1.72 (m, 2H), 1.43 (d, 3H, <i>J</i> = 7.0), 0.70 (t, 3H, <i>J</i> = 7.0). δ<sub>C</sub> (62.8 MHz, DMSO-<i>d</i><sub>6</sub>) 136.2, 128.4, 125.4, 121.2, 120.8, 119.2, 110.3, 101.3, 52.7, 29.9, 21.2, 11.1. <i>m</i>/<i>z</i> (ES) 174 ([M + H]<sup>+</sup>). HRMS, found 174.1275 (C<sub>12</sub>H<sub>16</sub>N requires 174.1283).</div></div><div id="sec4_1_1_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 1-(1-Methoxypropan-2-yl)-1<i>H</i>-indole <b>4g</b></h5><div class="NLM_p last">Prepared from indole (2.75 g, 23.5 mmol) and 1-methoxypropan-2-yl 4-methylbenzenesulfonate (6.0 mL, 6.9 g, 28 mmol), reacting at 55 °C overnight. Column eluent 40 → 50 → 67 → 100% toluene/hexane then 10% CH<sub>2</sub>Cl<sub>2</sub>/toluene. Title compound obtained as a pale-yellow oil (3.11 g, 70%). δ<sub>H</sub> (250 MHz, DMSO-<i>d</i><sub>6</sub>) 7.57–7.44 (m, 3H), 7.12 (dt, 1H, <i>J</i> = 1.5, 7.5), 7.05–6.97 (m, 1H), 6.45 (d, 1H, <i>J</i> = 3.0), 4.87–4.72 (m, 1H), 3.71–3.54 (m, 2H), 3.20 (s, 3H), 1.43 (d, 3H, <i>J</i> = 7.0). δ<sub>C</sub> (62.8 MHz, DMSO-<i>d</i><sub>6</sub>) 136.2, 128.5, 125.8, 121.3, 120.8, 119.4, 110.3, 101.4, 75.6, 58.8, 50.6, 18.0. <i>m</i>/<i>z</i> (ES) 190 ([M + H]<sup>+</sup>). HRMS, found 190.1224 (C<sub>12</sub>H<sub>16</sub>NO requires 190.1232). HPLC purity 99.4%.</div></div><div id="sec4_1_1_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 1-Isobutyl-1<i>H</i>-indole <b>4h</b></h5><div class="NLM_p last">Prepared from indole (2.34 g, 20 mmol) and 1-iodo-2-methylpropane (2.76 mL, 4.42 g, 24 mmol), reacting at rt for 1 h. Column eluent 5 → 10 → 20% CH<sub>2</sub>Cl<sub>2</sub>/light petroleum. Product obtained as a thick, colorless oil (0.54 g, 16%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 7.55 (d, 1H, <i>J</i> = 8.0), 7.46 (dd, 1H, <i>J</i> = 0.5, 8.0), 7.33 (d, 1H, <i>J</i> = 3.0), 7.14–7.09 (m, 1H), 7.03–6.98 (m, 1H), 6.43 (dd, 1H, <i>J</i> = 0.5, 3.0), 3.96 (d, 2H, <i>J</i> = 7.5), 2.17–2.05 (m, 1H), 0.84 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 136.4, 129.5, 128.5, 121.3, 120.8, 119.2, 110.4, 100.7, 53.3, 29.6, 20.4. <i>m</i>/<i>z</i> (ES) 174 ([M + H]<sup>+</sup>). HRMS, found 174.1275 (C<sub>12</sub>H<sub>16</sub>N requires 174.1283). HPLC purity 99.6%.</div></div><div id="sec4_1_1_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 1-((Tetrahydrofuran-2-yl)methyl)-1<i>H</i>-indole <b>4i</b></h5><div class="NLM_p last">Prepared from indole (2.34 g, 20 mmol) and tetrahydrofurfuryl bromide (2.70 mL, 3.96 g, 24 mmol), reacting at rt for 2 h. Column eluent 20 → 40 → 60 → 80% CH<sub>2</sub>Cl<sub>2</sub>/hexane. Product obtained as a pale-pink oil (1.33 g, 33%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 7.68 (d, 1H, <i>J</i> = 8.0), 7.42 (d, 1H, <i>J</i> = 8.0), 7.29–7.22 (m, 2H), 7.17–7.12 (m, 1H), 6.55 (d, 1H, <i>J</i> = 3.0), 4.33–4.19 (m, 3H), 3.91–3.85 (m, 1H), 3.82–3.76 (m, 1H), 2.03–1.94 (m, 1H), 1.92–1.73 (m, 2H), 1.66–1.56 (m, 1H). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 136.5, 128.7, 128.5, 121.5, 120.9, 119.3, 109.5, 101.4, 78.1, 68.3, 50.1, 29.1, 25.7. <i>m</i>/<i>z</i> (ES) 202 ([M + H]<sup>+</sup>). HRMS, found 202.1225 (C<sub>13</sub>H<sub>16</sub>NO requires 202.1232). HPLC purity 99.8%.</div></div><div id="sec4_1_1_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 1-(Oxetan-2-ylmethyl)-1<i>H</i>-indole <b>4o</b></h5><div class="NLM_p last">Indole (426 mg, 3.64 mmol) was dissolved in DMF (10 mL) and the solution cooled to 0 °C. Sodium hydride (60% dispersion in mineral oil, 160 mg, 4.00 mmol) was added in portions over 5 min, then after another 5 min stirring, oxetan-2-ylmethyl 4-methylbenzenesulfonate (0.97 g, 4.00 mmol) was added. The reaction was allowed to continue for 3 h, after which it was deemed essentially complete by TLC. It was quenched by dropwise addition of satd NH<sub>4</sub>Cl then extracted between EtOAc and water. The aqueous layer was extracted with further EtOAc then the combined organic extracts washed three times with water and once with brine. The solution was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated, giving an oil which was purified by flash column chromatography on silica gel, eluted with 10 → 20 → 33 → 45% EtOAc/hexane, to provide the title compound as a colorless oil (530 mg, 78%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 7.69 (dt, 1H, <i>J</i> = 1.0, 8.0), 7.41 (dd, 1H, <i>J</i> = 1.0, 8.0), 7.31–7.23 (m, 2H), 7.18–7.13 (m, 1H), 6.59 (dd, 1H, <i>J</i> = 1.0, 3.0), 5.23–5.15 (m, 1H), 4.67–4.59 (m, 1H), 4.42–4.32 (m, 3H), 2.72–2.62 (m, 1H), 2.42–2.32 (m, 1H). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 136.7, 128.8, 128.5, 121.6, 121.0, 119.4, 109.4, 101.7, 81.1, 68.5, 51.3, 24.6. <i>m</i>/<i>z</i> (ES) 188 ([M + H]<sup>+</sup>). HRMS, found 188.1084 (C<sub>12</sub>H<sub>14</sub>NO requires 188.1075). HPLC purity 99.0%.</div></div><div id="sec4_1_1_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 4-Chloro-1-isopropyl-1<i>H</i>-indole <b>67a</b></h5><div class="NLM_p last">Prepared from 4-chloroindole (3.03 g, 20 mmol) and 2-iodopropane (2.4 mL, 4.1 g, 24 mmol), reacting at rt overnight. Column eluent 5 → 10 → 20% CH<sub>2</sub>Cl<sub>2</sub>/hexane. Title compound obtained as a pale-yellow oil (2.04 g, 53%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 7.34–7.28 (m, 2H), 7.18–7.12 (m, 2H), 6.66 (d, 1H, <i>J</i> = 3.0), 4.69 (septet, 1H, <i>J</i> = 7.0), 1.56 (d, 6H, <i>J</i> = 7.0). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 136.3, 127.3, 126.2, 124.2, 121.8, 119.0, 108.2, 99.9, 47.6, 22.8. <i>m</i>/<i>z</i> (ES) 194 (100%; [M(<sup>35</sup>Cl) + H]<sup>+</sup>), 196 (30%; [M(<sup>37</sup>Cl) + H]<sup>+</sup>). HRMS, found 194.0741 (C<sub>11</sub>H<sub>13</sub>ClN requires 194.0737). HPLC purity 99.5%.</div></div><div id="sec4_1_1_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 5-Chloro-1-isopropyl-1<i>H</i>-indole <b>67b</b></h5><div class="NLM_p last">Prepared from 5-chloroindole (3.78 g, 25 mmol) and 2-iodopropane (3.0 mL, 5.1 g, 30 mmol), reacting at rt for 2 h. Column eluent 5 → 10 → 20% CH<sub>2</sub>Cl<sub>2</sub>/hexane. Title compound obtained as a viscous, colorless oil (2.46 g, 51%). δ<sub>H</sub> (250 MHz, DMSO-<i>d</i><sub>6</sub>) 7.58 (d, 1H, <i>J</i> = 2.0), 7.56–7.48 (m, 2H), 7.11 (dd, 1H, <i>J</i> = 2.0, 9.0), 6.44 (d, 1H, <i>J</i> = 3.0), 4.73 (septet, 1H, <i>J</i> = 6.5), 1.43 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (62.8 MHz, DMSO-<i>d</i><sub>6</sub>) 134.1, 129.7, 126.8, 124.0, 121.2, 120.0, 111.8, 101.1, 47.3, 22.9. <i>m</i>/<i>z</i> (ES) 194 (100%; [M(<sup>35</sup>Cl) + H]<sup>+</sup>), 196 (30%; [M(<sup>37</sup>Cl) + H]<sup>+</sup>). HRMS, found 194.0734 (C<sub>11</sub>H<sub>13</sub>ClN requires 194.0737). HPLC purity 99.4%.</div></div><div id="sec4_1_1_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 5-Chloro-1-(2-methoxyethyl)-1<i>H</i>-indole <b>67c</b></h5><div class="NLM_p last">Prepared from 5-chloroindole (1.32 g, 8.7 mmol) and 2-bromoethyl methyl ether (0.98 mL, 1.45 g, 10.5 mmol), reacting in THF at rt overnight. Column eluent 5 → 10 → 20% CH<sub>2</sub>Cl<sub>2</sub>/toluene. Product obtained as a colorless oil (1.07 g, 59%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 7.59 (d, 1H, <i>J</i> = 2.0), 7.52 (d, 1H, <i>J</i> = 9.0), 7.43 (d, 1H, <i>J</i> = 3.0), 7.12 (dd, 1H, <i>J</i> = 2.0, 9.0), 6.42 (dd, 1H, <i>J</i> = 0.5, 3.0), 4.33 (t, 2H, <i>J</i> = 5.5), 3.63 (t, 2H, <i>J</i> = 5.5), 3.20 (s, 3H). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 134.9, 131.2, 129.6, 124.1, 121.3, 119.9, 112.0, 100.8, 71.5, 58.5, 46.0. <i>m</i>/<i>z</i> (ES) 210 (100%; [M(<sup>35</sup>Cl) + H]<sup>+</sup>), 212 (25%; [M(<sup>37</sup>Cl) + H]<sup>+</sup>). HRMS, found 210.0694 (C<sub>11</sub>H<sub>13</sub>ClNO requires 210.0686). HPLC purity 99.4%.</div></div><div id="sec4_1_1_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 6-Chloro-1-isopropyl-1<i>H</i>-indole <b>67d</b></h5><div class="NLM_p last">Prepared from 6-chloroindole (3.03 g, 20 mmol) and 2-iodopropane (2.4 mL, 4.1 g, 24 mmol), reacting at rt for 48 h. Column eluent 5 → 10 → 20% CH<sub>2</sub>Cl<sub>2</sub>/hexane. Product obtained as a colorless oil (1.88 g, 49%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 7.56 (d, 1H, <i>J</i> = 8.5), 7.42–7.40 (m, 1H), 7.25 (d, 1H, <i>J</i> = 3.5), 7.10 (dd, 1H, <i>J</i> = 2.0, 8.5), 6.53 (dd, 1H, <i>J</i> = 0.5, 3.5), 4.63 (septet, 1H, <i>J</i> = 6.5), 1.56 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 135.9, 127.3, 127.1, 124.3, 121.8, 120.0, 109.5, 101.4, 47.3, 22.7. <i>m</i>/<i>z</i> (ES) 194 (100%; [M(<sup>35</sup>Cl) + H]<sup>+</sup>), 196 (35%; [M(<sup>37</sup>Cl) + H]<sup>+</sup>). HRMS, found 194.0730 (C<sub>11</sub>H<sub>13</sub>ClN requires 194.0737). HPLC purity 98.7%.</div></div><div id="sec4_1_1_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 7-Chloro-1-isopropyl-1<i>H</i>-indole <b>67e</b></h5><div class="NLM_p last">Prepared from 7-chloroindole (1.52 g, 10 mmol) and 2-iodopropane (1.2 mL, 2.0 g, 12 mmol), reacting at rt overnight. Column eluent 0 → 1→2.5 → 5→10% CH<sub>2</sub>Cl<sub>2</sub>/hexane. Product obtained as a colorless oil (0.50 g, 26%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 7.55 (dd, 1H, <i>J</i> = 1.0, 8.0), 7.34 (d, 1H, <i>J</i> = 3.5), 7.19 (dd, 1H, <i>J</i> = 1.0, 8.0), 7.02 (t, 1H, <i>J</i> = 8.0), 6.58 (d, 1H, <i>J</i> = 3.5), 5.75 (septet, 1H, <i>J</i> = 6.5), 1.56 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 131.8, 131.1, 124.9, 123.6, 119.9, 119.7, 116.5, 102.2, 47.9, 23.9. <i>m</i>/<i>z</i> (ES) 194 (100%; [M(<sup>35</sup>Cl) + H]<sup>+</sup>), 196 (35%; [M(<sup>37</sup>Cl) + H]<sup>+</sup>). HRMS, found 194.0731 (C<sub>11</sub>H<sub>13</sub>ClN requires 194.0737). HPLC purity 99.1%.</div></div><div id="sec4_1_1_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 4-Methoxy-1-isopropyl-1<i>H</i>-indole <b>67f</b></h5><div class="NLM_p last">Prepared from 4-methoxyindole (1.25 g, 8.5 mmol) and 2-iodopropane (1.02 mL, 1.73 g, 10.2 mmol), reacting at rt overnight. Column eluent 10 → 20 → 30 → 35% CH<sub>2</sub>Cl<sub>2</sub>/hexane. Title compound obtained as a slightly opaque, colorless oil (0.61 g, 38%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 7.24–7.16 (m, 2H), 7.06 (d, 1H, <i>J</i> = 8.5), 6.68 (d, 1H, <i>J</i> = 3.0), 6.57 (d, 1H, <i>J</i> = 7.5), 4.69 (septet, 1H, <i>J</i> = 6.5), 4.01 (s, 3H), 1.56 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 153.5, 137.0, 122.1, 122.0, 119.1, 103.1, 99.1, 98.4, 55.3, 47.3, 22.8. <i>m</i>/<i>z</i> (ES) 190 ([M + H]<sup>+</sup>). HRMS, found 190.1235 (C<sub>12</sub>H<sub>16</sub>NO requires 190.1232). HPLC purity 88.7%.</div></div><div id="sec4_1_1_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> 5-Methoxy-1-isopropyl-1<i>H</i>-indole <b>67g</b></h5><div class="NLM_p last">Prepared from 5-methoxyindole (1.55 g, 10.5 mmol) and 2-iodopropane (1.26 mL, 2.14 g, 12.6 mmol), reacting at rt overnight. Column eluent 10 → 20 → 25 → 33 → 40% CH<sub>2</sub>Cl<sub>2</sub>/hexane. Product initially obtained as an oil which crystallized on standing to an off-white solid (0.72 g, 36%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 7.31 (d, 1H, <i>J</i> = 9.0), 7.24 (d, 1H, <i>J</i> = 3.0), 7.14 (d, 1H, <i>J</i> = 2.5), 6.92 (dd, 1H, <i>J</i> = 2.5, 9.0), 6.48 (d, 1H, <i>J</i> = 3.0), 4.66 (septet, 1H, <i>J</i> = 7.0), 3.89 (s, 3H), 1.55 (d, 6H, <i>J</i> = 7.0). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 153.9, 130.9, 128.9, 124.1, 111.6, 110.2, 102.6, 100.7, 55.9, 47.2, 22.8. <i>m</i>/<i>z</i> (ES) 190 ([M + H]<sup>+</sup>). HRMS, found 190.1240 (C<sub>12</sub>H<sub>16</sub>NO requires 190.1232). HPLC purity 96.6%; mp 65–66 °C.</div></div><div id="sec4_1_1_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 5-Methoxy-1-(2-methoxyethyl)-1<i>H</i>-indole <b>67h</b></h5><div class="NLM_p last">Prepared from 5-methoxyindole (1.47 g, 10 mmol) and 2-bromoethyl methyl ether (1.13 mL, 1.67 g, 12 mmol), reacting in THF at 35 °C overnight. Column eluent 5 → 10 → 17.5 → 20% EtOAc/hexane. Title compound obtained as a pale-yellow oil (1.36 g, 66%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 7.37 (d, 1H, <i>J</i> = 9.0), 7.29 (d, 1H, <i>J</i> = 3.0), 7.05 (d, 1H, <i>J</i> = 2.5), 6.77 (dd, 1H, <i>J</i> = 2.5, 9.0), 6.33 (dd, 1H, <i>J</i> = 0.5, 3.0), 4.28 (t, 2H, <i>J</i> = 5.5), 3.75 (s, 3H), 3.62 (t, 2H, <i>J</i> = 5.5), 3.21 (s, 3H). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 153.9, 131.6, 129.9, 128.9, 111.5, 111.0, 102.5, 100.6, 71.6, 58.5, 55.8, 45.9. <i>m</i>/<i>z</i> (ES) 206 ([M + H]<sup>+</sup>). HRMS, found 206.1188 (C<sub>12</sub>H<sub>16</sub>NO<sub>2</sub> requires 206.1181). HPLC purity 99.3%.</div></div><div id="sec4_1_1_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> 6-Methoxy-1-isopropyl-1<i>H</i>-indole <b>67i</b></h5><div class="NLM_p last">Prepared from 6-methoxyindole (1.55 g, 10.5 mmol) and 2-iodopropane (1.26 mL, 2.14 g, 12.6 mmol), reacting at 35 °C overnight. Column eluent 20 → 30 → 40% CH<sub>2</sub>Cl<sub>2</sub>/hexane. Product obtained as a pale-yellow oil (0.72 g, 36%) which crystallized slowly on storage at −20 °C. δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 7.54 (d, 1H, <i>J</i> = 8.5), 7.16 (d, 1H, <i>J</i> = 3.0), 6.88 (d, 1H, <i>J</i> = 2.0), 6.82 (dd, 1H, <i>J</i> = 2.0, 8.5), 6.49 (d, 1H, <i>J</i> = 3.0), 4.63 (septet, 1H, <i>J</i> = 6.5), 3.92 (s, 3H), 3.28 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 156.0, 136.2, 122.9, 122.4, 121.5, 109.1, 101.1, 93.4, 55.8, 46.9, 22.7. <i>m</i>/<i>z</i> (ES) 190 ([M + H]<sup>+</sup>). HRMS, found 190.1237 (C<sub>12</sub>H<sub>16</sub>NO requires 190.1232). HPLC purity 98.2%. mp 30–31 °C.</div></div><div id="sec4_1_1_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> 7-Methoxy-1-isopropyl-1<i>H</i>-indole <b>67j</b></h5><div class="NLM_p last">Prepared from 7-methoxyindole (1.63 mL, 1.84 g, 12.5 mmol) and 2-iodopropane (1.5 mL, 2.6 g, 15 mmol), reacting at rt overnight. Column eluent 2.5 → 5→10% EtOAc/hexane. Title compound obtained as a slightly opaque, colorless oil (0.92 g, 39%) which crystallized slowly on storage at −20 °C. δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 7.31–7.25 (m, 2H), 7.05 (t, 1H, <i>J</i> = 8.0), 6.69 (d, 1H, <i>J</i> = 8.0), 6.54 (d, 1H, <i>J</i> = 3.0), 5.51 (septet, 1H, <i>J</i> = 6.5), 4.00 (s, 3H), 1.54 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 147.7, 130.7, 125.5, 123.7, 119.5, 113.8, 102.4, 101.6, 55.4, 48.9, 24.0. <i>m</i>/<i>z</i> (ES) 190 ([M + H]<sup>+</sup>). HRMS, found 190.1236 (C<sub>12</sub>H<sub>16</sub>NO requires 190.1232). HPLC purity 94.8%. mp 36–38 °C.</div></div><div id="sec4_1_1_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> 1-Isopropyl-1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridine <b>67k</b></h5><div class="NLM_p last">Prepared from 4-azaindole (1.18 g, 10 mmol) and 2-iodopropane (1.20 mL, 2.04 g, 12 mmol), reacting at rt for 90 min. Column eluent 2.5 → 5→7.5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>. Product obtained as a pale-pink oil (0.56 g, 35%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 8.47 (dd, 1H, <i>J</i> = 1.0, 4.5), 7.67 (dt, 1H, <i>J</i> = 1.0, 8.5), 7.46 (d, 1H, <i>J</i> = 3.5), 7.11 (dd, 1H, <i>J</i> = 4.5, 8.5), 6.73 (d, 1H, <i>J</i> = 3.5), 4.66 (septet, 1H, <i>J</i> = 6.5), 1.55 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 147.0, 143.1, 128.4, 127.0, 116.5, 116.0, 102.3, 47.6, 22.7. <i>m</i>/<i>z</i> (ES) 161 ([M + H]<sup>+</sup>). HRMS, found 161.1072 (C<sub>10</sub>H<sub>13</sub>N<sub>2</sub> requires 161.1079). HPLC purity 98.0%.</div></div><div id="sec4_1_1_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> 1-Isopropyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridine <b>67l</b></h5><div class="NLM_p last">Prepared from 5-azaindole (2.95 g, 25 mmol) and 2-iodopropane (3.0 mL, 5.1 g, 30 mmol), reacting at rt for 2 h. Column eluent 0 → 5→10 → 12.5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>. Product obtained as a pale-orange oil (1.78 g, 44%) which crystallized on standing to give an off-white solid. δ<sub>H</sub> (250 MHz, DMSO-<i>d</i><sub>6</sub>) 8.81 (d, 1H, <i>J</i> = 1.0), 8.18 (d, 1H, <i>J</i> = 6.0), 7.59 (d, 1H, <i>J</i> = 3.0), 7.51 (d, 1H, <i>J</i> = 6.0), 6.62–6.59 (m, 1H), 4.77 (septet, 1H, <i>J</i> = 6.5), 1.44 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (62.8 MHz, DMSO-<i>d</i><sub>6</sub>) 143.7, 140.3, 138.9, 126.6, 125.5, 105.8, 100.9, 47.4, 22.8. <i>m</i>/<i>z</i> (ES) 161 ([M + H]<sup>+</sup>). HRMS, found 161.1077 (C<sub>10</sub>H<sub>13</sub>N<sub>2</sub> requires 161.1079). HPLC purity 99.7%. mp 71–72 °C.</div></div><div id="sec4_1_1_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> 1-Isopropyl-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine <b>67m</b></h5><div class="NLM_p last">Prepared from 6-azaindole (2.95 g, 25 mmol) and 2-iodopropane (3.0 mL, 5.1 g, 30 mmol), reacting at rt for 75 min. Column eluent 0 → 5→10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>. Title compound obtained as a yellow oil (1.88 g, 47%) which crystallized slowly, forming a waxy, off-white solid on storage at −20 °C. δ<sub>H</sub> (250 MHz, DMSO-<i>d</i><sub>6</sub>) 8.92 (s, 1H), 8.11 (d, 1H, <i>J</i> = 5.5), 7.72 (s, 1H, <i>J</i> = 3.0), 7.51 (dd, 1H, <i>J</i> = 1.0, 5.0), 6.50 (dd, 1H, <i>J</i> = 1.0, 3.0), 4.89 (septet, 1H, <i>J</i> = 6.5), 1.48 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (62.8 MHz, DMSO-<i>d</i><sub>6</sub>) 138.3, 133.7, 132.85, 132.78, 129.1, 115.3, 100.6, 47.8, 23.1. <i>m</i>/<i>z</i> (ES) 161 ([M + H]<sup>+</sup>). HRMS, found 161.1083 (C<sub>10</sub>H<sub>13</sub>N<sub>2</sub> requires 161.1079). HPLC purity 99.5%. mp 35–36 °C.</div></div><div id="sec4_1_1_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> 1-Isopropyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>67n</b></h5><div class="NLM_p last">Prepared from 7-azaindole (2.95 g, 25 mmol) and 2-iodopropane (3.0 mL, 5.1 g, 30 mmol), reacting at rt for 2.5 h. Column eluent 33 → 50 → 67 → 100% CH<sub>2</sub>Cl<sub>2</sub>/hexane then 1 → 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>. Title compound obtained as a slightly cloudy, colorless oil (2.20 g, 55%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 8.24 (dd, 1H, <i>J</i> = 1.5, 4.5), 7.94 (dd, 1H, <i>J</i> = 1.5, 8.0), 7.66 (d, 1H, <i>J</i> = 3.5), 7.07 (dd, 1H, <i>J</i> = 4.5, 8.0), 6.48 (d, 1H, <i>J</i> = 3.5), 5.10 Hz (septet, 1H, <i>J</i> = 7.0), 1.46 (d, 6H, <i>J</i> = 7.0). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 146.9, 142.5, 128.8, 126.0, 120.6, 116.0, 99.6, 45.5, 22.9. <i>m</i>/<i>z</i> (ES) 161 ([M + H]<sup>+</sup>). HRMS, found 161.1077 (C<sub>10</sub>H<sub>13</sub>N<sub>2</sub> requires 161.1079). HPLC purity 89.6%.</div></div><div id="sec4_1_1_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> 1-(2-Methoxyethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine <b>67o</b></h5><div class="NLM_p last">Prepared from 7-azaindole (1.18 g, 10 mmol) and 2-bromoethyl methyl ether (1.13 mL, 1.67 g, 12 mmol), reacting at rt for 5 h. Column eluent 0 → 1→2 → 4→5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>. Product obtained as a pale-yellow oil (1.16 g, 66%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 8.33 (dd, 1H, <i>J</i> = 1.5, 4.5), 7.92 (dd, 1H, <i>J</i> = 1.5, 8.0), 7.35 (d, 1H, <i>J</i> = 3.0), 7.07 (dd, 1H, <i>J</i> = 4.5, 8.0), 6.47 (d, 1H, <i>J</i> = 3.0), 4.50 (t, 2H, <i>J</i> = 5.0), 3.77 (t, 2H, <i>J</i> = 5.0), 3.35 (s, 3H). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 147.4, 142.6, 129.0, 128.7, 120.7, 115.7, 99.3, 71.7, 58.9, 44.3. <i>m</i>/<i>z</i> (ES) 177 ([M + H]<sup>+</sup>). HRMS, found 177.1023 (C<sub>10</sub>H<sub>13</sub>N<sub>2</sub>O requires 177.1028). HPLC purity 98.2%.</div></div></div><div id="sec4_1_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 1-Cyclopentyl-1<i>H</i>-indole <b>4k</b></h4><div class="NLM_p last">Indole (2.57 g, 21.9 mmol), DMAP (7.70 g, 65.7 mmol), cyclopentylboronic acid (5.00 g, 43.9 mmol), and Cu(OAc)<sub>2</sub> (0.40 g, 2.2 mmol) were added to a flame-dried, 3-neck flask equipped with a reflux condenser. Anhydrous toluene (40 mL) was introduced via cannula, then sodium hexamethyldisilazane (0.6 M solution in toluene, 36.5 mL, 21.9 mmol) was added to the resultant deep-blue suspension. A stream of dry air was introduced, bubbling through the reaction mixture, which was then heated to 95 °C and maintained at this temperature overnight. EtOAc (100 mL) and 1 M HCl (200 mL) were added and the mixture shaken thoroughly then vacuum filtered. The layers were separated and the aqueous phase extracted once more with EtOAc. The combined extracts were then dried over MgSO<sub>4</sub>, filtered, and evaporated, leaving a thick-brown oil, which was purified by flash column chromatography on silica gel, eluted with 5 → 10 → 15% CH<sub>2</sub>Cl<sub>2</sub>/light petroleum, yielding the title compound as a pale-yellow oil (1.37 g, 34%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 7.56–7.48 (m, 2H), 7.44 (d, 1H, <i>J</i> = 3.0), 7.15–7.10 (m, 1H), 7.05–6.99 (m, 1H), 6.44 (d, 1H, <i>J</i> = 3.0), 4.87 (quintet, 1H, <i>J</i> = 7.0), 2.18–2.08 (m, 2H), 1.90–1.78 (m, 4H), 1.77–1.65 (m, 2H). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 136.3, 128.7, 125.7, 121.3, 120.8, 119.4, 110.5, 101.2, 56.6, 32.6, 24.1. <i>m</i>/<i>z</i> (ES) 186 ([M + H]<sup>+</sup>). HRMS, found 186.1274 (C<sub>11</sub>H<sub>16</sub>N requires 186.1283). HPLC purity 98.8%.</div></div><div id="sec4_1_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 1-(1<i>H</i>-Indol-1-yl)-2-methylpropan-2-ol <b>69</b></h4><div class="NLM_p last">A solution of indole (2.81 g, 24 mmol) in anhydrous DMF (90 mL) was cooled to 0 °C, then sodium hydride (60% dispersion in mineral oil, 0.96 g, 24 mmol) added in small portions over 15 min. After a further 10 min stirring at 0 °C, isobutene oxide (533 μL, 433 mg, 6 mmol) was added dropwise and stirring continued for an additional 50 min, at which point the cooling was removed. The reaction mixture was stirred at rt for 5.5 h at rt then 4 h at 30 °C, followed by addition of more isobutene oxide (89 μL, 72 mg, 1 mmol), after which stirring was continued at 30 °C overnight. The reaction was quenched by dropwise addition of brine, then evaporated under vacuum. The resultant orange slurry was partitioned between Et<sub>2</sub>O and water (∼100 mL each). AcOH (0.2 mL) was added, then the mixture extracted and the layers separated. The aqueous phase was extracted again with Et<sub>2</sub>O and the combined extracts washed three times with brine, dried over MgSO<sub>4</sub>, filtered, and evaporated. Further purification was carried out by flash column chromatography on silica gel, eluted with 0 → 1→2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>, affording the title compound as a pale-pink oil (0.98 g, 74%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 7.55–7.50 (m, 2H), 7.33 (d, 1H, <i>J</i> = 3.0), 7.12–7.07 (m, 1H), 6.98 (dt, 1H, <i>J</i> = 1.0, 7.5), 6.42 (dd, 1H, <i>J</i> = 0.5, 3.0), 4.66 (s, 1H), 4.07 (s, 2H), 1.09 (s, 6H). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 137.3, 130.6, 128.1, 121.1, 120.5, 119.0, 111.1, 100.6, 70.9, 56.6, 27.9. <i>m</i>/<i>z</i> (ES) 190 ([M + H]<sup>+</sup>). HRMS, found 190.1237 (C<sub>12</sub>H<sub>16</sub>NO requires 190.1232). HPLC purity 99.4%.</div></div><div id="sec4_1_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 1-(2-Methoxy-2-methylpropyl)-1<i>H</i>-indole <b>4k</b></h4><div class="NLM_p last">Alcohol <b>69</b> (874 mg, 4.62 mmol) was dissolved in anhydrous THF (100 mL) at 0 °C, then sodium hydride (60% dispersion in mineral oil, 231 mg, 5.77 mmol) added in portions over 5 min. Methyl iodide (359 μL, 819 mg, 5.77 mmol) was introduced 10 min later, then the reaction mixture stirred at 0 °C for 4.5 h then rt for 4.5 h. TLC analysis (3:1 CH<sub>2</sub>Cl<sub>2</sub>/hexane) indicated reaction was incomplete, so additional methyl iodide (72 μL, 165 mg, 1.16 mmol) was added and stirring continued at 35 °C overnight. The reaction was then quenched by dropwise addition of satd NH<sub>4</sub>Cl, evaporated to dryness and the residue extracted between EtOAc and water. The aqueous phase was extracted again with EtOAc, and the combined organic extracts washed with satd NH<sub>4</sub>Cl, dried over MgSO<sub>4</sub>, filtered, and evaporated. The oily residue was purified by flash column chromatography on silica gel, eluted with 10 → 20 → 33 → 50% CH<sub>2</sub>Cl<sub>2</sub>/hexane, giving the title compound as a viscous, pale-yellow oil (492 mg, 52%). δ<sub>H</sub> (250 MHz, DMSO-<i>d</i><sub>6</sub>) 7.56–7.49 (m, 2H), 7.27 (d, 1H, <i>J</i> = 3.0), 7.11 (dt, 1H, <i>J</i> = 1.0, 7.0), 6.99 (dt, 1H, <i>J</i> = 1.0, 7.0), 6.43 (dd, 1H, <i>J</i> = 1.0, 3.0), 4.15 (s, 2H), 3.16 (s, 3H), 1.07 (s, 6H). δ<sub>C</sub> (62.8 MHz, DMSO-<i>d</i><sub>6</sub>) 137.4, 130.4, 128.1, 121.3, 120.6, 119.1, 111.0, 100.9, 75.9, 53.9, 49.5, 22.8. <i>m</i>/<i>z</i> (ES) 204 ([M + H]<sup>+</sup>). HRMS, found 204.1384 (C<sub>13</sub>H<sub>18</sub>NO requires 204.1388). HPLC purity 99.3%.</div></div><div id="sec4_1_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Ethyl 2-(1<i>H</i>-Indol-1-yl)propanoate <b>70</b></h4><div class="NLM_p last">Indole (5.86 g, 50 mmol) was dissolved in anhydrous DMF (175 mL) and the solution cooled to 0 °C, after which sodium hydride (60% dispersion in mineral oil, 2.20 g, 55 mmol) was added portionwise over 15 min. Stirring was continued for a further 15 min, then ethyl 2-bromopropionate (7.14 mL, 9.96 g, 55 mmol) was added. The reaction was then maintained at 40 °C for 5 h and continued at rt overnight before being quenched by careful, dropwise addition of water. The mixture was evaporated under vacuum and the residue extracted with Et<sub>2</sub>O and water. The aqueous layer was extracted a second time with Et<sub>2</sub>O then the combined extracts washed twice with water and twice with brine before drying over Na<sub>2</sub>SO<sub>4</sub> and evaporating to leave an orange oil. This crude material was subjected to flash column chromatography on silica gel, eluted with 20 → 33 → 50 → 65% CH<sub>2</sub>Cl<sub>2</sub>/hexane, to provide the title compound as a somewhat cloudy, pale-yellow oil (8.03 g, 74%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 7.56 (d, 1H, <i>J</i> = 8.0), 7.47 (d, 1H, <i>J</i> = 3.0), 7.43 (d, 1H, <i>J</i> = 8.0), 7.16–7.11 (m, 1H), 7.07–7.02 (m, 1H), 6.50 (dd, 1H, <i>J</i> = 0.5, 3.0), 5.46 (q, 1H, <i>J</i> = 7.5), 4.12 (q, 2H, <i>J</i> = 7.0), 1.73 (d, 3H, <i>J</i> = 7.5), 1.15 (t, 3H, <i>J</i> = 7.0). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 171.6, 136.3, 128.6, 126.9, 121.7, 120.9, 119.8, 110.2, 102.1, 61.5, 53.5, 17.7, 14.5. <i>m</i>/<i>z</i> (ES) 218 ([M + H]<sup>+</sup>). HRMS, found 218.1189 (C<sub>13</sub>H<sub>16</sub>NO<sub>2</sub> requires 218.1181). HPLC purity 98.1%.</div></div><div id="sec4_1_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Ethyl 2-(1<i>H</i>-Indol-1-yl)-2-methylpropanoate <b>71</b></h4><div class="NLM_p last">A solution of intermediate <b>70</b> (7.93 g, 36.5 mmol) in dry THF (100 mL) was cooled to −78 °C, then LDA (2.0 M solution in THF, 22 mL, 44 mmol) was added over 10 min. The mixture was stirred at −78 °C for 45 min, at which point methyl iodide (3.77 mL, 8.60 g, 60.6 mmol) was added, then the reaction continued and allowed to warm slowly to rt overnight before being quenched by dropwise addition of satd NH<sub>4</sub>Cl then EtOH (∼5 mL each). After an additional 30 min stirring, the mixture was evaporated under vacuum and the residue extracted with Et<sub>2</sub>O and water. The aqueous layer was extracted again with Et<sub>2</sub>O and the combined organic solutions washed twice with brine, dried over MgSO<sub>4</sub>, filtered, and evaporated to give a viscous orange oil. Additional purification by flash column chromatography on silica gel, eluted with 20 → 30 → 40 → 50 → 60% CH<sub>2</sub>Cl<sub>2</sub>/hexane, gave the title compound as a pale-yellow oil which crystallized on standing to a greasy, off-white solid (7.22 g, 86%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 7.58 (dt, 1H, <i>J</i> = 1.0, 8.0), 7.52 (d, 1H, <i>J</i> = 3.5), 7.13–7.09 (m, 2H), 7.07–7.00 (m, 1H), 6.47 (d, 1H, <i>J</i> = 3.5), 4.12 (q, 2H, <i>J</i> = 7.0), 1.81 (s, 6H), 1.06 (t, 3H, <i>J</i> = 7.0). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 173.7, 135.1, 129.8, 126.0, 121.6, 121.3, 119.7, 111.4, 101.2, 61.8, 60.9, 25.9, 14.3. <i>m</i>/<i>z</i> (ES) 232 ([M + H]<sup>+</sup>). HRMS, found 232.1332 (C<sub>14</sub>H<sub>18</sub>NO<sub>2</sub> requires 232.1338). HPLC purity 97.9%.</div></div><div id="sec4_1_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 2-(1<i>H</i>-Indol-1-yl)-2-methylpropan-1-ol <b>72</b></h4><div class="NLM_p last">A solution of ester <b>71</b> (7.12 g, 30.8 mmol) in anhydrous THF (85 mL) was added over 15 min to a suspension of LiAlH<sub>4</sub> (1.28 g, 33.9 mmol) in the same solvent (40 mL) at −78 °C (some exotherm observed over the addition period). The reaction temperature was brought back down to −78 °C then stirring continued overnight, allowing for gradual warming to rt. The mixture was cooled to −78 °C once more then quenched by very cautious, dropwise addition of satd NH<sub>4</sub>Cl, after which it was allowed to warm slowly to rt once more. The solvent was removed by evaporation under vacuum, then the residue extracted with Et<sub>2</sub>O and water. The mixture was filtered under vacuum to remove suspended solids, then the layers separated and the aqueous phase extracted with more Et<sub>2</sub>O. The combined organic extracts were washed with water then brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. Purification by flash column chromatography on silica gel, eluted with 0 → 1→2 → 3% MeOH/CH<sub>2</sub>Cl<sub>2</sub>, afforded the title compound as a yellow oil which slowly crystallized on standing to a pale-yellow solid (4.56 g, 78%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 7.69–7.64 (m, 1H), 7.56–7.51 (m, 1H), 7.43 (d, 1H, <i>J</i> = 3.5), 7.10–7.05 (m, 1H), 7.02–6.97 (m, 1H), 6.38 (dd, 1H, <i>J</i> = 1.0, 3.5), 5.08 (t, 1H, <i>J</i> = 4.5), 3.82 (d, 2H, <i>J</i> = 4.5), 1.62 (s, 6H), δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 135.1, 130.3, 127.6, 121.0, 120.7, 118.9, 113.7, 100.1, 67.6, 60.1, 25.2, <i>m</i>/<i>z</i> (ES) 190 ([M + H]<sup>+</sup>), HRMS, found 190.1232 (C<sub>12</sub>H<sub>16</sub>NO requires 190.1232), HPLC purity 99.3%, mp 68–71 °C.</div></div><div id="sec4_1_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 1-(1-Methoxy-2-methylpropan-2-yl)-1<i>H</i>-indole <b>4l</b></h4><div class="NLM_p last">Sodium hydride (60% dispersion in mineral oil, 248 mg, 6.2 mmol) was added in portions over 5 min to a solution of alcohol <b>72</b> (1.01 g, 4.97 mmol) in anhydrous THF (50 mL) at 0 °C. After 5 min more, methyl iodide (467 μL, 1.06 g, 7.5 mmol) was added. The mixture was stirred at 0 °C for 30 min then rt for 3 h and quenched by dropwise addition of satd NH<sub>4</sub>Cl. The mixture was evaporated under vacuum, extracted with Et<sub>2</sub>O and water, the aqueous phase re-extracted with Et<sub>2</sub>O, and the combined extracts dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. Flash column chromatography on silica gel, eluted with 20 → 30 → 40% CH<sub>2</sub>Cl<sub>2</sub>/hexane, provided the title compound as a colorless oil (856 mg, 79%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 7.71–7.68 (m, 1H), 7.54 (d, 1H, <i>J</i> = 8.0), 7.37 (d, 1H, <i>J</i> = 3.5), 7.11–7.06 (m, 1H), 7.03–6.98 (m, 1H), 6.39 (dd, 1H, <i>J</i> = 0.5, 3.5), 3.75 (s, 2H), 3.18 (s, 3H), 1.65 (s, 6H). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 135.0, 130.2, 127.5, 121.1, 120.9, 119.1, 113.6, 100.4, 78.2, 59.00, 58.97, 25.5. <i>m</i>/<i>z</i> (ES) 204 ([M + H]<sup>+</sup>). HRMS, found 204.1381 (C<sub>13</sub>H<sub>18</sub>NO requires 204.1388). HPLC purity 99.6%.</div></div><div id="sec4_1_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Ethyl 2-(2-(1<i>H</i>-Indol-1-yl)-2-methylpropoxy)acetate <b>4m</b></h4><div class="NLM_p last">Ethyl bromoacetate (665 μL, 1.00 g, 6.0 mmol) and alcohol <b>72</b> (945 mg, 5.0 mmol) were dissolved in dry DMF, then sodium hydride (60% dispersion in mineral oil, 0.24 g, 6.0 mmol) was added slowly, in small portions, over 40 min. After stirring overnight at rt, additional ethyl bromoacetate (277 μL, 417 mg, 2.5 mmol) was added, followed by sodium hydride (60% dispersion in mineral oil, 100 mg, 2.5 mmol) over 30 min. The mixture was stirred at rt for a further 2 h then quenched by dropwise addition of satd NH<sub>4</sub>Cl and evaporated under vacuum. The residue was extracted with EtOAc and satd NH<sub>4</sub>Cl (100 mL each), then the aqueous layer extracted three more times with EtOAc. The combined organic extracts were then washed twice with water, then brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. Flash column chromatography on silica gel was carried out, eluted with 20 → 33 → 50% CH<sub>2</sub>Cl<sub>2</sub>/toluene, affording the title compound as an orange gum (400 mg, 29%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 7.65 (t, 2H, <i>J</i> = 8.5), 7.42 (d, 1H, <i>J</i> = 3.0), 7.21–7.15 (m, 1H), 7.15–7.09 (m, 1H), 6.51 (d, 1H, <i>J</i> = 3.0), 4.19 (q, 2H, <i>J</i> = 7.0), 3.99 (s, 2H), 3.95 (s, 2H), 1.82 (s, 6H), 1.27 (t, 3H, <i>J</i> = 7.0). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 168.6, 133.0, 128.4, 124.4, 119.4, 118.9, 117.1, 111.1, 98.7, 66.6, 59.0, 56.9, 23.4, 12.3. <i>m</i>/<i>z</i> (ES) 276 ([M + H]<sup>+</sup>). HRMS, found 276.1610 (C<sub>16</sub>H<sub>22</sub>NO<sub>3</sub> requires 276.1600. HPLC purity 92.0%. Additional material from mixed column fractions was further purified by preparative HPLC, using a gradient of 40–70% MeCN/water, to give an additional portion of the title compound as a thick, orange–brown oil (40 mg, 3%; combined yield 440 mg, 32%).</div></div><div id="sec4_1_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Methyl 3-(1<i>H</i>-Indol-1-yl)propanoate <b>4n</b></h4><div class="NLM_p last">Methyl acrylate (1.35 mL, 1.29 g, 15 mmol) and DBU (772 μL, 5 mmol) were added to a solution of indole (1.17 g, 10 mmol) in anhydrous MeCN (50 mL). The mixture was heated at 50 °C for 6 h, rt for 48 h, then 50 °C for 6 h and evaporated to dryness. EtOAc and water (50 mL) each were added, and after the residue had fully dissolved, the aqueous layer was adjusted to pH 6 with 1 M HCl and the mixture extracted. The aqueous layer was extracted with additional EtOAc (3 × 30 mL), then the combined organic solutions washed twice with water, then brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. Flash column chromatography on silica gel, eluted with 50 → 67 → 100% toluene/hexane, yielded the title compound as an oil (865 mg, 43%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 7.66 (dt, 1H, <i>J</i> = 1.0, 8.0), 7.38 (dd, 1H, <i>J</i> = 0.5, 8.5), 7.32–7.12 (m, 3H), 4.49 (t, 2H, <i>J</i> = 7.0), 3.70 (s, 3H), 2.86 (t, 2H, <i>J</i> = 7.0). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 171.7, 135.6, 128.7, 128.0, 121.7, 121.1, 119.5, 109.1, 101.6, 52.0, 41.9, 34.8. <i>m</i>/<i>z</i> (ES) 204 ([M + H]<sup>+</sup>). HRMS, found 204.1033 (C<sub>12</sub>H<sub>14</sub>NO<sub>2</sub> requires 204.1025). HPLC purity 97.8%.</div></div><div id="sec4_1_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 2-Isopropoxy-5-nitropyridine <b>74</b></h4><div class="NLM_p last">Sodium hydride (60% dispersion in mineral oil, 2.40 g, 60 mmol) was added in portions to anhydrous propan-2-ol (150 mL), then stirring of the suspension continued for 30 min. 2-Chloro-5-nitropyridine (9.51 g, 60 mmol) was then added and the reaction allowed to continue for 1 h before quenching by cautious, dropwise addition of water. The mixture was then evaporated under vacuum and the residue purified by flash column chromatography on silica gel, eluted with 1:19 EtOAc/hexane, affording the title compound as pale-yellow crystals (8.6 g, 64%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 9.25 (d, 1H, <i>J</i> = 3.0), 8.45 (dd, 1H, <i>J</i> = 3.0, 9.0), 6.96 (d, 1H, <i>J</i> = 9.0), 5.37 (septet, 1H, <i>J</i> = 6.0), 1.34 (d, 6H, <i>J</i> = 6.0). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 166.7, 145.2, 139.5, 135.1, 112.2, 70.6, 22.0. <i>m</i>/<i>z</i> (ES) 183 ([M + H]<sup>+</sup>). HRMS, found 183.0762 (C<sub>8</sub>H<sub>11</sub>N<sub>2</sub>O<sub>3</sub> requires 183.0770). mp 47–50 °C.</div></div><div id="sec4_1_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 2-<i>tert</i>-Butoxy-5-nitropyridine <b>75</b></h4><div class="NLM_p last">2-Chloro-5-nitropyridine (2.38 g, 15 mmol) and <i>tert</i>-butanol (3.6 mL, 45 mmol) were dissolved in dry DMF (20 mL), then sodium hydride (60% dispersion in mineral oil, 0.72 g, 18 mmol) added slowly in small portions. During the addition, the reaction mixture was cooled in ice to control the observed exotherm. After addition was complete, stirring was continued at rt for 4 h, then water added dropwise to quench the reaction. The mixture was evaporated under vacuum and the residue purified by flash column chromatography on silica gel, eluted with 2 → 4→6 → 10% EtOAc/hexane, to give the title compound as a dark-brown oil (1.34 g, 46%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 9.06 (d, 1H, <i>J</i> = 3.0), 8.30 (dd, 1H, <i>J</i> = 3.0, 9.0), 6.71 (d, 1H, <i>J</i> = 9.0), 1.65 (s, 9H). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 167.3, 144.3, 138.6, 133.4, 113.0, 82.8, 28.4. <i>m</i>/<i>z</i> (GC-MS, EI) 196 (M<sup>+</sup>). HRMS, found 196.0838 (C<sub>9</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub> requires 196.0842). HPLC purity 91.9%.</div></div><div id="sec4_1_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Ethyl 2-(5-Nitropyridin-2-yloxy)acetate <b>76</b></h4><div class="NLM_p last">Sodium hydride (60% dispersion in mineral oil, 0.80 g, 20 mmol) was added in small portions, slowly over 1.75 h, to a solution of 2-chloro-5-nitropyridine (3.18 g, 20 mmol) and ethyl glycolate (1.58 mL, 1.73 g, 16.6 mmol) in anhydrous THF (100 mL). After stirring at rt for 2 h more, the reaction was carefully quenched by dropwise addition of water, then the mixture evaporated under vacuum. The residue was partitioned between EtOAc and water, the layers separated, and the aqueous phase extracted with additional EtOAc. The combined extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated, then the residue purified by flash column chromatography on silica gel, eluted with 5 → 10 → 15 → 20% EtOAc/hexane, to provide the title compound as a pale-yellow solid (2.96 g, 65%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 9.05 (d, 1H, <i>J</i> = 3.0), 8.43 (dd, 1H, <i>J</i> = 3.0, 9.0), 7.01 (d, 1H, <i>J</i> = 9.0), 5.01 (s, 2H), 4.27 (q, 2H, <i>J</i> = 7.0), 1.31 (t, 3H, <i>J</i> = 7.0). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 168.1, 165.7, 144.4, 134.4, 111.4, 63.5, 61.5, 14.1. <i>m</i>/<i>z</i> (ES) 227 ([M + H]<sup>+</sup>). HRMS, found 227.0675 (C<sub>9</sub>H<sub>11</sub>N<sub>2</sub>O<sub>5</sub> requires 227.0668). HPLC purity 99.2%. mp 51–52 °C.</div></div><div id="sec4_1_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Hydrogenation of Nitro-compounds <b>74</b>–<b>76</b> to Amines <b>77</b>–<b>79</b>: General Procedure</h4><div class="NLM_p">A 0.1 M solution of the nitro-compound in MeOH was hydrogenated over 10% Pd/C, using a ThalesNano H-Cube reactor in full H<sub>2</sub> mode at a flow rate of 0.5 mL min<sup>–1</sup>. Evaporation of the solvent and further drying under vacuum gave the amine products, which were used without further purification.</div><div id="sec4_1_1_43" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> 6-Isopropoxypyridin-3-amine <b>77</b></h5><div class="NLM_p last">Hydrogenation of <b>74</b> (767 mg, 4.2 mmol) gave the title compound as a peach-colored oil (397 mg, 62%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 7.49 (d, 1H, <i>J</i> = 3.0), 6.97 (dd, 1H, <i>J</i> = 3.0, 9.0), 6.46 (d, 1H, <i>J</i> = 9.0), 4.71 (septet, 1H, <i>J</i> = 6.0), 1.21 (d, 6H, <i>J</i> = 6.0). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 166.7, 145.2, 139.5, 135.1, 112.2, 70.6, 20.1. <i>m</i>/<i>z</i> (ES) 153 ([M + H]<sup>+</sup>). HRMS, found 153.1022 (C<sub>8</sub>H<sub>13</sub>N<sub>2</sub>O<sub>3</sub> requires 153.1028).</div></div><div id="sec4_1_1_44" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> 6-<i>tert</i>-Butoxypyridin-3-amine <b>78</b></h5><div class="NLM_p last">Hydrogenation of <b>75</b> (640 mg, 3.86 mmol) gave the title compound as a brown solid (475 mg, 88%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 7.70 (d, 1H, <i>J</i> = 3.0), 6.99 (dd, 1H, <i>J</i> = 3.0, 9.0), 6.58 (d, 1H, <i>J</i> = 9.0), 3.27 (br s, 2H), 1.49 (s, 9H). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 156.9, 137.2, 133.5, 126.5, 115.0, 78.9, 28.9. <i>m</i>/<i>z</i> (ES) 167 ([M + H]<sup>+</sup>). HRMS, found 167.1188 (C<sub>9</sub>H<sub>15</sub>N<sub>2</sub>O requires 167.1184). HPLC purity 90.4%. mp 77–78 °C (decomp).</div></div><div id="sec4_1_1_45" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> Ethyl 2-(5-Aminopyridin-2-yloxy)acetate <b>79</b></h5><div class="NLM_p last">Hydrogenation of <b>76</b> (1.46 g, 6.46 mmol) provided the title compound as an off-white solid (1.21 g, 95%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 7.42 (dd, 1H, <i>J</i> = 0.5, 3.0), 7.03 (dd, 1H, <i>J</i> = 3.0, 8.5), 6.63 (dd, 1H, <i>J</i> = 0.5, 8.5), 4.80 (s, 2H), 4.73 (s, 2H), 4.11 (q, 2H, <i>J</i> = 7.0), 1.17 (t, 2H, <i>J</i> = 7.0). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 169.9, 154.4, 140.5, 131.0, 126.9, 110.6, 62.2, 60.6, 14.5. <i>m</i>/<i>z</i> (ES) 197 ([M + H]<sup>+</sup>). HRMS, found 197.0930 (C<sub>9</sub>H<sub>13</sub>N<sub>2</sub>O<sub>3</sub> requires 197.0926). HPLC purity 98.9%. mp 101–104 °C.</div></div></div><div id="sec4_1_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> One-Pot Synthesis of Indole-3-glyoxylamide Derivatives <b>5</b>–<b>35</b>, <b>56</b>–<b>60</b>, <b>62</b>, and <b>64</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>a): General Procedure</h4><div class="NLM_p last">The appropriate starting indole <b>4a</b>–<b>o</b> (1.5 mmol) was dissolved in anhydrous THF (15 mL), then oxalyl chloride (144 μL, 209 mg, 1.65 mmol) was added. The solution was stirred at rt for 3 h, then DIPEA (610 μL, 452 mg, 3.5 mmol) added followed by the requisite amine (R<sup>2</sup>-NH<sub>2</sub>, 1.8 mmol) and DMAP (catalytic amount). The suspension was stirred at rt overnight then evaporated to dryness. The residue was extracted with EtOAc and water, then the organic layer evaporated once more to provide the crude product which was purified as specified in each case. Unless stated otherwise, purification was achieved by two successive recrystallizations: first from EtOAc/hexane, then from propan-2-ol/water. Characterization data, HPLC purity, and any additional purification details are provided for each example in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec4_1_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Synthesis of Indole-3-glyoxylate Methyl Esters <b>68a</b>–<b>j</b> from Indoles <b>67a</b>–<b>j</b>: General Procedure</h4><div class="NLM_p">The relevant indole compound <b>67a</b>–<b>j</b> was dissolved in anhydrous CH<sub>2</sub>Cl<sub>2</sub> at a concentration of 0.1 M, then the solution was cooled to 0 °C. AlCl<sub>3</sub> (typically 1.25 equiv) and methyl chlorooxoacetate (typically 1.25 equiv) were added and the reaction continued at 0 °C until acceptable conversion was seen as judged by TLC (reaction duration specified below for each case). Methanol was added to quench the reaction, then the mixture poured into satd NaHCO<sub>3</sub> and extracted thoroughly. If an emulsion resulted, the entire mixture was filtered under vacuum and the filtrate returned to the separating funnel. The organic layer was collected and the aqueous phase extracted with additional CH<sub>2</sub>Cl<sub>2</sub>. The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated. Further purification was carried out by flash column chromatography on silica gel, using an eluent indicated in each case, to afford the desired product <b>68a</b>–<b>j</b>.</div><div id="sec4_1_1_48" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> Methyl 2-(4-Chloro-1-isopropyl-1<i>H</i>-indol-3-yl)-2-oxoacetate <b>68a</b></h5><div class="NLM_p last">Prepared from <b>67a</b> (520 μL, 581 mg, 3.0 mmol), AlCl<sub>3</sub> (600 mg, 4.5 mmol), and methyl chlorooxoacetate (414 μL, 551 mg, 4.5 mmol). Reaction duration 1 h. Column eluent 20 → 33 → 50% EtOAc/hexane. Title compound obtained as a yellow gum (280 mg, 33%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 8.28 (s, 1H), 7.38–7.21 (m, 3H), 4.71 (septet, 1H, <i>J</i> = 6.5), 3.96 (s, 3H), 1.60 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 178.4, 164.5, 138.3, 135.7, 127.5, 124.5, 124.2, 113.6, 109.0, 52.7, 48.6, 22.4. <i>m</i>/<i>z</i> (ES) 280 (100%; [M(<sup>35</sup>Cl) + H]<sup>+</sup>), 282 (30%; [M(<sup>37</sup>Cl) + H]<sup>+</sup>). HRMS, found 280.0731 (C<sub>14</sub>H<sub>15</sub>ClNO<sub>3</sub> requires 280.0740). HPLC purity 98.6%.</div></div><div id="sec4_1_1_49" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> Methyl 2-(5-Chloro-1-(2-methoxyethyl)-1<i>H</i>-indol-3-yl)-2-oxoacetate <b>68c</b></h5><div class="NLM_p last">Prepared from <b>67c</b> (285 mg, 1.36 mmol), AlCl<sub>3</sub> (227 mg, 1.70 mmol), and methyl chlorooxoacetate (156 μL, 208 mg, 1.70 mmol). Reaction duration 1 h. Column eluent 20 → 33 → 50 → 67% EtOAc/hexane. Title compound obtained as a greasy, yellow solid (111 mg, 28%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 8.45 (s, 1H), 8.44 (dd, 1H, <i>J</i> = 0.5, 2.0), 7.35–7.28 (m, 2H), 4.33 (t, 2H, <i>J</i> = 5.0), 3.97 (s, 3H), 3.76 (t, 2H, <i>J</i> = 5.0), 3.34 (s, 3H). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 176.9, 163.0, 141.0, 135.2, 129.6, 128.2, 124.5, 122.4, 112.6, 111.2, 70.6, 59.2, 52.8, 47.5. <i>m</i>/<i>z</i> (ES) 296 (100%; [M(<sup>35</sup>Cl) + H]<sup>+</sup>), 298 (35%; [M(<sup>37</sup>Cl) + H]<sup>+</sup>). HRMS, found 296.0694 (C<sub>14</sub>H<sub>15</sub>ClNO<sub>4</sub> requires 296.0690). HPLC purity 95.9%. mp 88–90 °C.</div></div><div id="sec4_1_1_50" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> Methyl 2-(6-Chloro-1-isopropyl-1<i>H</i>-indol-3-yl)-2-oxoacetate <b>68d</b></h5><div class="NLM_p last">Prepared using <b>67d</b> (347 μL, 387 mg, 2.0 mmol), AlCl<sub>3</sub> (667 mg, 5.0 mmol), and methyl chlorooxoacetate (460 μL, 613 mg, 5.0 mmol). Reaction duration 100 min (at rt). Column eluent 20 → 30 → 40% EtOAc/hexane. Title compound obtained as a crystalline yellow solid (142 mg, 25%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 8.49 (s, 1H), 8.38 (d, 1H, <i>J</i> = 8.5), 7.44 (s, 1H), 7.33 (d, 1H, <i>J</i> = 8.5), 4.66 (septet, 1H, <i>J</i> = 6.5), 3.98 (s, 3H), 1.64 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 176.7, 163.2, 136.9, 136.4, 130.0, 125.8, 124.1, 123.9, 113.1, 110.5, 52.8, 48.7, 22.5. <i>m</i>/<i>z</i> (ES) 280 (100%; [M(<sup>35</sup>Cl) + H]<sup>+</sup>), 282 (35%; [M(<sup>37</sup>Cl) + H]<sup>+</sup>). HRMS, found 280.0742 (C<sub>14</sub>H<sub>15</sub>ClNO<sub>3</sub> requires 280.0740). HPLC purity 99.7%. mp 94–95 °C.</div></div><div id="sec4_1_1_51" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> Methyl 2-(7-Chloro-1-isopropyl-1<i>H</i>-indol-3-yl)-2-oxoacetate <b>68e</b></h5><div class="NLM_p last">Prepared using <b>67e</b> (441 mg, 2.28 mmol), AlCl<sub>3</sub> (380 mg, 2.85 mmol), and methyl chlorooxoacetate (262 μL, 349 mg, 2.85 mmol). Reaction duration 1 h. Column eluent 15 → 33 → 50 → 67% CH<sub>2</sub>Cl<sub>2</sub>/hexane then 20 → 33% EtOAc/hexane. Title compound obtained as a waxy yellow solid (195 mg, 31%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 8.60 (s, 1H), 8.45 (dd, 1H, <i>J</i> = 1.0, 8.0), 7.32 (dd, 1H, <i>J</i> = 1.0, 8.0), 7.25 (t, 1H, <i>J</i> = 8.0), 5.73 (septet, 1H, <i>J</i> = 6.5), 3.98 (s, 3H), 1.64 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 176.7, 163.2, 137.0, 132.1, 130.2, 126.4, 124.1, 121.6, 117.2, 113.1, 52.8, 49.6, 23.8. <i>m</i>/<i>z</i> (ES) 280 (100%; [M(<sup>35</sup>Cl) + H]<sup>+</sup>), 282 (30%; [M(<sup>37</sup>Cl) + H]<sup>+</sup>). HRMS, found 280.0734 (C<sub>14</sub>H<sub>15</sub>ClNO<sub>3</sub> requires 280.0740). HPLC purity 99.2%; mp 62 °C.</div></div><div id="sec4_1_1_52" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> Methyl 2-(1-Isopropyl-4-methoxy-1<i>H</i>-indol-3-yl)-2-oxoacetate <b>68f</b></h5><div class="NLM_p last">Prepared using <b>67f</b> (405 mg, 2.14 mmol), AlCl<sub>3</sub> (428 mg, 3.21 mmol), and methyl chlorooxoacetate (295 μL, 393 mg, 3.21 mmol). Reaction duration 80 min. Column eluent 10 → 20 → 33 → 50% EtOAc/pentanes. Title compound obtained as a bright-yellow gum (120 mg, 20%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 8.13 (s, 1H), 7.26 (t, 1H, <i>J</i> = 8.0), 7.07 (d, 1H, <i>J</i> = 8.0), 6.72 (d, 1H, <i>J</i> = 8.0), 4.68 (septet, 1H, <i>J</i> = 6.5), 3.95 (s, 3H), 3.94 (s, 3H), 1.59 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 182.0, 165.6, 154.1, 138.3, 132.6, 124.4, 115.9, 113.5, 103.8, 103.4, 55.6, 52.3, 48.5, 22.6. <i>m</i>/<i>z</i> (ES) 276 ([M + H]<sup>+</sup>). HRMS, found 276.1232 (C<sub>15</sub>H<sub>18</sub>NO<sub>4</sub> requires 276.1236). HPLC purity 98.1%.</div></div><div id="sec4_1_1_53" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> Methyl 2-(1-Isopropyl-5-methoxy-1<i>H</i>-indol-3-yl)-2-oxoacetate <b>68g</b></h5><div class="NLM_p last">Prepared using <b>67g</b> (315 mg, 1.66 mmol), AlCl<sub>3</sub> (277 mg, 2.08 mmol), and methyl chlorooxoacetate (191 μL, 255 mg, 2.08 mmol). Reaction duration 50 min. Column eluent 10 → 20 → 30 → 40% EtOAc/hexane. Title compound obtained as a thick, orange oil (146 mg, 32%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 8.43 (s, 1H), 7.98 (d, 1H, <i>J</i> = 2.5), 7.33 (d, 1H, <i>J</i> = 9.0), 6.98 (dd, 1H, <i>J</i> = 2.5, 9.0), 4.67 (septet, 1H, <i>J</i> = 6.5), 3.97 (s, 3H), 3.93 (s, 3H), 1.61 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 176.8, 163.6, 157.1, 135.7, 131.2, 128.3, 114.2, 112.8, 111.1, 104.3, 55.8, 52.7, 48.7, 22.6. <i>m</i>/<i>z</i> (ES) 276 ([M + H]<sup>+</sup>). HRMS, found 276.1226 (C<sub>15</sub>H<sub>18</sub>NO<sub>4</sub> requires 276.1236). HPLC purity 92.1%.</div></div><div id="sec4_1_1_54" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> Methyl 2-(5-Methoxy-1-(2-methoxyethyl)-1<i>H</i>-indol-3-yl)-2-oxoacetate <b>68h</b></h5><div class="NLM_p last">Prepared using <b>67h</b> (308 mg, 1.50 mmol), AlCl<sub>3</sub> (251 mg, 1.88 mmol), and methyl chlorooxoacetate (173 μL, 230 mg, 1.88 mmol). Reaction duration 40 min. Column eluent 20 → 40 → 60 → 80% EtOAc/hexane. Title compound obtained as a viscous, bright-yellow oil (134 mg, 31%) which crystallized on storage at −20 °C, giving a yellow solid. δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 8.38 (s, 1H), 7.97 (d, 1H, <i>J</i> = 2.5), 7.30 (d, 1H, <i>J</i> = 9.0), 6.98 (dd, 1H, <i>J</i> = 2.5, 9.0), 4.32 (t, 2H, <i>J</i> = 5.0), 3.97 (s, 3H), 3.93 (s, 3H), 3.76 (t, 2H, <i>J</i> = 5.0), 3.34 (s, 3H). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 177.1, 163.5, 157.1, 140.1, 131.6, 128.2, 114.3, 112.9, 110.9, 104.3, 70.6, 59.1, 55.8, 52.7, 47.5. <i>m</i>/<i>z</i> (ES) 292 ([M + H]<sup>+</sup>). HRMS, found 292.1186 (C<sub>15</sub>H<sub>18</sub>ClNO<sub>5</sub> requires 292.1185). HPLC purity 97.8%. mp 80–82 °C.</div></div><div id="sec4_1_1_55" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> Methyl 2-(1-Isopropyl-6-methoxy-1<i>H</i>-indol-3-yl)-2-oxoacetate <b>68i</b></h5><div class="NLM_p last">Prepared using <b>67i</b> (348 mg, 1.84 mmol), AlCl<sub>3</sub> (307 mg, 2.30 mmol), and methyl chlorooxoacetate (212 μL, 282 mg, 2.30 mmol). Reaction duration 70 min. Column eluent 15 → 30 → 40% EtOAc/hexane. Title compound obtained as a thick, yellow oil (175 mg, 35%) which crystallized on storage at −20 °C to give a yellow solid. δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 8.40 (s, 1H), 8.34 (d, 1H, <i>J</i> = 8.5), 7.00 (dd, 1H, <i>J</i> = 2.0, 8.5), 6.89 (d, 1H, <i>J</i> = 2.0), 4.64 (septet, 1H, <i>J</i> = 6.5), 3.96 (s, 3H), 3.90 (s, 3H), 1.62 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 176.7, 163.5, 157.6, 137.4, 135.3, 123.6, 121.2, 113.2, 112.2, 94.6, 55.8, 52.6, 48.3, 22.4. <i>m</i>/<i>z</i> (ES) 276 ([M + H]<sup>+</sup>). HRMS, found 276.1243 (C<sub>15</sub>H<sub>18</sub>NO<sub>4</sub> requires 276.1236). HPLC purity 95.9%. mp 91 °C.</div></div><div id="sec4_1_1_56" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> Methyl 2-(1-Isopropyl-7-methoxy-1<i>H</i>-indol-3-yl)-2-oxoacetate <b>68j</b></h5><div class="NLM_p last">Prepared using <b>67j</b> (379 mg, 2.0 mmol), AlCl<sub>3</sub> (333 mg, 2.5 mmol), and methyl chlorooxoacetate (230 μL, 306 mg, 2.5 mmol). Reaction duration 1 h. Column eluent 5 → 10 → 20 → 30% EtOAc/pentanes. Title compound obtained as a viscous orange oil (150 mg, 27%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 8.46 (s, 1H), 8.09 (dd, 1H, <i>J</i> = 1.0, 8.0), 7.26 (t, 1H, <i>J</i> = 8.0), 6.82–6.79 (m, 1H), 5.46 (septet, 1H, <i>J</i> = 6.5), 3.98 (s, 3H), 3.97 (s, 3H), 1.58 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 176.8, 163.6, 147.5, 135.8, 129.5, 126.2, 124.2, 115.3, 113.1, 105.4, 55.5, 52.7, 50.7, 23.6. <i>m</i>/<i>z</i> (ES) 276 ([M + H]<sup>+</sup>). HRMS, found 276.1232 (C<sub>15</sub>H<sub>18</sub>NO<sub>4</sub> requires 276.1236). HPLC purity 80.2%.</div></div></div><div id="sec4_1_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> Synthesis of Azaindole-3-glyoxylate Methyl Esters <b>68k</b>–<b>o</b> from Azaindoles <b>67k</b>–<b>o</b>: General Procedure</h4><div class="NLM_p">The relevant azaindole compound <b>67k</b>–<b>o</b> was dissolved in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (30 mL/mmol), then AlCl<sub>3</sub> (5 equiv) was added and the suspension stirred for 1 h. Methyl chlorooxoacetate (5 equiv) was added and reaction continued for the duration specified in each case. Methanol was added to quench the reaction, then the mixture was evaporated to dryness under vacuum. Further purification was carried out by flash column chromatography on silica gel, using an eluent indicated in each case, to afford the desired product <b>68k</b>–<b>o</b>.</div><div id="sec4_1_1_58" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> Methyl 2-(1-Isopropyl-1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-3-yl)-2-oxoacetate <b>68k</b></h5><div class="NLM_p last">Prepared from <b>67k</b> (365 mg, 2.28 mmol), AlCl<sub>3</sub> (1.52 g, 11.4 mmol), and methyl chlorooxoacetate (1.05 mL, 1.40 mg, 11.4 mmol). Reaction duration 4.5 h. In this case, after quenching with MeOH, extraction between EtOAc and water was carried out and the organic layer collected and evaporated. Column eluent 2.5 → 5→10% MeOH/CHCl<sub>3</sub>. Product obtained as a golden brown gum (40 mg, 7%). Given the poor recovery in this case, it is suspected the majority of material was either retained by the column or decomposed on silica. δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 8.71 (dd, 1H, <i>J</i> = 1.5, 4.5), 8.57 (s, 1H), 7.75 (dd, 1H, <i>J</i> = 1.5, 8.5), 7.24 (dd, 1H, <i>J</i> = 4.5, 8.5), 4.71 (septet, 1H, <i>J</i> = 6.5), 3.97 (s, 3H), 1.62 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 177.4, 164.1, 146.6, 144.9, 136.7, 129.4, 118.2, 117.9, 112.6, 52.8, 49.1, 22.4. <i>m</i>/<i>z</i> (ES) 247 ([M + H]<sup>+</sup>). HRMS, found 247.1082 (C<sub>13</sub>H<sub>15</sub>N<sub>2</sub>O<sub>3</sub> requires 247.1083). HPLC purity 95.8%.</div></div><div id="sec4_1_1_59" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> Methyl 2-(1-Isopropyl-1<i>H</i>-pyrrolo[3,2-<i>c</i>]pyridin-3-yl)-2-oxoacetate <b>68l</b></h5><div class="NLM_p last">Prepared from <b>67l</b> (320 mg, 2.0 mmol), AlCl<sub>3</sub> (1.33 g, 10 mmol), and methyl chlorooxoacetate (0.92 mL, 1.23 mg, 10 mmol). Reaction duration 2 h. Column eluent 0 → 2→4 → 6→8% MeOH/CH<sub>2</sub>Cl<sub>2</sub>. Product obtained as a waxy, off-white solid (191 mg, 39%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 9.66 (d, 1H, <i>J</i> = 1.0), 8.54 (s, 1H), 8.51 (d, 1H, <i>J</i> = 6.0), 7.36 (dd, 1H, <i>J</i> = 1.0, 6.0), 4.73 (septet, 1H, <i>J</i> = 7.0), 3.99 (s, 3H), 1.65 (d, 6H, <i>J</i> = 7.0). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 176.6, 162.8, 145.9, 143.3, 140.4, 136.5, 123.6, 113.2, 105.5, 52.9, 48.9, 22.5. <i>m</i>/<i>z</i> (ES) 247 ([M + H]<sup>+</sup>). HRMS, found 247.1081 (C<sub>13</sub>H<sub>15</sub>N<sub>2</sub>O<sub>3</sub> requires 247.1083). HPLC purity 94.1%.</div></div><div id="sec4_1_1_60" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> Methyl 2-(1-Isopropyl-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridin-3-yl)-2-oxoacetate <b>68m</b></h5><div class="NLM_p last">Prepared from <b>67m</b> (320 mg, 2.0 mmol), AlCl<sub>3</sub> (1.33 g, 10 mmol), and methyl chlorooxoacetate (0.92 mL, 1.23 mg, 10 mmol). Reaction duration 2 h. Column eluent 0 → 1→2 → 4→6% MeOH/CH<sub>2</sub>Cl<sub>2</sub>. Product obtained as a waxy, off-white solid (263 mg, 53%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 9.14 (d, 1H, <i>J</i> = 1.0), 8.71 (s, 1H), 8.42 (d, 1H, <i>J</i> = 5.5), 8.07 (dd, 1H, <i>J</i> = 1.0, 5.5), 5.04 (septet, 1H, <i>J</i> = 6.5), 3.92 (s, 3H), 1.58 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 178.7, 163.8, 142.7, 140.0, 135.2, 133.5, 131.8, 116.0, 111.7, 53.2, 49.8, 22.6. <i>m</i>/<i>z</i> (ES) 247 ([M + H]<sup>+</sup>). HRMS, found 247.1074 (C<sub>13</sub>H<sub>15</sub>N<sub>2</sub>O<sub>3</sub> requires 247.1083). HPLC purity 97.4%.</div></div><div id="sec4_1_1_61" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> Methyl 2-(1-Isopropyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-2-oxoacetate <b>68n</b></h5><div class="NLM_p last">Prepared from <b>67n</b> (320 mg, 2.0 mmol), AlCl<sub>3</sub> (1.33 g, 10 mmol), and methyl chlorooxoacetate (0.92 mL, 1.23 mg, 10 mmol). Reaction duration 2.5 h. Column eluent 67 → 100% CH<sub>2</sub>Cl<sub>2</sub>/hexane then 0.5 → 1→2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>. Product obtained as a waxy, off-white solid (421 mg, 86%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 8.73 (s, 1H), 8.49 (dd, 1H, <i>J</i> = 1.5, 8.0), 8.45 (dd, 1H, <i>J</i> = 1.5, 4.5), 7.39 (dd, 1H, <i>J</i> = 4.5, 8.0), 5.15 (septet, 1H, <i>J</i> = 7.0), 3.92 (s, 3H), 1.56 (d, 6H, <i>J</i> = 7.0). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 178.8, 163.8, 147.9, 145.3, 138.2, 130.4, 119.9, 119.1, 110.6, 53.2, 47.7, 22.4. <i>m</i>/<i>z</i> (ES) 247 ([M + H]<sup>+</sup>). HRMS, found 247.1089 (C<sub>13</sub>H<sub>15</sub>N<sub>2</sub>O<sub>3</sub> requires 247.1083).</div></div><div id="sec4_1_1_62" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> Methyl 2-(1-(2-Methoxyethyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)-2-oxoacetate <b>68o</b></h5><div class="NLM_p last">Prepared from <b>67o</b> (325 μL, 352 mg, 2.0 mmol), AlCl<sub>3</sub> (1.33 g, 10 mmol), and methyl chlorooxoacetate (0.92 mL, 1.23 mg, 10 mmol). Reaction duration 5 h. Column eluent 0 → 1→2 → 4% MeOH/CH<sub>2</sub>Cl<sub>2</sub>. Product obtained as a pale-yellow oil which crystallized on standing to a beige solid (324 mg, 62%). δ<sub>H</sub> (400 MHz, CDCl<sub>3</sub>) 8.68 (dd, 1H, <i>J</i> = 1.5, 8.0), 8.62 (s, 1H), 8.42 (dd, 1H, <i>J</i> = 1.5, 5.0), 7.30 (dd, 1H, <i>J</i> = 5.0, 8.0), 4.55 (t, 2H, <i>J</i> = 5.0), 3.98 (s, 3H), 3.80 (t, 2H, <i>J</i> = 5.0), 3.36 (s, 3H). δ<sub>C</sub> (101 MHz, CDCl<sub>3</sub>) 177.1, 162.8, 148.0, 145.0, 140.6, 131.2, 119.6, 119.4, 111.3, 70.6, 59.0, 52.8, 45.3. <i>m</i>/<i>z</i> (ES) 263 ([M + H]<sup>+</sup>). HRMS, found 263.1038 (C<sub>13</sub>H<sub>15</sub>N<sub>2</sub>O<sub>4</sub> requires 263.1032). HPLC purity 98.3%. mp 69–70 °C.</div></div></div><div id="sec4_1_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Conversion of Esters <b>68a</b> and<b>68c</b>–<b>o</b> into Amides <b>36</b>, <b>38</b>, and <b>40</b>–<b>51</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>b): General Procedure</h4><div class="NLM_p last">The starting ester, the relevant amine (R<sup>2</sup>-NH<sub>2</sub>, 1.2 equiv) and TBD (30 mol %) were combined in the minimum volume of toluene (typically 1–2 mL), then the mixture was heated at 85 °C overnight. The solvent was removed by rotary evaporation then the residue purified further. Unless stated otherwise, this was achieved as follows. Hexane was added to a solution of the crude material in boiling EtOAc, with continuing heating, until cloudiness persisted, at which point the mixture was left to stand for 1–2 min. A sticky film of brown gum (mostly unreacted amine component) quickly accumulated at the bottom of the flask from which the remainder of the suspension could readily be decanted into a separate flask, at which point, the mixture was evaporated to dryness. Recrystallization of the remaining residue from propan-2-ol/water provided the amide product, which was collected by filtration and dried. Characterization data, HPLC purity, and any additional purification details are provided for each example in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec4_1_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Synthesis of Alkynes <b>81</b>–<b>83</b> from 2-Bromopyridine: General Procedure</h4><div class="NLM_p">PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (2 mol %), triphenylphosphine (4 mol %), and CuI (4 mol %) were added in succession to a 0.5 M solution of 2-bromopyridine in TEA. The resulting suspension was stirred for 30 min, then the relevant alkyne (1.0 equiv) was added. The reaction mixture was then stirred overnight in the dark, quenched by addition of satd NH<sub>4</sub>Cl, and evaporated under vacuum. The residual slurry was extracted with EtOAc and water, the aqueous phase was extracted with more EtOAc, then the combined organic extracts washed with water then brine, and evaporated under vacuum. Flash column chromatography on silica gel, eluted as specified in each individual case, then afforded the pure alkyne products.</div><div id="sec4_1_1_65" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> 2-(Pentyn-1-yl)pyridine <b>81</b></h5><div class="NLM_p last">Synthesized using 2-bromopyridine (954 μL, 1.58 g, 10 mmol), PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (140 mg, 0.2 mmol), PPh<sub>3</sub> (105 mg, 0.4 mmol), CuI (76 mg, 0.4 mmol), and pent-1-yne (986 μL, 10 mmol). Column eluent 10 → 15 → 20% EtOAc/hexane. Product obtained as an amber oil (1.13 g, 78%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 8.51 (d, 1H, <i>J</i> = 5.0), 7.76 (dt, 1H, <i>J</i> = 2.0, 8.0), 7.45 (d, 1H, <i>J</i> = 8.0), 7.35–7.31 (m, 1H), 2.43 (t, 2H, <i>J</i> = 7.0), 1.58 (sextet, 2H, <i>J</i> = 7.0), 1.00 (t, 3H, <i>J</i> = 7.0). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 150.3, 143.4, 137.0, 127.3, 123.3, 90.8, 81.4, 21.9, 20.8, 13.8. <i>m</i>/<i>z</i> (ES) 146 ([M + H]<sup>+</sup>). HRMS, found 146.0965 (C<sub>10</sub>H<sub>12</sub>N requires 146.0970).</div></div><div id="sec4_1_1_66" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> 2-(4-Methylpent-1-ynyl)pyridine <b>82</b></h5><div class="NLM_p last">Synthesized using 2-bromopyridine (3.81 mL, 6.32 g, 40 mmol), PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (562 mg, 0.8 mmol), PPh<sub>3</sub> (420 mg, 1.6 mmol), CuI (305 mg, 1.6 mmol), and 4-methylpent-1-yne (4.71 mL, 3.29 g, 40 mmol). Column eluent 5 → 10 → 15 → 20 → 25% EtOAc/hexane. Product obtained as a brown oil (4.48 g, 70%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 8.53 (d, 1H, <i>J</i> = 4.5), 7.75 (dt, 1H, <i>J</i> = 2.0, 8.0), 7.45 (d, 1H, <i>J</i> = 8.0), 7.33 (ddd, 1H, <i>J</i> = 1.0, 4.5, 6.0), 2.35 (d, 2H, <i>J</i> = 6.5), 1.85 (septet, 1H, <i>J</i> = 6.5), 0.98 (d, 6H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 150.3, 143.5, 137.0, 127.3, 123.3, 89.8, 82.1, 27.94, 27.91, 22.2. <i>m</i>/<i>z</i> (ES) 160 ([M + H]<sup>+</sup>). HRMS, found 160.1120 (C<sub>11</sub>H<sub>14</sub>N requires 160.1126). HPLC purity 99.5%.</div></div><div id="sec4_1_1_67" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> 5-(Pyridin-2-yl)pent-4-yn-1-ol <b>83</b></h5><div class="NLM_p last">Synthesized using 2-bromopyridine (2.38 mL, 3.95 g, 25 mmol), PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (351 mg, 0.5 mmol), PPh<sub>3</sub> (262 mg, 1.0 mmol), CuI (190 mg, 1.0 mmol), and pent-4-yn-1-ol (2.33 mL, 2.10 g, 25 mmol). Column eluent 2.5 → 5→10 → 15% MeOH/CH<sub>2</sub>Cl<sub>2</sub>. Product obtained as a yellow oil (2.46 g, 61%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 8.52 (d, 1H, <i>J</i> = 5.0), 7.76 (dt, 1H, <i>J</i> = 1.5, 7.5), 7.44 (d, 1H, <i>J</i> = 7.5), 7.33 (ddd, 1H, <i>J</i> = 1.5, 5.0, 5.5), 4.59 (t, 1H, <i>J</i> = 5.5), 3.53 (q, 2H, <i>J</i> = 5.5), 2.50 (t, 2H, <i>J</i> = 7.0), 1.74–1.67 (m, 2H). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 150.3, 143.5, 137.0, 127.3, 123.3, 90.9, 81.1, 59.9, 31.7, 15.6. <i>m</i>/<i>z</i> (ES) 162 ([M + H]<sup>+</sup>). HRMS, found 162.0912 (C<sub>10</sub>H<sub>12</sub>NO requires 162.0919). HPLC purity 99.0%.</div></div></div><div id="sec4_1_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 2-(5-Methoxypent-1-ynyl)pyridine <b>84</b></h4><div id="sec4_1_1_68_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> By Methylation of <b>83</b> (Method A)</h5><div class="NLM_p last">Alcohol <b>83</b> (1.14 g, 7.08 mmol) and methyl iodide (0.53 mL, 1.21 g, 8.5 mmol) were dissolved in anhydrous DMF (25 mL) at 0 °C, then sodium hydride (60% dispersion in mineral oil, 0.34 g, 8.5 mmol) was added in small portions over 5 min. After stirring for 30 min at 0 °C, the cooling was removed and reaction continued at rt for 3 h. Water was added dropwise to quench any remaining NaH, then the mixture evaporated under vacuum. The residue was extracted between EtOAc and water, the aqueous phase extracted with more EtOAc, then the combined organic extracts washed with brine, water then brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The resulting brown oil was purified by preparative HPLC, using a gradient of 5–15% MeCN in water (containing 0.1% v/v TFA) over 20 min. After evaporation of pooled fractions, the remaining yellow oil was partitioned between EtOAc and satd NaHCO<sub>3</sub> to regenerate the free base form of the product. After separation of the layers, the aqueous phase was extracted again with EtOAc and the combined organics dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated to dryness once more to afford the title compound as a yellow/orange oil (337 mg, 27%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 8.56–8.50 (m, 1H), 7.77 (dt, 1H, <i>J</i> = 1.5, 7.5), 7.45 (d, 1H, <i>J</i> = 7.5), 7.34 (dd, 1H, <i>J</i> = 5.0, 7.5), 3.44 (t, 2H, <i>J</i> = 6.5), 3.25 (s, 3H), 2.49 (t, 2H, <i>J</i> = 6.5), 1.78 (quintet, 2H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 149.8, 142.9, 136.6, 126.8, 122.9, 89.8, 80.8, 70.4, 57.9, 27.9, 15.3. <i>m</i>/<i>z</i> (ES) 176 ([M + H]<sup>+</sup>). HRMS, found 176.1075 (C<sub>11</sub>H<sub>14</sub>NO requires 176.1075). HPLC purity 99.7%.</div></div><div id="sec4_1_1_68_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> By Two-Step Synthesis from Pent-4-yn-1-ol (Method B)</h5><div class="NLM_p last">A solution of pent-4-yn-1-ol (3.26 mL, 2.94 g, 35 mmol) and methyl iodide (4.36 mL, 9.94 g, 70 mmol) in dry THF (60 mL) was cooled to 0 °C, then sodium hydride (60% dispersion in mineral oil, 1.68 g, 42 mmol) was added portionwise over 10 min. After 5 min more, the cooling was removed and the reaction mixture heated at 50 °C for 2.5 h. The suspension was poured carefully into ice-cold water (250 mL) then extracted twice with Et<sub>2</sub>O. The combined extracts were washed with water, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, then evaporated slowly under vacuum, maintaining the water bath at 4 °C and using an air bleed to control the evaporation rate. Slow evaporation was necessary to prevent significant loss of the volatile intermediate, 5-methoxypent-1-yne. Once the solution of this crude alkyne had been concentrated to approximately 25 mL, it was used immediately as the alkyne component of a Sonogashira cross-coupling with 2-bromopyridine (3.34 mL, 5.53 g, 35 mmol), according to the general procedure described above, also using PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (491 mg, 0.7 mmol), PPh<sub>3</sub> (367 mg, 1.4 mmol), and CuI (267 mg, 1.4 mmol). Column eluent 0 → 1→2.5 → 4→6% MeOH/CH<sub>2</sub>Cl<sub>2</sub>. Title compound obtained as an orange/brown oil (1.11 g, 18% over 2 steps). Analytical data were in agreement with the sample prepared by method A.</div></div></div><div id="sec4_1_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> Cyclization of 2-Alkynylpyridines <b>81</b>, <b>82</b>, and <b>84</b> to 3-Alkylindolizines <b>85</b>–<b>87</b>: General Procedure</h4><div class="NLM_p">CuCl (1 equiv) was added to a 0.45 M solution of starting 2-alkynylpyridine in dry DMA/TEA (7:1). The mixture was stirred at rt for 10 min then heated to 130 °C for the duration specified in each case. The reaction mixture was poured into a 1:1 mixture of EtOAc and water, which was then extracted thoroughly. Following vacuum filtration to remove suspended solids, the filtrate was poured into a separating funnel and the layers separated. The aqueous layer was extracted twice more with EtOAc, repeating the filtration step as necessary. The combined extracts were washed with water then brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. Purification was carried out by flash column chromatography on silica gel, using the eluent specified in each case, and making sure to run the column as quickly as possible to minimize decomposition of the indolizine product. After evaporation and drying, the indolizines were stored at −20 °C until further use.</div><div id="sec4_1_1_70" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> 3-Ethylindolizine <b>85</b></h5><div class="NLM_p last">Prepared from alkyne <b>81</b> (500 mg, 3.44 mmol) and CuCl (341 mg, 3.44 mmol). Reaction duration 7.5 h. Column eluent 0 → 10% EtOAc/hexane. Title compound obtained as a yellow oil (161 mg, 32%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 7.99 (d, 1H, <i>J</i> = 7.0), 7.40 (d, 1H, <i>J</i> = 9.0), 6.66–6.61 (m, 1H), 6.59–6.54 (m, 2H), 6.34 (d, 1H, <i>J</i> = 4.0), 2.80 (q, 2H, <i>J</i> = 7.5), 1.30 (t, 3H, <i>J</i> = 7.5). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 132.1, 126.0, 122.7, 119.4, 115.8, 111.1, 110.3, 98.3, 18.9, 12.2. <i>m</i>/<i>z</i> (ES) 146 ([M + H]<sup>+</sup>). HRMS, found 146.0972 (C<sub>10</sub>H<sub>12</sub>N requires 146.0970).</div></div><div id="sec4_1_1_71" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> 3-Isopropylindolizine <b>86</b></h5><div class="NLM_p last">Prepared from alkyne <b>82</b> (4.01 g, 25.2 mmol) and CuCl (2.49 g, 25.2 mmol). Reaction duration 6.5 h. Column eluent 0 → 5→10% EtOAc/hexane. Title compound obtained as a bright-yellow oil (1.24 g, 31%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 8.00 (d, 1H, <i>J</i> = 7.0), 7.40 (d, 1H, <i>J</i> = 9.0), 6.65–6.60 (m, 1H), 6.58–6.52 (m, 2H), 6.35 (d, 1H, <i>J</i> = 4.0), 3.24 (septet, 1H, <i>J</i> = 7.0), 1.28 (d, 6H, <i>J</i> = 7.0). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 132.2, 130.7, 122.8, 119.6, 115.7, 110.2, 109.4, 98.4, 24.8, 21.6. <i>m</i>/<i>z</i> (ES) 160 ([M + H]<sup>+</sup>). HRMS, found 160.1127 (C<sub>11</sub>H<sub>14</sub>N requires 160.1126). HPLC purity 94.2%.</div></div><div id="sec4_1_1_72" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> 3-(2-Methoxyethyl)indolizine <b>87</b></h5><div class="NLM_p last">Prepared from alkyne <b>84</b> (1.09 g, 6.22 mmol) and CuCl (616 mg, 6.22 mmol). Reaction duration 4 h. Column eluent 5 → 10 → 20% EtOAc/pentanes. Title compound obtained as a bright-yellow oil (591 mg, 54%). δ<sub>H</sub> (400 MHz, DMSO-<i>d</i><sub>6</sub>) 8.06 (dd, 1H, <i>J</i> = 1.0, 6.5), 7.39 (dt, 1H, <i>J</i> = 1.0, 9.0), 6.64 (ddd, 1H, <i>J</i> = 1.0, 6.5, 9.0), 6.59 (d, 1H, <i>J</i> = 4.0), 6.55 (dt, 1H, <i>J</i> = 1.0, 6.5), 6.35 (d, 1H, <i>J</i> = 4.0), 3.65 (t, 2H, <i>J</i> = 6.5), 3.28 (s, 3H), 3.09 (t, 2H, <i>J</i> = 6.5). δ<sub>C</sub> (101 MHz, DMSO-<i>d</i><sub>6</sub>) 132.2, 123.0, 121.9, 119.3, 115.9, 112.7, 110.3, 98.5, 70.8, 58.4, 26.2. <i>m</i>/<i>z</i> (ES) 176 ([M + H]<sup>+</sup>). HRMS, found 176.1073 (C<sub>11</sub>H<sub>14</sub>NO requires 176.1075). HPLC purity 99.1%.</div></div></div><div id="sec4_1_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> Synthesis of Indolizine-1-glyoxylamides <b>52</b>–<b>55</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>): General Procedure</h4><div class="NLM_p last">These reactions were carried out using the same protocol as the one-pot indole-3-glyoxylamide syntheses described above, except the first step (reaction with oxalyl chloride) was carried out at 0 °C instead of rt. Characterization data, HPLC purity, and any additional purification details are provided for each example in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec4_1_1_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> Preparation of <b>61</b>, <b>63</b>, and <b>65</b> via Ester Deprotection: General Procedure</h4><div class="NLM_p last">These reactions were not run under N<sub>2</sub>. The starting ester, either <b>62</b>, <b>64</b>, or ethyl 2-(2-(3-(2-(6-methoxypyridin-3-ylamino)-2-oxoacetyl)-1<i>H</i>-indol-1-yl)-2-methylpropoxy)acetate (prepared from <b>4m</b> by the general procedure for one-pot indole-3-glyoxylamide synthesis), was dissolved in 1:1 THF/water to a final concentration of approximately 0.1 M, then 5 M NaOH (2.5 equiv) was added. The reaction mixture was stirred at rt for 2 h. Complete reaction was confirmed by TLC, then the solution was adjusted to pH 7 with 1 M HCl and evaporated under vacuum. The residue was extracted with EtOAc and 1 M HCl, the aqueous layer extracted three times further with EtOAc, then the combined organic solutions dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. Purification was carried out by preparative HPLC, using the conditions specified in each case. Characterization data, HPLC purity, and full purification details are provided for each example in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> HPLC Solubility Assay</h4><div class="NLM_p last">The maximal aqueous solubility of compounds <b>12</b>, <b>13</b>, and <b>32</b> was estimated as follows: dilutions of compound from 10 mM DMSO stock solutions were made into water at final concentrations ranging from 1–100 μM (typically 1, 2, 4, 6, 10, 15, 20, 30, 50, and 100 μM). These solutions were mixed overnight at rt then centrifuged in a benchtop microcentrifuge at 13000 rpm (approximately 17000<i>g</i>) for 5 min to remove any suspended precipitate. Supernatants were analyzed by HPLC using a C<sub>18</sub> 5 μm column, 4.6 mm × 150 mm, and a gradient of 5–55% MeCN/water over 9 min; ramp to 100% MeCN over 4 min; hold at 100% MeCN for 5 min, with UV detection at 254 nm. Plots of peak area against concentration were constructed, and the point at which each plot deviated from linearity was estimated as the threshold aqueous solubility of the test compound (above which point the plot leveled off, indicating saturation).</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> Biology</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> Cell Lines and Culture</h4><div class="NLM_p last">Cell lines were obtained from the American Type Culture Collection (FaDu, SCC-4, SK-MEL-28) or the European Collection of Cell Cultures (MES-SA, MES-SA/Dx5, SH-SY5Y, Caco-2) and cultured at 37 °C as recommended in each case, with the exception of FaDu, which was grown in RPMI-1640 medium supplemented with 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine. Additionally, all cell culture medium was supplemented with 100 IU/mL penicillin and 100 μg/mL streptomycin.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> Cytotoxicity (MTT) Assay</h4><div class="NLM_p last">Cells were distributed into 96-well tissue culture plates (Greiner Bio-One) at an appropriate density in a volume of 100 μL/well and incubated for 24 h to allow for cell attachment. Test compound solutions were prepared by dilution from 10 mM DMSO stock solutions into full growth medium at 2× the required final screening concentration and dosed in triplicate at 100 μL/well (i.e., final assay volume ∼200 μL/well). After incubation for 72 h, medium was removed from the wells, the cells were washed with PBS, and 100 μL/well of a solution of MTT in PBS (0.5 mg/mL) was added. The plate was incubated once more for 45–60 min then the solution removed and 0.1 M HCl in 2-propanol added (40 μL/well). After gentle agitation to dissolve the formazan crystals, absorbance values at 570 nm were read using a microplate reader (reference wavelength 650 nm). Data was processed using Microsoft Excel, expressed as viability relative to vehicle control (DMSO only), and plotted in dose–response form using GraphPad Prism 6 (GraphPad Software, Inc.), allowing derivation of LC<sub>50</sub> values by nonlinear regression.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> Tubulin Polymerization Assay (OD<sub>340</sub> Method)</h4><div class="NLM_p last">Purified porcine brain tubulin and other reagents were obtained commercially in kit form (Cytoskeleton, Inc.). Assays were carried out in half-area 96-well plates at 37 °C and a final concentration of 3.6 mg/mL tubulin, 9.2% glycerol, and 900 μM GTP in 100 μL total volume. Test compounds were preplated at 10× final assay concentration in water (10 μL/well), then a solution of tubulin (4 mg/mL) in G-PEM buffer (80 mM PIPES pH 6.9, 2 mM MgCl<sub>2</sub>, 0.5 mM EGTA) containing 10.2% glycerol and 1 mM GTP was prepared freshly on ice and promptly distributed into reaction wells at 90 μL/well. Reactions were followed at 37 °C over 60 min, monitoring OD<sub>340</sub> at 1 min intervals. Data from each well was normalized relative to initial readings, and plots of ΔOD<sub>max</sub> (final–initial values) against compound concentration, expressed relative to vehicle control (DMSO only), were used to calculate IC<sub>50</sub> values (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S1</a>).</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> Tubulin Polymerization Assay (DAPI Fluorescence Method)</h4><div class="NLM_p last">Purified tubulin and other reagents were sourced in kit form (Cytoskeleton, Inc.) as above. Assays were run in a total volume of 55 μL, in half-area 96-well black plates at 37 °C in G-PEM buffer containing 1.45 mg/mL tubulin, 900 μM GTP, 4.97 μM DAPI, and 13.75% glycerol. Reactions were monitored by measuring DAPI fluorescence (excitation 360 nm, emission 450 nm) once per minute over a period of 60 min. Data was normalized and processed as per the OD<sub>340</sub> method (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figures S2,S3</a>).</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> Tubulin Competitive Binding Assay</h4><div class="NLM_p last">Assays were performed in 96-well plates in duplicate. Biotinylated porcine tubulin (750 ng/well, >99% purity, Cytoskeleton Inc.) was incubated with tritiated tubulin binders (0.1 μM [<sup>3</sup>H]-colchicine (PerkinElmer), 0.2 μM [<sup>3</sup>H]-vinblastine (ARC Inc.), or 0.05 μM [<sup>3</sup>H]-paclitaxel (BioTrend)) and test compounds at various concentrations in 200 μL G-PEM buffer containing 1 mM GTP at a final DMSO concentration of 3% and a total volume of 200 μL/well. For the [<sup>3</sup>H]-colchicine binding assay, the plate was incubated for 2 h at 37 °C, after which 79.2 μg/well streptavidin yttrium silicate SPA beads (PerkinElmer) was added in 20 μL of G-PEM buffer (final volume 220 μL) then samples incubated for a further 45 min at 37 °C before bound radioactivity was determined using a Wallac 1450 Microbeta (PerkinElmer). For the [<sup>3</sup>H]-vinblastine binding assay, SPA beads were added together with the other assay components and the plate incubated for 15 min at rt before reading. For the [<sup>3</sup>H]-paclitaxel binding assay, biotinylated tubulin was precoupled to the SPA beads for 30 min at 4 °C, before the addition of test compounds and radiolabel, after which the plate was incubated for a further 25 min at rt before reading. Inhibition at each compound concentration was calculated according to <a class="ref internalNav" href="#eq1" aria-label="eq 1">eq 1</a>, where CPM = counts per minute, CPM<sub>[NSB]</sub> is the reading obtained in the presence of a 1000-fold molar excess of unlabeled ligand, and CPM<sub>[TB]</sub> is the reading for vehicle control (3% DMSO).<span class="NLM_disp-formula" id="eq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/jm-2015-01312h_m001.gif" alt="" /></img><span class="labelSpan">(1)</span></span>IC<sub>50</sub> values were determined from seven-point semilog concentration–inhibition curves in XLfit (ID Business Solutions) or GraphPad Prism 6 (GraphPad Software, Inc.) using a four-parameter inhibition model.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> Cell Cycle Analysis</h4><div class="NLM_p last">FaDu cells were seeded into 12-well plates at 10<sup>5</sup> cells/well in 1 mL of full growth medium, then incubated overnight to allow for cell attachment. Test compounds were prepared at 2× final screening concentration in full growth medium then dosed at 1 mL/well (final assay volume ∼2 mL), after which plates were incubated at 37 °C for 24 h. Medium was removed and cells washed with PBS (500 μL/well) then harvested by detachment with 0.05% trypsin–EDTA (500 μL/well) followed by centrifugation (2000<i>g</i>, 5 min) in 1.5 mL microcentrifuge tubes. The cells were washed with flow cytometry buffer (100 mM PBS pH 7.4, 0.1% w/v BSA, 0.1% w/v NaN<sub>3</sub>; 500 μL) and centrifuged once more. Buffer was removed and each cell pellet fixed by dropwise addition of ice-cold 70% ethanol (1.0 mL) with mixing using a vortex mixer. Samples were kept on ice for 30 min then centrifuged (2000<i>g</i>, 5 min) and the fixing solution removed. After washing with flow cytometry buffer as above, samples were treated with RNase A (100 μg/mL in PBS, 50 μL) at rt for at least 15 min, then propidium iodide (50 μg/mL in PBS, 200 μL) was added and incubation continued overnight, in the dark. Samples were analyzed by flow cytometry using a FACSCalibur instrument (BD Biosciences), collecting a minimum of 10000 events per sample and data was then analyzed using Flowing Software 2.5.1 (<a href="http://www.flowingsoftware.com" class="extLink">www.flowingsoftware.com</a>).</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> Immunofluorescence Staining</h4><div class="NLM_p last">FaDu cells were seeded onto glass coverslips in 24-well plates at 15000 cells/well in 500 μL of full growth medium, then incubated for 24 h to allow for cell attachment. Test compounds were prepared at 2× final assay concentration in full growth medium then added at 500 μL/well and the plate incubated for 24 h. Medium was removed by aspiration and the cells washed with PBS, then treated for 3 min with PHEM buffer (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl<sub>2</sub>, pH 6.9) containing 0.5% v/v Triton X-100 and 10 μM paclitaxel (this treatment removes unassembled tubulin dimers while preserving intact microtubules<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a>). Each culture was fixed by treatment with PHEM containing 8% w/v paraformaldehyde and 0.3% w/v glutaraldehyde on ice for 10 min. The fixative was removed and the cells washed three times with PBS, then blocked by treatment with 2% FCS and 1% BSA in PBS for 30 min. The blocking solution was removed and the samples incubated with FITC-conjugated mouse anti-α-tubulin antibody (clone DM1A, Sigma, 1:500) in PBS for 40 min. The cells were washed three times with PBS then incubated with DAPI (5 μg/mL in PBS) for 5 min. After a further three PBS washes, coverslips were removed from the assay plate and slide mounted using ProLong Diamond Antifade Mountant (ThermoFisher Scientific). Slides were subsequently imaged using a spinning disc confocal microscope (Olympus IX81, PerkinElmer, UK) by capturing confocal z-stack images in 0.5 μm increments at 100× magnification.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> Mouse Microsomal Stability Assay</h4><div class="NLM_p last">Stock solutions of test compounds (2 mM in DMSO) were diluted to 0.1 mM with MeCN, and these solutions further diluted to 1.25 μM in 50 mM potassium phosphate buffer (pH 7.4) containing 0.63 mg/mL micromosal protein from pooled CD-1 (male) mouse liver microsome preparation (20 mg/mL; BD Biosciences). An aliquot of the resultant solution (80 μL) was preincubated for 5 min at 37 °C in a shaking incubator before reaction was initiated by addition of NADPH (5 mM in potassium phosphate buffer, 20 μL) or buffer alone (for no cofactor control, 20 μL). Parallel reactions were stopped at 0 and 30 min time points by the addition of two volumes of ice-cold acetonitrile. The quenched samples were centrifuged (3000<i>g</i>, 30 min, 4 °C) and the resultant supernatants analyzed for parent compound by LC-MS/MS, monitoring ion transitions for parent and daughter ions. Results of determinations carried out in duplicate are reported as mean percent parent compound remaining at 30 min. Final incubation conditions were 1 μM test compound, 0.5 mg/mL microsomal protein, and 1 mM NADPH.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> Bidirectional Caco-2 Permeability Assay</h4><div class="NLM_p">Caco-2 cells were seeded onto 24-well transwell plates at 20000 cells/well and used as confluent monolayers after a 21 day culture. Test and control compounds (propranolol, vinblastine) were prepared at 10 μM in HBSS supplemented with 25 mM HEPES, pH 7.4, at a final DMSO concentration of 0.1%. These solutions were added to donor compartments for both apical to basolateral (A → B) and basolateral to apical (B → A) measurements. After incubation at 37 °C for 60 min, samples were analyzed by mass spectrometry using an analytical internal standard. Apparent permeability (<i>P</i><sub>app</sub>) values, expressed as ×10<sup>–6</sup> cm s<sup>–1</sup>, were determined according to <a class="ref internalNav" href="#eq2" aria-label="eq 2">eq 2</a> where <i>V</i><sub>acceptor</sub> and <i>V</i><sub>donor</sub> are the volumes of the transwell compartments (apical 125 μL, basolateral 600 μL), <i>T</i> is the incubation time (in min), <i>A</i> is the area of cells exposed (in cm<sup>2</sup>), and the concentrations are relative mass spectroscopic responses normalized to the internal standard:<span class="NLM_disp-formula" id="eq2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/jm-2015-01312h_m002.gif" alt="" /></img><span class="labelSpan">(2)</span></span></div><div class="NLM_p last">Lucifer yellow was added to the apical buffer in each well to assess cell viability as a control for integrity of the monolayer. Results from any well with a lucifer yellow <i>P</i><sub>app</sub> > 10 × 10<sup>–6</sup> cm s<sup>–1</sup> were rejected. Efflux ratios are expressed as <i>P</i><sub>app</sub>(B → A)/<i>P</i><sub>app</sub>(A → B). Values for control compounds were as expected: propranolol <i>P</i><sub>app</sub>(A → B) 66.7 × 10<sup>–6</sup> cm s<sup>–1</sup>, efflux ratio 0.7; vinblastine <i>P</i><sub>app</sub>(A → B) < 0.2 × 10<sup>–6</sup> cm s<sup>–1</sup>, efflux ratio >288.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> Multicellular Tumor Spheroid Cytotoxicity Screen</h4><div class="NLM_p last">Multicellular tumor spheroids were prepared from the FaDu cell line using the forced-floating method, in 100 μL/well full growth medium in 96-well tissue culture plates, as described previously.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> After spheroids had formed, test compounds were dosed essentially as for the 2D cytotoxicity assay but using <i>n</i> = 6 rather than triplicates, accommodating a nine-point dose–response experiment with vehicle control (DMSO) on each plate. Images were captured at regular intervals (0, 1, 2, 3, 4, and 7 days postdosing) using a Zeiss Axiovert 200 M light microscope with AxioCam MRm camera and AxioVision 4.6 software (Carl Zeiss Inc., Germany) and size measurements made using AxioVision. These values were converted into spheroid volume expressed relative to DMSO control and EC<sub>50</sub> values determined by nonlinear regression using GraphPad Prism 6 (GraphPad Software, Inc.), as above.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> Mouse Xenograft Model</h4><div class="NLM_p last">Male CD1 athymic mice (aged 7–8 weeks, stock number 000711; Charles River UK) were kept in ventilated cages with food and water provided ad libitum. FaDu cells, verified mycoplasma free, were suspended in PBS (pH 7.4) at a density of 5 × 10<sup>7</sup> mL<sup>–1</sup> and each animal received a subcutaneous injection of 5 × 10<sup>6</sup> cells (100 μL) from this suspension. Once xenografts were established, tumors were measured with a digital caliper and the volume calculated as (length × width<sup>2</sup>)/2. Mice with palpable tumors (100–300 mm<sup>3</sup>) were assigned randomly into groups (<i>n</i> = 9) before beginning the treatment schedule. The control group received 200 μL vehicle (95:5 water/glycerol containing 0.25% v/v Tween-20 and 2.3% v/v DMSO) by oral gavage once daily for 10 days, with the treatment groups receiving either <b>33</b> (10 mg/kg), <b>59</b> (10 mg/kg), or <b>59</b> (20 mg/kg) diluted from stock solutions in 100% DMSO in 200 μL of the same formulation, by the same route and schedule. In a parallel experiment to compare the effect of vinblastine treatment, two groups received either vehicle (200 μL PBS) or vinblastine (3 mg/kg in 200 μL PBS) by the intraperitoneal route on days 1, 4, and 7 only. For all groups, tumor volumes were monitored regularly, and mice were culled when tumors reached the maximum permitted size (15 mm diameter). All animal procedures were conducted in accordance with the UK Home Office Regulations under the Animals (Scientific Procedures) Act 1986 and the awarded project license number under which these protocols were performed is PPL:40/3424. In addition, the University of Sheffield Animal Welfare and Ethical Review Body approved all the in vivo experiments used in this study.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i112"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01312">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68512" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68512" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01312" class="ext-link">10.1021/acs.jmedchem.5b01312</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Characterization data, purification details, and HPLC purity for all screening compounds; NMR spectra for all screening compounds and synthetic intermediates (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf">jm5b01312_si_001.pdf (9.65 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_002.csv">jm5b01312_si_002.csv (8.68 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01312" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40100" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40100" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Helen E. Colley</span> - <span class="hlFld-Affiliation affiliation">School
of Clinical Dentistry, University of Sheffield, 19 Claremont Crescent, Sheffield S10 2TA, U.K.</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1f77317c7073737a665f6c777a7979767a737b317e7c316a74"><span class="__cf_email__" data-cfemail="c2aaeca1adaeaea7bb82b1aaa7a4a4aba7aea6eca3a1ecb7a9">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark J. Thompson</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Sheffield, Brook Hill, Sheffield S3 7HF, U.K.</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b9d497d397cdd1d6d4c9cad6d7f9cad1dcdfdfd0dcd5dd97d8da97ccd2"><span class="__cf_email__" data-cfemail="b4d99ade9ac0dcdbd9c4c7dbdaf4c7dcd1d2d2ddd1d8d09ad5d79ac1df">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Munitta Muthana</span> - <span class="hlFld-Affiliation affiliation">Department
of Oncology, The University of Sheffield,
Medical School, Beech
Hill Road, Sheffield S10
2RX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah J. Danson</span> - <span class="hlFld-Affiliation affiliation">Academic
Unit of Clinical Oncology and Sheffield Experimental Medicine Centre, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lucinda V. Jackson</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Sheffield, Brook Hill, Sheffield S3 7HF, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew L. Brett</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Sheffield, Brook Hill, Sheffield S3 7HF, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joanne Harrison</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Sheffield, Brook Hill, Sheffield S3 7HF, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sean F. Coole</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Sheffield, Brook Hill, Sheffield S3 7HF, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel P. Mason</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, University of Sheffield, Brook Hill, Sheffield S3 7HF, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luke R. Jennings</span> - <span class="hlFld-Affiliation affiliation">School
of Clinical Dentistry, University of Sheffield, 19 Claremont Crescent, Sheffield S10 2TA, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melanie Wong</span> - <span class="hlFld-Affiliation affiliation">Charles
River, 8−9 Spire
Green Centre, Harlow, Harlow, Essex CM19 5TR, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vamshi Tulasi</span> - <span class="hlFld-Affiliation affiliation">Charles
River, 8−9 Spire
Green Centre, Harlow, Harlow, Essex CM19 5TR, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dennis Norman</span> - <span class="hlFld-Affiliation affiliation">Charles
River, 8−9 Spire
Green Centre, Harlow, Harlow, Essex CM19 5TR, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter M. Lockey</span> - <span class="hlFld-Affiliation affiliation">Charles
River, 8−9 Spire
Green Centre, Harlow, Harlow, Essex CM19 5TR, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lynne Williams</span> - <span class="hlFld-Affiliation affiliation">Department
of Oncology, The University of Sheffield,
Medical School, Beech
Hill Road, Sheffield S10
2RX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander G. Dossetter</span> - <span class="hlFld-Affiliation affiliation">MedChemica
Limited, Ebenezer House,
Ryecroft, Newcastle-Under-Lyme, Staffordshire ST5 2BE, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edward J. Griffen</span> - <span class="hlFld-Affiliation affiliation">MedChemica
Limited, Ebenezer House,
Ryecroft, Newcastle-Under-Lyme, Staffordshire ST5 2BE, U.K.</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>M.J.T. wrote the manuscript with assistance from the other authors specified (H.E.C., M.W., E.J.G., and M.M.). All authors have approved the manuscript prior to submission.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d1997e7852-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i114">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35277" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35277" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We gratefully acknowledge funding from Weston Park Hospital Cancer Charity (grant refs SG110 to M.J.T., H.E.C., and S.J.D.; CA135 to M.J.T., M.M., H.E.C., and S.J.D.), Sheffield Healthcare Gateway Faculty Innovation Fund (University of Sheffield, to H.E.C. and M.J.T.), and the University of Sheffield Early Career Researcher Scheme (grants to M.J.T. and H.E.C.). We thank Michael Briggs, Sharon Wicks, Lisa Strong, Richard Newman, Roshini Markandu, and Lynsey Crowley (Charles River) for their contributions to in vitro ADME work, and also Drs. David Clark, Steve Price, and Mark Albertella (Charles River) for helpful collaboration; Simon Thorpe (University of Sheffield) for assistance with mass spectrometry, and Dr. Simon Tazzyman (University of Sheffield) for valuable help with confocal microscopy.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i115" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i115"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i116" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i116"> Abbreviations Used</h2><tr><td class="NLM_term">ABCG2</td><td class="NLM_def"><p class="first last">ATP-binding cassette subfamily G member 2</p></td></tr><tr><td class="NLM_term">Akt</td><td class="NLM_def"><p class="first last">RAC-α serine/threonine-protein kinase</p></td></tr><tr><td class="NLM_term">BCRP</td><td class="NLM_def"><p class="first last">breast cancer resistance protein</p></td></tr><tr><td class="NLM_term">DAPI</td><td class="NLM_def"><p class="first last">4′,6-diamidino-2-phenylindole</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DLS</td><td class="NLM_def"><p class="first last">dynamic light scattering</p></td></tr><tr><td class="NLM_term">5-FU</td><td class="NLM_def"><p class="first last">5-fluorouracil</p></td></tr><tr><td class="NLM_term">GTP</td><td class="NLM_def"><p class="first last">guanosine 5′-triphosphate</p></td></tr><tr><td class="NLM_term">HBSS</td><td class="NLM_def"><p class="first last">Hanks’ Balanced Salt Solution</p></td></tr><tr><td class="NLM_term">HNC</td><td class="NLM_def"><p class="first last">head and neck cancer</p></td></tr><tr><td class="NLM_term">LC<sub>50</sub></td><td class="NLM_def"><p class="first last">lethal concentration for 50% of the population</p></td></tr><tr><td class="NLM_term">MCTS</td><td class="NLM_def"><p class="first last">multicellular tumor spheroid</p></td></tr><tr><td class="NLM_term">MMPA</td><td class="NLM_def"><p class="first last">matched molecular pair analysis</p></td></tr><tr><td class="NLM_term">MRP1</td><td class="NLM_def"><p class="first last">multidrug resistance-associated protein 1</p></td></tr><tr><td class="NLM_term">MRP2</td><td class="NLM_def"><p class="first last">multidrug resistance-associated protein 2</p></td></tr><tr><td class="NLM_term">MTA</td><td class="NLM_def"><p class="first last">microtubule-targeting agent</p></td></tr><tr><td class="NLM_term">mTor</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">PAINS</td><td class="NLM_def"><p class="first last">pan-assay interference compounds</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PN</td><td class="NLM_def"><p class="first last">peripheral neuropathy</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term">TBD</td><td class="NLM_def"><p class="first last">1,5,7-triazabicyclo[4.4.0]dec-5-ene</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i117">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21505" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21505" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 103 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Nitika, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapil, K.</span><span> </span><span class="NLM_article-title">Microtubule targeting agents: a benchmark in cancer therapy</span> <span class="citation_source-journal">Curr. Drug Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">196</span><span class="refDoi"> DOI: 10.2174/15748855113086660011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.2174%2F15748855113086660011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=189-196&author=V.+Nitikaauthor=K.+Kapil&title=Microtubule+targeting+agents%3A+a+benchmark+in+cancer+therapy&doi=10.2174%2F15748855113086660011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2174%2F15748855113086660011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15748855113086660011%26sid%3Dliteratum%253Aachs%26aulast%3DNitika%26aufirst%3DV.%26aulast%3DKapil%26aufirst%3DK.%26atitle%3DMicrotubule%2520targeting%2520agents%253A%2520a%2520benchmark%2520in%2520cancer%2520therapy%26jtitle%3DCurr.%2520Drug%2520Ther.%26date%3D2014%26volume%3D8%26spage%3D189%26epage%3D196%26doi%3D10.2174%2F15748855113086660011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Risinger, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">Microtubule dynamics as a target in oncology</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span><span class="refDoi"> DOI: 10.1016/j.ctrv.2008.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.ctrv.2008.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=19117686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVantrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=255-261&author=A.+L.+Risingerauthor=F.+J.+Gilesauthor=S.+L.+Mooberry&title=Microtubule+dynamics+as+a+target+in+oncology&doi=10.1016%2Fj.ctrv.2008.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule dynamics as a target in oncology</span></div><div class="casAuthors">Risinger, April L.; Giles, Francis J.; Mooberry, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-261</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Drugs that affect microtubule dynamics, including the taxanes and vinca alkaloids, have been a mainstay in the treatment of leukemias and solid tumors for decades.  New, more effective microtubule-targeting agents continue to enter into clin. trials and some, including the epothilone ixapebilone, have been approved for use.  In contrast, several other drugs of this class with promising preclin. data were later shown to be ineffective or intolerable in animal models or clin. trials.  In this review, we discuss the mol. mechanisms as well as preclin. and clin. results for a variety of microtubule-targeting agents in various stages of development.  We also offer a frank discussion of which microtubule-targeting agents are amenable to further development based on their availability, efficacy and toxic profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh2wR_5ls3DLVg90H21EOLACvtfcHk0ljfBoozG1Nu3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVantrg%253D&md5=2d18cb599b5c35f1e0bc0292c183826f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2008.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2008.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DRisinger%26aufirst%3DA.%2BL.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DMicrotubule%2520dynamics%2520as%2520a%2520target%2520in%2520oncology%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2009%26volume%3D35%26spage%3D255%26epage%3D261%26doi%3D10.1016%2Fj.ctrv.2008.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Stanton, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gernert, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aneja, R.</span><span> </span><span class="NLM_article-title">Drugs that target dynamic microtubules: a new molecular perspective</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">481</span><span class="refDoi"> DOI: 10.1002/med.20242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1002%2Fmed.20242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=21381049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksVKlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=443-481&author=R.+A.+Stantonauthor=K.+M.+Gernertauthor=J.+H.+Nettlesauthor=R.+Aneja&title=Drugs+that+target+dynamic+microtubules%3A+a+new+molecular+perspective&doi=10.1002%2Fmed.20242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs that target dynamic microtubules: A new molecular perspective</span></div><div class="casAuthors">Stanton, Richard A.; Gernert, Kim M.; Nettles, James H.; Aneja, Ritu</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">443-481</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Microtubules have long been considered an ideal target for anticancer drugs because of the essential role they play in mitosis, forming the dynamic spindle app.  As such, there is a wide variety of compds. currently in clin. use and in development that act as antimitotic agents by altering microtubule dynamics.  Although these diverse mols. are known to affect microtubule dynamics upon binding to one of the three established drug domains (taxane, vinca alkaloid, or colchicine site), the exact mechanism by which each drug works is still an area of intense speculation and research.  In this study, we review the effects of microtubule-binding chemotherapeutic agents from a new perspective, considering how their mode of binding induces conformational changes and alters biol. function relative to the mol. vectors of microtubule assembly or disassembly.  These "biol. vectors" can thus be used as a spatiotemporal context to describe mol. mechanisms by which microtubule-targeting drugs work. © 2011 Wiley Periodicals, Inc.  Med Res Rev, 31, No. 3, 443-481, 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB6_lcUQbXYrVg90H21EOLACvtfcHk0lgn1sHIIe3kAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksVKlsLs%253D&md5=acce5b9cc89581a7dab0236072b68c72</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fmed.20242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20242%26sid%3Dliteratum%253Aachs%26aulast%3DStanton%26aufirst%3DR.%2BA.%26aulast%3DGernert%26aufirst%3DK.%2BM.%26aulast%3DNettles%26aufirst%3DJ.%2BH.%26aulast%3DAneja%26aufirst%3DR.%26atitle%3DDrugs%2520that%2520target%2520dynamic%2520microtubules%253A%2520a%2520new%2520molecular%2520perspective%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2011%26volume%3D31%26spage%3D443%26epage%3D481%26doi%3D10.1002%2Fmed.20242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Barbier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsvetkov, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breuzard, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devred, F.</span><span> </span><span class="NLM_article-title">Deciphering the molecular mechanisms of anti-tubulin plant derived drugs</span> <span class="citation_source-journal">Phytochem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1007/s11101-013-9302-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1007%2Fs11101-013-9302-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislCksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=157-169&author=P.+Barbierauthor=P.+O.+Tsvetkovauthor=G.+Breuzardauthor=F.+Devred&title=Deciphering+the+molecular+mechanisms+of+anti-tubulin+plant+derived+drugs&doi=10.1007%2Fs11101-013-9302-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Deciphering the molecular mechanisms of anti-tubulin plant derived drugs</span></div><div class="casAuthors">Barbier, P.; Tsvetkov, P. O.; Breuzard, G.; Devred, F.</div><div class="citationInfo"><span class="NLM_cas:title">Phytochemistry Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">157-169</span>CODEN:
                <span class="NLM_cas:coden">PRHEBS</span>;
        ISSN:<span class="NLM_cas:issn">1568-7767</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Even though commercialized anticancer drugs are now produced by pharmaceutical companies, most of them were originally obtained from natural sources, and more particularly from plants.  Indeed, many structurally diverse compds. isolated from plants or marine flora have been purified and synthesized for their anticancer bioactivity.  Among these, several mols. belong to the class of anticancer drugs which target the microtubule cytoskeleton, either by stabilizing it or destabilizing it.  To characterize the activity of these drugs and to understand in which physiol. context they are more likely to be used as therapeutic agents, it is necessary to fully det. their interaction with tubulin.  Understanding the mol. basis of their effects on microtubule cytoskeleton is an important step in designing analogs with greater pharmacol. activity and with fewer side effects.  In addn., knowing the mol. mechanism of action of each drug that is already used in chemotherapy protocols will also help to find strategies to circumvent resistance.  By taking examples of known anti-tubulin plant derived drugs, we show how identification of microtubule targeting agents and further characterization of their activity can be achieved combining biophys. and biochem. approaches.  We also illustrate how continuing in depth study of mols. with already known primary mechanisms of action can lead to the discovery of new targets or biomarkers which can open new perspectives in anticancer strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi3RE25Y1WjLVg90H21EOLACvtfcHk0lgn1sHIIe3kAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislCksb0%253D&md5=080159383138e7ed1f86783ed272d360</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs11101-013-9302-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11101-013-9302-8%26sid%3Dliteratum%253Aachs%26aulast%3DBarbier%26aufirst%3DP.%26aulast%3DTsvetkov%26aufirst%3DP.%2BO.%26aulast%3DBreuzard%26aufirst%3DG.%26aulast%3DDevred%26aufirst%3DF.%26atitle%3DDeciphering%2520the%2520molecular%2520mechanisms%2520of%2520anti-tubulin%2520plant%2520derived%2520drugs%26jtitle%3DPhytochem.%2520Rev.%26date%3D2014%26volume%3D13%26spage%3D157%26epage%3D169%26doi%3D10.1007%2Fs11101-013-9302-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Rohena, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities</span> <span class="citation_source-journal">Nat. Prod. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">355</span><span class="refDoi"> DOI: 10.1039/c3np70092e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1039%2Fc3np70092e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=24481420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVagsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=335-355&author=C.+C.+Rohenaauthor=S.+L.+Mooberry&title=Recent+progress+with+microtubule+stabilizers%3A+new+compounds%2C+binding+modes+and+cellular+activities&doi=10.1039%2Fc3np70092e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities</span></div><div class="casAuthors">Rohena, Cristina C.; Mooberry, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">335-355</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Covering: late 2008 to August 2013Nature has yielded numerous classes of chem. distinct microtubule stabilizers.  Several of these, including paclitaxel (Taxol) and docetaxel (Taxotere), are important drugs used in the treatment of cancer.  New microtubule stabilizers and novel formulations of these agents continue to provide advances in cancer therapy.  In this review we cover recent progress in the chem. and biol. of these diverse microtubule stabilizers focusing on the wide range of organisms that produce these compds., their mechanisms of inhibiting microtubule-dependent processes, mechanisms of drug resistance, and their interactions with tubulin including their distinct binding sites and modes.  A new potential role for microtubule stabilizers in neurodegenerative diseases is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGbuNICZ6-bLVg90H21EOLACvtfcHk0lgn1sHIIe3kAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVagsro%253D&md5=50febeef8c139e67374a92250e7e2a7a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1039%2Fc3np70092e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3np70092e%26sid%3Dliteratum%253Aachs%26aulast%3DRohena%26aufirst%3DC.%2BC.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DRecent%2520progress%2520with%2520microtubule%2520stabilizers%253A%2520new%2520compounds%252C%2520binding%2520modes%2520and%2520cellular%2520activities%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2014%26volume%3D31%26spage%3D335%26epage%3D355%26doi%3D10.1039%2Fc3np70092e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Jordan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horwitz, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correia, J. J.</span><span> </span><span class="NLM_article-title">Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">S6</span><span class="NLM_x">–</span> <span class="NLM_lpage">S12</span><span class="refDoi"> DOI: 10.1053/j.seminoncol.2008.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1053%2Fj.seminoncol.2008.01.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2008&pages=S6-S12&author=M.+A.+Jordanauthor=S.+B.+Horwitzauthor=S.+Lobertauthor=J.+J.+Correia&title=Exploring+the+mechanisms+of+action+of+the+novel+microtubule+inhibitor+vinflunine&doi=10.1053%2Fj.seminoncol.2008.01.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2008.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2008.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DHorwitz%26aufirst%3DS.%2BB.%26aulast%3DLobert%26aufirst%3DS.%26aulast%3DCorreia%26aufirst%3DJ.%2BJ.%26atitle%3DExploring%2520the%2520mechanisms%2520of%2520action%2520of%2520the%2520novel%2520microtubule%2520inhibitor%2520vinflunine%26jtitle%3DSemin.%2520Oncol.%26date%3D2008%26volume%3D35%26spage%3DS6%26epage%3DS12%26doi%3D10.1053%2Fj.seminoncol.2008.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Field, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakkanthara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, J. H.</span><span> </span><span class="NLM_article-title">Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">5050</span><span class="NLM_x">–</span> <span class="NLM_lpage">5059</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.bmc.2014.02.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=24650703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksVWqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=5050-5059&author=J.+J.+Fieldauthor=A.+Kanakkantharaauthor=J.+H.+Miller&title=Microtubule-targeting+agents+are+clinically+successful+due+to+both+mitotic+and+interphase+impairment+of+microtubule+function&doi=10.1016%2Fj.bmc.2014.02.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function</span></div><div class="casAuthors">Field, Jessica J.; Kanakkanthara, Arun; Miller, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5050-5059</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Microtubules undergo continual dynamic changes in mitotic cells as the mitotic spindle forms and is broken down and in interphase cells where they play a central role in intracellular trafficking, cell signaling, cell migration, and angiogenesis.  Compds. that target the microtubule have been hugely successful in the clinic as chemotherapeutics, and this success is likely due to their ability to target cells regardless of their cell cycle stage.  Addnl., new generation antibody-conjugated microtubule-targeting agents are improving the targeting of these drugs to tumors.  Microtubule-targeting agents have been shown to have anti-angiogenic and vascular-disrupting properties as well as effects on cellular migration, intracellular trafficking, and cell secretion.  There are a no. of these compds. in development that target the vasculature, and different formulations of clin. used drugs are being developed to take advantage of these anti-angiogenic properties.  Microtubule-targeting agents have also been shown to have the potential to treat neurodegenerative diseases, such as Alzheimer's disease.  Thus, drugs that target the microtubule will continue to have a major impact in oncol. not only as anti-mitotics but also as potent inhibitors of interphase functions, and in future may also prove to be effective in reducing the consequences of neurodegenerative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2d-DR0ciixrVg90H21EOLACvtfcHk0lhcJT2EWBJTFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksVWqsrw%253D&md5=e3ec8c5c15dfe25d1c527cecaec20d2f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.035%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DJ.%2BJ.%26aulast%3DKanakkanthara%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DJ.%2BH.%26atitle%3DMicrotubule-targeting%2520agents%2520are%2520clinically%2520successful%2520due%2520to%2520both%2520mitotic%2520and%2520interphase%2520impairment%2520of%2520microtubule%2520function%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D5050%26epage%3D5059%26doi%3D10.1016%2Fj.bmc.2014.02.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Zasadil, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeum, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocque, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilke, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tevaarwerk, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raines, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkard, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, B. A.</span><span> </span><span class="NLM_article-title">Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">229ra43</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3007965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1126%2Fscitranslmed.3007965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=24670687" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=229ra43&author=L.+M.+Zasadilauthor=K.+A.+Andersenauthor=D.+Yeumauthor=G.+B.+Rocqueauthor=L.+G.+Wilkeauthor=A.+J.+Tevaarwerkauthor=R.+T.+Rainesauthor=M.+E.+Burkardauthor=B.+A.+Weaver&title=Cytotoxicity+of+paclitaxel+in+breast+cancer+is+due+to+chromosome+missegregation+on+multipolar+spindles&doi=10.1126%2Fscitranslmed.3007965"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3007965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3007965%26sid%3Dliteratum%253Aachs%26aulast%3DZasadil%26aufirst%3DL.%2BM.%26aulast%3DAndersen%26aufirst%3DK.%2BA.%26aulast%3DYeum%26aufirst%3DD.%26aulast%3DRocque%26aufirst%3DG.%2BB.%26aulast%3DWilke%26aufirst%3DL.%2BG.%26aulast%3DTevaarwerk%26aufirst%3DA.%2BJ.%26aulast%3DRaines%26aufirst%3DR.%2BT.%26aulast%3DBurkard%26aufirst%3DM.%2BE.%26aulast%3DWeaver%26aufirst%3DB.%2BA.%26atitle%3DCytotoxicity%2520of%2520paclitaxel%2520in%2520breast%2520cancer%2520is%2520due%2520to%2520chromosome%2520missegregation%2520on%2520multipolar%2520spindles%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D229ra43%26doi%3D10.1126%2Fscitranslmed.3007965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Ogden, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rida, P. C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aneja, R.</span><span> </span><span class="NLM_article-title">Interphase microtubules: chief casualties in the war on cancer?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">824</span><span class="NLM_x">–</span> <span class="NLM_lpage">829</span><span class="refDoi"> DOI: 10.1016/j.drudis.2013.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.drudis.2013.10.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=24201225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvValtbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=824-829&author=A.+Ogdenauthor=P.+C.+G.+Ridaauthor=M.+D.+Reidauthor=R.+Aneja&title=Interphase+microtubules%3A+chief+casualties+in+the+war+on+cancer%3F&doi=10.1016%2Fj.drudis.2013.10.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Interphase microtubules: chief casualties in the war on cancer?</span></div><div class="casAuthors">Ogden, Angela; Rida, Padmashree C. G.; Reid, Michelle D.; Aneja, Ritu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">824-829</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Microtubule-targeting agents (MTAs) profoundly affect interphase cells, such as by disrupting axonal transport, transcription, translation, mitochondrial permeability, immune cell function, directional migration and centrosome clustering.  This finding is antithetical to the conventionally held notion that MTAs act on mitosis to trigger arrest-mediated apoptotic cell death.  Furthermore, the paucity of mitotic cells in patient tumors and lack of correlation of MTA efficacy with tumor proliferation rate provide strong impetus to re-examine the mechanistic basis of action of MTAs, with an eye toward interphase activities.  Whereas targeted antimitotics have unequivocally failed their promise across clin. studies, MTAs constitute a mainstay of chemotherapy.  This paradox necessitates the conclusion that MTAs exert mitosis-independent effects, spurring a dramatic paradigm shift in our understanding of the mode of action of MTAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ1qu2htK9XLVg90H21EOLACvtfcHk0ljANfyf4irRKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvValtbjK&md5=adedd47ce4b6fdf0239e9d107c62c751</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DOgden%26aufirst%3DA.%26aulast%3DRida%26aufirst%3DP.%2BC.%2BG.%26aulast%3DReid%26aufirst%3DM.%2BD.%26aulast%3DAneja%26aufirst%3DR.%26atitle%3DInterphase%2520microtubules%253A%2520chief%2520casualties%2520in%2520the%2520war%2520on%2520cancer%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D824%26epage%3D829%26doi%3D10.1016%2Fj.drudis.2013.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Fürst, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vollmar, A. M.</span><span> </span><span class="NLM_article-title">A new perspective on old drugs: non-mitotic actions of tubulin-binding drugs play a major role in cancer treatment</span> <span class="citation_source-journal">Pharmazie</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">478</span><span class="NLM_x">–</span> <span class="NLM_lpage">483</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=478-483&author=R.+F%C3%BCrstauthor=A.+M.+Vollmar&title=A+new+perspective+on+old+drugs%3A+non-mitotic+actions+of+tubulin-binding+drugs+play+a+major+role+in+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DF%25C3%25BCrst%26aufirst%3DR.%26aulast%3DVollmar%26aufirst%3DA.%2BM.%26atitle%3DA%2520new%2520perspective%2520on%2520old%2520drugs%253A%2520non-mitotic%2520actions%2520of%2520tubulin-binding%2520drugs%2520play%2520a%2520major%2520role%2520in%2520cancer%2520treatment%26jtitle%3DPharmazie%26date%3D2013%26volume%3D68%26spage%3D478%26epage%3D483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Mitchison, T. J.</span><span> </span><span class="NLM_article-title">The proliferation rate paradox in antimitotic chemotherapy</span> <span class="citation_source-journal">Mol. Biol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1091/mbc.E10-04-0335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1091%2Fmbc.E10-04-0335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=22210845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVylsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=1-6&author=T.+J.+Mitchison&title=The+proliferation+rate+paradox+in+antimitotic+chemotherapy&doi=10.1091%2Fmbc.E10-04-0335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The proliferation rate paradox in antimitotic chemotherapy</span></div><div class="casAuthors">Mitchison, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1939-4586</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">A review.  Cytotoxic cancer chemotherapy drugs are believed to gain selectivity by targeting cells that proliferate rapidly.  However, the proliferation rate is low in many chemosensitive human cancers, and it is not clear how a drug that only kills dividing cells could promote tumor regression.  Four potential solns. to this "proliferation rate paradox" are discussed for the microtubule-stabilizing drug paclitaxel: drug retention in tumors, killing of quiescent cells, targeting of noncancer cells in the tumor, and bystander effects.  Testing these potential mechanisms of drug action will facilitate rational improvement of antimitotic chemotherapy and perhaps cytotoxic chemotherapy more generally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGostPy_gyyJCLVg90H21EOLACvtfcHk0ljANfyf4irRKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVylsA%253D%253D&md5=32fea5a5b4d14d23feca77c5f5ab6823</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1091%2Fmbc.E10-04-0335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.E10-04-0335%26sid%3Dliteratum%253Aachs%26aulast%3DMitchison%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520proliferation%2520rate%2520paradox%2520in%2520antimitotic%2520chemotherapy%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2012%26volume%3D23%26spage%3D1%26epage%3D6%26doi%3D10.1091%2Fmbc.E10-04-0335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Seligmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Twelves, C.</span><span> </span><span class="NLM_article-title">Tubulin: an example of targeted chemotherapy</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">339</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span><span class="refDoi"> DOI: 10.4155/fmc.12.217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.4155%2Ffmc.12.217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=23464522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsVKnurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=339-352&author=J.+Seligmannauthor=C.+Twelves&title=Tubulin%3A+an+example+of+targeted+chemotherapy&doi=10.4155%2Ffmc.12.217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin: an example of targeted chemotherapy</span></div><div class="casAuthors">Seligmann, Jenny; Twelves, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">339-352</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Anticancer drugs directed against the microtubule, including taxanes and vinca alkaloids, have been the backbone of many chemotherapy regimes for decades.  These drugs have, however, significant limitations, which have prompted the development of novel microtubule targeting agents (MTAs).  This article will discuss MTAs for anticancer therapies and recent debates regarding their mechanisms of action.  Furthermore, the limitations of taxanes, including hypersensitivity reactions, neurotoxicity, drug resistance and lack of validated biomarkers to guide therapy will be discussed, all of which have driven the development of novel agents.  The mechanisms of action and drug development of new generations of MTAs will also be outlined.  Agents demonstrating utility in Phase III clin. trials, including eribulin, ixabepilone, cabazitaxel and trastuzumab-DM1 will be highlighted, as well as novel agents currently in development and future directions for MTAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon5RB5hJ7vGbVg90H21EOLACvtfcHk0ljANfyf4irRKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsVKnurg%253D&md5=2a2816f2805d063776f113aabdd3c28e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.217%26sid%3Dliteratum%253Aachs%26aulast%3DSeligmann%26aufirst%3DJ.%26aulast%3DTwelves%26aufirst%3DC.%26atitle%3DTubulin%253A%2520an%2520example%2520of%2520targeted%2520chemotherapy%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2013%26volume%3D5%26spage%3D339%26epage%3D352%26doi%3D10.4155%2Ffmc.12.217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Kavallaris, M.</span><span> </span><span class="NLM_article-title">Microtubules and resistance to tubulin-binding agents</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">194</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span><span class="refDoi"> DOI: 10.1038/nrc2803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1038%2Fnrc2803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=20147901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvVKrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=194-204&author=M.+Kavallaris&title=Microtubules+and+resistance+to+tubulin-binding+agents&doi=10.1038%2Fnrc2803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules and resistance to tubulin-binding agents</span></div><div class="casAuthors">Kavallaris, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">194-204</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic structures composed of α-β-tubulin heterodimers that are essential in cell division and are important targets for cancer drugs.  Mutations in β-tubulin that affect microtubule polymer mass and/or drug binding are assocd. with resistance to tubulin-binding agents such as paclitaxel.  The aberrant expression of specific β-tubulin isotypes, in particular βIII-tubulin, or of microtubule-regulating proteins is important clin. in tumor aggressiveness and resistance to chemotherapy.  In addn., changes in actin regulation can also mediate resistance to tubulin-binding agents.  Understanding the mol. mechanisms that mediate resistance to tubulin-binding agents will be vital to improve the efficacy of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNkoVu03ikmrVg90H21EOLACvtfcHk0ljkaQDoZCzs8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvVKrtbg%253D&md5=1ce71cc537091459d7ee6866c0950b33</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrc2803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2803%26sid%3Dliteratum%253Aachs%26aulast%3DKavallaris%26aufirst%3DM.%26atitle%3DMicrotubules%2520and%2520resistance%2520to%2520tubulin-binding%2520agents%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D194%26epage%3D204%26doi%3D10.1038%2Fnrc2803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Katsetos, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Draber, P.</span><span> </span><span class="NLM_article-title">Tubulins as therapeutic targets in cancer: from bench to bedside</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2778</span><span class="NLM_x">–</span> <span class="NLM_lpage">2792</span><span class="refDoi"> DOI: 10.2174/138161212800626193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.2174%2F138161212800626193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=22390762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC38XoslCrs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2778-2792&author=C.+D.+Katsetosauthor=P.+Draber&title=Tubulins+as+therapeutic+targets+in+cancer%3A+from+bench+to+bedside&doi=10.2174%2F138161212800626193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulins as therapeutic targets in cancer: from bench to bedside</span></div><div class="casAuthors">Katsetos, Christos D.; Draber, Pavel</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2778-2792</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tubulin is the target of some of the most widely used and time-honored anticancer tubulin-binding agents (TBAs).  The clin. usefulness of many TBAs has been held back as a result of tumor cell drug-resistance.  The elucidation of the three-dimensional structure of αβ-tubulin dimer has provided an opportunity for rational drug design aimed at generating compds. that will target tubulin in therapeutically more efficacious ways compared to presently available drugs.  An issue to be addressed is which one(s) of the tubulin species, their isotypes, or their posttranslationally modified forms, should be specifically targeted in cancer chemotherapy.  This review offers a crit. appraisal of current knowledge on tubulins in cancer and an update on new anti-neoplastic microtubule-targeted treatment strategies.  Specifically, it examines, across disciplines, cellular/mol., biochem., clin./pathol., and pharmacol. aspects of β-tubulin isotypes, posttranslational modifications of tubulin dimers, γ-tubulin and microtubule nucleation, and microtubule regulatory proteins.  Emphasis is placed on the overexpression of (i) the βIII isotypes, which functions as a survival factor assocd. with dynamic instability of microtubules; (ii) γ-tubulin, a key microtubule nucleating protein; and (iii) the microtubule severing enzyme spastin, involved in cell motility and proliferation of glioblastoma cells.  The role of βIII-tubulin in resistance of cancer cells to taxanes is examd.  Attention is called to the novel concept that βIII-tubulin functions as a "gateway" for prosurvival signals in partnership with GTPases, such as GBP1.  Appraisal is also offered on epothilones and the concept of hypersensitization to TBAs as promising therapeutic strategies in taxane resistant epithelial cancers and in high-grade gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxdmReNG2Qw7Vg90H21EOLACvtfcHk0ljkaQDoZCzs8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XoslCrs7k%253D&md5=cc9638610d51334759aa081a624f7abe</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F138161212800626193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212800626193%26sid%3Dliteratum%253Aachs%26aulast%3DKatsetos%26aufirst%3DC.%2BD.%26aulast%3DDraber%26aufirst%3DP.%26atitle%3DTubulins%2520as%2520therapeutic%2520targets%2520in%2520cancer%253A%2520from%2520bench%2520to%2520bedside%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D2778%26epage%3D2792%26doi%3D10.2174%2F138161212800626193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Murray, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briasoulis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bafaloukos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadimitriou, C.</span><span> </span><span class="NLM_article-title">Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">890</span><span class="NLM_x">–</span> <span class="NLM_lpage">903</span><span class="refDoi"> DOI: 10.1016/j.ctrv.2012.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.ctrv.2012.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=22465195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVyrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2012&pages=890-903&author=S.+Murrayauthor=E.+Briasoulisauthor=H.+Linardouauthor=D.+Bafaloukosauthor=C.+Papadimitriou&title=Taxane+resistance+in+breast+cancer%3A+mechanisms%2C+predictive+biomarkers+and+circumvention+strategies&doi=10.1016%2Fj.ctrv.2012.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies</span></div><div class="casAuthors">Murray, S.; Briasoulis, E.; Linardou, H.; Bafaloukos, D.; Papadimitriou, C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">890-903</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Taxanes are established in the treatment of metastatic breast cancer (MBC) and early breast cancer (EBC) as potent chemotherapy agents.  However, their therapeutic usefulness is limited by de-novo refractoriness or acquired resistance, which are common drawbacks to most anti-cancer cytotoxics.  Considering that the taxanes will remain principle chemotherapeutic agents for the treatment of breast cancer, we reviewed known mechanisms of resistance in with an outlook of optimizing their clin. use.We searched the PubMed and MEDLINE databases for articles (from inception through to 9th Jan. 2012; last search 10/01/2012) and journals known to publish information relevant to taxane chemotherapy.  We imposed no language restrictions.  Search terms included: cancer, breast cancer, response, resistance, taxane, paclitaxel, docetaxel, taxol.  Due to the possibility of alternative mechanisms of resistance all combination chemotherapy treated data sets were removed from our overview.Over-expression of the MDR-1 gene product Pgp was extensively studied in vitro in assocn. with taxane resistance, but data are conflicting.  Similarly, the target components microtubules, which are thought to mediate refractoriness through alterations of the expression pattern of tubulins or microtubule assocd. proteins and the expression of alternative tubulin isoforms, failed to confirm such assocns.  Little consensus has been generated for reported assocns. between taxane-sensitivity and mutated p53, or taxane-resistance and overexpression of Bcl-2, Bcl-xL or NFkB.  In contrary sufficient in vitro data support an assocn. of spindle assembly checkpoint (SAC) defects with resistance.  Clin. data have been limited and inconsistent, which relate to the variety of methods used, lack of standardization of cut-offs for quantitation, differences in clin. endpoints measured and in methods of tissue collection prepn. and storage, and study/patient heterogeneity.  The most prominent finding is that pharmaceutical down-regulation of HER-2 appears to reverse the taxane resistance.Currently no valid practical biomarkers exist that can predict resistance to the taxanes in breast cancer supporting the principle of individualized cancer therapy.  The incorporation of several biomarker analyses into prospectively designed studies in this setting are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUEZD9NN-37LVg90H21EOLACvtfcHk0ljkaQDoZCzs8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVyrsLo%253D&md5=62f84f64bb7f97bc4741ce4e5d435fd0</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2012.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2012.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DS.%26aulast%3DBriasoulis%26aufirst%3DE.%26aulast%3DLinardou%26aufirst%3DH.%26aulast%3DBafaloukos%26aufirst%3DD.%26aulast%3DPapadimitriou%26aufirst%3DC.%26atitle%3DTaxane%2520resistance%2520in%2520breast%2520cancer%253A%2520mechanisms%252C%2520predictive%2520biomarkers%2520and%2520circumvention%2520strategies%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2012%26volume%3D38%26spage%3D890%26epage%3D903%26doi%3D10.1016%2Fj.ctrv.2012.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Gan, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kavallaris, M.</span><span> </span><span class="NLM_article-title">Tubulin-targeted drug action: functional significance of class II and class IVb β-tubulin in <i>Vinca</i> alkaloid sensitivity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9817</span><span class="NLM_x">–</span> <span class="NLM_lpage">9824</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-1501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1158%2F0008-5472.CAN-08-1501" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9817-9824&author=P.+P.+Ganauthor=M.+Kavallaris&title=Tubulin-targeted+drug+action%3A+functional+significance+of+class+II+and+class+IVb+%CE%B2-tubulin+in+Vinca+alkaloid+sensitivity&doi=10.1158%2F0008-5472.CAN-08-1501"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1501%26sid%3Dliteratum%253Aachs%26aulast%3DGan%26aufirst%3DP.%2BP.%26aulast%3DKavallaris%26aufirst%3DM.%26atitle%3DTubulin-targeted%2520drug%2520action%253A%2520functional%2520significance%2520of%2520class%2520II%2520and%2520class%2520IVb%2520%25CE%25B2-tubulin%2520in%2520Vinca%2520alkaloid%2520sensitivity%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9817%26epage%3D9824%26doi%3D10.1158%2F0008-5472.CAN-08-1501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Carlson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ocean, A. J.</span><span> </span><span class="NLM_article-title">Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach</span> <span class="citation_source-journal">Clin. Breast Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1016/j.clbc.2011.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.clbc.2011.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=21569993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKisrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=73-81&author=K.+Carlsonauthor=A.+J.+Ocean&title=Peripheral+neuropathy+with+microtubule-targeting+agents%3A+occurrence+and+management+approach&doi=10.1016%2Fj.clbc.2011.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral neuropathy with micortubule-targeting agents: occurrence and management approach</span></div><div class="casAuthors">Carlson, Karen; Ocean, Allyson J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">73-81</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Microtubule-targeting agents (MTAs), which include vinca alkaloids, taxanes, and the recently introduced epothilone, ixabepilone, are widely used chemotherapeutic agents for treatment of patients with cancer.  MTAs interfere with the normal structure and function of microtubules, leading to cell-cycle arrest and tumor cell death.  Microtubule function is crit. to normal neuronal function, thus MTA therapy is commonly assocd. with some form of neuropathy.  There is poor agreement between tools for clin. assessment of MTA-assocd. peripheral neuropathy, and standardization of grading scales is needed to reduce variability.  For a majority of patients, MTA-assocd. neuropathy is mild to moderate in intensity and reversible, but it can be severe and resolve incompletely.  The incidence and severity of MTA-assocd. neuropathy is drug, dose, and schedule dependent.  The first-generation vinca alkaloids (eg, vincristine) are assocd. with severe mixed sensory and motor neuropathy, whereas the newer vinca alkaloids (eg, vinorelbine, vinflunine) induce a milder sensory neuropathy.  Taxane-assocd. sensory neuropathy occurs more often with std. (polyoxyethylated castor oil-based) and albumin-bound paclitaxel than with docetaxel.  The incidence and presentation of peripheral neuropathy with ixabepilone, alone or in combination with capecitabine, are similar to that with taxanes.  Management of neuropathy may involve reducing or delaying the MTA dose, or in severe persistent or disabling cases discontinuing treatment.  Reversal of neuropathy after dosage intervention appears to be more rapid with ixabepilone than with other MTAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVEwY7MtdfdbVg90H21EOLACvtfcHk0lgY0FhodL3e2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKisrnN&md5=36df2eda9b12ae15fa5de5b79e335b62</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2011.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2011.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DCarlson%26aufirst%3DK.%26aulast%3DOcean%26aufirst%3DA.%2BJ.%26atitle%3DPeripheral%2520neuropathy%2520with%2520microtubule-targeting%2520agents%253A%2520occurrence%2520and%2520management%2520approach%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D73%26epage%3D81%26doi%3D10.1016%2Fj.clbc.2011.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Canta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiorazzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavaletti, G.</span><span> </span><span class="NLM_article-title">Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1315</span><span class="NLM_x">–</span> <span class="NLM_lpage">1324</span><span class="refDoi"> DOI: 10.2174/092986709787846488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.2174%2F092986709787846488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=19355888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltVeqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=1315-1324&author=A.+Cantaauthor=A.+Chiorazziauthor=G.+Cavaletti&title=Tubulin%3A+a+target+for+antineoplastic+drugs+into+the+cancer+cells+but+also+in+the+peripheral+nervous+system&doi=10.2174%2F092986709787846488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin as a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system</span></div><div class="casAuthors">Canta, Annalisa; Chiorazzi, Alessia; Cavaletti, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1315-1324</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the introduction into clin. practice of vinca alkaloids, tubulin has become a key and well-established target of modern antineoplastic chemotherapy.  When taxanes became available their broad spectrum of activity was striking and opened up new horizons for cancer patients' treatment.  However, taxanes' susceptibility to drug resistance caused by the drug efflux pump protein, P-glycoprotein, is not infrequent and their use may be limited by poor soly., synthetic problems and toxicity.  The epothilones are a new class of chemotherapeutic agents with a mechanism of action similar to that of taxanes, but different enough to escape, for example, the multidrug resistance caused by P-glycoprotein.  Moreover, the epothilones (that are strong promoters of tubulin polymn.) have significant antitumor activity against human cancer cells that are taxane-resistant, express the multidrug resistance gene MDR-1, and have acquired tubulin mutations.  Finally, starting from the natural mols., several synthetic analogs have been developed.  Besides their antineoplastic efficacy, all the antitubulin drugs share a common toxicity on the peripheral nervous system and peripheral neurotoxicity is a major, potentially dose-limiting side effect also of the epothilones.  The current knowledge regarding the features of epothilones' peripheral neurotoxicity and their comparison with taxanes will be reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrud9z8vnFGFLVg90H21EOLACvtfcHk0lgY0FhodL3e2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltVeqsbo%253D&md5=88fe8b8400cb3ec5be160439503c914f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F092986709787846488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986709787846488%26sid%3Dliteratum%253Aachs%26aulast%3DCanta%26aufirst%3DA.%26aulast%3DChiorazzi%26aufirst%3DA.%26aulast%3DCavaletti%26aufirst%3DG.%26atitle%3DTubulin%253A%2520a%2520target%2520for%2520antineoplastic%2520drugs%2520into%2520the%2520cancer%2520cells%2520but%2520also%2520in%2520the%2520peripheral%2520nervous%2520system%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2009%26volume%3D16%26spage%3D1315%26epage%3D1324%26doi%3D10.2174%2F092986709787846488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Dumontet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, M. A.</span><span> </span><span class="NLM_article-title">Microtubule-binding agents: a dynamic field of cancer therapeutics</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">790</span><span class="NLM_x">–</span> <span class="NLM_lpage">803</span><span class="refDoi"> DOI: 10.1038/nrd3253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1038%2Fnrd3253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=20885410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=790-803&author=C.+Dumontetauthor=M.+A.+Jordan&title=Microtubule-binding+agents%3A+a+dynamic+field+of+cancer+therapeutics&doi=10.1038%2Fnrd3253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-binding agents: a dynamic field of cancer therapeutics</span></div><div class="casAuthors">Dumontet, Charles; Jordan, Mary Ann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">790-803</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic filamentous cytoskeletal proteins composed of tubulin and are an important therapeutic target in tumor cells.  Agents that bind to microtubules have been part of the pharmacopoeia of anticancer therapy for decades and until the advent of targeted therapy, microtubules were the only alternative to DNA as a therapeutic target in cancer.  The screening of a range of botanical species and marine organisms has yielded promising new antitubulin agents with novel properties.  In the current search for novel microtubule-binding agents, enhanced tumor specificity, reduced neurotoxicity and insensitivity to chemoresistance mechanisms are the three main objectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ43DyXjdN7rVg90H21EOLACvtfcHk0lgY0FhodL3e2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI&md5=9fc6fd966859785605936ecbe6dca44e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrd3253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3253%26sid%3Dliteratum%253Aachs%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DM.%2BA.%26atitle%3DMicrotubule-binding%2520agents%253A%2520a%2520dynamic%2520field%2520of%2520cancer%2520therapeutics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D790%26epage%3D803%26doi%3D10.1038%2Fnrd3253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Kingston, D. G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, J. P.</span><span> </span><span class="NLM_article-title">The quest for a simple bioactive analog of paclitaxel as a potential anticancer agent</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2682</span><span class="NLM_x">–</span> <span class="NLM_lpage">2691</span><span class="refDoi"> DOI: 10.1021/ar500203h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar500203h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyqsL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2014&pages=2682-2691&author=D.+G.+I.+Kingstonauthor=J.+P.+Snyder&title=The+quest+for+a+simple+bioactive+analog+of+paclitaxel+as+a+potential+anticancer+agent&doi=10.1021%2Far500203h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The Quest for a Simple Bioactive Analog of Paclitaxel as a Potential Anticancer Agent</span></div><div class="casAuthors">Kingston, David G. I.; Snyder, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2682-2691</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Paclitaxel (PTX), introduced into the clinic in 1991, has revealed itself as an effective antimicrotubule drug for treatment of a range of otherwise intractable cancers.  Along with docetaxel (DTX) and in combination with other agents such as cisplatin, it has proven to be a first-line therapy.  Unfortunately, PTX and DTX carry severe liabilities such as debilitating side effects, rapid onset of resistance, and rather complex mol. structures offering substantial challenges to ease of synthetic manipulation.  Consequently, the past 15 years has witnessed many efforts to synthesize and test highly modified analogs based on intuitive structural similarity relationships with the PTX mol. skeleton, as well as efforts to mimic the conformational profile of the ligand obsd. in the macromol. tubulin-PTX complex.  Highly successful improvements in potency, up to 50-fold increases in IC50, have been achieved by constructing bridges between distal centers in PTX that imitate the conformer of the electron crystallog. binding pose.  Much less successful have been numerous attempts to truncate PTX by replacing the baccatin core with simpler moieties to achieve PTX-like potencies and applying a wide range of flexible synthesis-based chemistries.  Reported efforts, characterized by a fascinating array of baccatin substitutes, have failed to surpass the bioactivities of PTX in both microtubule disassembly assays and cytotoxicity measurements against a range of cell types.  Most of the structures retain the main elements of the PTX C13 side chain, while seeking a smaller rigid bicycle as a baccatin replacement adorned with substituents to mimic the C2 benzoyl moiety and the oxetane ring.  We surmise that past studies have been handicapped by soly. and membrane permeability issues, but primarily by the existence of an expansive taxane binding pocket and the discrepancy in mol. size between PTX and the pruned analogs.  A no. of these mols. offer mol. vols. 50-60% that of PTX, fewer contacts with the tubulin protein, severe mismatches with the PTX pharmacophore, lessened capacity to dispel binding site waters contributing to ΔGbind, and unanticipated binding poses.  The latter is a crit. drawback if mol. designs of simpler PTX structures are based on a perceived or known PTX binding conformation.  We conclude that design and synthesis of a highly cytotoxic tubulin-assembly agent based on the paclitaxel pharmacophore remains an unsolved challenge, but one that can be overcome by focus on the architecture of the taxane binding site independent of the effective, but not unique, hand-in-glove match represented by the PTX-tubulin complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ5O3QzLeCZLVg90H21EOLACvtfcHk0ljrYh-Dhvm0CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyqsL3O&md5=6d9271e63a706174a82bd62247507031</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Far500203h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far500203h%26sid%3Dliteratum%253Aachs%26aulast%3DKingston%26aufirst%3DD.%2BG.%2BI.%26aulast%3DSnyder%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520quest%2520for%2520a%2520simple%2520bioactive%2520analog%2520of%2520paclitaxel%2520as%2520a%2520potential%2520anticancer%2520agent%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2014%26volume%3D47%26spage%3D2682%26epage%3D2691%26doi%3D10.1021%2Far500203h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Gerullis, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ecke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eimer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishahi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, T.</span><span> </span><span class="NLM_article-title">Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span><span class="refDoi"> DOI: 10.1097/CAD.0b013e3283404db0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1097%2FCAD.0b013e3283404db0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=9-17&author=H.+Gerullisauthor=T.+Eckeauthor=C.+Eimerauthor=M.+Wishahiauthor=T.+Otto&title=Vinflunine+as+second-line+treatment+in+platin-resistant+metastatic+urothelial+carcinoma%3A+a+review&doi=10.1097%2FCAD.0b013e3283404db0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1097%2FCAD.0b013e3283404db0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0b013e3283404db0%26sid%3Dliteratum%253Aachs%26aulast%3DGerullis%26aufirst%3DH.%26aulast%3DEcke%26aufirst%3DT.%26aulast%3DEimer%26aufirst%3DC.%26aulast%3DWishahi%26aufirst%3DM.%26aulast%3DOtto%26aufirst%3DT.%26atitle%3DVinflunine%2520as%2520second-line%2520treatment%2520in%2520platin-resistant%2520metastatic%2520urothelial%2520carcinoma%253A%2520a%2520review%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2011%26volume%3D22%26spage%3D9%26epage%3D17%26doi%3D10.1097%2FCAD.0b013e3283404db0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Gourmelon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frenel, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campone, M.</span><span> </span><span class="NLM_article-title">Eribulin mesylate for the treatment of late-stage breast cancer</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2883</span><span class="NLM_x">–</span> <span class="NLM_lpage">2890</span><span class="refDoi"> DOI: 10.1517/14656566.2011.637490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1517%2F14656566.2011.637490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=22087618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsV2ju7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=2883-2890&author=C.+Gourmelonauthor=J.+S.+Frenelauthor=M.+Campone&title=Eribulin+mesylate+for+the+treatment+of+late-stage+breast+cancer&doi=10.1517%2F14656566.2011.637490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Eribulin mesylate for the treatment of late-stage breast cancer</span></div><div class="casAuthors">Gourmelon, Carole; Frenel, Jean Sebastien; Campone, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2883-2890</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Chemotherapy agents, particularly anthracycline and taxane, have demonstrated their significance in metastatic breast cancer.  However, improving overall survival in late-stage breast cancer remains a challenge.  Eribulin mesylate, a new chemotherapy agent, has a proven significance in this setting.  Eribulin mesylate is a synthetic analog of a macrolide isolated from a marine sponge.  It inhibits microtubule polymn., inducing mitosis arrest and apoptosis, and aggregates sol. tubulin in nonproductive form.  In Phase II studies, this drug has shown a partial and stable response.  The Phase III EMBRACE study showed that eribulin mesylate improved overall survival, compared with the physician's choice of treatment, in women who had received two to five prior chemotherapy regimens, including anthracycline and taxane for advanced breast cancer (median overall survival: 13.1 vs. 10.6 mo HR 0.81, p == 0.041).  This compd. is well tolerated.  The most common adverse event is neutropenia.  This paper provides an introduction to the drug, eribulin mesylate, along with an overview of the current drug market for late-stage breast cancer; it also reviews its pharmacodynamics, pharmacokinetics and clin. efficacy.  Currently, eribulin mesylate is only the third single-agent chemotherapy that has improved overall survival (after anthracycline and taxane) in advanced breast cancer.  These results, particularly in heavily pretreated breast cancer, suggest that this drug could become a new std. in the treatment of metastatic breast cancer, and should, therefore, be further developed in its earlier stages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-4HFg_jLJIbVg90H21EOLACvtfcHk0ljrYh-Dhvm0CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsV2ju7jO&md5=af96bd55472db449e26d5791421b1e97</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1517%2F14656566.2011.637490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2011.637490%26sid%3Dliteratum%253Aachs%26aulast%3DGourmelon%26aufirst%3DC.%26aulast%3DFrenel%26aufirst%3DJ.%2BS.%26aulast%3DCampone%26aufirst%3DM.%26atitle%3DEribulin%2520mesylate%2520for%2520the%2520treatment%2520of%2520late-stage%2520breast%2520cancer%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2011%26volume%3D12%26spage%3D2883%26epage%3D2890%26doi%3D10.1517%2F14656566.2011.637490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Preston, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trivedi, M. V.</span><span> </span><span class="NLM_article-title">Eribulin: a novel cytotoxic chemotherapy agent</span> <span class="citation_source-journal">Ann. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">802</span><span class="NLM_x">–</span> <span class="NLM_lpage">811</span><span class="refDoi"> DOI: 10.1345/aph.1Q636</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1345%2Faph.1Q636" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2012&pages=802-811&author=J.+N.+Prestonauthor=M.+V.+Trivedi&title=Eribulin%3A+a+novel+cytotoxic+chemotherapy+agent&doi=10.1345%2Faph.1Q636"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1345%2Faph.1Q636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1345%252Faph.1Q636%26sid%3Dliteratum%253Aachs%26aulast%3DPreston%26aufirst%3DJ.%2BN.%26aulast%3DTrivedi%26aufirst%3DM.%2BV.%26atitle%3DEribulin%253A%2520a%2520novel%2520cytotoxic%2520chemotherapy%2520agent%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2012%26volume%3D46%26spage%3D802%26epage%3D811%26doi%3D10.1345%2Faph.1Q636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montero, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glück, S.</span><span> </span><span class="NLM_article-title">Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span><span class="refDoi"> DOI: 10.1016/j.ctrv.2011.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.ctrv.2011.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=21550727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVaitLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2012&pages=143-151&author=J.+Cortesauthor=A.+J.+Monteroauthor=S.+Gl%C3%BCck&title=Eribulin+mesylate%2C+a+novel+microtubule+inhibitor+in+the+treatment+of+breast+cancer&doi=10.1016%2Fj.ctrv.2011.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer</span></div><div class="casAuthors">Cortes, Javier; Montero, Alberto J.; Glueck, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-151</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Background: Microtubule-targeted agents are one of the most common classes of chemotherapeutic drug for the treatment of breast cancer.  Limitations of current microtubule-targeted agents such as primary or secondary resistance of cancer cells and side effects like neuropathy prompted the discovery and introduction of newer more effective drugs.  This review aims to provide a summary of the novel halichondrin B analog eribulin mesylate (E7389) and illustrate where it is placed in the treatment arena vs. other agents that are approved or are currently in various stages of clin. development.  Methods: Preclin. and clin. trial (phases I-III) data for eribulin were obtained from scientific journals and meeting abstrs., posters, and oral presentations.  The use of current and other emerging microtubule inhibiting agents in breast cancer was also surveyed and briefly reviewed.  Results: Eribulin mesylate at a dose of 1.4 mg/m2 given on days 1 and 8 of a 21-day cycle increased overall survival in patients with metastatic breast cancer (MBC).  Neutropenia, fatigue, alopecia, nausea and anemia were common adverse events (AEs) assocd. with eribulin in clin. studies.  A low incidence of peripheral neuropathy was also assocd. with eribulin in clin. studies (21-26%).  Other emerging microtubule targeted agents, such as vinflunine and larotaxel, also reported efficacy in patients with MBC who had received prior chemotherapy, with grade 3/4 neutropenia being the most common AEs for both agents.  Conclusions: Eribulin mesylate offers clin. activity in advanced breast cancer through improved overall survival, its favorable side-effect profile and convenience of prepn. and administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5f0GUSxcP1rVg90H21EOLACvtfcHk0ljrYh-Dhvm0CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVaitLc%253D&md5=3c5f83244f6b3fe79104d05503c9fce9</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2011.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2011.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DMontero%26aufirst%3DA.%2BJ.%26aulast%3DGl%25C3%25BCck%26aufirst%3DS.%26atitle%3DEribulin%2520mesylate%252C%2520a%2520novel%2520microtubule%2520inhibitor%2520in%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2012%26volume%3D38%26spage%3D143%26epage%3D151%26doi%3D10.1016%2Fj.ctrv.2011.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Brogdon, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canetta, R. M.</span><span> </span><span class="NLM_article-title">Development of other microtubule-stabilizer families: the epothilones and their derivatives</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">599</span><span class="NLM_x">–</span> <span class="NLM_lpage">609</span><span class="refDoi"> DOI: 10.1097/CAD.0000000000000071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1097%2FCAD.0000000000000071" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=599-609&author=C.+F.+Brogdonauthor=F.+Y.+Leeauthor=R.+M.+Canetta&title=Development+of+other+microtubule-stabilizer+families%3A+the+epothilones+and+their+derivatives&doi=10.1097%2FCAD.0000000000000071"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000071%26sid%3Dliteratum%253Aachs%26aulast%3DBrogdon%26aufirst%3DC.%2BF.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DCanetta%26aufirst%3DR.%2BM.%26atitle%3DDevelopment%2520of%2520other%2520microtubule-stabilizer%2520families%253A%2520the%2520epothilones%2520and%2520their%2520derivatives%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2014%26volume%3D25%26spage%3D599%26epage%3D609%26doi%3D10.1097%2FCAD.0000000000000071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Edelman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shvartsbeyn, M.</span><span> </span><span class="NLM_article-title">Epothilones in development for non-small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance</span> <span class="citation_source-journal">Clin. Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1016/j.cllc.2011.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.cllc.2011.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=22133291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVSmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=171-180&author=M.+J.+Edelmanauthor=M.+Shvartsbeyn&title=Epothilones+in+development+for+non-small-cell+lung+cancer%3A+novel+anti-tubulin+agents+with+the+potential+to+overcome+taxane+resistance&doi=10.1016%2Fj.cllc.2011.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Epothilones in Development for Non-Small-Cell Lung Cancer: Novel Anti-Tubulin Agents With the Potential to Overcome Taxane Resistance</span></div><div class="casAuthors">Edelman, Martin J.; Shvartsbeyn, Marianna</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lung Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-180</span>CODEN:
                <span class="NLM_cas:coden">CLCLCA</span>;
        ISSN:<span class="NLM_cas:issn">1525-7304</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Progress in the treatment of non-small-cell lung cancer (NSCLC) will require the introduction of new agents as well as better use of existing therapies.  Targeted therapies are likely to have a profound effect on the treatment of NSCLC after identification of patients who are most likely to benefit.  The epothilones are novel anti-tubulin agents derived from Sorangium cellulosum. β III tubulin overexpression has been implicated as a mechanism of anti-tubulin resistance that can be overcome by epothilones.  Several epothilones have advanced to clin. trials; ixabepilone (BMS247550, aza-epothilone B, Bristol-Myers Squibb, New York, NY), patupilone (EPO906, Novartis, Basel, Switzerland) and sagopilone (ZK-EPO, ZK-219477, Schering AG, Berlin-Wedding, Germany) are currently in active development.  Several of the epothilones, most notably ixabepilone, have demonstrated activity in lung cancer in phase I and II trials, including taxane-resistant patients.  Although a phase II study failed to show superior outcome in patients with β III tubulin overexpression, other aspects of the epothilones argue for their continued development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOd1ey7FnY17Vg90H21EOLACvtfcHk0lgiIrPRV0Xa-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVSmsrY%253D&md5=97e1a9c969690719ef30bfd0bd513a66</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.cllc.2011.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cllc.2011.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DEdelman%26aufirst%3DM.%2BJ.%26aulast%3DShvartsbeyn%26aufirst%3DM.%26atitle%3DEpothilones%2520in%2520development%2520for%2520non-small-cell%2520lung%2520cancer%253A%2520novel%2520anti-tubulin%2520agents%2520with%2520the%2520potential%2520to%2520overcome%2520taxane%2520resistance%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2012%26volume%3D13%26spage%3D171%26epage%3D180%26doi%3D10.1016%2Fj.cllc.2011.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Sadeghi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olevsky, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurvitz, S. A.</span><span> </span><span class="NLM_article-title">Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine</span> <span class="citation_source-journal">Pharmacogenomics Pers. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">338</span><span class="refDoi"> DOI: 10.2147/PGPM.S47524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.2147%2FPGPM.S47524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=25378946" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=329-338&author=S.+Sadeghiauthor=O.+Olevskyauthor=S.+A.+Hurvitz&title=Profiling+and+targeting+HER2-positive+breast+cancer+using+trastuzumab+emtansine&doi=10.2147%2FPGPM.S47524"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2147%2FPGPM.S47524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FPGPM.S47524%26sid%3Dliteratum%253Aachs%26aulast%3DSadeghi%26aufirst%3DS.%26aulast%3DOlevsky%26aufirst%3DO.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26atitle%3DProfiling%2520and%2520targeting%2520HER2-positive%2520breast%2520cancer%2520using%2520trastuzumab%2520emtansine%26jtitle%3DPharmacogenomics%2520Pers.%2520Med.%26date%3D2014%26volume%3D7%26spage%3D329%26epage%3D338%26doi%3D10.2147%2FPGPM.S47524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Coen van Hasselt, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussein, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijnen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huitema, A. D. R.</span><span> </span><span class="NLM_article-title">Population pharmacokinetic–pharmacodynamic analysis for eribulin mesylate-associated neutropenia</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">412</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span><span class="refDoi"> DOI: 10.1111/bcp.12143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1111%2Fbcp.12143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=23601153" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2013&pages=412-424&author=J.+G.+Coen+van+Hasseltauthor=A.+Guptaauthor=Z.+Husseinauthor=J.+H.+Beijnenauthor=J.+H.+M.+Schellensauthor=A.+D.+R.+Huitema&title=Population+pharmacokinetic%E2%80%93pharmacodynamic+analysis+for+eribulin+mesylate-associated+neutropenia&doi=10.1111%2Fbcp.12143"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12143%26sid%3Dliteratum%253Aachs%26aulast%3DCoen%2Bvan%2BHasselt%26aufirst%3DJ.%2BG.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DHussein%26aufirst%3DZ.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DHuitema%26aufirst%3DA.%2BD.%2BR.%26atitle%3DPopulation%2520pharmacokinetic%25E2%2580%2593pharmacodynamic%2520analysis%2520for%2520eribulin%2520mesylate-associated%2520neutropenia%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D76%26spage%3D412%26epage%3D424%26doi%3D10.1111%2Fbcp.12143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Valero, V.</span><span> </span><span class="NLM_article-title">Managing ixabepilone adverse events with dose reduction</span> <span class="citation_source-journal">Clin. Breast Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1016/j.clbc.2012.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.clbc.2012.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=23098573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnslyquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1-6&author=V.+Valero&title=Managing+ixabepilone+adverse+events+with+dose+reduction&doi=10.1016%2Fj.clbc.2012.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Managing Ixabepilone Adverse Events With Dose Reduction</span></div><div class="casAuthors">Valero, Vicente</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Ixabepilone is a synthetic analog of epothilone B approved for the treatment of patients with metastatic or locally advanced breast cancer in combination with capecitabine for cancer resistant to an anthracycline and a taxane, and as monotherapy for cancer resistant or refractory to anthracyclines, taxanes, and capecitabine.  The principal dose-limiting adverse events (AEs) of ixabepilone's std. dose (40 mg/m2 administered by 3-h infusion once every 3 wk) are peripheral neuropathy, neutropenia, and fatigue.  An effective strategy to manage ixabepilone-related AEs is dose redn. by 20% (from 40 to 32 to 25 mg/m2); this does not appear to affect treatment efficacy and enables continuation of treatment after recovery (grade 1 or resolved).  When appropriate, treatment can be restarted with a 20% dose redn. (to 32 mg/m2).  For heavily pretreated patients, esp. those with a low performance status, 32 mg/m2 is an appropriate initial dose; the dose of capecitabine should also be lowered by 20%.  Weekly ixabepilone (15-20 mg/m2 on days 1, 8, and 15 every 28 days) may have an improved tolerability profile, but prospective studies with a large no. of patients are required to det. whether it has therapeutic benefit comparable with the current approved regimen.  More information is required on dosage and scheduling of ixabepilone in combination with other agents, including novel targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDnYGjenLYcbVg90H21EOLACvtfcHk0lgiIrPRV0Xa-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnslyquw%253D%253D&md5=b0857bc68e040bcc7421d424d88ab217</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2012.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2012.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DValero%26aufirst%3DV.%26atitle%3DManaging%2520ixabepilone%2520adverse%2520events%2520with%2520dose%2520reduction%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D1%26epage%3D6%26doi%3D10.1016%2Fj.clbc.2012.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Ebenezer, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donovan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobham, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cigler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramnarain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vahdat, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polydefkis, M.</span><span> </span><span class="NLM_article-title">Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients</span> <span class="citation_source-journal">Ann. Clin. Transl. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">639</span><span class="NLM_x">–</span> <span class="NLM_lpage">649</span><span class="refDoi"> DOI: 10.1002/acn3.90</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1002%2Facn3.90" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=25493278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yisLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2014&pages=639-649&author=G.+J.+Ebenezerauthor=K.+Carlsonauthor=D.+Donovanauthor=M.+Cobhamauthor=E.+Chuangauthor=A.+Mooreauthor=T.+Ciglerauthor=M.+Wardauthor=M.+E.+Laneauthor=A.+Ramnarainauthor=L.+T.+Vahdatauthor=M.+Polydefkis&title=Ixabepilone-induced+mitochondria+and+sensory+axon+loss+in+breast+cancer+patients&doi=10.1002%2Facn3.90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients</span></div><div class="casAuthors">Ebenezer, Gigi J.; Carlson, Karen; Donovan, Diana; Cobham, Marta; Chuang, Ellen; Moore, Anne; Cigler, Tessa; Ward, Maureen; Lane, Maureen E.; Ramnarain, Anita; Vahdat, Linda T.; Polydefkis, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Clinical and Translational Neurology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">639-649</span>CODEN:
                <span class="NLM_cas:coden">ACTNCG</span>;
        ISSN:<span class="NLM_cas:issn">2328-9503</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Background : We sought to define the clin. and ultrastructure effects of ixabepilone (Ix), a microtubule-stabilizing chemotherapy agent on cutaneous sensory nerves and to investigate a potential mitochondrial toxicity mechanism.  Methods : Ten breast cancer patients receiving Ix underwent total neuropathy score clin. (TNSc) assessment, distal leg skin biopsies at cycle (Cy) 3 (80-90 mg/m2), Cy5 (160-190 mg/m2), and Cy7 (>200 mg/m2) and were compared to 5 controls.  Skin blocks were processed for EM and ultrastructural morphometry of Remak axons done.  Results : At baseline, Ix-treated subjects had higher TNSc values (4.5 ± 0.8 vs. 0.0 ± 0.0), greater percentage of empty (denervated) Schwann cells (29% vs. 12%), altered axonal diam. (422.9 ± 17 vs. 354.9 ± 14.8 nm, P = 0.01), and axon profiles without mitochondria tended to increase compared to control subjects (71% vs. 70%).  With increasing cumulative Ix exposure, an increase in TNSc values (Cy3: 5.4 ± 1.2, Cy7: 10 ± 4, P < 0.001), empty Schwann cells (39% by Cy7), and dilated axons (in nm, Cy3: 506.3 ± 22.1, Cy5: 534.8 ± 33, Cy7: 527.8 ± 24.4; P < 0.001) was obsd.  In addn., axon profiles without mitochondria (Cy3:74%, Cy7:78%) and mitochondria with abnormal morphol. (grade 3 or 4) increased from 24% to 79%.  Schwann cells with atypical mitochondria and perineuronal macrophage infiltration in dermis were noted.  Interpretation : This study provides functional and structural evidence that Ix exposure induces a dose-dependent toxicity on small sensory fibers with an increase in TNSc scores and progressive axonal loss.  Mitochondria appear to bear the cumulative toxic effect and chemotherapy-induced toxicity can be monitored through serial skin biopsy-based anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx6GF4qIrHyrVg90H21EOLACvtfcHk0liyJPn1oLdLEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yisLzL&md5=ed2873b30eb7638c3a8d62479b4815ff</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Facn3.90&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Facn3.90%26sid%3Dliteratum%253Aachs%26aulast%3DEbenezer%26aufirst%3DG.%2BJ.%26aulast%3DCarlson%26aufirst%3DK.%26aulast%3DDonovan%26aufirst%3DD.%26aulast%3DCobham%26aufirst%3DM.%26aulast%3DChuang%26aufirst%3DE.%26aulast%3DMoore%26aufirst%3DA.%26aulast%3DCigler%26aufirst%3DT.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DLane%26aufirst%3DM.%2BE.%26aulast%3DRamnarain%26aufirst%3DA.%26aulast%3DVahdat%26aufirst%3DL.%2BT.%26aulast%3DPolydefkis%26aufirst%3DM.%26atitle%3DIxabepilone-induced%2520mitochondria%2520and%2520sensory%2520axon%2520loss%2520in%2520breast%2520cancer%2520patients%26jtitle%3DAnn.%2520Clin.%2520Transl.%2520Neurol.%26date%3D2014%26volume%3D1%26spage%3D639%26epage%3D649%26doi%3D10.1002%2Facn3.90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Vahdat, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellegrino, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindquist, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iannotti, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopalakrishna, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparano, J. A.</span><span> </span><span class="NLM_article-title">Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized phase II study comparing the incidence of peripheral neuropathy</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">140</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">351</span><span class="refDoi"> DOI: 10.1007/s10549-013-2574-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1007%2Fs10549-013-2574-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=23877339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOktrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2013&pages=341-351&author=L.+T.+Vahdatauthor=A.+A.+Garciaauthor=C.+Vogelauthor=C.+Pellegrinoauthor=D.+L.+Lindquistauthor=N.+Iannottiauthor=P.+Gopalakrishnaauthor=J.+A.+Sparano&title=Eribulin+mesylate+versus+ixabepilone+in+patients+with+metastatic+breast+cancer%3A+a+randomized+phase+II+study+comparing+the+incidence+of+peripheral+neuropathy&doi=10.1007%2Fs10549-013-2574-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy</span></div><div class="casAuthors">Vahdat, Linda T.; Garcia, Agustin A.; Vogel, Charles; Pellegrino, Christine; Lindquist, Deborah L.; Iannotti, Nicholas; Gopalakrishna, Prashanth; Sparano, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">341-351</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Peripheral neuropathy is a common toxicity assocd. with tubulin-targeted chemotherapeutic agents.  This Phase II study compares the incidence and severity of neuropathy assocd. with eribulin mesylate or ixabepilone in metastatic breast cancer (MBC).  The primary objective was to assess the incidence of neuropathy; the study was designed to detect a difference in neuropathy rate of 35 % for eribulin vs. 63 % for ixabepilone (odds ratio 0.316, 80 % power, 0.05 two-sided significance level).  Eligibility criteria included: MBC; prior taxane therapy; at least one chemotherapy for advanced disease; no or minimal pre-existing neuropathy (Grade 0 or 1).  The intent-to-treat population comprised 104 patients randomized (1:1) to eribulin mesylate (1.4 mg/m2, 2-5 min i.v. on days 1 and 8) or ixabepilone (40 mg/m2, 3 h i.v. on day 1) on a 21-day cycle. 101 patients in the safety population received a median of 5.0 eribulin and 3.5 ixabepilone cycles.  Incidence of neuropathy (any grade) was 33.3 and 48.0 %, and peripheral neuropathy was 31.4 and 44.0 % for eribulin and ixabepilone, resp.  After controlling for pre-existing neuropathy and no. of prior chemotherapies, these differences were not significant.  Compared with ixabepilone, fewer patients receiving eribulin discontinued treatment due to neuropathy (3.9 vs. 18.0 %) or adverse events (AEs) in general (11.8 vs. 32.0 %).  Time to onset of neuropathy was 35.9 wk for eribulin and 11.6 wk for ixabepilone, and time to resoln. was 48 vs. 10 wk, resp.; other AEs were comparable.  Objective responses were 15.4 vs. 5.8 % and clin. benefit rates were 26.9 vs. 19.2 %.  In conclusion, after controlling for pre-existing neuropathy and no. of prior chemotherapies, the differences in the incidence of neuropathy with eribulin and ixabepilone were not statistically significant.  Onset of neuropathy tended to occur later with eribulin and resolve later.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP_yjKO0ZQ0bVg90H21EOLACvtfcHk0liyJPn1oLdLEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOktrzP&md5=2a4b931926deb65e362b92e54a08be0f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2Fs10549-013-2574-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-013-2574-2%26sid%3Dliteratum%253Aachs%26aulast%3DVahdat%26aufirst%3DL.%2BT.%26aulast%3DGarcia%26aufirst%3DA.%2BA.%26aulast%3DVogel%26aufirst%3DC.%26aulast%3DPellegrino%26aufirst%3DC.%26aulast%3DLindquist%26aufirst%3DD.%2BL.%26aulast%3DIannotti%26aufirst%3DN.%26aulast%3DGopalakrishna%26aufirst%3DP.%26aulast%3DSparano%26aufirst%3DJ.%2BA.%26atitle%3DEribulin%2520mesylate%2520versus%2520ixabepilone%2520in%2520patients%2520with%2520metastatic%2520breast%2520cancer%253A%2520a%2520randomized%2520phase%2520II%2520study%2520comparing%2520the%2520incidence%2520of%2520peripheral%2520neuropathy%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2013%26volume%3D140%26spage%3D341%26epage%3D351%26doi%3D10.1007%2Fs10549-013-2574-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Wozniak, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapidus, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carozzi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavaletti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayakawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosokawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towle, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littlefield, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slusher, B. S.</span><span> </span><span class="NLM_article-title">Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel and ixabepilone in mice</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">3952</span><span class="NLM_x">–</span> <span class="NLM_lpage">3962</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-4184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1158%2F0008-5472.CAN-10-4184" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=3952-3962&author=K.+M.+Wozniakauthor=K.+Nomotoauthor=R.+G.+Lapidusauthor=Y.+Wuauthor=V.+Carozziauthor=G.+Cavalettiauthor=K.+Hayakawaauthor=S.+Hosokawaauthor=M.+J.+Towleauthor=B.+A.+Littlefieldauthor=B.+S.+Slusher&title=Comparison+of+neuropathy-inducing+effects+of+eribulin+mesylate%2C+paclitaxel+and+ixabepilone+in+mice&doi=10.1158%2F0008-5472.CAN-10-4184"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4184%26sid%3Dliteratum%253Aachs%26aulast%3DWozniak%26aufirst%3DK.%2BM.%26aulast%3DNomoto%26aufirst%3DK.%26aulast%3DLapidus%26aufirst%3DR.%2BG.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DCarozzi%26aufirst%3DV.%26aulast%3DCavaletti%26aufirst%3DG.%26aulast%3DHayakawa%26aufirst%3DK.%26aulast%3DHosokawa%26aufirst%3DS.%26aulast%3DTowle%26aufirst%3DM.%2BJ.%26aulast%3DLittlefield%26aufirst%3DB.%2BA.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26atitle%3DComparison%2520of%2520neuropathy-inducing%2520effects%2520of%2520eribulin%2520mesylate%252C%2520paclitaxel%2520and%2520ixabepilone%2520in%2520mice%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D3952%26epage%3D3962%26doi%3D10.1158%2F0008-5472.CAN-10-4184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">LaPointe, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morfini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brady, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinstein, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, M. A.</span><span> </span><span class="NLM_article-title">Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy</span> <span class="citation_source-journal">NeuroToxicology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="NLM_x">–</span> <span class="NLM_lpage">239</span><span class="refDoi"> DOI: 10.1016/j.neuro.2013.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.neuro.2013.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=23711742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSmurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2013&pages=231-239&author=N.+E.+LaPointeauthor=G.+Morfiniauthor=S.+T.+Bradyauthor=S.+C.+Feinsteinauthor=L.+Wilsonauthor=M.+A.+Jordan&title=Effects+of+eribulin%2C+vincristine%2C+paclitaxel+and+ixabepilone+on+fast+axonal+transport+and+kinesin-1+driven+microtubule+gliding%3A+implications+for+chemotherapy-induced+peripheral+neuropathy&doi=10.1016%2Fj.neuro.2013.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: Implications for chemotherapy-induced peripheral neuropathy</span></div><div class="casAuthors">LaPointe, Nichole E.; Morfini, Gerardo; Brady, Scott T.; Feinstein, Stuart C.; Wilson, Leslie; Jordan, Mary Ann</div><div class="citationInfo"><span class="NLM_cas:title">NeuroToxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">231-239</span>CODEN:
                <span class="NLM_cas:coden">NRTXDN</span>;
        ISSN:<span class="NLM_cas:issn">0161-813X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Chemotherapy-induced peripheral neuropathy (CIPN) is a serious, painful and dose-limiting side effect of cancer drugs that target microtubules.  The mechanisms underlying the neuronal damage are unknown, but may include disruption of fast axonal transport, an essential microtubule-based process that moves cellular components over long distances between neuronal cell bodies and nerve terminals.  This idea is supported by the "dying back" pattern of degeneration obsd. in CIPN, and by the selective vulnerability of sensory neurons bearing the longest axonal projections.  In this study, we test the hypothesis that microtubule-targeting drugs disrupt fast axonal transport using vesicle motility assays in isolated squid axoplasm and a cell-free microtubule gliding assay with defined components.  We compare four clin.-used drugs, eribulin, vincristine, paclitaxel and ixabepilone.  Of these, eribulin is assocd. with a relatively low incidence of severe neuropathy, while vincristine has a relatively high incidence.  In vesicle motility assays, we found that all four drugs inhibited anterograde (conventional kinesin-dependent) fast axonal transport, with the potency being vincristine = ixabepilone > paclitaxel = eribulin.  Interestingly, eribulin and paclitaxel did not inhibit retrograde (cytoplasmic dynein-dependent) fast axonal transport, in contrast to vincristine and ixabepilone.  Similarly, vincristine and ixabepilone both exerted significant inhibitory effects in an in vitro microtubule gliding assay consisting of recombinant kinesin (kinesin-1) and microtubules composed of purified bovine brain tubulin, whereas paclitaxel and eribulin had negligible effects.  Our results suggest that (i) inhibition of microtubule-based fast axonal transport may be a significant contributor to neurotoxicity induced by microtubule-targeting drugs, and (ii) that individual microtubule-targeting drugs affect fast axonal transport through different mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxrFqowG6Y2rVg90H21EOLACvtfcHk0lgsVGf5lgXGtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSmurvI&md5=afe584faafb51bd439dfc89cf9e9ccc7</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.neuro.2013.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuro.2013.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DLaPointe%26aufirst%3DN.%2BE.%26aulast%3DMorfini%26aufirst%3DG.%26aulast%3DBrady%26aufirst%3DS.%2BT.%26aulast%3DFeinstein%26aufirst%3DS.%2BC.%26aulast%3DWilson%26aufirst%3DL.%26aulast%3DJordan%26aufirst%3DM.%2BA.%26atitle%3DEffects%2520of%2520eribulin%252C%2520vincristine%252C%2520paclitaxel%2520and%2520ixabepilone%2520on%2520fast%2520axonal%2520transport%2520and%2520kinesin-1%2520driven%2520microtubule%2520gliding%253A%2520implications%2520for%2520chemotherapy-induced%2520peripheral%2520neuropathy%26jtitle%3DNeuroToxicology%26date%3D2013%26volume%3D37%26spage%3D231%26epage%3D239%26doi%3D10.1016%2Fj.neuro.2013.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Polastro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aftimos, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awada, A.</span><span> </span><span class="NLM_article-title">Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">649</span><span class="NLM_x">–</span> <span class="NLM_lpage">665</span><span class="refDoi"> DOI: 10.1586/14737140.2014.920693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1586%2F14737140.2014.920693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=24852360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVWitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=649-665&author=L.+Polastroauthor=P.+G.+Aftimosauthor=A.+Awada&title=Eribulin+mesylate+in+the+management+of+metastatic+breast+cancer+and+other+solid+cancers%3A+a+drug+review&doi=10.1586%2F14737140.2014.920693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review</span></div><div class="casAuthors">Polastro, Laura; Aftimos, Philippe G.; Awada, Ahmad</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">649-665</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  In the new era of 'precision' cancer medicine, new drug development has shifted from cytotoxic chemotherapy to molecularly targeted agents.  Eribulin mesylate, a microtubule-destabilizing agent, is the only 'classical' cytotoxic agent approved for the treatment of breast cancer in the last 7 years.  This synthetic analog of halichondrin B, isolated from the marine sponge 'Halicondria Okaida', was responsible for prolonging overall survival of heavily pretreated metastatic breast cancer patients in a large Phase III trial.  Eribulin is now under clin. development in earlier settings such as the neo-adjuvant and adjuvant settings.  Furthermore, its unique mechanism of action and the absence of cross-resistance with taxanes have led to the design of clin. trials in multiple indications: bladder cancer, lung cancer, prostate cancer...  The main adverse events are neutropenia, fatigue and peripheral neuropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEFzLnmwuRM7Vg90H21EOLACvtfcHk0lgsVGf5lgXGtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVWitLk%253D&md5=65618013db9faa8001320d9e58016224</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1586%2F14737140.2014.920693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.2014.920693%26sid%3Dliteratum%253Aachs%26aulast%3DPolastro%26aufirst%3DL.%26aulast%3DAftimos%26aufirst%3DP.%2BG.%26aulast%3DAwada%26aufirst%3DA.%26atitle%3DEribulin%2520mesylate%2520in%2520the%2520management%2520of%2520metastatic%2520breast%2520cancer%2520and%2520other%2520solid%2520cancers%253A%2520a%2520drug%2520review%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2014%26volume%3D14%26spage%3D649%26epage%3D665%26doi%3D10.1586%2F14737140.2014.920693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Laughney, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprachman, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohler, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchison, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissleder, R.</span><span> </span><span class="NLM_article-title">Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">261ra152</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3009318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1126%2Fscitranslmed.3009318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=25378644" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=261ra152&author=A.+M.+Laughneyauthor=E.+Kimauthor=M.+M.+Sprachmanauthor=M.+A.+Millerauthor=R.+H.+Kohlerauthor=K.+S.+Yangauthor=J.+D.+Orthauthor=T.+J.+Mitchisonauthor=R.+Weissleder&title=Single-cell+pharmacokinetic+imaging+reveals+a+therapeutic+strategy+to+overcome+drug+resistance+to+the+microtubule+inhibitor+eribulin&doi=10.1126%2Fscitranslmed.3009318"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3009318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3009318%26sid%3Dliteratum%253Aachs%26aulast%3DLaughney%26aufirst%3DA.%2BM.%26aulast%3DKim%26aufirst%3DE.%26aulast%3DSprachman%26aufirst%3DM.%2BM.%26aulast%3DMiller%26aufirst%3DM.%2BA.%26aulast%3DKohler%26aufirst%3DR.%2BH.%26aulast%3DYang%26aufirst%3DK.%2BS.%26aulast%3DOrth%26aufirst%3DJ.%2BD.%26aulast%3DMitchison%26aufirst%3DT.%2BJ.%26aulast%3DWeissleder%26aufirst%3DR.%26atitle%3DSingle-cell%2520pharmacokinetic%2520imaging%2520reveals%2520a%2520therapeutic%2520strategy%2520to%2520overcome%2520drug%2520resistance%2520to%2520the%2520microtubule%2520inhibitor%2520eribulin%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D261ra152%26doi%3D10.1126%2Fscitranslmed.3009318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. D.</span><span> </span><span class="NLM_article-title">An overview of tubulin inhibitors that interact with the colchicine binding site</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2943</span><span class="NLM_x">–</span> <span class="NLM_lpage">2971</span><span class="refDoi"> DOI: 10.1007/s11095-012-0828-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1007%2Fs11095-012-0828-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=22814904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOis7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=2943-2971&author=Y.+Luauthor=J.+Chenauthor=M.+Xiaoauthor=W.+Liauthor=D.+D.+Miller&title=An+overview+of+tubulin+inhibitors+that+interact+with+the+colchicine+binding+site&doi=10.1007%2Fs11095-012-0828-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site</span></div><div class="casAuthors">Lu, Yan; Chen, Jianjun; Xiao, Min; Li, Wei; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2943-2971</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Tubulin dynamics is a promising target for new chemotherapeutic agents.  The colchicine binding site is one of the most important pockets for potential tubulin polymn. destabilizers.  Colchicine binding site inhibitors (CBSI) exert their biol. effects by inhibiting tubulin assembly and suppressing microtubule formation.  A large no. of mols. interacting with the colchicine binding site have been designed and synthesized with significant structural diversity.  CBSIs have been modified as to chem. structure as well as pharmacokinetic properties, and tested in order to find a highly potent, low toxicity agent for treatment of cancers.  CBSIs are believed to act by a common mechanism via binding to the colchicine site on tubulin.  The present review is a synopsis of compds. that have been reported in the past decade that have provided an increase in our understanding of the actions of CBSIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFrFQVgeCbBbVg90H21EOLACvtfcHk0ljVuuYTRkW45A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOis7vN&md5=dfe42e8eb1f0ff22b256641aaa8c17ab</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs11095-012-0828-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-012-0828-z%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DAn%2520overview%2520of%2520tubulin%2520inhibitors%2520that%2520interact%2520with%2520the%2520colchicine%2520binding%2520site%26jtitle%3DPharm.%2520Res.%26date%3D2012%26volume%3D29%26spage%3D2943%26epage%3D2971%26doi%3D10.1007%2Fs11095-012-0828-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Patil, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. D.</span><span> </span><span class="NLM_article-title">Indole molecules as inhibitors of tubulin polymerization: potential new anticancer agents</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">2085</span><span class="NLM_x">–</span> <span class="NLM_lpage">2115</span><span class="refDoi"> DOI: 10.4155/fmc.12.141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.4155%2Ffmc.12.141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=23157240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ynsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=2085-2115&author=S.+A.+Patilauthor=R.+Patilauthor=D.+D.+Miller&title=Indole+molecules+as+inhibitors+of+tubulin+polymerization%3A+potential+new+anticancer+agents&doi=10.4155%2Ffmc.12.141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Indole molecules as inhibitors of tubulin polymerization: potential new anticancer agents</span></div><div class="casAuthors">Patil, Shivaputra A.; Patil, Renukadevi; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2085-2115</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Agents that interfere with tubulin function have a broad anti-tumor spectrum and they represent one of the most significant classes of anticancer agents.  In the past few years, several small synthetic mols. that have an indole nucleus as a core structure have been identified as tubulin inhibitors.  Among these, several aroylindoles, arylthioindoles, diarylindoles and indolylglyoxyamides have shown good inhibition towards the tubulin polymn.  This article reviews the synthesis, biol. activities and SARs of these main classes of indoles.  Brief mention has also been made about the fused indole analogs as tubulin inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-6yFCbyEmnrVg90H21EOLACvtfcHk0ljVuuYTRkW45A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ynsbjP&md5=341d510a2a4fe59892af97fe3d40fbb7</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.141%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DS.%2BA.%26aulast%3DPatil%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DIndole%2520molecules%2520as%2520inhibitors%2520of%2520tubulin%2520polymerization%253A%2520potential%2520new%2520anticancer%2520agents%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D2085%26epage%3D2115%26doi%3D10.4155%2Ffmc.12.141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Kaur, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bariwal, J.</span><span> </span><span class="NLM_article-title">Recent developments in tubulin polymerization inhibitors: an overview</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.09.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.ejmech.2014.09.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=25240869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOltbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2014&pages=89-124&author=R.+Kaurauthor=G.+Kaurauthor=R.+K.+Gillauthor=R.+Soniauthor=J.+Bariwal&title=Recent+developments+in+tubulin+polymerization+inhibitors%3A+an+overview&doi=10.1016%2Fj.ejmech.2014.09.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in tubulin polymerization inhibitors: An overview</span></div><div class="casAuthors">Kaur, Ramandeep; Kaur, Gurneet; Gill, Rupinder Kaur; Soni, Richard; Bariwal, Jitender</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-124</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Microtubules are protein biopolymers formed through polymn. of heterodimers of α- and β-tubulins.  Disruption of microtubules can induce cell cycle arrest in G2-M phase and formation of abnormal mitotic spindles.  Their importance in mitosis and cell division makes microtubules an attractive target for anticancer drug discovery.  A no. of naturally occurring compds. such as paclitaxel, epothilones, vinblastine, combretastatin, and colchicines exert their effect by changing dynamics of tubulin such as polymn. and depolymn.  During past few years, rapid development of the novel tubulin polymn. inhibitors has been witnessed.  Diverse classes of chem. compds. from the natural as well as from the synthetic origin have been extensively studied.  This review highlights the various classes of synthetically derived chem. compds. those have been reported in last few years as potential tubulin polymn. inhibitors.  A brief synthetic methodol. to access these compds. has been highlighted along with the brief SAR studies.  We strongly believe that this review will provide a platform to the synthetic chemists and biologists to design and synthesize new and potent compds. to inhibit the tubulin polymn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV6nQysY8nvbVg90H21EOLACvtfcHk0ljVuuYTRkW45A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOltbzE&md5=2ffd2f9bb073a7830f4aae7c29f070d9</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.09.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.09.051%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DR.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DGill%26aufirst%3DR.%2BK.%26aulast%3DSoni%26aufirst%3DR.%26aulast%3DBariwal%26aufirst%3DJ.%26atitle%3DRecent%2520developments%2520in%2520tubulin%2520polymerization%2520inhibitors%253A%2520an%2520overview%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D87%26spage%3D89%26epage%3D124%26doi%3D10.1016%2Fj.ejmech.2014.09.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Liu, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, J.-P.</span><span> </span><span class="NLM_article-title">Tubulin inhibitors: a patent review</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="NLM_x">–</span> <span class="NLM_lpage">88</span><span class="refDoi"> DOI: 10.1517/13543776.2014.859247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1517%2F13543776.2014.859247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=24313741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFSlurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=69-88&author=Y.-M.+Liuauthor=H.-L.+Chenauthor=H.-Y.+Leeauthor=J.-P.+Liou&title=Tubulin+inhibitors%3A+a+patent+review&doi=10.1517%2F13543776.2014.859247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin inhibitors: a patent review</span></div><div class="casAuthors">Liu, Yi-Min; Chen, Hsiao-Ling; Lee, Hsueh-Yun; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-88</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Microtubules play an important role in several cellular processes, particularly in the formation of the mitotic spindle during the process of mitosis.  These highly dynamic mitotic-spindle microtubules have become a successful target of cancer therapy.  Microtubule-targeting agents, such as vinca alkaloids and taxanes, were used in clinic over 50 years.  In past decades, development of new antimicrotubule agents that possess different structure and binding sites of tubulin has shown potent activity against the proliferation of various cancer cells, as well as in multidrug-resistant cancers.  Interestingly, many of these agents represent an attractive ability that targeting the tumor blood vessels results in tumor vascular disruption.  Therefore, exploring new agents and strategies may provide more effective therapeutic options in the related treatment of cancer.  Areas covered: In past few years, there are many chem. compds. that successfully interferes the microtubules and display antitumor effect.  In these, published compds. supply the fresh minds in modification of present drugs and new insights into the development of tubulin inhibitors.  Expert opinion: This article arranges the microtubule-targeting agents that have published in patent in recent years.  It may help in the investigation of new tubulin binding site and development of novel drug candidate in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtnvpvVK8NmrVg90H21EOLACvtfcHk0lg8sfG4jvdU4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFSlurvP&md5=e17a15b0f0538911f2a80035edbf89b7</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.859247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.859247%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.-M.%26aulast%3DChen%26aufirst%3DH.-L.%26aulast%3DLee%26aufirst%3DH.-Y.%26aulast%3DLiou%26aufirst%3DJ.-P.%26atitle%3DTubulin%2520inhibitors%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D69%26epage%3D88%26doi%3D10.1517%2F13543776.2014.859247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Wienecke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacher, G.</span><span> </span><span class="NLM_article-title">Indibulin, a novel microtubule inhibitor, discriminates between mature neuronal and nonneuronal tubulin</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">177</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-1342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1158%2F0008-5472.CAN-08-1342" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=171-177&author=A.+Wieneckeauthor=G.+Bacher&title=Indibulin%2C+a+novel+microtubule+inhibitor%2C+discriminates+between+mature+neuronal+and+nonneuronal+tubulin&doi=10.1158%2F0008-5472.CAN-08-1342"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1342%26sid%3Dliteratum%253Aachs%26aulast%3DWienecke%26aufirst%3DA.%26aulast%3DBacher%26aufirst%3DG.%26atitle%3DIndibulin%252C%2520a%2520novel%2520microtubule%2520inhibitor%252C%2520discriminates%2520between%2520mature%2520neuronal%2520and%2520nonneuronal%2520tubulin%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D171%26epage%3D177%26doi%3D10.1158%2F0008-5472.CAN-08-1342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Desai, A.; Ratain, M. J.; Moshier, K.; Tipton, M.; Dooley, W.; Hocknell, K.; Dahl, T.; Sherman, M.; Limentani, S.</span><span> </span><span class="NLM_article-title">A phase I, dose-escalation trial of STA-5312, a microtubule inhibitor with a novel binding site, in advanced or metastatic solid malignancies</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">13040</span>, <div class="note"><p class="first last">2006 ASCO Annual Meeting Proceedings Part I</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=13040&author=A.+Desai&author=M.+J.+Ratain&author=K.+Moshier&author=M.+Tipton&author=W.+Dooley&author=K.+Hocknell&author=T.+Dahl&author=M.+Sherman&author=S.+Limentani&title=A+phase+I%2C+dose-escalation+trial+of+STA-5312%2C+a+microtubule+inhibitor+with+a+novel+binding+site%2C+in+advanced+or+metastatic+solid+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DA.%26atitle%3DA%2520phase%2520I%252C%2520dose-escalation%2520trial%2520of%2520STA-5312%252C%2520a%2520microtubule%2520inhibitor%2520with%2520a%2520novel%2520binding%2520site%252C%2520in%2520advanced%2520or%2520metastatic%2520solid%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D13040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42a"><span><span class="NLM_label">(a) </span><span> </span><span class="NLM_article-title">STA-5312 administered on alternate weekdays every two weeks to patients with hematologic malignancies and patients with solid tumors, NCT00088101</span>. <a href="http://www.clinicaltrials.gov" class="extLink">www.clinicaltrials.gov</a> (accessed December 30, 2014).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+STA-5312+administered+on+alternate+weekdays+every+two+weeks+to+patients+with+hematologic+malignancies+and+patients+with+solid+tumors%2C+NCT00088101.+www.clinicaltrials.gov+%28accessed+December+30%2C+2014%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DSTA-5312%2520administered%2520on%2520alternate%2520weekdays%2520every%2520two%2520weeks%2520to%2520patients%2520with%2520hematologic%2520malignancies%2520and%2520patients%2520with%2520solid%2520tumors%252C%2520NCT00088101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit42b"><span><span class="NLM_label">(b) </span><span> </span><span class="NLM_article-title">A phase I study of STA-5312 in subjects with advanced or metastatic solid tumors, NCT00276913</span>. <a href="http://www.clinicaltrials.gov" class="extLink">www.clinicaltrials.gov</a> (accessed December 30, 2014).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+A+phase+I+study+of+STA-5312+in+subjects+with+advanced+or+metastatic+solid+tumors%2C+NCT00276913.+www.clinicaltrials.gov+%28accessed+December+30%2C+2014%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520phase%2520I%2520study%2520of%2520STA-5312%2520in%2520subjects%2520with%2520advanced%2520or%2520metastatic%2520solid%2520tumors%252C%2520NCT00276913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Bacher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emig, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhoefer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shandra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klenner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckers, T.</span><span> </span><span class="NLM_article-title">D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">392</span><span class="NLM_x">–</span> <span class="NLM_lpage">399</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=392-399&author=G.+Bacherauthor=B.+Nickelauthor=P.+Emigauthor=U.+Vanhoeferauthor=S.+Seeberauthor=A.+Shandraauthor=T.+Klennerauthor=T.+Beckers&title=D-24851%2C+a+novel+synthetic+microtubule+inhibitor%2C+exerts+curative+antitumoral+activity+in+vivo%2C+shows+efficacy+toward+multidrug-resistant+tumor+cells%2C+and+lacks+neurotoxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBacher%26aufirst%3DG.%26aulast%3DNickel%26aufirst%3DB.%26aulast%3DEmig%26aufirst%3DP.%26aulast%3DVanhoefer%26aufirst%3DU.%26aulast%3DSeeber%26aufirst%3DS.%26aulast%3DShandra%26aufirst%3DA.%26aulast%3DKlenner%26aufirst%3DT.%26aulast%3DBeckers%26aufirst%3DT.%26atitle%3DD-24851%252C%2520a%2520novel%2520synthetic%2520microtubule%2520inhibitor%252C%2520exerts%2520curative%2520antitumoral%2520activity%2520in%2520vivo%252C%2520shows%2520efficacy%2520toward%2520multidrug-resistant%2520tumor%2520cells%252C%2520and%2520lacks%2520neurotoxicity%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D392%26epage%3D399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Kuppens, I. E. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witteveen, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuessler, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daehling, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijnen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voest, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H. M.</span><span> </span><span class="NLM_article-title">Phase I dose-finding and pharmacokinetic trial of orally administered Indibulin (D-24851) to patients with solid tumors</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">235</span><span class="refDoi"> DOI: 10.1007/s10637-006-9027-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1007%2Fs10637-006-9027-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=227-235&author=I.+E.+L.+M.+Kuppensauthor=P.+O.+Witteveenauthor=M.+Schotauthor=V.+M.+Schuesslerauthor=A.+Daehlingauthor=J.+H.+Beijnenauthor=E.+E.+Voestauthor=J.+H.+M.+Schellens&title=Phase+I+dose-finding+and+pharmacokinetic+trial+of+orally+administered+Indibulin+%28D-24851%29+to+patients+with+solid+tumors&doi=10.1007%2Fs10637-006-9027-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs10637-006-9027-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-006-9027-2%26sid%3Dliteratum%253Aachs%26aulast%3DKuppens%26aufirst%3DI.%2BE.%2BL.%2BM.%26aulast%3DWitteveen%26aufirst%3DP.%2BO.%26aulast%3DSchot%26aufirst%3DM.%26aulast%3DSchuessler%26aufirst%3DV.%2BM.%26aulast%3DDaehling%26aufirst%3DA.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DVoest%26aufirst%3DE.%2BE.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DPhase%2520I%2520dose-finding%2520and%2520pharmacokinetic%2520trial%2520of%2520orally%2520administered%2520Indibulin%2520%2528D-24851%2529%2520to%2520patients%2520with%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2007%26volume%3D25%26spage%3D227%26epage%3D235%26doi%3D10.1007%2Fs10637-006-9027-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Oostendorp, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witteveen, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vainchtein, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nol, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosing, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijnen, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voest, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H. M.</span><span> </span><span class="NLM_article-title">Dose-finding and pharmacokinetic study of orally administered Indibulin (D-24851) to patients with advanced solid tumors</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">–</span> <span class="NLM_lpage">170</span><span class="refDoi"> DOI: 10.1007/s10637-009-9244-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1007%2Fs10637-009-9244-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=163-170&author=R.+L.+Oostendorpauthor=P.+O.+Witteveenauthor=B.+Schwartzauthor=L.+D.+Vainchteinauthor=M.+Schotauthor=A.+Nolauthor=H.+Rosingauthor=B.+H.+Beijnenauthor=E.+E.+Voestauthor=J.+H.+M.+Schellens&title=Dose-finding+and+pharmacokinetic+study+of+orally+administered+Indibulin+%28D-24851%29+to+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-009-9244-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1007%2Fs10637-009-9244-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-009-9244-6%26sid%3Dliteratum%253Aachs%26aulast%3DOostendorp%26aufirst%3DR.%2BL.%26aulast%3DWitteveen%26aufirst%3DP.%2BO.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DVainchtein%26aufirst%3DL.%2BD.%26aulast%3DSchot%26aufirst%3DM.%26aulast%3DNol%26aufirst%3DA.%26aulast%3DRosing%26aufirst%3DH.%26aulast%3DBeijnen%26aufirst%3DB.%2BH.%26aulast%3DVoest%26aufirst%3DE.%2BE.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DDose-finding%2520and%2520pharmacokinetic%2520study%2520of%2520orally%2520administered%2520Indibulin%2520%2528D-24851%2529%2520to%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2010%26volume%3D28%26spage%3D163%26epage%3D170%26doi%3D10.1007%2Fs10637-009-9244-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Semenova, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiselyov, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Titov, I. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raihstat, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molodtsov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grishchuk, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiridonov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semenov, V. V.</span><span> </span><span class="NLM_article-title"><i>In vivo</i> evaluation of indolyl glyoxylamides in the phenotypic sea urchin embryo assay</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">–</span> <span class="NLM_lpage">490</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00591.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1111%2Fj.1747-0285.2007.00591.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=17991295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=485-490&author=M.+N.+Semenovaauthor=A.+S.+Kiselyovauthor=I.+Y.+Titovauthor=M.+M.+Raihstatauthor=M.+Molodtsovauthor=E.+Grishchukauthor=I.+Spiridonovauthor=V.+V.+Semenov&title=In+vivo+evaluation+of+indolyl+glyoxylamides+in+the+phenotypic+sea+urchin+embryo+assay&doi=10.1111%2Fj.1747-0285.2007.00591.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo evaluation of indolyl glyoxamides in the phenotypic sea urchin embryo assay</span></div><div class="casAuthors">Semenova, Marina N.; Kiselyov, Alex S.; Titov, Ilia Y.; Raihstat, Mikhail M.; Molodtsov, Maxim; Grishchuk, Ekaterina; Spiridonov, Ilia; Semenov, Victor V.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">485-490</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The authors have devised a 'one-pot' phenotypic in vivo assay for the rapid evaluation of potential tubulin inhibitors using the sea urchin embryo model.  An effect of a small mol. on two specific developmental stages of sea urchin embryo, namely: (i) fertilized egg test for antimitotic activity and (ii) behavioral monitoring of a free-swimming blastulae for changes in the embryo swimming pattern could be quantified by a threshold concn. resulting in resp. abnormalities.  Derivs. of the clin. candidate D-24851 featured good correlation between activity in tubulin polymn. assay and the in vivo data.  Importantly, the authors demonstrated that in these series, the N-substitution of indole is nonessential to attain profound in vitro and cellular effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhFSq68fWM97Vg90H21EOLACvtfcHk0li4sYrJrvdPAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsb3F&md5=ab32c91067df926c7943b1c221f94d2c</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00591.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00591.x%26sid%3Dliteratum%253Aachs%26aulast%3DSemenova%26aufirst%3DM.%2BN.%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DTitov%26aufirst%3DI.%2BY.%26aulast%3DRaihstat%26aufirst%3DM.%2BM.%26aulast%3DMolodtsov%26aufirst%3DM.%26aulast%3DGrishchuk%26aufirst%3DE.%26aulast%3DSpiridonov%26aufirst%3DI.%26aulast%3DSemenov%26aufirst%3DV.%2BV.%26atitle%3DIn%2520vivo%2520evaluation%2520of%2520indolyl%2520glyoxylamides%2520in%2520the%2520phenotypic%2520sea%2520urchin%2520embryo%2520assay%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D70%26spage%3D485%26epage%3D490%26doi%3D10.1111%2Fj.1747-0285.2007.00591.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J. F.</span><span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability – are too many aromatic rings a liability in drug design?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1011</span><span class="NLM_x">–</span> <span class="NLM_lpage">1020</span><span class="refDoi"> DOI: 10.1016/j.drudis.2009.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.drudis.2009.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=19729075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1011-1020&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonald&title=The+impact+of+aromatic+ring+count+on+compound+developability+%E2%80%93+are+too+many+aromatic+rings+a+liability+in+drug+design%3F&doi=10.1016%2Fj.drudis.2009.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47aR"><div class="casContent"><span class="casTitleNuber">47a</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: Are too many aromatic rings a liability in drug design?</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">21/22</span>),
    <span class="NLM_cas:pages">1011-1020</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of arom. ring count (the no. of arom. and heteroarom. rings) in mols. has been analyzed against various developability parameters, aq. soly., lipophilicity, serum albumin binding, CyP450 inhibition and hERG inhibition.  On the basis of this anal., it was concluded that the fewer arom. rings contained in an oral drug candidate, the more developable that candidate is probably to be; in addn., more than three arom. rings in a mol. correlates with poorer compd. developability and, thus, an increased risk of attrition in development.  Data are also presented that demonstrate that even within a defined lipophilicity range, increased arom. ring count leads to decreased aq. soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hOeD6TNGUbVg90H21EOLACvtfcHk0li4sYrJrvdPAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP&md5=48454c9809e8225b4336ea76aad3f3ba</span></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%2520%25E2%2580%2593%2520are%2520too%2520many%2520aromatic%2520rings%2520a%2520liability%2520in%2520drug%2520design%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D1011%26epage%3D1020%26doi%3D10.1016%2Fj.drudis.2009.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit47b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, S. D.</span><span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">164</span><span class="NLM_x">–</span> <span class="NLM_lpage">171</span><span class="refDoi"> DOI: 10.1016/j.drudis.2010.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.drudis.2010.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=21129497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=164-171&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=R.+J.+Youngauthor=S.+D.+Pickett&title=The+impact+of+aromatic+ring+count+on+compound+developability%3A+further+insights+by+examining+carbo-+and+hetero-aromatic+and+-aliphatic+ring+types&doi=10.1016%2Fj.drudis.2010.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47bR"><div class="casContent"><span class="casTitleNuber">47b</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Young, Robert J.; Pickett, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3/4</span>),
    <span class="NLM_cas:pages">164-171</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of carboarom., heteroarom., carboaliph. and heteroaliph. ring counts and fused arom. ring count on several developability measures (soly., lipophilicity, protein binding, P 450 inhibition and hERG binding) is the topic for this review article.  Recent results indicate that increasing ring counts have detrimental effects on developability in the order carboaroms. » heteroaroms. > carboaliphatics > heteroaliphatics, with heteroaliphatics exerting a beneficial effect in many cases.  Increasing arom. ring count exerts effects on several developability parameters that are lipophilicity- and size-independent, and fused arom. systems have a beneficial effect relative to their nonfused counterparts.  Increasing arom. ring count has a detrimental effect on human bioavailability parameters, and heteroarom. ring count (but not other ring counts) has increased over time in marketed oral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJYPC7hkoyv7Vg90H21EOLACvtfcHk0li4sYrJrvdPAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D&md5=8e2d0e4e499d2f07d66ca2f385defb2d</span></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%253A%2520further%2520insights%2520by%2520examining%2520carbo-%2520and%2520hetero-aromatic%2520and%2520-aliphatic%2520ring%2520types%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.drudis.2010.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Lovering, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bikker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, C.</span><span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6752</span><span class="NLM_x">–</span> <span class="NLM_lpage">6756</span><span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0ljllDbVGaPUHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Ishikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, Y.</span><span> </span><span class="NLM_article-title">Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1539</span><span class="NLM_x">–</span> <span class="NLM_lpage">1554</span><span class="refDoi"> DOI: 10.1021/jm101356p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101356p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1539-1554&author=M.+Ishikawaauthor=Y.+Hashimoto&title=Improvement+in+aqueous+solubility+in+small+molecule+drug+discovery+programs+by+disruption+of+molecular+planarity+and+symmetry&doi=10.1021%2Fjm101356p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry</span></div><div class="casAuthors">Ishikawa, Minoru; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1539-1554</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKbtbfvqKZjrVg90H21EOLACvtfcHk0ljllDbVGaPUHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D&md5=a88804b3850625ef9c3f7424366acb91</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm101356p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101356p%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DImprovement%2520in%2520aqueous%2520solubility%2520in%2520small%2520molecule%2520drug%2520discovery%2520programs%2520by%2520disruption%2520of%2520molecular%2520planarity%2520and%2520symmetry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1539%26epage%3D1554%26doi%3D10.1021%2Fjm101356p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Mok, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenk, R.</span><span> </span><span class="NLM_article-title">Locating sweet spots for screening hits and evaluating pan-assay interference filters from the performance analysis of two lead-like libraries</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">534</span><span class="NLM_x">–</span> <span class="NLM_lpage">544</span><span class="refDoi"> DOI: 10.1021/ci300382f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci300382f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtlGhtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=534-544&author=N.+Y.+Mokauthor=S.+Maxeauthor=R.+Brenk&title=Locating+sweet+spots+for+screening+hits+and+evaluating+pan-assay+interference+filters+from+the+performance+analysis+of+two+lead-like+libraries&doi=10.1021%2Fci300382f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Locating Sweet Spots for Screening Hits and Evaluating Pan-Assay Interference Filters from the Performance Analysis of Two Lead-like Libraries</span></div><div class="casAuthors">Mok, N. Yi; Maxe, Sara; Brenk, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">534-544</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The efficiency of automated compd. screening is heavily influenced by the design and the quality of the screening libraries used.  We recently reported on the assembly of one diverse and one target-focused lead-like screening library.  Using data from 15 enzyme-based screenings conducted using these libraries, their performance was investigated.  Both libraries delivered screening hits across a range of targets, with the hits distributed across the entire chem. space represented by both libraries.  On closer inspection, however, hit distribution was uneven across the chem. space, with enrichments obsd. in octants characterized by compds. at the higher end of the mol. wt. and lipophilicity spectrum for lead-like compds., while polar and sp3-carbon atom rich compds. were underrepresented among the screening hits.  Based on these observations, we propose that screening libraries should not be evenly distributed in lead-like chem. space but be enriched in polar, aliph. compds.  In conjunction with variable concn. screening, this could lead to more balanced hit rates across the chem. space and screening hits of higher ligand efficiency will be captured.  Apart from chem. diversity, both screening libraries were shown to be clean from any pan-assay interference (PAINS) behavior.  Even though some compds. were flagged to contain PAINS structural motifs, some of these motifs were demonstrated to be less problematic than previously suggested.  To maximize the diversity of the chem. space sampled in a screening campaign, we therefore consider it justifiable to retain compds. contg. PAINS structural motifs that were apparently clean in this anal. when assembling screening libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp51XFLjlCNULVg90H21EOLACvtfcHk0ljllDbVGaPUHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtlGhtbg%253D&md5=3662f26e446cb8166adf6edabdc71482</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fci300382f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci300382f%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DN.%2BY.%26aulast%3DMaxe%26aufirst%3DS.%26aulast%3DBrenk%26aufirst%3DR.%26atitle%3DLocating%2520sweet%2520spots%2520for%2520screening%2520hits%2520and%2520evaluating%2520pan-assay%2520interference%2520filters%2520from%2520the%2520performance%2520analysis%2520of%2520two%2520lead-like%2520libraries%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D534%26epage%3D544%26doi%3D10.1021%2Fci300382f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Hennemann, B.</span><span> </span><span class="NLM_article-title">Palliative chemotherapy of head and neck cancer: present status and future development</span> <span class="citation_source-journal">Laryngorhinootologie</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">172</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1055/s-2005-921107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1055%2Fs-2005-921107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=16547892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A280%3ADC%252BD287lslOntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2006&pages=172-178&author=B.+Hennemann&title=Palliative+chemotherapy+of+head+and+neck+cancer%3A+present+status+and+future+development&doi=10.1055%2Fs-2005-921107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Palliative chemotherapy of head and neck cancer: present status and future development</span></div><div class="casAuthors">Hennemann B</div><div class="citationInfo"><span class="NLM_cas:title">Laryngo- rhino- otologie</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">172-8</span>
        ISSN:<span class="NLM_cas:issn">0935-8943</span>.
    </div><div class="casAbstract">BACKGROUND:  Patients with head and neck tumors are treated with palliative chemotherapy in case of the detection of distant metastases or local recurrence without the option of surgical therapy or radiation.  Alongside 5-fluorouracil (5-FU) in combination with cisplatin or carboplatin, taxanes, gemcitabine and vinorelbine as well as monoclonal antibodies or small molecule tyrosine kinase inhibitors have been used.  METHODS:  This review analyses the published literature of the past 15 years, including selected abstracts with view to response rate, overall survival and adverse effects.  RESULTS:  5-FU plus cisplatin or carboplatin can still be considered as standard treatment, achieving response rates of 20-30 %.  The addition of taxanes increases the objective response rate but adds remarkable toxicity to the treatment protocol.  Phase III studies demonstrate higher response rates but fail to demonstrate a significant increase of the overall survival after polychemotherapy as compared to monotherapy protocols.  Thus, patients with a reduced performance can be treated with monotherapy.  In case of disease progression after cisplatin-containing chemotherapy further treatment should only be offered to selected patients.  For this situation, platin-free chemotherapy protocols containing taxanes, gemcitabine or vinorelbine seem promising.  Recent studies with monoclonal antibodies or small molecule tyrosine kinase inhibitors report on a response rate of 10-20 %.  CONCLUSION:  The use of new drugs increases the response rate and amends the side effects of the chemotherapy.  However, phase III studies documenting an improved overall survival are lacking.  Targeted therapies broaden the therapeutic armament, and possibly, EGFR inhibition will help to overcome chemotherapy resistance in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9gCiZ2w69GzAEfvC7EH1LfW6udTcc2eYV5viKeeTLDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287lslOntA%253D%253D&md5=8c0dd62ee6f0e44791f8680844747c23</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1055%2Fs-2005-921107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2005-921107%26sid%3Dliteratum%253Aachs%26aulast%3DHennemann%26aufirst%3DB.%26atitle%3DPalliative%2520chemotherapy%2520of%2520head%2520and%2520neck%2520cancer%253A%2520present%2520status%2520and%2520future%2520development%26jtitle%3DLaryngorhinootologie%26date%3D2006%26volume%3D85%26spage%3D172%26epage%3D178%26doi%3D10.1055%2Fs-2005-921107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Cullen, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schumaker, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikitakis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goloubeva, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarlis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haddad, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posner, M. R.</span><span> </span><span class="NLM_article-title">β-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">6222</span><span class="NLM_x">–</span> <span class="NLM_lpage">6228</span><span class="refDoi"> DOI: 10.1200/JCO.2009.23.0953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1200%2FJCO.2009.23.0953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=19917838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1agsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=6222-6228&author=K.+J.+Cullenauthor=L.+Schumakerauthor=N.+Nikitakisauthor=O.+Goloubevaauthor=M.+Tanauthor=M.+J.+Sarlisauthor=R.+I.+Haddadauthor=M.+R.+Posner&title=%CE%B2-Tubulin-II+expression+strongly+predicts+outcome+in+patients+receiving+induction+chemotherapy+for+locally+advanced+squamous+carcinoma+of+the+head+and+neck%3A+a+companion+analysis+of+the+TAX+324+trial&doi=10.1200%2FJCO.2009.23.0953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">β-tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial</span></div><div class="casAuthors">Cullen, Kevin J.; Schumaker, Lisa; Nikitakis, Nikolaos; Goloubeva, Olga; Tan, Ming; Sarlis, Nicholas J.; Haddad, Robert I.; Posner, Marshall R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">6222-6228</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose TAX 324 was a phase III trial comparing induction chemotherapy (IC) with docetaxel, cisplatin, and fluorouracil (TPF) with cisplatin and fluorouracil (PF) followed by concomitant chemoradiotherapy in locally advanced squamous cell cancer of the head and neck (LASCCHN).  This study evaluates a series of tumor markers in pretreatment biopsies from that trial TAX 324 and correlates expression with survival.  Methods Pretherapy biopsy specimens were available for 265 of 501 participants.  Expression of a series of six markers (p53, thymidylate synthase, glutathione s-transferase pi [GST-π], Bcl 2, beta tubulin II [βT-2], and HER2 neu) was evaluated by immunohistochem.  Results For patients with low βT-II expression, median overall survival (OS) was 58.6 mo (95% CI, not reached [NR]), compared with 18.2 mo for patients with high βT-II expression (95% CI, 13.11 to 30.06: hazard ratio [HR], 2.39; 95% CI, 1.67 to 3.72; P < .0001).  Progression-free survival in patients with low βT-II expression was 43.2 mo (95% CI, 24.4 to NR) vs. 9.8 mo (95% CI, 7.06 to 18.53) for high βT-II expression, with a HR of 1.9 (95% CI, 1.43 to 2.77; P < .0001).  The predictive value of βT-II expression was greater in the TPF vs. PF arm than in the PF arm.  Conclusion Increased tumor expression of βT-II is strongly assocd. with adverse outcome in LASCCHN patients treated with IC, and our data suggest low expression of βT-II may predict patients most likely to benefit from induction TPF therapy.  Further, simple models which combine expression of βT-II with a carefully defined set of addnl. immunohistochem. markers may have significant prognostic impact for patients with LASCCHN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEHq9fHSMDPbVg90H21EOLACvtfcHk0lirwpY1q4cvnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1agsbw%253D&md5=e183d97af6833796fb97c02987c53ae0</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.23.0953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.23.0953%26sid%3Dliteratum%253Aachs%26aulast%3DCullen%26aufirst%3DK.%2BJ.%26aulast%3DSchumaker%26aufirst%3DL.%26aulast%3DNikitakis%26aufirst%3DN.%26aulast%3DGoloubeva%26aufirst%3DO.%26aulast%3DTan%26aufirst%3DM.%26aulast%3DSarlis%26aufirst%3DM.%2BJ.%26aulast%3DHaddad%26aufirst%3DR.%2BI.%26aulast%3DPosner%26aufirst%3DM.%2BR.%26atitle%3D%25CE%25B2-Tubulin-II%2520expression%2520strongly%2520predicts%2520outcome%2520in%2520patients%2520receiving%2520induction%2520chemotherapy%2520for%2520locally%2520advanced%2520squamous%2520carcinoma%2520of%2520the%2520head%2520and%2520neck%253A%2520a%2520companion%2520analysis%2520of%2520the%2520TAX%2520324%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D6222%26epage%3D6228%26doi%3D10.1200%2FJCO.2009.23.0953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Schena, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barone, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birocco, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dongiovanni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Numico, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colantonio, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertetto, O.</span><span> </span><span class="NLM_article-title">Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">276</span><span class="refDoi"> DOI: 10.1007/s00280-004-0875-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1007%2Fs00280-004-0875-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=15592837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVCnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2005&pages=271-276&author=M.+Schenaauthor=C.+Baroneauthor=N.+Biroccoauthor=D.+Dongiovanniauthor=G.+Numicoauthor=I.+Colantonioauthor=O.+Bertetto&title=Weekly+cisplatin+paclitaxel+and+continuous+infusion+fluorouracil+in+patients+with+recurrent+and%2For+metastatic+head+and+neck+squamous+cell+carcinoma%3A+a+phase+II+study&doi=10.1007%2Fs00280-004-0875-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study</span></div><div class="casAuthors">Schena, M.; Barone, C.; Birocco, N.; Dongiovanni, D.; Numico, G.; Colantonio, I.; Bertetto, O.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">271-276</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Background: Cisplatin, paclitaxel and 5-fluorouracil (5-FU) have demonstrated significant activity in patients with advanced squamous head and neck cancer (HNSCC) despite relevant toxicity.  A weekly administration of cisplatin and paclitaxel with continuous infusion of 5-FU could offer a better toxicity profile without affecting dose intensity or treatment outcome.  We evaluated the toxicity and the activity of weekly cisplatin/paclitaxel with continuous infusion 5-FU in patients with recurrent and/or metastatic HNSCC.  Methods: A total of 44 patients were studied.  Treatment consisted of two 6-wk cycles with weekly cisplatin 20 mg/m2 and paclitaxel 60 mg/m2 and daily continuous infusion 5-FU 200 mg/m2 from day 1 to 42.  Patients were evaluated for toxicity and response.  Results: 40 out of 44 patients were evaluable for response.  After two cycles we obsd. seven complete responses (16) and 12 partial responses (27), with a 43 (95 CI 28-58) overall response rate.  Stable disease was seen in 13 patients (29) and progressive disease in 12 patients (27).  Toxicity was mild in treated patients: we obsd. less than 10 of grade 3/4 hematol. and gastroenteric toxicity.  Conclusions: A weekly schedule of cisplatin and paclitaxel assocd. with continuous infusion 5-FU showed low toxicity in the treatment of advanced HNSCC while significant activity was conserved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU80o4H-qxE7Vg90H21EOLACvtfcHk0lirwpY1q4cvnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVCnsg%253D%253D&md5=1caa5634a2555153fb4bf436b28f8a2d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2Fs00280-004-0875-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-004-0875-1%26sid%3Dliteratum%253Aachs%26aulast%3DSchena%26aufirst%3DM.%26aulast%3DBarone%26aufirst%3DC.%26aulast%3DBirocco%26aufirst%3DN.%26aulast%3DDongiovanni%26aufirst%3DD.%26aulast%3DNumico%26aufirst%3DG.%26aulast%3DColantonio%26aufirst%3DI.%26aulast%3DBertetto%26aufirst%3DO.%26atitle%3DWeekly%2520cisplatin%2520paclitaxel%2520and%2520continuous%2520infusion%2520fluorouracil%2520in%2520patients%2520with%2520recurrent%2520and%252For%2520metastatic%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%253A%2520a%2520phase%2520II%2520study%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2005%26volume%3D55%26spage%3D271%26epage%3D276%26doi%3D10.1007%2Fs00280-004-0875-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Pointreau, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garaud, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sire, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuchais, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tortochaux, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faivre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrif, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfonsi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calais, G.</span><span> </span><span class="NLM_article-title">Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">498</span><span class="NLM_x">–</span> <span class="NLM_lpage">506</span><span class="refDoi"> DOI: 10.1093/jnci/djp007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1093%2Fjnci%2Fdjp007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=19318632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFWrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2009&pages=498-506&author=Y.+Pointreauauthor=P.+Garaudauthor=S.+Chapetauthor=C.+Sireauthor=C.+Tuchaisauthor=J.+Tortochauxauthor=S.+Faivreauthor=S.+Guerrifauthor=M.+Alfonsiauthor=G.+Calais&title=Randomized+trial+of+induction+chemotherapy+with+cisplatin+and+5-fluorouracil+with+or+without+docetaxel+for+larynx+preservation&doi=10.1093%2Fjnci%2Fdjp007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Larynx Preservation</span></div><div class="casAuthors">Pointreau, Yoann; Garaud, Pascal; Chapet, Sophie; Sire, Christian; Tuchais, Claude; Tortochaux, Jacques; Faivre, Sandrine; Guerrif, Stephane; Alfonsi, Marc; Calais, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">498-506</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Chemotherapy with cisplatin (P) and 5-fluorouracil (F) followed by radiotherapy in patients who respond to chemotherapy is an alternative to total laryngectomy for patients with locally advanced larynx and hypopharynx cancer.  Data suggest that docetaxel (T) may add to the efficacy of PF.  The objective of this trial was to det. whether adding T to PF could increase the larynx preservation rate.  Methods: Patients who had larynx and hypopharynx cancer that required total laryngectomy were randomly assigned to receive three cycles of TPF or PF.  Patients who responded to chemotherapy received radiotherapy with or without addnl. chemotherapy.  Patients who did not respond to chemotherapy underwent total laryngectomy followed by radiotherapy with or without addnl. chemotherapy.  The primary endpoint was 3-yr larynx preservation rate.  Secondary endpoints included acute toxicities and overall response.  All statistical tests were two-sided.  Results: Baseline patient and tumor characteristics were well balanced between the TPF (n = 110) and PF (n = 103) groups.  With a median follow-up of 36 mo, the 3-yr actuarial larynx preservation rate was 70.3% with TPF vs 57.5% with PF (difference = 12.8%; P = .03).  Patients in the TPF group had more grade 2 alopecia, grade 4 neutropenia, and febrile neutropenia, whereas patients in the PF group had more grade 3 and 4 stomatitis, thrombocytopenia, and grade 4 creatinine elevation.  The overall response was 80.0% in the TPF group vs 59.2% in the PF group (difference = 20.8%; P = .002).  Conclusions: In patients with advanced larynx and hypopharynx carcinomas, TPF induction chemotherapy was superior to the PF regimen in terms of overall response rate.  These results suggest that larynx preservation could be achieved for a higher proportion of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBs1fGBsp_-LVg90H21EOLACvtfcHk0lgTSA4WQImgIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFWrtbc%253D&md5=059750feb70a2c7f11cb3c5258e27034</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjp007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjp007%26sid%3Dliteratum%253Aachs%26aulast%3DPointreau%26aufirst%3DY.%26aulast%3DGaraud%26aufirst%3DP.%26aulast%3DChapet%26aufirst%3DS.%26aulast%3DSire%26aufirst%3DC.%26aulast%3DTuchais%26aufirst%3DC.%26aulast%3DTortochaux%26aufirst%3DJ.%26aulast%3DFaivre%26aufirst%3DS.%26aulast%3DGuerrif%26aufirst%3DS.%26aulast%3DAlfonsi%26aufirst%3DM.%26aulast%3DCalais%26aufirst%3DG.%26atitle%3DRandomized%2520trial%2520of%2520induction%2520chemotherapy%2520with%2520cisplatin%2520and%25205-fluorouracil%2520with%2520or%2520without%2520docetaxel%2520for%2520larynx%2520preservation%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2009%26volume%3D101%26spage%3D498%26epage%3D506%26doi%3D10.1093%2Fjnci%2Fdjp007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Paccagnella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghi, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loreggian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buffoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koussis, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mione, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campostrini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardizzoia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dondi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guaraldi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavallo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gava, A.</span><span> </span><span class="NLM_article-title">Concomintant chemoradiotherapy versus induction docetaxel, cisplatin and 5-fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1515</span><span class="NLM_x">–</span> <span class="NLM_lpage">1522</span><span class="refDoi"> DOI: 10.1093/annonc/mdp573</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1093%2Fannonc%2Fmdp573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=20032123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A280%3ADC%252BC3crovVGksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=1515-1522&author=A.+Paccagnellaauthor=M.+G.+Ghiauthor=L.+Loreggianauthor=A.+Buffoliauthor=H.+Koussisauthor=C.+A.+Mioneauthor=A.+Bonettiauthor=F.+Campostriniauthor=G.+Gardaniauthor=A.+Ardizzoiaauthor=D.+Dondiauthor=M.+Guaraldiauthor=R.+Cavalloauthor=L.+Tomioauthor=A.+Gava&title=Concomintant+chemoradiotherapy+versus+induction+docetaxel%2C+cisplatin+and+5-fluorouracil+%28TPF%29+followed+by+concomitant+chemoradiotherapy+in+locally+advanced+head+and+neck+cancer%3A+a+phase+II+randomized+study&doi=10.1093%2Fannonc%2Fmdp573"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study</span></div><div class="casAuthors">Paccagnella A; Ghi M G; Loreggian L; Buffoli A; Koussis H; Mione C A; Bonetti A; Campostrini F; Gardani G; Ardizzoia A; Dondi D; Guaraldi M; Cavallo R; Tomio L; Gava A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1515-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Concomitant chemoradiotherapy (CT/RT) is the standard treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN).  We evaluated the efficacy of induction docetaxel (Taxotere), cisplatin, and 5-fluorouracil (TPF) before CT/RT versus CT/RT alone.  PATIENTS AND METHODS:  Patients with stage III-IVM0 SCCHN, Eastern Cooperative Oncology Group performance status of zero to one, were randomly assigned to receive CT/RT alone (arm A: two cycles of cisplatin 20 mg/m(2), days1-4, plus 5-fluorouracil 800 mg/m(2)/day 96 h continuous infusion, during weeks 1 and 6 of radiotherapy) or three cycles of TPF (arm B: docetaxel 75 mg/m(2) and cisplatin 80 mg/m(2), day 1, and 5-fluorouracil 800 mg/m(2)/day 96 h continuous infusion, every 3 weeks) followed by the same CT/RT.  The primary end point was the rate of radiologic complete response (CR) at 6-8 weeks after the end of CT/RT.  RESULTS:  A total of 101 patients were randomly allocated to the study (51 arm A; 50 arm B).  CR rates were 21.2% (arm A) versus 50% (arm B).  Median progression-free survival and overall survival were, respectively, 19.7 and 33.3 months (arm A) and 30.4 and 39.6 months (arm B).  Hematologic and non-hematologic toxic effects during CT/RT were similar in the two arms.  CONCLUSION:  Induction TPF followed by CT/RT was associated with higher radiologic CR in patients with locally advanced SCCHN with no negative impact on CT/RT feasibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlH16FjxFCdc25P7XSLhESfW6udTcc2eaB_mDYNgG-B7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3crovVGksQ%253D%253D&md5=2ceb3f018ab8a5a8eb152101690e1861</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdp573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdp573%26sid%3Dliteratum%253Aachs%26aulast%3DPaccagnella%26aufirst%3DA.%26aulast%3DGhi%26aufirst%3DM.%2BG.%26aulast%3DLoreggian%26aufirst%3DL.%26aulast%3DBuffoli%26aufirst%3DA.%26aulast%3DKoussis%26aufirst%3DH.%26aulast%3DMione%26aufirst%3DC.%2BA.%26aulast%3DBonetti%26aufirst%3DA.%26aulast%3DCampostrini%26aufirst%3DF.%26aulast%3DGardani%26aufirst%3DG.%26aulast%3DArdizzoia%26aufirst%3DA.%26aulast%3DDondi%26aufirst%3DD.%26aulast%3DGuaraldi%26aufirst%3DM.%26aulast%3DCavallo%26aufirst%3DR.%26aulast%3DTomio%26aufirst%3DL.%26aulast%3DGava%26aufirst%3DA.%26atitle%3DConcomintant%2520chemoradiotherapy%2520versus%2520induction%2520docetaxel%252C%2520cisplatin%2520and%25205-fluorouracil%2520%2528TPF%2529%2520followed%2520by%2520concomitant%2520chemoradiotherapy%2520in%2520locally%2520advanced%2520head%2520and%2520neck%2520cancer%253A%2520a%2520phase%2520II%2520randomized%2520study%26jtitle%3DAnn.%2520Oncol.%26date%3D2010%26volume%3D21%26spage%3D1515%26epage%3D1522%26doi%3D10.1093%2Fannonc%2Fmdp573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Theile, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketabi-Kiyanvash, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herold-Mende, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyckhoff, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efferth, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertholet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haefeli, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span> </span><span class="NLM_article-title">Evaluation of drug transporters’ significance in for multidrug resistance in head and neck squamous cell carcinoma</span> <span class="citation_source-journal">Head Neck</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">959</span><span class="NLM_x">–</span> <span class="NLM_lpage">968</span><span class="refDoi"> DOI: 10.1002/hed.21559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1002%2Fhed.21559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=20737486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A280%3ADC%252BC3MngtlWltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2011&pages=959-968&author=D.+Theileauthor=N.+Ketabi-Kiyanvashauthor=C.+Herold-Mendeauthor=G.+Dyckhoffauthor=T.+Efferthauthor=V.+Bertholetauthor=W.+E.+Haefeliauthor=J.+Weiss&title=Evaluation+of+drug+transporters%E2%80%99+significance+in+for+multidrug+resistance+in+head+and+neck+squamous+cell+carcinoma&doi=10.1002%2Fhed.21559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma</span></div><div class="casAuthors">Theile Dirk; Ketabi-Kiyanvash Nahal; Herold-Mende Christel; Dyckhoff Gerhardt; Efferth Thomas; Bertholet Vincent; Haefeli Walter Emil; Weiss Johanna</div><div class="citationInfo"><span class="NLM_cas:title">Head & neck</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">959-68</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Multidrug resistance (MDR) hampers chemotherapy in head and neck squamous cell carcinoma (HNSCC).  There is little information about MDR mediating drug transporters in HNSCC.  METHODS:  Nine HNSCC cell lines were characterized concerning drug transporter expression and susceptibility to cisplatin, paclitaxel, and 5-fluorouracil (5-FU) using a DNA microarray and proliferation assays.  Three cells lines were precisely investigated for transporter expression using reverse transcriptase-polymerase chain reaction (RT-PCR) and drug resistance before and after simulated chemotherapies.  RESULTS:  The cell lines differed in drug resistance and transporter expression.  Cisplatin and paclitaxel resistances were inversely associated.  Drugs rendered HNSCC cells resistant, cross-resistant, or cross-sensitive.  Sensitivity changes were accompanied by transporter mRNA expression changes.  CONCLUSION:  Paclitaxel was identified as a potent inducer of numerous drug transporters and phenotypic MDR in HNSCC.  Thus, cytostatic susceptibility of HNSCC cannot exclusively be deduced from the expression of single transporters but more likely of the entire transportome and non-transporter modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRGdLhGwPYWrFU0A1HOshhfW6udTcc2eaB_mDYNgG-B7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MngtlWltg%253D%253D&md5=27d8ca174adeb58d6f2d2b679cfc2a74</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2Fhed.21559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhed.21559%26sid%3Dliteratum%253Aachs%26aulast%3DTheile%26aufirst%3DD.%26aulast%3DKetabi-Kiyanvash%26aufirst%3DN.%26aulast%3DHerold-Mende%26aufirst%3DC.%26aulast%3DDyckhoff%26aufirst%3DG.%26aulast%3DEfferth%26aufirst%3DT.%26aulast%3DBertholet%26aufirst%3DV.%26aulast%3DHaefeli%26aufirst%3DW.%2BE.%26aulast%3DWeiss%26aufirst%3DJ.%26atitle%3DEvaluation%2520of%2520drug%2520transporters%25E2%2580%2599%2520significance%2520in%2520for%2520multidrug%2520resistance%2520in%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%26jtitle%3DHead%2520Neck%26date%3D2011%26volume%3D33%26spage%3D959%26epage%3D968%26doi%3D10.1002%2Fhed.21559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jacobs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velez-Garcia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhar, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochster, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodnough, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortimer, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einhorn, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schacter, L.</span><span> </span><span class="NLM_article-title">A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1732427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A280%3ADyaK387itF2gtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1992&pages=257-263&author=C.+Jacobsauthor=G.+Lymanauthor=E.+Velez-Garciaauthor=K.+S.+Sridharauthor=W.+Knightauthor=H.+Hochsterauthor=L.+T.+Goodnoughauthor=J.+E.+Mortimerauthor=L.+H.+Einhornauthor=L.+Schacter&title=A+phase+III+randomized+study+comparing+cisplatin+and+fluorouracil+as+single+agents+and+in+combination+for+advanced+squamous+cell+carcinoma+of+the+head+and+neck"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57aR"><div class="casContent"><span class="casTitleNuber">57a</span><div class="casTitle"><span class="NLM_cas:atitle">A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck</span></div><div class="casAuthors">Jacobs C; Lyman G; Velez-Garcia E; Sridhar K S; Knight W; Hochster H; Goodnough L T; Mortimer J E; Einhorn L H; Schacter L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-63</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">PURPOSE:  To determine whether combination chemotherapy is superior to single agents for recurrent/metastatic head and neck cancer, we compared the efficacy and toxicity of cisplatin (CP) and fluorouracil (5-FU), alone and in combination in a phase III trial.  PATIENTS AND METHODS:  Two hundred forty-nine patients with recurrent head and neck cancer were randomized to one of three treatments: CP (100 mg/m2) and 5-FU (1 g/m2 x 4), CP, or 5-FU every 3 weeks.  RESULTS:  The overall response rate to the combination (32%) was superior to that of CP (17%) or 5-FU (13%) (P = .035).  Response was associated with good performance status (PS) but not with primary site, site of recurrence, histology, prior irradiation, or relative dose intensity.  Median time to progression was less than 2.5 months, and there was no significant difference in median survival (5.7 months) among the groups.  By multivariate analysis, patients with better PS and poorly differentiated tumors had superior survival.  Hematologic toxicity and alopecia were worse in the combination arm.  CONCLUSION:  Although the response rate to the combination of CP plus 5-FU was superior to that achieved with single agents, survival did not improve.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTf8lbNGCbaB75oR8RchjrrfW6udTcc2eZXnjY40oLBGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK387itF2gtA%253D%253D&md5=3d5f4f4b74b0eef2f61d140033e0e196</span></div><a href="/servlet/linkout?suffix=cit57a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DC.%26aulast%3DLyman%26aufirst%3DG.%26aulast%3DVelez-Garcia%26aufirst%3DE.%26aulast%3DSridhar%26aufirst%3DK.%2BS.%26aulast%3DKnight%26aufirst%3DW.%26aulast%3DHochster%26aufirst%3DH.%26aulast%3DGoodnough%26aufirst%3DL.%2BT.%26aulast%3DMortimer%26aufirst%3DJ.%2BE.%26aulast%3DEinhorn%26aufirst%3DL.%2BH.%26aulast%3DSchacter%26aufirst%3DL.%26atitle%3DA%2520phase%2520III%2520randomized%2520study%2520comparing%2520cisplatin%2520and%2520fluorouracil%2520as%2520single%2520agents%2520and%2520in%2520combination%2520for%2520advanced%2520squamous%2520cell%2520carcinoma%2520of%2520the%2520head%2520and%2520neck%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1992%26volume%3D10%26spage%3D257%26epage%3D263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit57b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Forastiere, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metch, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuller, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ensley, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchins, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Triozzi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClure, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VonFeldt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williamson, S. K.</span><span> </span><span class="NLM_article-title">Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1245</span><span class="NLM_x">–</span> <span class="NLM_lpage">1251</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1634913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A280%3ADyaK38zktFWguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1992&pages=1245-1251&author=A.+A.+Forastiereauthor=B.+Metchauthor=D.+E.+Schullerauthor=J.+F.+Ensleyauthor=L.+F.+Hutchinsauthor=P.+Triozziauthor=J.+A.+Kishauthor=S.+McClureauthor=E.+VonFeldtauthor=S.+K.+Williamson&title=Randomized+comparison+of+cisplatin+plus+fluorouracil+and+carboplatin+plus+fluorouracil+versus+methotrexate+in+advanced+squamous-cell+carcinoma+of+the+head+and+neck%3A+a+Southwest+Oncology+Group+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57bR"><div class="casContent"><span class="casTitleNuber">57b</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study</span></div><div class="casAuthors">Forastiere A A; Metch B; Schuller D E; Ensley J F; Hutchins L F; Triozzi P; Kish J A; McClure S; VonFeldt E; Williamson S K</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1245-51</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">PURPOSE:  The Southwest Oncology Group (SWOG) conducted a randomized comparison of cisplatin plus fluorouracil (5-FU) and carboplatin plus 5-FU versus single-agent methotrexate (MTX) in patients with recurrent and metastatic squamous-cell carcinoma (SCC) of the head and neck.  The primary objective was to compare separately the response rates of each combination regimen to standard weekly MTX.  PATIENTS AND METHODS:  Two hundred seventy-seven patients diagnosed with SCC of the head and neck were randomized to one of three treatments: (1) cisplatin 100 mg/m2 intravenously (IV) on day 1 and 5-FU 1,000 mg/m2 per day for a 96-hour continuous infusion repeated every 21 days; (2) carboplatin 300 mg/m2 IV on day 1 and 5-FU 1,000 mg/m2 per day for a 96-hour continuous infusion repeated every 28 days; and (3) MTX 40 mg/m2 IV given weekly.  RESULTS:  All three treatment regimens were well tolerated.  However, both hematologic and nonhematologic toxicities were significantly greater with cisplatin plus 5-FU compared with MTX (P = .001).  Toxicity from carboplatin plus 5-FU was intermediate compared with the other regimens.  The complete and partial response rates were 32% for cisplatin plus 5-FU, 21% for carboplatin plus 5-FU, and 10% for MTX.  The comparison of cisplatin plus 5-FU to MTX was statistically significant (P less than .001), and the comparison of carboplatin plus 5-FU to MTX was of borderline statistical significance (P = .05).  Median response durations and median survival times were similar for all three treatment groups.  Logistic regression models showed that only treatment assigned was associated significantly with response (P = .001).  Cox proportional hazards models indicated that only performance status was associated significantly with survival (P less than .01).  CONCLUSIONS:  We conclude that combination chemotherapy resulted in improved response rates but was associated with an increased toxicity and no improvement in overall survival.  Therefore, new treatments that may alter the course of disease in recurrent head and neck cancer patients still need to be identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQP_hlUnrjdhIFEOhA_Im3cfW6udTcc2eZXnjY40oLBGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38zktFWguw%253D%253D&md5=b9f04fd3109000f6e490c1c174d1a300</span></div><a href="/servlet/linkout?suffix=cit57b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DForastiere%26aufirst%3DA.%2BA.%26aulast%3DMetch%26aufirst%3DB.%26aulast%3DSchuller%26aufirst%3DD.%2BE.%26aulast%3DEnsley%26aufirst%3DJ.%2BF.%26aulast%3DHutchins%26aufirst%3DL.%2BF.%26aulast%3DTriozzi%26aufirst%3DP.%26aulast%3DKish%26aufirst%3DJ.%2BA.%26aulast%3DMcClure%26aufirst%3DS.%26aulast%3DVonFeldt%26aufirst%3DE.%26aulast%3DWilliamson%26aufirst%3DS.%2BK.%26atitle%3DRandomized%2520comparison%2520of%2520cisplatin%2520plus%2520fluorouracil%2520and%2520carboplatin%2520plus%2520fluorouracil%2520versus%2520methotrexate%2520in%2520advanced%2520squamous-cell%2520carcinoma%2520of%2520the%2520head%2520and%2520neck%253A%2520a%2520Southwest%2520Oncology%2520Group%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1992%26volume%3D10%26spage%3D1245%26epage%3D1251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, C.</span><span> </span><span class="NLM_article-title">Current status of experimental therapeutics for head and neck cancer</span> <span class="citation_source-journal">Exp. Biol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">236</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">389</span><span class="refDoi"> DOI: 10.1258/ebm.2010.010354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1258%2Febm.2010.010354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXms1ahs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=236&publication_year=2011&pages=375-389&author=J.+Leeauthor=C.+Moon&title=Current+status+of+experimental+therapeutics+for+head+and+neck+cancer&doi=10.1258%2Febm.2010.010354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Current status of experimental therapeutics for head and neck cancer</span></div><div class="casAuthors">Lee, Juna; Moon, Chulso</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Biology and Medicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">236</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">375-389</span>CODEN:
                <span class="NLM_cas:coden">EBMMBE</span>;
        ISSN:<span class="NLM_cas:issn">1535-3702</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Medicine Press Ltd.</span>)
        </div><div class="casAbstract">A review.  As with many cancers, early detection of head and neck cancer increases a patient's survival rate.  If diagnosed early, its five-year survival nears 90% with std. therapy alone.  Unfortunately, the av. survival rate for head and neck cancer is low due to the difficulty in early detection and achieving a sustainable response.  Conventional treatments are not adequate for the majority of advanced or recurrent head and neck cancer patients because of the remarkable resistance of tumors to chemotherapy and radiation, and the situation is esp. devastating for the first time treatment failure.  The major limitations of these treatments are the lack of specificity for the tumor cell and unacceptable toxicity to the patient.  As a result, current research in therapeutics for advanced, chemotherapy-resistant or recurrent head and neck cancer patients has focused on new treatment modalities that exploit biol. differences between tumor and normal cells.  These therapies include monoclonal antibodies, mol. inhibitors, gene therapy and photodynamic therapy.  This article reviews the current preclin. and clin. evidence of these exptl. therapeutics as they relate to head and neck cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjv1Q3E-v2g7Vg90H21EOLACvtfcHk0lin_NTtM8PKuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXms1ahs70%253D&md5=f983309484e5aedb0e4d3f543f8f9257</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1258%2Febm.2010.010354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1258%252Febm.2010.010354%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMoon%26aufirst%3DC.%26atitle%3DCurrent%2520status%2520of%2520experimental%2520therapeutics%2520for%2520head%2520and%2520neck%2520cancer%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D2011%26volume%3D236%26spage%3D375%26epage%3D389%26doi%3D10.1258%2Febm.2010.010354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Machiels, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitz, S.</span><span> </span><span class="NLM_article-title">New advances in targeted therapies for squamous cell carcinoma of the head and neck</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">626</span><span class="NLM_x">–</span> <span class="NLM_lpage">633</span><span class="refDoi"> DOI: 10.1097/CAD.0b013e328341071e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1097%2FCAD.0b013e328341071e" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=626-633&author=J.+P.+Machielsauthor=S.+Schmitz&title=New+advances+in+targeted+therapies+for+squamous+cell+carcinoma+of+the+head+and+neck&doi=10.1097%2FCAD.0b013e328341071e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1097%2FCAD.0b013e328341071e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0b013e328341071e%26sid%3Dliteratum%253Aachs%26aulast%3DMachiels%26aufirst%3DJ.%2BP.%26aulast%3DSchmitz%26aufirst%3DS.%26atitle%3DNew%2520advances%2520in%2520targeted%2520therapies%2520for%2520squamous%2520cell%2520carcinoma%2520of%2520the%2520head%2520and%2520neck%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2011%26volume%3D22%26spage%3D626%26epage%3D633%26doi%3D10.1097%2FCAD.0b013e328341071e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Matta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ralhan, R.</span><span> </span><span class="NLM_article-title">Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma</span> <span class="citation_source-journal">Head Neck Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">6</span><span class="refDoi"> DOI: 10.1186/1758-3284-1-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1186%2F1758-3284-1-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=19284526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A280%3ADC%252BD1M3jtVagtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=6&author=A.+Mattaauthor=R.+Ralhan&title=Overview+of+current+and+future+biologically+based+targeted+therapies+in+head+and+neck+squamous+cell+carcinoma&doi=10.1186%2F1758-3284-1-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma</span></div><div class="casAuthors">Matta Ajay; Ralhan Ranju</div><div class="citationInfo"><span class="NLM_cas:title">Head & neck oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recent advances in genomics, proteomics, bioinformatics and systems biology have unraveled the complex aberrant signaling networks in cancer.  The knowledge accrued has dramatically increased the opportunities for discovery of novel molecular targets for drug development.  Major emphasis is being laid on designing new therapeutic strategies targeting multiple signaling pathways for more effective disease management.  However, the translation of in vitro findings to patient management often poses major challenges that limit their clinical efficacy.  Here we will discuss how understanding the dysregulated signaling networks can explain the pitfalls in translating the laboratory findings from the bench-to-bedside and suggest novel approaches to overcome these problems using head and neck cancer as a prototype.  The five year survival rates of HNSCC patients (about 50% at 5 years) have not improved significantly despite advancements in multimodality therapy including surgery, radiation and chemotherapy.  Molecular targeted therapies with inhibitors of EGFR and VEGF either alone, or in combination with conventional treatments have shown limited improved efficacy.  The key deregulated signaling pathways in head and neck squamous cell carcinoma (HNSCC) include EGFR, Ras, TGFbeta, NFkappaB, Stat, Wnt/beta-catenin and PI3-K/AKT/mTOR.  The aberrant activities of these interrelated signaling pathways contribute to HNSCC development.  In depth understanding of the cross-talks between these pathways and networks will form the basis of developing novel strategies for targeting multiple molecular components for more effective prevention and treatment of HNSCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDlBeNme77Bs25P7XSLhESfW6udTcc2eYa_zrgrQr3Zbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3jtVagtQ%253D%253D&md5=d95688c22b5b568d48cabbfa411f5002</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1186%2F1758-3284-1-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1758-3284-1-6%26sid%3Dliteratum%253Aachs%26aulast%3DMatta%26aufirst%3DA.%26aulast%3DRalhan%26aufirst%3DR.%26atitle%3DOverview%2520of%2520current%2520and%2520future%2520biologically%2520based%2520targeted%2520therapies%2520in%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%26jtitle%3DHead%2520Neck%2520Oncol.%26date%3D2009%26volume%3D1%26spage%3D6%26doi%3D10.1186%2F1758-3284-1-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Raza, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornblum, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kancharla, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baig, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kavalar, M.</span><span> </span><span class="NLM_article-title">Emerging therapies in the treatment of locally advanced squamous cell carcinomas of the head and neck</span> <span class="citation_source-journal">Recent Pat. Anti-Cancer Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">246</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span><span class="refDoi"> DOI: 10.2174/157489211795328477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.2174%2F157489211795328477" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=246-257&author=S.+Razaauthor=N.+Kornblumauthor=V.+P.+Kancharlaauthor=M.+A.+Baigauthor=A.+B.+Singhauthor=M.+Kavalar&title=Emerging+therapies+in+the+treatment+of+locally+advanced+squamous+cell+carcinomas+of+the+head+and+neck&doi=10.2174%2F157489211795328477"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.2174%2F157489211795328477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157489211795328477%26sid%3Dliteratum%253Aachs%26aulast%3DRaza%26aufirst%3DS.%26aulast%3DKornblum%26aufirst%3DN.%26aulast%3DKancharla%26aufirst%3DV.%2BP.%26aulast%3DBaig%26aufirst%3DM.%2BA.%26aulast%3DSingh%26aufirst%3DA.%2BB.%26aulast%3DKavalar%26aufirst%3DM.%26atitle%3DEmerging%2520therapies%2520in%2520the%2520treatment%2520of%2520locally%2520advanced%2520squamous%2520cell%2520carcinomas%2520of%2520the%2520head%2520and%2520neck%26jtitle%3DRecent%2520Pat.%2520Anti-Cancer%2520Drug%2520Discovery%26date%3D2011%26volume%3D6%26spage%3D246%26epage%3D257%26doi%3D10.2174%2F157489211795328477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Denaro, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russi, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colantonio, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlano, M. C.</span><span> </span><span class="NLM_article-title">The role of antiangiogenic agents in the treatment of head and neck cancer</span> <span class="citation_source-journal">Oncology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1159/000339542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1159%2F000339542" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2012&pages=108-116&author=N.+Denaroauthor=E.+G.+Russiauthor=I.+Colantonioauthor=V.+Adamoauthor=M.+C.+Merlano&title=The+role+of+antiangiogenic+agents+in+the+treatment+of+head+and+neck+cancer&doi=10.1159%2F000339542"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1159%2F000339542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000339542%26sid%3Dliteratum%253Aachs%26aulast%3DDenaro%26aufirst%3DN.%26aulast%3DRussi%26aufirst%3DE.%2BG.%26aulast%3DColantonio%26aufirst%3DI.%26aulast%3DAdamo%26aufirst%3DV.%26aulast%3DMerlano%26aufirst%3DM.%2BC.%26atitle%3DThe%2520role%2520of%2520antiangiogenic%2520agents%2520in%2520the%2520treatment%2520of%2520head%2520and%2520neck%2520cancer%26jtitle%3DOncology%26date%3D2012%26volume%3D83%26spage%3D108%26epage%3D116%26doi%3D10.1159%2F000339542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Faller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ertl, P.</span><span> </span><span class="NLM_article-title">Computational approaches to determine drug solubility</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">533</span><span class="NLM_x">–</span> <span class="NLM_lpage">545</span><span class="refDoi"> DOI: 10.1016/j.addr.2007.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.addr.2007.05.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2007&pages=533-545&author=B.+Fallerauthor=P.+Ertl&title=Computational+approaches+to+determine+drug+solubility&doi=10.1016%2Fj.addr.2007.05.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63a&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2007.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2007.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DFaller%26aufirst%3DB.%26aulast%3DErtl%26aufirst%3DP.%26atitle%3DComputational%2520approaches%2520to%2520determine%2520drug%2520solubility%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2007%26volume%3D59%26spage%3D533%26epage%3D545%26doi%3D10.1016%2Fj.addr.2007.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit63b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Delaney, J. S.</span><span> </span><span class="NLM_article-title">Predicting aqueous solubility from structure</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span><span class="refDoi"> DOI: 10.1016/S1359-6446(04)03365-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2FS1359-6446%2804%2903365-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=15708748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlajsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=289-295&author=J.+S.+Delaney&title=Predicting+aqueous+solubility+from+structure&doi=10.1016%2FS1359-6446%2804%2903365-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63bR"><div class="casContent"><span class="casTitleNuber">63b</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting aqueous solubility from structure</span></div><div class="casAuthors">Delaney, John S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">289-295</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The aq. soly. of a drug is one of the key phys. properties that affect both its ADME profile and 'screenability' in HTS.  This review critically surveys a range of methods that can be used to predict the soly. of a compd. in water and presents some of the main issues that affect the applicability of different techniques.  As ever, there are trade-offs to be made between the speed, accuracy and transparency of methods, but current programs can provide ests. to well within an order of magnitude in favorable cases.  The need for new ways to predict soly. in more challenging systems (e.g solvents such as DMSO and charged solutes) is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjIB-nQrVm0rVg90H21EOLACvtfcHk0liPsv6w4C0VVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlajsbs%253D&md5=efdd8087ce60bc613501b00420b22d6d</span></div><a href="/servlet/linkout?suffix=cit63b&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903365-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903365-3%26sid%3Dliteratum%253Aachs%26aulast%3DDelaney%26aufirst%3DJ.%2BS.%26atitle%3DPredicting%2520aqueous%2520solubility%2520from%2520structure%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D289%26epage%3D295%26doi%3D10.1016%2FS1359-6446%2804%2903365-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tetko, I. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanchuk, V. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasheva, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, A. E.</span><span> </span><span class="NLM_article-title">Estimation of aqueous solubility of chemical compounds using E-state indices</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1488</span><span class="NLM_x">–</span> <span class="NLM_lpage">1493</span><span class="refDoi"> DOI: 10.1021/ci000392t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci000392t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=1488-1493&author=I.+V.+Tetkoauthor=V.+Y.+Tanchukauthor=T.+N.+Kashevaauthor=A.+E.+Villa&title=Estimation+of+aqueous+solubility+of+chemical+compounds+using+E-state+indices&doi=10.1021%2Fci000392t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64a&amp;dbid=16384&amp;doi=10.1021%2Fci000392t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci000392t%26sid%3Dliteratum%253Aachs%26aulast%3DTetko%26aufirst%3DI.%2BV.%26aulast%3DTanchuk%26aufirst%3DV.%2BY.%26aulast%3DKasheva%26aufirst%3DT.%2BN.%26aulast%3DVilla%26aufirst%3DA.%2BE.%26atitle%3DEstimation%2520of%2520aqueous%2520solubility%2520of%2520chemical%2520compounds%2520using%2520E-state%2520indices%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2001%26volume%3D41%26spage%3D1488%26epage%3D1493%26doi%3D10.1021%2Fci000392t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit64b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tetko, I. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasteiger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todeschini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livingstone, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ertl, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palyulin, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radchenko, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zefirov, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makarenko, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanchuk, V. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prokopenko, V. V.</span><span> </span><span class="NLM_article-title">Virtual computational chemistry laboratory – design and description</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">453</span><span class="NLM_x">–</span> <span class="NLM_lpage">463</span><span class="refDoi"> DOI: 10.1007/s10822-005-8694-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1007%2Fs10822-005-8694-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=16231203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFaht77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=453-463&author=I.+V.+Tetkoauthor=J.+Gasteigerauthor=R.+Todeschiniauthor=A.+Mauriauthor=D.+Livingstoneauthor=P.+Ertlauthor=V.+A.+Palyulinauthor=E.+V.+Radchenkoauthor=N.+S.+Zefirovauthor=A.+S.+Makarenkoauthor=V.+Y.+Tanchukauthor=V.+V.+Prokopenko&title=Virtual+computational+chemistry+laboratory+%E2%80%93+design+and+description&doi=10.1007%2Fs10822-005-8694-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64bR"><div class="casContent"><span class="casTitleNuber">64b</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual computational chemistry laboratory - design and description</span></div><div class="casAuthors">Tetko, Igor V.; Gasteiger, Johann; Todeschini, Roberto; Mauri, Andrea; Livingstone, David; Ertl, Peter; Palyulin, Vladimir A.; Radchenko, Eugene V.; Zefirov, Nikolay S.; Makarenko, Alexander S.; Tanchuk, Vsevolod Yu.; Prokopenko, Volodymyr V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">453-463</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Internet technol. offers an excellent opportunity for the development of tools by the cooperative effort of various groups and institutions.  We have developed a multi-platform software system, Virtual Computational Chem. Lab., http://www.vcclab.org, allowing the computational chemist to perform a comprehensive series of mol. indexes/properties calcns. and data anal.  The implemented software is based on a three-tier architecture that is one of the std. technologies to provide client-server services on the Internet.  The developed software includes several popular programs, including the indexes generation program, DRAGON, a 3D structure generator, CORINA, a program to predict lipophilicity and aq. soly. of chems., ALOGPS and others.  All these programs are running at the host institutes located in five countries over Europe.  In this article we review the main features and statistics of the developed system that can be used as a prototype for academic and industry models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHcQMybC6rRrVg90H21EOLACvtfcHk0ljuMiDhqzra-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFaht77F&md5=6e48f916c58c1e772ade43fa8e4b4b1a</span></div><a href="/servlet/linkout?suffix=cit64b&amp;dbid=16384&amp;doi=10.1007%2Fs10822-005-8694-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-005-8694-y%26sid%3Dliteratum%253Aachs%26aulast%3DTetko%26aufirst%3DI.%2BV.%26aulast%3DGasteiger%26aufirst%3DJ.%26aulast%3DTodeschini%26aufirst%3DR.%26aulast%3DMauri%26aufirst%3DA.%26aulast%3DLivingstone%26aufirst%3DD.%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DPalyulin%26aufirst%3DV.%2BA.%26aulast%3DRadchenko%26aufirst%3DE.%2BV.%26aulast%3DZefirov%26aufirst%3DN.%2BS.%26aulast%3DMakarenko%26aufirst%3DA.%2BS.%26aulast%3DTanchuk%26aufirst%3DV.%2BY.%26aulast%3DProkopenko%26aufirst%3DV.%2BV.%26atitle%3DVirtual%2520computational%2520chemistry%2520laboratory%2520%25E2%2580%2593%2520design%2520and%2520description%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2005%26volume%3D19%26spage%3D453%26epage%3D463%26doi%3D10.1007%2Fs10822-005-8694-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit64c"><span><span class="NLM_label">(c) </span>VCCLAB; <span class="NLM_publisher-name">Virtual Computational Chemistry Laboratory</span>; <a href="http://www.vcclab.org" class="extLink">http://www.vcclab.org</a>, (accessed October 17, 2015).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=VCCLAB%3B+Virtual+Computational+Chemistry+Laboratory%3B+http%3A%2F%2Fwww.vcclab.org%2C+%28accessed+October+17%2C+2015%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DVCCLAB%26pub%3DVirtual%2520Computational%2520Chemistry%2520Laboratory" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Tetko, I. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanchuk, V. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasheva, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, A. E. P.</span><span> </span><span class="NLM_article-title">Internet software for the calculation of the lipophilicity and aqeuous solubility of chemical compounds</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">246</span><span class="NLM_x">–</span> <span class="NLM_lpage">252</span><span class="refDoi"> DOI: 10.1021/ci000393l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci000393l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=246-252&author=I.+V.+Tetkoauthor=V.+Y.+Tanchukauthor=T.+N.+Kashevaauthor=A.+E.+P.+Villa&title=Internet+software+for+the+calculation+of+the+lipophilicity+and+aqeuous+solubility+of+chemical+compounds&doi=10.1021%2Fci000393l"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fci000393l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci000393l%26sid%3Dliteratum%253Aachs%26aulast%3DTetko%26aufirst%3DI.%2BV.%26aulast%3DTanchuk%26aufirst%3DV.%2BY.%26aulast%3DKasheva%26aufirst%3DT.%2BN.%26aulast%3DVilla%26aufirst%3DA.%2BE.%2BP.%26atitle%3DInternet%2520software%2520for%2520the%2520calculation%2520of%2520the%2520lipophilicity%2520and%2520aqeuous%2520solubility%2520of%2520chemical%2520compounds%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2001%26volume%3D41%26spage%3D246%26epage%3D252%26doi%3D10.1021%2Fci000393l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Leach, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosgrove, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruston, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacFaul, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, B.</span><span> </span><span class="NLM_article-title">Matched molecular pairs as a guide in the optimization of pharmaceutical properties: a study of aqueous solubility, plasma protein binding and oral exposure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6672</span><span class="NLM_x">–</span> <span class="NLM_lpage">6682</span><span class="refDoi"> DOI: 10.1021/jm0605233</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0605233" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6672-6682&author=A.+G.+Leachauthor=H.+D.+Jonesauthor=D.+A.+Cosgroveauthor=P.+W.+Kennyauthor=L.+Rustonauthor=P.+MacFaulauthor=J.+M.+Woodauthor=N.+Colcloughauthor=B.+Law&title=Matched+molecular+pairs+as+a+guide+in+the+optimization+of+pharmaceutical+properties%3A+a+study+of+aqueous+solubility%2C+plasma+protein+binding+and+oral+exposure&doi=10.1021%2Fjm0605233"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66a&amp;dbid=16384&amp;doi=10.1021%2Fjm0605233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0605233%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DJones%26aufirst%3DH.%2BD.%26aulast%3DCosgrove%26aufirst%3DD.%2BA.%26aulast%3DKenny%26aufirst%3DP.%2BW.%26aulast%3DRuston%26aufirst%3DL.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DLaw%26aufirst%3DB.%26atitle%3DMatched%2520molecular%2520pairs%2520as%2520a%2520guide%2520in%2520the%2520optimization%2520of%2520pharmaceutical%2520properties%253A%2520a%2520study%2520of%2520aqueous%2520solubility%252C%2520plasma%2520protein%2520binding%2520and%2520oral%2520exposure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6672%26epage%3D6682%26doi%3D10.1021%2Fjm0605233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit66b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gleeson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, D.</span><span> </span><span class="NLM_article-title">ADMET rules of thumb II: a comparison of the effects of common substituents on a range of ADMET parameters</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5906</span><span class="NLM_x">–</span> <span class="NLM_lpage">5919</span><span class="refDoi"> DOI: 10.1016/j.bmc.2009.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.bmc.2009.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=19632124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps1Crs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=5906-5919&author=P.+Gleesonauthor=G.+Braviauthor=S.+Modiauthor=D.+Lowe&title=ADMET+rules+of+thumb+II%3A+a+comparison+of+the+effects+of+common+substituents+on+a+range+of+ADMET+parameters&doi=10.1016%2Fj.bmc.2009.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66bR"><div class="casContent"><span class="casTitleNuber">66b</span><div class="casTitle"><span class="NLM_cas:atitle">ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters</span></div><div class="casAuthors">Gleeson, Paul; Bravi, Gianpaolo; Modi, Sandeep; Lowe, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5906-5919</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A systematic anal. of data generated in key in vitro assays within GSK has been undertaken to identify what impact a range of common substituents have on a range of ADMET parameters.  These include; P 450 1A2, 2C9, 2C19, 2D6 and 3A4 inhibition, hERG inhibition, phosphate buffer soly. and artificial membrane permeability.  We do this by identifying all matched mol. pairs, differing by the replacement of a hydrogen atom with a list of predefined substituents.  For each substituent we calc. the mean difference in the ADMET parameter for all the matched mol. pairs identified, making a statistical assessment of the difference, as well as assessing the diversity for each example to ensure that the results can be generalized.  We also relate the change in activity obsd. for each substituent to differences in their mol. properties in an effort to identify any structural alerts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk7HA_bqdilrVg90H21EOLACvtfcHk0ljuMiDhqzra-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps1Crs7o%253D&md5=fce672cbaadb66c4d7212aa1b92bd7d2</span></div><a href="/servlet/linkout?suffix=cit66b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DGleeson%26aufirst%3DP.%26aulast%3DBravi%26aufirst%3DG.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DLowe%26aufirst%3DD.%26atitle%3DADMET%2520rules%2520of%2520thumb%2520II%253A%2520a%2520comparison%2520of%2520the%2520effects%2520of%2520common%2520substituents%2520on%2520a%2520range%2520of%2520ADMET%2520parameters%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D5906%26epage%3D5919%26doi%3D10.1016%2Fj.bmc.2009.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit66c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Griffen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robb, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, D. J.</span><span> </span><span class="NLM_article-title">Matched molecular pairs as a medicinal chemistry tool</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7739</span><span class="NLM_x">–</span> <span class="NLM_lpage">7750</span><span class="refDoi"> DOI: 10.1021/jm200452d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200452d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Wks7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7739-7750&author=E.+Griffenauthor=A.+G.+Leachauthor=G.+R.+Robbauthor=D.+J.+Warner&title=Matched+molecular+pairs+as+a+medicinal+chemistry+tool&doi=10.1021%2Fjm200452d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66cR"><div class="casContent"><span class="casTitleNuber">66c</span><div class="casTitle"><span class="NLM_cas:atitle">Matched Molecular Pairs as a Medicinal Chemistry Tool</span></div><div class="casAuthors">Griffen, Ed; Leach, Andrew G.; Robb, Graeme R.; Warner, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7739-7750</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">At the very heart of the role of a medicinal chemist or drug designer is the ability to link chem. structure to mol. properties.  This is the structure-activity relationship(SAR) or structure-property relationship(SPR).  Drug discovery projects often discover that a particular structural change causes a change to a property of interest.  The authors of this paper have been involved in developing and implementing some variations on the original theme of MMPA (matched mol. pairs anal.) and felt this to be the time to highlight some of these and to point toward future developments.  All of them are involved in the process of drug design, and it is within this context that they will set their comments.  In outline, they introduce matched mol. pair anal. and highlight why it fits so well with the kind of problem solving that is required in the process of drug design.  This will be followed by some comments concerning when the application of the methodol. is appropriate.  Then in a section intended for those with more computational interests, the authors describe the various ways that have been devised for identifying such matched pairs.  Throughout the paper, the authors have elected to use a publicly available data set to illustrate some of the comments: the ChEMBL database of inhibitors of the epidermal growth factor receptor tyrosine kinase (EGFR).  This consists of 2899 measurements of an IC50 annotated as a binding measurement on 2348 unique compds.  These measurements are drawn from a no. of sources, having been abstracted from the scientific literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMGFfO8Flm5bVg90H21EOLACvtfcHk0lgKODyw0NaFNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Wks7jK&md5=fab3344d790d1c0ae688ec65830d9143</span></div><a href="/servlet/linkout?suffix=cit66c&amp;dbid=16384&amp;doi=10.1021%2Fjm200452d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200452d%26sid%3Dliteratum%253Aachs%26aulast%3DGriffen%26aufirst%3DE.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DRobb%26aufirst%3DG.%2BR.%26aulast%3DWarner%26aufirst%3DD.%2BJ.%26atitle%3DMatched%2520molecular%2520pairs%2520as%2520a%2520medicinal%2520chemistry%2520tool%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7739%26epage%3D7750%26doi%3D10.1021%2Fjm200452d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Fishburn, C. S.</span><span> </span><span class="NLM_article-title">Attenuating attrition</span>.  <span class="citation_source-journal">SciBX</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">26</span>), doi:<span class="refDoi"> DOI: 10.1038/scibx.2013.647</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1038%2Fscibx.2013.647" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&issue=26&author=C.+S.+Fishburn&title=Attenuating+attrition&doi=10.1038%2Fscibx.2013.647"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fscibx.2013.647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fscibx.2013.647%26sid%3Dliteratum%253Aachs%26aulast%3DFishburn%26aufirst%3DC.%2BS.%26atitle%3DAttenuating%2520attrition%26jtitle%3DSciBX%26date%3D2013%26volume%3D6%26issue%3D26%26doi%3D10.1038%2Fscibx.2013.647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Hussain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rea, C.</span><span> </span><span class="NLM_article-title">Computationally efficient algorithm to identify matched molecular pairs (MMPs) in large data sets</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">339</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span><span class="refDoi"> DOI: 10.1021/ci900450m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci900450m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=339-348&author=J.+Hussainauthor=C.+Rea&title=Computationally+efficient+algorithm+to+identify+matched+molecular+pairs+%28MMPs%29+in+large+data+sets&doi=10.1021%2Fci900450m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Computationally Efficient Algorithm to Identify Matched Molecular Pairs (MMPs) in Large Data Sets</span></div><div class="casAuthors">Hussain, Jameed; Rea, Ceara</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">339-348</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Modern drug discovery organizations generate large vols. of SAR data.  A promising methodol. that can be used to mine this chem. data to identify novel structure-activity relationships is the matched mol. pair (MMP) methodol.  However, before the full potential of the MMP methodol. can be utilized, a MMP identification method that is capable of identifying all MMPs in large chem. data sets on modest computational hardware is required.  In this paper we report an algorithm that is capable of systematically generating all MMPs in chem. data sets.  Addnl., the algorithm is computationally efficient enough to be applied on large data sets.  As an example the algorithm was used to identify the MMPs in the ∼300k NIH MLSMR set.  The algorithm identified ∼5.3 million matched mol. pairs in the set.  These pairs cover ∼2.6 million unique mol. transformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF0rN8jaKSjrVg90H21EOLACvtfcHk0lgKODyw0NaFNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWltr4%253D&md5=23964abebc23274f5c36c319bee52bab</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fci900450m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci900450m%26sid%3Dliteratum%253Aachs%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DRea%26aufirst%3DC.%26atitle%3DComputationally%2520efficient%2520algorithm%2520to%2520identify%2520matched%2520molecular%2520pairs%2520%2528MMPs%2529%2520in%2520large%2520data%2520sets%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26spage%3D339%26epage%3D348%26doi%3D10.1021%2Fci900450m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Warner, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St-Gallay, S. A.</span><span> </span><span class="NLM_article-title">WizePairZ: a novel algorithm to identify, encode, and exploit matched molecular pairs with unspecified cores in medicinal chemistry</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1350</span><span class="NLM_x">–</span> <span class="NLM_lpage">1357</span><span class="refDoi"> DOI: 10.1021/ci100084s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci100084s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVSgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=1350-1357&author=D.+J.+Warnerauthor=E.+Griffenauthor=S.+A.+St-Gallay&title=WizePairZ%3A+a+novel+algorithm+to+identify%2C+encode%2C+and+exploit+matched+molecular+pairs+with+unspecified+cores+in+medicinal+chemistry&doi=10.1021%2Fci100084s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">WizePairZ: A Novel Algorithm to Identify, Encode, and Exploit Matched Molecular Pairs with Unspecified Cores in Medicinal Chemistry</span></div><div class="casAuthors">Warner, Daniel J.; Griffen, Edward J.; St-Gallay, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1350-1357</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An algorithm to automatically identify and ext. matched mol. pairs from a collection of compds. has been developed, allowing the learning assocd. with each mol. transformation to be readily exploited in drug discovery projects.  Here, we present the application to an example data set of 11 histone deacetylase inhibitors.  The matched pairs were identified, and corresponding differences in activity and lipophilicity were recorded.  These property differences were assocd. with the chem. transformations encoded in the SMIRKS reaction notation.  The transformations identified a subseries with the optimal balance of these two parameters.  Enumeration of a virtual library of compds. using the extd. transformations identified two addnl. compds. initially excluded from the anal. with an accurate estn. of their biol. activity.  We describe how the WizePairZ system can be used to archive and apply medicinal chem. knowledge from one drug discovery project to another as well as identify common bioisosteres.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSWafs2qQ4UbVg90H21EOLACvtfcHk0lgKODyw0NaFNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVSgs7c%253D&md5=9d83eb14cdb56079429761e79beeb292</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fci100084s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci100084s%26sid%3Dliteratum%253Aachs%26aulast%3DWarner%26aufirst%3DD.%2BJ.%26aulast%3DGriffen%26aufirst%3DE.%26aulast%3DSt-Gallay%26aufirst%3DS.%2BA.%26atitle%3DWizePairZ%253A%2520a%2520novel%2520algorithm%2520to%2520identify%252C%2520encode%252C%2520and%2520exploit%2520matched%2520molecular%2520pairs%2520with%2520unspecified%2520cores%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26spage%3D1350%26epage%3D1357%26doi%3D10.1021%2Fci100084s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Papadatos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alkarouri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillet, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willett, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadirkamanathan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luscombe, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A. W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J. F.</span><span> </span><span class="NLM_article-title">Lead optimization using matched molecular pairs: inclusion of contextual information for enchanced prediction of hERG inhibition, solubility and lipophilicity</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1872</span><span class="NLM_x">–</span> <span class="NLM_lpage">1886</span><span class="refDoi"> DOI: 10.1021/ci100258p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci100258p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Whs7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=1872-1886&author=G.+Papadatosauthor=M.+Alkarouriauthor=V.+J.+Gilletauthor=P.+Willettauthor=V.+Kadirkamanathanauthor=C.+N.+Luscombeauthor=G.+Braviauthor=N.+J.+Richmondauthor=S.+D.+Pickettauthor=J.+Hussainauthor=J.+M.+Pritchardauthor=A.+W.+J.+Cooperauthor=S.+J.+F.+Macdonald&title=Lead+optimization+using+matched+molecular+pairs%3A+inclusion+of+contextual+information+for+enchanced+prediction+of+hERG+inhibition%2C+solubility+and+lipophilicity&doi=10.1021%2Fci100258p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization Using Matched Molecular Pairs: Inclusion of Contextual Information for Enhanced Prediction of hERG Inhibition, Solubility, and Lipophilicity</span></div><div class="casAuthors">Papadatos, George; Alkarouri, Muhammad; Gillet, Valerie J.; Willett, Peter; Kadirkamanathan, Visakan; Luscombe, Christopher N.; Bravi, Gianpaolo; Richmond, Nicola J.; Pickett, Stephen D.; Hussain, Jameed; Pritchard, John M.; Cooper, Anthony W. J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1872-1886</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Previous studies of the anal. of mol. matched pairs (MMPs) have often assumed that the effect of a substructural transformation on a mol. property is independent of the context (i.e., the local structural environment in which that transformation occurs).  Expts. with large sets of hERG, soly., and lipophilicity data demonstrate that the inclusion of contextual information can enhance the predictive power of MMP analyses, with significant trends (both pos. and neg.) being identified that are not apparent when using conventional, context-independent approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLZfW5E3jgX7Vg90H21EOLACvtfcHk0lgoifokDzY4Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Whs7jJ&md5=464dff86e047cf1b0273571f82786994</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Fci100258p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci100258p%26sid%3Dliteratum%253Aachs%26aulast%3DPapadatos%26aufirst%3DG.%26aulast%3DAlkarouri%26aufirst%3DM.%26aulast%3DGillet%26aufirst%3DV.%2BJ.%26aulast%3DWillett%26aufirst%3DP.%26aulast%3DKadirkamanathan%26aufirst%3DV.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DBravi%26aufirst%3DG.%26aulast%3DRichmond%26aufirst%3DN.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DPritchard%26aufirst%3DJ.%2BM.%26aulast%3DCooper%26aufirst%3DA.%2BW.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DLead%2520optimization%2520using%2520matched%2520molecular%2520pairs%253A%2520inclusion%2520of%2520contextual%2520information%2520for%2520enchanced%2520prediction%2520of%2520hERG%2520inhibition%252C%2520solubility%2520and%2520lipophilicity%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26spage%3D1872%26epage%3D1886%26doi%3D10.1021%2Fci100258p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Thompson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louth, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorrell, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cochrane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gever, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxendale, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silber, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roehl, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span> </span><span class="NLM_article-title">Discovery of 6-substituted indole-3-glyoxylamides as lead antiprion agents with enhanced cell line activity, improved microsomal stability and low toxicity</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4125</span><span class="NLM_x">–</span> <span class="NLM_lpage">4132</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2011.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.ejmech.2011.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=21726921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2rt7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=4125-4132&author=M.+J.+Thompsonauthor=J.+C.+Louthauthor=S.+Ferraraauthor=M.+P.+Jacksonauthor=F.+J.+Sorrellauthor=E.+J.+Cochraneauthor=J.+Geverauthor=S.+Baxendaleauthor=M.+B.+Silberauthor=H.+H.+Roehlauthor=B.+Chen&title=Discovery+of+6-substituted+indole-3-glyoxylamides+as+lead+antiprion+agents+with+enhanced+cell+line+activity%2C+improved+microsomal+stability+and+low+toxicity&doi=10.1016%2Fj.ejmech.2011.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-substituted indole-3-glyoxylamides as lead antiprion agents with enhanced cell line activity, improved microsomal stability and low toxicity</span></div><div class="casAuthors">Thompson, Mark J.; Louth, Jennifer C.; Ferrara, Steven; Jackson, Matthew P.; Sorrell, Fiona J.; Cochrane, Edward J.; Gever, Joel; Baxendale, Sarah; Silber, B. Michael; Roehl, Henry H.; Chen, Beining</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4125-4132</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of highly potent indole-3-glyoxylamide based antiprion agents was previously characterized, focusing on optimization of structure-activity relationship (SAR) at positions 1-3 of the indole system.  New libraries interrogating the SAR at indole C-4 to C-7 now demonstrate that introducing electron-withdrawing substituents at C-6 may improve biol. activity by up to an order of magnitude, and addnl. confer higher metabolic stability.  For the present screening libraries, both the degree of potency and trends in SAR were consistent across two cell line models of prion disease, and the large majority of compds. showed no evidence of toxic effects in zebrafish.  The foregoing observations thus make the indole-3-glyoxylamides an attractive lead series for continuing development as potential therapeutic agents against prion disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwDFVhW3qW9bVg90H21EOLACvtfcHk0lgoifokDzY4Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2rt7fF&md5=fa78e940d0023a888c4e0f2f5878fb04</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DM.%2BJ.%26aulast%3DLouth%26aufirst%3DJ.%2BC.%26aulast%3DFerrara%26aufirst%3DS.%26aulast%3DJackson%26aufirst%3DM.%2BP.%26aulast%3DSorrell%26aufirst%3DF.%2BJ.%26aulast%3DCochrane%26aufirst%3DE.%2BJ.%26aulast%3DGever%26aufirst%3DJ.%26aulast%3DBaxendale%26aufirst%3DS.%26aulast%3DSilber%26aufirst%3DM.%2BB.%26aulast%3DRoehl%26aufirst%3DH.%2BH.%26aulast%3DChen%26aufirst%3DB.%26atitle%3DDiscovery%2520of%25206-substituted%2520indole-3-glyoxylamides%2520as%2520lead%2520antiprion%2520agents%2520with%2520enhanced%2520cell%2520line%2520activity%252C%2520improved%2520microsomal%2520stability%2520and%2520low%2520toxicity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D4125%26epage%3D4132%26doi%3D10.1016%2Fj.ejmech.2011.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span> </span><span class="NLM_article-title">An effective procedure for the acylation of azaindoles at C-3</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">6226</span><span class="NLM_x">–</span> <span class="NLM_lpage">6227</span><span class="refDoi"> DOI: 10.1021/jo020135i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo020135i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2002&pages=6226-6227&author=Z.+Zhangauthor=Z.+Yangauthor=H.+Wongauthor=J.+Zhuauthor=N.+A.+Meanwellauthor=J.+F.+Kadowauthor=T.+Wang&title=An+effective+procedure+for+the+acylation+of+azaindoles+at+C-3&doi=10.1021%2Fjo020135i"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjo020135i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo020135i%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DWang%26aufirst%3DT.%26atitle%3DAn%2520effective%2520procedure%2520for%2520the%2520acylation%2520of%2520azaindoles%2520at%2520C-3%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2002%26volume%3D67%26spage%3D6226%26epage%3D6227%26doi%3D10.1021%2Fjo020135i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Sabot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meunier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mioskowski, C.</span><span> </span><span class="NLM_article-title">A convenient aminolysis of esters catalyzed by 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) under solvent-free conditions</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">3863</span><span class="NLM_x">–</span> <span class="NLM_lpage">3866</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2007.03.146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.tetlet.2007.03.146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvFyqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=3863-3866&author=C.+Sabotauthor=K.+A.+Kumarauthor=S.+Meunierauthor=C.+Mioskowski&title=A+convenient+aminolysis+of+esters+catalyzed+by+1%2C5%2C7-triazabicyclo%5B4.4.0%5Ddec-5-ene+%28TBD%29+under+solvent-free+conditions&doi=10.1016%2Fj.tetlet.2007.03.146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">A convenient aminolysis of esters catalyzed by 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) under solvent-free conditions</span></div><div class="casAuthors">Sabot, Cyrille; Kumar, Kanduluru Ananda; Meunier, Stephane; Mioskowski, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3863-3866</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Aminolysis of esters by using the organocatalyst 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) is reported.  Secondary and tertiary amides were synthesized from alkyl or aryl esters with a variety of primary and secondary amines in good to excellent yields (60-94%) under solvent-free conditions (SFC).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpWg2wOwFmFLVg90H21EOLACvtfcHk0lgH1vYLtS9WLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvFyqs70%253D&md5=3d668f04b0b3a294db6822d467a04876</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2007.03.146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2007.03.146%26sid%3Dliteratum%253Aachs%26aulast%3DSabot%26aufirst%3DC.%26aulast%3DKumar%26aufirst%3DK.%2BA.%26aulast%3DMeunier%26aufirst%3DS.%26aulast%3DMioskowski%26aufirst%3DC.%26atitle%3DA%2520convenient%2520aminolysis%2520of%2520esters%2520catalyzed%2520by%25201%252C5%252C7-triazabicyclo%255B4.4.0%255Ddec-5-ene%2520%2528TBD%2529%2520under%2520solvent-free%2520conditions%26jtitle%3DTetrahedron%2520Lett.%26date%3D2007%26volume%3D48%26spage%3D3863%26epage%3D3866%26doi%3D10.1016%2Fj.tetlet.2007.03.146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Tsuritani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strotman, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasuda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mase, T.</span><span> </span><span class="NLM_article-title"><i>N</i>-Cyclopropylation of indoles and cyclic amides with copper(II) reagent</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1653</span><span class="NLM_x">–</span> <span class="NLM_lpage">1655</span><span class="refDoi"> DOI: 10.1021/ol800376f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol800376f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsVOmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=1653-1655&author=T.+Tsuritaniauthor=N.+A.+Strotmanauthor=Y.+Yamamotoauthor=M.+Kawasakiauthor=N.+Yasudaauthor=T.+Mase&title=N-Cyclopropylation+of+indoles+and+cyclic+amides+with+copper%28II%29+reagent&doi=10.1021%2Fol800376f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">N-Cyclopropylation of Indoles and Cyclic Amides with Copper(II) Reagent</span></div><div class="casAuthors">Tsuritani, Takayuki; Strotman, Neil A.; Yamamoto, Yuhei; Kawasaki, Masashi; Yasuda, Nobuyoshi; Mase, Toshiaki</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1653-1655</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Copper-mediated coupling reactions of cyclopropylboronic acid with indoles and cyclic amides are described.  The process utilizes catalytic or stoichiometric amts. of copper(II) acetate, DMAP, and NaHMDS at 95 °C under an atm. contg. oxygen.  A variety of functional groups remain intact throughout the reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeYQQwBWe-k7Vg90H21EOLACvtfcHk0lgH1vYLtS9WLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsVOmsLs%253D&md5=85663665b757993739702914df92f335</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fol800376f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol800376f%26sid%3Dliteratum%253Aachs%26aulast%3DTsuritani%26aufirst%3DT.%26aulast%3DStrotman%26aufirst%3DN.%2BA.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DYasuda%26aufirst%3DN.%26aulast%3DMase%26aufirst%3DT.%26atitle%3DN-Cyclopropylation%2520of%2520indoles%2520and%2520cyclic%2520amides%2520with%2520copper%2528II%2529%2520reagent%26jtitle%3DOrg.%2520Lett.%26date%3D2008%26volume%3D10%26spage%3D1653%26epage%3D1655%26doi%3D10.1021%2Fol800376f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Nguyen, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duong, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, J.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johannes, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pincheng, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, D. K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuying, E. L.</span><span> </span><span class="NLM_article-title">Cascade fluorofunctionalisatdon of 2,3-unsubstituted indoles by means of electrophilic fluorination</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">10602</span><span class="NLM_x">–</span> <span class="NLM_lpage">10604</span><span class="refDoi"> DOI: 10.1039/c3cc46564k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1039%2Fc3cc46564k" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=10602-10604&author=T.+M.+Nguyenauthor=H.+A.+Duongauthor=J.-A.+Richardauthor=C.+W.+Johannesauthor=F.+Pinchengauthor=D.+K.+J.+Yeauthor=E.+L.+Shuying&title=Cascade+fluorofunctionalisatdon+of+2%2C3-unsubstituted+indoles+by+means+of+electrophilic+fluorination&doi=10.1039%2Fc3cc46564k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1039%2Fc3cc46564k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3cc46564k%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DT.%2BM.%26aulast%3DDuong%26aufirst%3DH.%2BA.%26aulast%3DRichard%26aufirst%3DJ.-A.%26aulast%3DJohannes%26aufirst%3DC.%2BW.%26aulast%3DPincheng%26aufirst%3DF.%26aulast%3DYe%26aufirst%3DD.%2BK.%2BJ.%26aulast%3DShuying%26aufirst%3DE.%2BL.%26atitle%3DCascade%2520fluorofunctionalisatdon%2520of%25202%252C3-unsubstituted%2520indoles%2520by%2520means%2520of%2520electrophilic%2520fluorination%26jtitle%3DChem.%2520Commun.%26date%3D2013%26volume%3D49%26spage%3D10602%26epage%3D10604%26doi%3D10.1039%2Fc3cc46564k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Conner, S. E.; Gossett, L. S.; Green, J. E.; Jones, W. D.,  Jr.; Mantlo, N. B.; Matthews, D. P.; Mayhugh, D. R.; Smith, D. L.; Vance, J. A.; Wang, X.; Warshawsky, A. M.; Winneroski, L. L.,  Jr.; Xu, Y.; Zhu, G.</span><span> </span><span class="NLM_article-title">Preparation of sulfonamide derivatives, in particular <i>N</i>,<i>N</i>-benzo[<i>b</i>]thiophene sulfonamides, as PPAR modulators, especially PPAR agonists</span>. (Eli Lilly & Co., USA) WO 2004073606 A2, <span class="NLM_month">September</span><span class="NLM_day">2</span>,<span class="NLM_x"> </span><span class="NLM_year">2004</span><span class="NLM_x">; </span>SciFinder Scholar AN 2004:718289;.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=S.+E.+Conner&author=L.+S.+Gossett&author=J.+E.+Green&author=W.+D.+Jones&author=N.+B.+Mantlo&author=D.+P.+Matthews&author=D.+R.+Mayhugh&author=D.+L.+Smith&author=J.+A.+Vance&author=X.+Wang&author=A.+M.+Warshawsky&author=L.+L.+Winneroski&author=Y.+Xu&author=G.+Zhu&title=Preparation+of+sulfonamide+derivatives%2C+in+particular+N%2CN-benzo%5Bb%5Dthiophene+sulfonamides%2C+as+PPAR+modulators%2C+especially+PPAR+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DConner%26aufirst%3DS.%2BE.%26atitle%3DPreparation%2520of%2520sulfonamide%2520derivatives%252C%2520in%2520particular%2520N%252CN-benzo%255Bb%255Dthiophene%2520sulfonamides%252C%2520as%2520PPAR%2520modulators%252C%2520especially%2520PPAR%2520agonists%26date%3D2004%26jtitle%3DSciFinder%2520Scholar" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit76b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wilson, D.; Fanning, L. T. D.; Sheth, U.; Martinborough, E.; Termin, A.; Neubert, T.; Zimmermann, N.; Knoll, T.; Whitney, T.; Kawatkar, A.; Lehsten, D.; Stamos, D.; Zhou, J.; Arumugam, V.; Gutierrez, C.</span><span> </span><span class="NLM_article-title">Heterocyclic derivatives as modulators of ion channels and their preparation, pharmaceutical compositions and use in the treatment of diseases</span>. (Vertex Pharmaceuticals Inc., USA) WO 2007075892 A2, <span class="NLM_month">July</span><span class="NLM_day">5</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>SciFinder Scholar AN 2007:730896.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=D.+Wilson&author=L.+T.+D.+Fanning&author=U.+Sheth&author=E.+Martinborough&author=A.+Termin&author=T.+Neubert&author=N.+Zimmermann&author=T.+Knoll&author=T.+Whitney&author=A.+Kawatkar&author=D.+Lehsten&author=D.+Stamos&author=J.+Zhou&author=V.+Arumugam&author=C.+Gutierrez&title=Heterocyclic+derivatives+as+modulators+of+ion+channels+and+their+preparation%2C+pharmaceutical+compositions+and+use+in+the+treatment+of+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DD.%26atitle%3DHeterocyclic%2520derivatives%2520as%2520modulators%2520of%2520ion%2520channels%2520and%2520their%2520preparation%252C%2520pharmaceutical%2520compositions%2520and%2520use%2520in%2520the%2520treatment%2520of%2520diseases%26date%3D2007%26jtitle%3DSciFinder%2520Scholar" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Yeom, C.-E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B. M.</span><span> </span><span class="NLM_article-title">1,8-Diazabycyclo[5.4.0]undec-7-ene (DBU)-promoted efficient and versatile aza-Michael reaction</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">904</span><span class="NLM_x">–</span> <span class="NLM_lpage">909</span><span class="refDoi"> DOI: 10.1016/j.tet.2006.11.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.tet.2006.11.037" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2007&pages=904-909&author=C.-E.+Yeomauthor=M.+J.+Kimauthor=B.+M.+Kim&title=1%2C8-Diazabycyclo%5B5.4.0%5Dundec-7-ene+%28DBU%29-promoted+efficient+and+versatile+aza-Michael+reaction&doi=10.1016%2Fj.tet.2006.11.037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2006.11.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2006.11.037%26sid%3Dliteratum%253Aachs%26aulast%3DYeom%26aufirst%3DC.-E.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DKim%26aufirst%3DB.%2BM.%26atitle%3D1%252C8-Diazabycyclo%255B5.4.0%255Dundec-7-ene%2520%2528DBU%2529-promoted%2520efficient%2520and%2520versatile%2520aza-Michael%2520reaction%26jtitle%3DTetrahedron%26date%3D2007%26volume%3D63%26spage%3D904%26epage%3D909%26doi%3D10.1016%2Fj.tet.2006.11.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Amato, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roeloffs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigdon, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonio, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mersch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNaughton-Smith, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickenden, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suto, M. J.</span><span> </span><span class="NLM_article-title"><i>N</i>-Pyridyl and pyrimidine benzamides as KCNQ2/Q3 potassium channel openers for the treatment of epilepsy</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">481</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span><span class="refDoi"> DOI: 10.1021/ml200053x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200053x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=481-484&author=G.+Amatoauthor=R.+Roeloffsauthor=G.+C.+Rigdonauthor=B.+Antonioauthor=T.+Merschauthor=G.+McNaughton-Smithauthor=A.+G.+Wickendenauthor=P.+Fritchauthor=M.+J.+Suto&title=N-Pyridyl+and+pyrimidine+benzamides+as+KCNQ2%2FQ3+potassium+channel+openers+for+the+treatment+of+epilepsy&doi=10.1021%2Fml200053x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fml200053x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200053x%26sid%3Dliteratum%253Aachs%26aulast%3DAmato%26aufirst%3DG.%26aulast%3DRoeloffs%26aufirst%3DR.%26aulast%3DRigdon%26aufirst%3DG.%2BC.%26aulast%3DAntonio%26aufirst%3DB.%26aulast%3DMersch%26aufirst%3DT.%26aulast%3DMcNaughton-Smith%26aufirst%3DG.%26aulast%3DWickenden%26aufirst%3DA.%2BG.%26aulast%3DFritch%26aufirst%3DP.%26aulast%3DSuto%26aufirst%3DM.%2BJ.%26atitle%3DN-Pyridyl%2520and%2520pyrimidine%2520benzamides%2520as%2520KCNQ2%252FQ3%2520potassium%2520channel%2520openers%2520for%2520the%2520treatment%2520of%2520epilepsy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D481%26epage%3D484%26doi%3D10.1021%2Fml200053x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Kel'in, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sromek, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gevorgyan, V.</span><span> </span><span class="NLM_article-title">A novel Cu-assisted cycloisomerization of alkynyl imines: efficient synthesis of pyrroles and pyrrole-containing heterocycles</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">2074</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span><span class="refDoi"> DOI: 10.1021/ja0058684</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0058684" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2001&pages=2074-2075&author=A.+V.+Kel%27inauthor=A.+W.+Sromekauthor=V.+Gevorgyan&title=A+novel+Cu-assisted+cycloisomerization+of+alkynyl+imines%3A+efficient+synthesis+of+pyrroles+and+pyrrole-containing+heterocycles&doi=10.1021%2Fja0058684"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fja0058684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0058684%26sid%3Dliteratum%253Aachs%26aulast%3DKel%2527in%26aufirst%3DA.%2BV.%26aulast%3DSromek%26aufirst%3DA.%2BW.%26aulast%3DGevorgyan%26aufirst%3DV.%26atitle%3DA%2520novel%2520Cu-assisted%2520cycloisomerization%2520of%2520alkynyl%2520imines%253A%2520efficient%2520synthesis%2520of%2520pyrroles%2520and%2520pyrrole-containing%2520heterocycles%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2001%26volume%3D123%26spage%3D2074%26epage%3D2075%26doi%3D10.1021%2Fja0058684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span> </span><span class="NLM_article-title">Development of a practical synthesis of STA-5312, a novel indolizine oxalylamide microtubule inhibitor</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">246</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span><span class="refDoi"> DOI: 10.1021/op6002852</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op6002852" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVyitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=246-250&author=H.+Liauthor=Z.+Xiaauthor=S.+Chenauthor=K.+Koyaauthor=M.+Onoauthor=L.+Sun&title=Development+of+a+practical+synthesis+of+STA-5312%2C+a+novel+indolizine+oxalylamide+microtubule+inhibitor&doi=10.1021%2Fop6002852"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a practical synthesis of STA-5312, a novel indolizine oxalylamide microtubule inhibitor</span></div><div class="casAuthors">Li, Hao; Xia, Zhiqiang; Chen, Shoujun; Koya, Keizo; Ono, Mitsunori; Sun, Lijun</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-250</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An efficient synthesis of the novel microtubule inhibitor STA-5312 (3-[(4-cyanophenyl)methyl]-N-(3-methyl-5-isothiazolyl)-α-oxo-1-indolizineacetamide) was developed.  A novel DMF/Me2SO4 directed regioselective synthesis of the 3-(4-cyanobenzoyl)-indolizine (4) was a crit. transformation within the four-step process.  Alternatively, a CuCl mediated synthesis of 3-(4-cyanobenzyl)indolizine (5) was also developed.  All intermediates were obtained in high quality and were used directly for the next step without extensive purifn.  The drug substance itself was purified by recrystn. from a mixt. of THF and water, resulting in a high purity product (HPLC >98%).  The process was applied successfully in the manufg. of kilograms of GMP API.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEfERaIRQgoLVg90H21EOLACvtfcHk0lh-9-sWH_DB2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVyitb4%253D&md5=4bb3dbe5cca1398bef973cef1bb83920</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fop6002852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop6002852%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DKoya%26aufirst%3DK.%26aulast%3DOno%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DL.%26atitle%3DDevelopment%2520of%2520a%2520practical%2520synthesis%2520of%2520STA-5312%252C%2520a%2520novel%2520indolizine%2520oxalylamide%2520microtubule%2520inhibitor%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2007%26volume%3D11%26spage%3D246%26epage%3D250%26doi%3D10.1021%2Fop6002852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Debnar, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreisigacker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menche, D.</span><span> </span><span class="NLM_article-title">Highly regioselective opening of zirconacyclopentadienes by remote coordination: concise synthesis of the furan core of the leupyrrins</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">725</span><span class="NLM_x">–</span> <span class="NLM_lpage">727</span><span class="refDoi"> DOI: 10.1039/C2CC37678D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1039%2FC2CC37678D" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=725-727&author=T.+Debnarauthor=S.+Dreisigackerauthor=D.+Menche&title=Highly+regioselective+opening+of+zirconacyclopentadienes+by+remote+coordination%3A+concise+synthesis+of+the+furan+core+of+the+leupyrrins&doi=10.1039%2FC2CC37678D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1039%2FC2CC37678D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2CC37678D%26sid%3Dliteratum%253Aachs%26aulast%3DDebnar%26aufirst%3DT.%26aulast%3DDreisigacker%26aufirst%3DS.%26aulast%3DMenche%26aufirst%3DD.%26atitle%3DHighly%2520regioselective%2520opening%2520of%2520zirconacyclopentadienes%2520by%2520remote%2520coordination%253A%2520concise%2520synthesis%2520of%2520the%2520furan%2520core%2520of%2520the%2520leupyrrins%26jtitle%3DChem.%2520Commun.%26date%3D2013%26volume%3D49%26spage%3D725%26epage%3D727%26doi%3D10.1039%2FC2CC37678D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Chen, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, S.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wistuba, I. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, C.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, K.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, T.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, C.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M.-C.</span><span> </span><span class="NLM_article-title">Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e21428</span><span class="refDoi"> DOI: 10.1371/journal.pone.0021428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1371%2Fjournal.pone.0021428" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e21428&author=Y.-J.+Chenauthor=W.-C.+Huangauthor=Y.-L.+Weiauthor=S.-C.+Hsuauthor=P.+Yuanauthor=H.+Y.+Linauthor=I.+I.+Wistubaauthor=J.+J.+Leeauthor=C.-J.+Yenauthor=W.-C.+Suauthor=K.-Y.+Changauthor=W.-C.+Changauthor=T.-C.+Chouauthor=C.-K.+Chouauthor=C.-H.+Tsaiauthor=M.-C.+Hung&title=Elevated+BCRP%2FABCG2+expression+confers+acquired+resistance+to+gefitinib+in+wild-type+EGFR-expressing+cells&doi=10.1371%2Fjournal.pone.0021428"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0021428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0021428%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.-J.%26aulast%3DHuang%26aufirst%3DW.-C.%26aulast%3DWei%26aufirst%3DY.-L.%26aulast%3DHsu%26aufirst%3DS.-C.%26aulast%3DYuan%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DH.%2BY.%26aulast%3DWistuba%26aufirst%3DI.%2BI.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DYen%26aufirst%3DC.-J.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DChang%26aufirst%3DK.-Y.%26aulast%3DChang%26aufirst%3DW.-C.%26aulast%3DChou%26aufirst%3DT.-C.%26aulast%3DChou%26aufirst%3DC.-K.%26aulast%3DTsai%26aufirst%3DC.-H.%26aulast%3DHung%26aufirst%3DM.-C.%26atitle%3DElevated%2520BCRP%252FABCG2%2520expression%2520confers%2520acquired%2520resistance%2520to%2520gefitinib%2520in%2520wild-type%2520EGFR-expressing%2520cells%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De21428%26doi%3D10.1371%2Fjournal.pone.0021428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shelanski, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaskin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantor, C. R.</span><span> </span><span class="NLM_article-title">Microtubule assembly in the absence of added nucleotides</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">765</span><span class="NLM_x">–</span> <span class="NLM_lpage">768</span><span class="refDoi"> DOI: 10.1073/pnas.70.3.765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1073%2Fpnas.70.3.765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=4514990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADyaE3sXhsVCgtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1973&pages=765-768&author=M.+L.+Shelanskiauthor=F.+Gaskinauthor=C.+R.+Cantor&title=Microtubule+assembly+in+the+absence+of+added+nucleotides&doi=10.1073%2Fpnas.70.3.765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83aR"><div class="casContent"><span class="casTitleNuber">83a</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule assembly in the absence of added nucleotides</span></div><div class="casAuthors">Shelanski, Michael L.; Gaskin, Felicia; Cantor, Charles R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">765-8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Microtubule assembly was enhanced by the addn. of M sucrose or 4 M glycerol to the reassembly mixt.  Tubulin was purified from guinea pig brain readily and in good yield by tycles of assembly in glycerol-contg. solns  The tubules assembled in glycerol and sucrose were more stable than tubules formed in the absence of these compds.  Assembly occurred in glycerol or sucrose in he absence of ATP or GT but was greatly accelerated by their presence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVpPUVyzxhcbVg90H21EOLACvtfcHk0lh4OXsRlTjqfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXhsVCgtrs%253D&md5=c0eb0f728884f0a0eba421d633c9031b</span></div><a href="/servlet/linkout?suffix=cit83a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.70.3.765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.70.3.765%26sid%3Dliteratum%253Aachs%26aulast%3DShelanski%26aufirst%3DM.%2BL.%26aulast%3DGaskin%26aufirst%3DF.%26aulast%3DCantor%26aufirst%3DC.%2BR.%26atitle%3DMicrotubule%2520assembly%2520in%2520the%2520absence%2520of%2520added%2520nucleotides%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1973%26volume%3D70%26spage%3D765%26epage%3D768%26doi%3D10.1073%2Fpnas.70.3.765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit83b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timasheff, S. N.</span><span> </span><span class="NLM_article-title">In vitro reconstitution of calf brain microtubules: effects of solution variables</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1754</span><span class="NLM_x">–</span> <span class="NLM_lpage">1764</span><span class="refDoi"> DOI: 10.1021/bi00627a037</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00627a037" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADyaE2sXhvVCkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1977&pages=1754-1764&author=J.+C.+Leeauthor=S.+N.+Timasheff&title=In+vitro+reconstitution+of+calf+brain+microtubules%3A+effects+of+solution+variables&doi=10.1021%2Fbi00627a037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83bR"><div class="casContent"><span class="casTitleNuber">83b</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro reconstitution of calf brain microtubules:  effects of solution variables</span></div><div class="casAuthors">Lee, James C.; Timasheff, Serge N.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1754-64</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">The effects of soln. variables on the in vitro reconstitution of calf brain tubulin were investigated at pH 7.0.  Reconstitution of microtubules was successful in a variety of buffer systems.  Microtubule formation was promoted by Mg2+ and GTP, but inhibited by Ca2+.  The dependence of the apparent assocn. const. for microtubule formation on ligand concn. was analyzed.  The formation of a tubulin-tubulin contact involves the binding of 1 addnl. Mg2+/tubulin dimer.  Microtubule formation is also accompanied by the apparent binding of 1 addnl. proton and the release of H2O mols., as suggested by thermodyn. parameters.  The reaction is entropy driven with an apparent heat capacity change, ΔCp, of -1500 cal/degree-mol.  The enhancement of tubulin reassembly by glycerol is most likely due to nonspecific protein-solvent general thermodyn. interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMRSO63LMZTrVg90H21EOLACvtfcHk0lh4OXsRlTjqfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXhvVCkuro%253D&md5=0764be20538284d0834b08ca054e751e</span></div><a href="/servlet/linkout?suffix=cit83b&amp;dbid=16384&amp;doi=10.1021%2Fbi00627a037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00627a037%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTimasheff%26aufirst%3DS.%2BN.%26atitle%3DIn%2520vitro%2520reconstitution%2520of%2520calf%2520brain%2520microtubules%253A%2520effects%2520of%2520solution%2520variables%26jtitle%3DBiochemistry%26date%3D1977%26volume%3D16%26spage%3D1754%26epage%3D1764%26doi%3D10.1021%2Fbi00627a037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Bonne, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heusèle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantaloni, D.</span><span> </span><span class="NLM_article-title">4′,6-Diamidino-2-phenylindole, a fluorescent probe for tubulin and microtubules</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">260</span><span class="NLM_x">, </span> <span class="NLM_fpage">2819</span><span class="NLM_x">–</span> <span class="NLM_lpage">2825</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=260&publication_year=1985&pages=2819-2825&author=D.+Bonneauthor=C.+Heus%C3%A8leauthor=C.+Simonauthor=D.+Pantaloni&title=4%E2%80%B2%2C6-Diamidino-2-phenylindole%2C+a+fluorescent+probe+for+tubulin+and+microtubules"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBonne%26aufirst%3DD.%26aulast%3DHeus%25C3%25A8le%26aufirst%3DC.%26aulast%3DSimon%26aufirst%3DC.%26aulast%3DPantaloni%26aufirst%3DD.%26atitle%3D4%25E2%2580%25B2%252C6-Diamidino-2-phenylindole%252C%2520a%2520fluorescent%2520probe%2520for%2520tubulin%2520and%2520microtubules%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1985%26volume%3D260%26spage%3D2819%26epage%3D2825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Cortese, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharyya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolff, J.</span><span> </span><span class="NLM_article-title">Podophyllotoxin as a probe for the colchicine binding site of tubulin</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">252</span><span class="NLM_x">, </span> <span class="NLM_fpage">1134</span><span class="NLM_x">–</span> <span class="NLM_lpage">1140</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=252&publication_year=1977&pages=1134-1140&author=F.+Corteseauthor=B.+Bhattacharyyaauthor=J.+Wolff&title=Podophyllotoxin+as+a+probe+for+the+colchicine+binding+site+of+tubulin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCortese%26aufirst%3DF.%26aulast%3DBhattacharyya%26aufirst%3DB.%26aulast%3DWolff%26aufirst%3DJ.%26atitle%3DPodophyllotoxin%2520as%2520a%2520probe%2520for%2520the%2520colchicine%2520binding%2520site%2520of%2520tubulin%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1977%26volume%3D252%26spage%3D1134%26epage%3D1140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Wallner, B. P.; Schwartz, B. E.; Komarnitsky, P. B.; Bacher, G.; Kutscher, B.; Raab, G.</span><span> </span><span class="NLM_article-title">Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer</span>. (Ziopharm Oncology Inc., USA) WO 2008066807 A1, <span class="NLM_month">Jun</span><span class="NLM_day">5</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>SciFinder Scholar AN 2008:673085.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=B.+P.+Wallner&author=B.+E.+Schwartz&author=P.+B.+Komarnitsky&author=G.+Bacher&author=B.+Kutscher&author=G.+Raab&title=Use+of+indolyl-3-glyoxylic+acid+derivatives+including+indibulin%2C+alone+or+in+combination+with+further+agents+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWallner%26aufirst%3DB.%2BP.%26atitle%3DUse%2520of%2520indolyl-3-glyoxylic%2520acid%2520derivatives%2520including%2520indibulin%252C%2520alone%2520or%2520in%2520combination%2520with%2520further%2520agents%2520for%2520treating%2520cancer%26date%3D2008%26jtitle%3DSciFinder%2520Scholar" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Yamada, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorbsky, G. J.</span><span> </span><span class="NLM_article-title">Spindle checkpoint function and cellular sensitivity to antimitotic drugs</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">2963</span><span class="NLM_x">–</span> <span class="NLM_lpage">2969</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1158%2F1535-7163.MCT-06-0319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=17172401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlagsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=2963-2969&author=H.+Y.+Yamadaauthor=G.+J.+Gorbsky&title=Spindle+checkpoint+function+and+cellular+sensitivity+to+antimitotic+drugs&doi=10.1158%2F1535-7163.MCT-06-0319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Spindle checkpoint function and cellular sensitivity to antimitotic drugs</span></div><div class="casAuthors">Yamada, Hiroshi Y.; Gorbsky, Gary J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2963-2969</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review which discusses the mitotic/postmitotic events and mol. signaling involved in cancer treatments with antimitotic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaGJPPHTlIL7Vg90H21EOLACvtfcHk0lg76gZXbA5KIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlagsb3O&md5=38e31d7e1983aa5400fa6d5896effaa6</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0319%26sid%3Dliteratum%253Aachs%26aulast%3DYamada%26aufirst%3DH.%2BY.%26aulast%3DGorbsky%26aufirst%3DG.%2BJ.%26atitle%3DSpindle%2520checkpoint%2520function%2520and%2520cellular%2520sensitivity%2520to%2520antimitotic%2520drugs%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D2963%26epage%3D2969%26doi%3D10.1158%2F1535-7163.MCT-06-0319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Harker, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sikic, B. I.</span><span> </span><span class="NLM_article-title">Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4091</span><span class="NLM_x">–</span> <span class="NLM_lpage">4096</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=4028002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADyaL2MXlslWmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1985&pages=4091-4096&author=W.+G.+Harkerauthor=B.+I.+Sikic&title=Multidrug+%28pleiotropic%29+resistance+in+doxorubicin-selected+variants+of+the+human+sarcoma+cell+line+MES-SA"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA</span></div><div class="casAuthors">Harker, W. Graydon; Sikic, Branimir Ivan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4091-6</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Doxorubicin (DOX)  [23214-92-8]-resistant sublines of the human sarcoma cell line MES-SA were selected by continuous in vitro exposure to DOX; stepwise increases in DOX concn. produced variants which were 25- and 100-fold resistant to DOX.  These sublines displayed marked cross-resistant to daunorubicin  [20830-81-3], dactinomycin  [50-76-0], mitoxantrone  [65271-80-9], colchicine  [64-86-8], vincristine  [57-22-7], vinblastine  [865-21-4], and etoposide  [33419-42-0] and moderate resistance to mitomycin C  [50-07-7] and melphalan  [148-82-3].  Cross-resistance was not obsd., however, to methotrexate  [59-05-2], 5-fluorouracil  [51-21-8], bleomycin  [11056-06-7], carmustine  [154-93-8], or cisplatin  [15663-27-1].  DOX resistance in these cell lines appeared to be stable despite long periods of growth in drug-free medium.  Two addnl. marker chromosomes were identified in the 100-fold resistant variant, which indicated clonal selection during drug exposure, but no double minute chromosomes or homogeneously staining regions were noted.  Doxorubicin accumulation in the DOX-resistant cells was reduced by approx. 50% compared to that of the sensitive MES-SA cells, as a result of enhanced efflux of DOX from the resistant cells.  There was no evidence of appreciable DOX metab. by either the sensitive or resistant cells.  These studies demonstrate marked DOX resistance and multidrug resistance arising in a human sarcoma line during exposure to DOX.  The pleiotropic nature of this resistance is similar to that described in other models.  Decreased drug accumulation due to enhanced drug efflux is identified as a major mechanism of resistance in these cells, although other factors may also be involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJX9_zdf-RX7Vg90H21EOLACvtfcHk0lg76gZXbA5KIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXlslWmtLY%253D&md5=d08d715f84eccd8fa0a3638a5c0e4a9a</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHarker%26aufirst%3DW.%2BG.%26aulast%3DSikic%26aufirst%3DB.%2BI.%26atitle%3DMultidrug%2520%2528pleiotropic%2529%2520resistance%2520in%2520doxorubicin-selected%2520variants%2520of%2520the%2520human%2520sarcoma%2520cell%2520line%2520MES-SA%26jtitle%3DCancer%2520Res.%26date%3D1985%26volume%3D45%26spage%3D4091%26epage%3D4096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffrézou, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durán, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sikic, B. I.</span><span> </span><span class="NLM_article-title">Prevalence of multidrug resistance related to activation of the <i>Mdr1</i> gene in human sarcoma mutants derived by single-step doxorubicin selection</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4980</span><span class="NLM_x">–</span> <span class="NLM_lpage">4987</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1994&pages=4980-4987&author=G.+Chenauthor=J.-P.+Jaffr%C3%A9zouauthor=W.+H.+Flemingauthor=G.+E.+Dur%C3%A1nauthor=B.+I.+Sikic&title=Prevalence+of+multidrug+resistance+related+to+activation+of+the+Mdr1+gene+in+human+sarcoma+mutants+derived+by+single-step+doxorubicin+selection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%26aulast%3DJaffr%25C3%25A9zou%26aufirst%3DJ.-P.%26aulast%3DFleming%26aufirst%3DW.%2BH.%26aulast%3DDur%25C3%25A1n%26aufirst%3DG.%2BE.%26aulast%3DSikic%26aufirst%3DB.%2BI.%26atitle%3DPrevalence%2520of%2520multidrug%2520resistance%2520related%2520to%2520activation%2520of%2520the%2520Mdr1%2520gene%2520in%2520human%2520sarcoma%2520mutants%2520derived%2520by%2520single-step%2520doxorubicin%2520selection%26jtitle%3DCancer%2520Res.%26date%3D1994%26volume%3D54%26spage%3D4980%26epage%3D4987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakaeda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohmoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirakawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuroda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasuga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okumura, K.</span><span> </span><span class="NLM_article-title">Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2 and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1124/dmd.30.1.4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1124%2Fdmd.30.1.4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=4-6&author=T.+Nakamuraauthor=T.+Sakaedaauthor=N.+Ohmotoauthor=T.+Tamuraauthor=N.+Aoyamaauthor=T.+Shirakawaauthor=T.+Nakamuraauthor=K.+I.+Kimauthor=S.+R.+Kimauthor=Y.+Kurodaauthor=M.+Matsuoauthor=M.+Kasugaauthor=K.+Okumura&title=Real-time+quantitative+polymerase+chain+reaction+for+MDR1%2C+MRP1%2C+MRP2+and+CYP3A-mRNA+levels+in+Caco-2+cell+lines%2C+human+duodenal+enterocytes%2C+normal+colorectal+tissues%2C+and+colorectal+adenocarcinomas&doi=10.1124%2Fdmd.30.1.4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.1.4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.1.4%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DSakaeda%26aufirst%3DT.%26aulast%3DOhmoto%26aufirst%3DN.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DAoyama%26aufirst%3DN.%26aulast%3DShirakawa%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DK.%2BI.%26aulast%3DKim%26aufirst%3DS.%2BR.%26aulast%3DKuroda%26aufirst%3DY.%26aulast%3DMatsuo%26aufirst%3DM.%26aulast%3DKasuga%26aufirst%3DM.%26aulast%3DOkumura%26aufirst%3DK.%26atitle%3DReal-time%2520quantitative%2520polymerase%2520chain%2520reaction%2520for%2520MDR1%252C%2520MRP1%252C%2520MRP2%2520and%2520CYP3A-mRNA%2520levels%2520in%2520Caco-2%2520cell%2520lines%252C%2520human%2520duodenal%2520enterocytes%252C%2520normal%2520colorectal%2520tissues%252C%2520and%2520colorectal%2520adenocarcinomas%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D4%26epage%3D6%26doi%3D10.1124%2Fdmd.30.1.4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Gutmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fricker, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Török, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michael, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beglinger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewe, J.</span><span> </span><span class="NLM_article-title">Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">402</span><span class="NLM_x">–</span> <span class="NLM_lpage">407</span><span class="refDoi"> DOI: 10.1023/A:1018825819249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1023%2FA%3A1018825819249" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1999&pages=402-407&author=H.+Gutmannauthor=G.+Frickerauthor=M.+T%C3%B6r%C3%B6kauthor=S.+Michaelauthor=C.+Beglingerauthor=J.+Drewe&title=Evidence+for+different+ABC-transporters+in+Caco-2+cells+modulating+drug+uptake&doi=10.1023%2FA%3A1018825819249"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1023%2FA%3A1018825819249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1018825819249%26sid%3Dliteratum%253Aachs%26aulast%3DGutmann%26aufirst%3DH.%26aulast%3DFricker%26aufirst%3DG.%26aulast%3DT%25C3%25B6r%25C3%25B6k%26aufirst%3DM.%26aulast%3DMichael%26aufirst%3DS.%26aulast%3DBeglinger%26aufirst%3DC.%26aulast%3DDrewe%26aufirst%3DJ.%26atitle%3DEvidence%2520for%2520different%2520ABC-transporters%2520in%2520Caco-2%2520cells%2520modulating%2520drug%2520uptake%26jtitle%3DPharm.%2520Res.%26date%3D1999%26volume%3D16%26spage%3D402%26epage%3D407%26doi%3D10.1023%2FA%3A1018825819249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Xia, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miwa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, L.-S.</span><span> </span><span class="NLM_article-title">Expression, localization and functional characteristics of breast cancer resistance protein in Caco-2 cells</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">637</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span><span class="refDoi"> DOI: 10.1124/dmd.104.003442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1124%2Fdmd.104.003442" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=637-643&author=C.+Q.+Xiaauthor=N.+Liuauthor=D.+Yangauthor=G.+Miwaauthor=L.-S.+Gan&title=Expression%2C+localization+and+functional+characteristics+of+breast+cancer+resistance+protein+in+Caco-2+cells&doi=10.1124%2Fdmd.104.003442"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1124%2Fdmd.104.003442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.104.003442%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DC.%2BQ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DMiwa%26aufirst%3DG.%26aulast%3DGan%26aufirst%3DL.-S.%26atitle%3DExpression%252C%2520localization%2520and%2520functional%2520characteristics%2520of%2520breast%2520cancer%2520resistance%2520protein%2520in%2520Caco-2%2520cells%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D637%26epage%3D643%26doi%3D10.1124%2Fdmd.104.003442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Breslin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Driscoll, L.</span><span> </span><span class="NLM_article-title">Three-dimensional cell culture: the missing link in drug discovery</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span><span class="refDoi"> DOI: 10.1016/j.drudis.2012.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.drudis.2012.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=23073387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1aqs7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=240-249&author=S.+Breslinauthor=L.+O%E2%80%99Driscoll&title=Three-dimensional+cell+culture%3A+the+missing+link+in+drug+discovery&doi=10.1016%2Fj.drudis.2012.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Three-dimensional cell culture: the missing link in drug discovery</span></div><div class="casAuthors">Breslin, Susan; O'Driscoll, Lorraine</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">240-249</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cells, grown as monolayers (2D models), are routinely used as initial model systems for evaluating the effectiveness and safety of libraries of mols. with potential as therapeutic drugs.  While this initial screening precedes preclin. animal studies before advancing to human clin. trials, cultured cells frequently det. the initial, yet crucial, 'stop/go' decisions on the progressing of the development of a drug.  Growing cells as three-dimensional (3D) models more analogous to their existence in vivo, for example, akin to a tumor, and possibly co-cultured with other cells and cellular components that naturally occur in their microenvironment may be more clin. relevant.  Here, in the context of anti-cancer drug screening, we review 2D and 3D culture approaches, consider the strengths and relevance of each method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6L1vxblLJJbVg90H21EOLACvtfcHk0lhgo98dGHpeIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1aqs7%252FN&md5=caec0a115779d0204fea9e083963487f</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2012.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2012.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DBreslin%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Driscoll%26aufirst%3DL.%26atitle%3DThree-dimensional%2520cell%2520culture%253A%2520the%2520missing%2520link%2520in%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D240%26epage%3D249%26doi%3D10.1016%2Fj.drudis.2012.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Hirschhaeuser, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menne, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittfeld, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller-Klieser, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunz-Schughart, L. A.</span><span> </span><span class="NLM_article-title">Multicellular tumor spheroids: an underestimated tool is catching up again</span> <span class="citation_source-journal">J. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">148</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span><span class="refDoi"> DOI: 10.1016/j.jbiotec.2010.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.jbiotec.2010.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=20097238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVOqtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2010&pages=3-15&author=F.+Hirschhaeuserauthor=H.+Menneauthor=C.+Dittfeldauthor=J.+Westauthor=W.+Mueller-Klieserauthor=L.+A.+Kunz-Schughart&title=Multicellular+tumor+spheroids%3A+an+underestimated+tool+is+catching+up+again&doi=10.1016%2Fj.jbiotec.2010.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Multicellular tumor spheroids: An underestimated tool is catching up again</span></div><div class="casAuthors">Hirschhaeuser, Franziska; Menne, Heike; Dittfeld, Claudia; West, Jonathan; Mueller-Klieser, Wolfgang; Kunz-Schughart, Leoni A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-15</span>CODEN:
                <span class="NLM_cas:coden">JBITD4</span>;
        ISSN:<span class="NLM_cas:issn">0168-1656</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The present article highlights the rationale, potential and flexibility of tumor spheroid mono- and cocultures for implementation into state of the art anti-cancer therapy test platforms.  Unlike classical monolayer-based models, spheroids strikingly mirror the 3D cellular context and therapeutically relevant pathophysiol. gradients of in vivo tumors.  Some concepts for standardization and automation of spheroid culturing, monitoring and anal. are discussed, and the challenges to define the most convenient anal. endpoints for therapy testing are outlined.  The potential of spheroids to contribute to either the elimination of poor drug candidates at the pre-animal and pre-clin. state or the identification of promising drugs that would fail in classical 2D cell assays is emphasized.  Microtechnologies, in the form of micropatterning and microfluidics, are also discussed and offer the exciting prospect of standardized spheroid mass prodn. to tackle high-throughput screening applications within the context of traditional lab. settings.  The extension towards more sophisticated spheroid coculture models which more closely reflect heterologous tumor tissues composed of tumor and various stromal cell types is also covered.  Examples are given with particular emphasis on tumor-immune cell cocultures and their usefulness for testing novel immunotherapeutic treatment strategies.  Finally, tumor cell heterogeneity and the extraordinary possibilities of putative cancer stem/tumor-initiating cell populations that can be maintained and expanded in sphere-forming assays are introduced.  The relevance of the cancer stem cell hypothesis for cancer cure is highlighted, with the resp. sphere cultures being envisioned as an integral tool for next generation drug development offensives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqdopugkTjz7Vg90H21EOLACvtfcHk0lh8VLuYD-Tufg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVOqtbc%253D&md5=a35667ebcc7c36348b9400a2239e6ae7</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.jbiotec.2010.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbiotec.2010.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DHirschhaeuser%26aufirst%3DF.%26aulast%3DMenne%26aufirst%3DH.%26aulast%3DDittfeld%26aufirst%3DC.%26aulast%3DWest%26aufirst%3DJ.%26aulast%3DMueller-Klieser%26aufirst%3DW.%26aulast%3DKunz-Schughart%26aufirst%3DL.%2BA.%26atitle%3DMulticellular%2520tumor%2520spheroids%253A%2520an%2520underestimated%2520tool%2520is%2520catching%2520up%2520again%26jtitle%3DJ.%2520Biotechnol.%26date%3D2010%26volume%3D148%26spage%3D3%26epage%3D15%26doi%3D10.1016%2Fj.jbiotec.2010.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Colley, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hearnden, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avila-Olias, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cecchin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canton, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNeil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeating, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armes, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murdoch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornhill, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battaglia, G.</span><span> </span><span class="NLM_article-title">Polymersome-mediated delivery of combination anticancer therapy to head and neck cancer cells: 2D and 3D <i>in vitro</i> evaluation</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1176</span><span class="NLM_x">–</span> <span class="NLM_lpage">1188</span><span class="refDoi"> DOI: 10.1021/mp400610b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp400610b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXis1ejt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=1176-1188&author=H.+E.+Colleyauthor=V.+Hearndenauthor=M.+Avila-Oliasauthor=D.+Cecchinauthor=I.+Cantonauthor=J.+Madsenauthor=S.+MacNeilauthor=N.+Warrenauthor=K.+Huauthor=J.+A.+McKeatingauthor=S.+P.+Armesauthor=C.+Murdochauthor=M.+H.+Thornhillauthor=G.+Battaglia&title=Polymersome-mediated+delivery+of+combination+anticancer+therapy+to+head+and+neck+cancer+cells%3A+2D+and+3D+in+vitro+evaluation&doi=10.1021%2Fmp400610b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Polymersome-Mediated Delivery of Combination Anticancer Therapy to Head and Neck Cancer Cells: 2D and 3D in Vitro Evaluation</span></div><div class="casAuthors">Colley, Helen E.; Hearnden, Vanessa; Avila-Olias, Milagros; Cecchin, Denis; Canton, Irene; Madsen, Jeppe; MacNeil, Sheila; Warren, Nicholas; Hu, Ke; McKeating, Jane A.; Armes, Steven P.; Murdoch, Craig; Thornhill, Martin H.; Battaglia, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1176-1188</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polymersomes have the potential to encapsulate and deliver chemotherapeutic drugs into tumor cells, reducing off-target toxicity that often compromises anticancer treatment.  Here, we assess the ability of the pH-sensitive poly 2-(methacryloyloxy)ethyl phosphorylcholine (PMPC)- poly 2-(diisopropylamino)ethyl methacrylate (PDPA) polymersomes to encapsulate chemotherapeutic agents for effective combinational anticancer therapy.  Polymersome uptake and ability to deliver encapsulated drugs into healthy normal oral cells and oral head and neck squamous cell carcinoma (HNSCC) cells was measured in two and three-dimensional culture systems.  PMPC-PDPA polymersomes were more rapidly internalized by HNSCC cells compared to normal oral cells.  Polymersome cellular uptake was found to be mediated by class B scavenger receptors.  We also obsd. that these receptors are more highly expressed by cancer cells compared to normal oral cells, enabling polymersome-mediated targeting.  Doxorubicin and paclitaxel were encapsulated into pH-sensitive PMPC-PDPA polymersomes with high efficiencies either in isolation or as a dual-load for both singular and combinational delivery.  In monolayer culture, only a short exposure to drug-loaded polymersomes was required to elicit a strong cytotoxic effect.  When delivered to three-dimensional tumor models, PMPC-PDPA polymersomes were able to penetrate deep into the center of the spheroid resulting in extensive cell damage when loaded with both singular and dual-loaded chemotherapeutics.  PMPC-PDPA polymersomes offer a novel system for the effective delivery of chemotherapeutics for the treatment of HNSCC.  Moreover, the preferential internalization of PMPC polymersomes by exploiting elevated scavenger receptor expression on cancer cells opens up the opportunity to target polymersomes to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFYzFKKeUtR7Vg90H21EOLACvtfcHk0lh8VLuYD-Tufg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXis1ejt7w%253D&md5=2497815bbd4096beea08d6423d5496d7</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fmp400610b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp400610b%26sid%3Dliteratum%253Aachs%26aulast%3DColley%26aufirst%3DH.%2BE.%26aulast%3DHearnden%26aufirst%3DV.%26aulast%3DAvila-Olias%26aufirst%3DM.%26aulast%3DCecchin%26aufirst%3DD.%26aulast%3DCanton%26aufirst%3DI.%26aulast%3DMadsen%26aufirst%3DJ.%26aulast%3DMacNeil%26aufirst%3DS.%26aulast%3DWarren%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DK.%26aulast%3DMcKeating%26aufirst%3DJ.%2BA.%26aulast%3DArmes%26aufirst%3DS.%2BP.%26aulast%3DMurdoch%26aufirst%3DC.%26aulast%3DThornhill%26aufirst%3DM.%2BH.%26aulast%3DBattaglia%26aufirst%3DG.%26atitle%3DPolymersome-mediated%2520delivery%2520of%2520combination%2520anticancer%2520therapy%2520to%2520head%2520and%2520neck%2520cancer%2520cells%253A%25202D%2520and%25203D%2520in%2520vitro%2520evaluation%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2014%26volume%3D11%26spage%3D1176%26epage%3D1188%26doi%3D10.1021%2Fmp400610b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kadletz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heiduschka, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domayer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enzenhofer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurnher, D.</span><span> </span><span class="NLM_article-title">Evaluation of spheroid head and neck squamous cell carcinoma cell models in comparison to monolayer cultures</span> <span class="citation_source-journal">Oncol. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">–</span> <span class="NLM_lpage">1286</span><span class="refDoi"> DOI: 10.3892/ol.2015.3487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.3892%2Fol.2015.3487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=26622664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsFOjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1281-1286&author=L.+Kadletzauthor=G.+Heiduschkaauthor=J.+Domayerauthor=R.+Schmidauthor=E.+Enzenhoferauthor=D.+Thurnher&title=Evaluation+of+spheroid+head+and+neck+squamous+cell+carcinoma+cell+models+in+comparison+to+monolayer+cultures&doi=10.3892%2Fol.2015.3487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96aR"><div class="casContent"><span class="casTitleNuber">96a</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of spheroid head and neck squamous cell carcinoma cell models in comparison to monolayer cultures</span></div><div class="casAuthors">Kadletz, Lorenz; Heiduschka, Gregor; Domayer, Julian; Schmid, Rainer; Enzenhofer, Elisabeth; Thurnher, Dietmar</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1281-1286</span>CODEN:
                <span class="NLM_cas:coden">OLNEB5</span>;
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Two-dimensional (2D) monolayer cell culture models are the most common method used to investigate tumor cells in vitro.  In the few last decades, a multicellular spheroid model has gained attention due to its adjacency to tumors in vivo.  The aim of the present study was to investigate immunohistochem. differences between these two cell culture systems.  The FaDu, CAL27 and SCC25 head and neck squamous cell carcinoma (HNSCC) cell lines were seeded out in monolayer and multicellular spheroids.  The FaDu and SCC25 cells were treated with increasing doses of cisplatin and irradn.  CAL27 cells were not used in theproliferation expts., since the spheroids of CAL27 cells were not able to process the reagent in CCK-8 assays.  Furthermore, they were stained to present alterations of the following antigens: Ki-67, vascular endothelial growth factor receptor, epithelial growth factor and survivin.  Differences in growth rates and expression patterns were detected in certain HNSCC cell lines.  The proliferation rates showed a significant divergence of cells grown in the three-dimensional model compared with cells grown in the 2D model.  Overall, multicellular spheroids are a promising method to reproduce the immunohistochem. aspects and characteristics of tumor cells, and may show different response rates to therapeutic options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQWw4Zv3SiGrVg90H21EOLACvtfcHk0lh8VLuYD-Tufg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsFOjs7s%253D&md5=ef475dde6298c46843244125b5aa4551</span></div><a href="/servlet/linkout?suffix=cit96a&amp;dbid=16384&amp;doi=10.3892%2Fol.2015.3487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2015.3487%26sid%3Dliteratum%253Aachs%26aulast%3DKadletz%26aufirst%3DL.%26aulast%3DHeiduschka%26aufirst%3DG.%26aulast%3DDomayer%26aufirst%3DJ.%26aulast%3DSchmid%26aufirst%3DR.%26aulast%3DEnzenhofer%26aufirst%3DE.%26aulast%3DThurnher%26aufirst%3DD.%26atitle%3DEvaluation%2520of%2520spheroid%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%2520cell%2520models%2520in%2520comparison%2520to%2520monolayer%2520cultures%26jtitle%3DOncol.%2520Lett.%26date%3D2015%26volume%3D10%26spage%3D1281%26epage%3D1286%26doi%3D10.3892%2Fol.2015.3487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit96b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tupper, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greco, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dachs, G. U.</span><span> </span><span class="NLM_article-title">Analysis of the horseradish peroxidase/indole-3-acetic acid combination in a three-dimensional tumor model</span> <span class="citation_source-journal">Cancer Gene Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">508</span><span class="NLM_x">–</span> <span class="NLM_lpage">513</span><span class="refDoi"> DOI: 10.1038/sj.cgt.7700713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1038%2Fsj.cgt.7700713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=15143345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlt1Crsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=508-513&author=J.+Tupperauthor=O.+Grecoauthor=G.+M.+Tozerauthor=G.+U.+Dachs&title=Analysis+of+the+horseradish+peroxidase%2Findole-3-acetic+acid+combination+in+a+three-dimensional+tumor+model&doi=10.1038%2Fsj.cgt.7700713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96bR"><div class="casContent"><span class="casTitleNuber">96b</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the horseradish peroxidase/indole-3-acetic acid combination in a three-dimensional tumor model</span></div><div class="casAuthors">Tupper, Joanna; Greco, Olga; Tozer, Gillian M.; Dachs, Gabi U.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Gene Therapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">508-513</span>CODEN:
                <span class="NLM_cas:coden">CGTHEG</span>;
        ISSN:<span class="NLM_cas:issn">0929-1903</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Horseradish peroxidase has previously been shown to catalyze the conversion of indole-3-acetic acid (IAA) to a potent cytotoxin in a gene therapy setting.  A three-dimensional spheroid model composed of a human head and neck carcinoma cell line, has been used to mimic the tumor microenvironment, such as regions of hypoxia.  Exposure of intact spheroids to 0.05-5 mM concns. of IAA and the halogenated indole, 5-bromoindole-3-acetic acid (5Br-IAA), resulted in decreased cell survival, and demonstrates that this combination is effective under tumor-simulated conditions.  In addn., 5Br-IAA, displayed selectivity for spheroids with a large hypoxic fraction following short exposure times.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8asu7z_mxnbVg90H21EOLACvtfcHk0lgUyLZSVBNFrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlt1Crsro%253D&md5=21db487304fbe11d2725491e75f245b5</span></div><a href="/servlet/linkout?suffix=cit96b&amp;dbid=16384&amp;doi=10.1038%2Fsj.cgt.7700713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cgt.7700713%26sid%3Dliteratum%253Aachs%26aulast%3DTupper%26aufirst%3DJ.%26aulast%3DGreco%26aufirst%3DO.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26aulast%3DDachs%26aufirst%3DG.%2BU.%26atitle%3DAnalysis%2520of%2520the%2520horseradish%2520peroxidase%252Findole-3-acetic%2520acid%2520combination%2520in%2520a%2520three-dimensional%2520tumor%2520model%26jtitle%3DCancer%2520Gene%2520Ther.%26date%3D2004%26volume%3D11%26spage%3D508%26epage%3D513%26doi%3D10.1038%2Fsj.cgt.7700713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Huang, T.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, S.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, P.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiou, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.-J.</span><span> </span><span class="NLM_article-title">Antiproliferative effects of <i>N</i>-heterocyclic indole glyoxylamide derivatives on human lung cancer cells</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">3407</span><span class="NLM_x">–</span> <span class="NLM_lpage">3416</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=21965754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2rsL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=3407-3416&author=T.-H.+Huangauthor=S.-J.+Chiuauthor=P.-H.+Chiangauthor=S.-H.+Chiouauthor=W.-T.+Liauthor=C.-T.+Chenauthor=C.+A.+Changauthor=J.-C.+Chenauthor=Y.-J.+Lee&title=Antiproliferative+effects+of+N-heterocyclic+indole+glyoxylamide+derivatives+on+human+lung+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Antiproliferative effects of N-heterocyclic indolyl glyoxylamide derivatives on human lung cancer cells</span></div><div class="casAuthors">Huang, Tien-Heng; Chiu, Shu-Jun; Chiang, Pei-Hsiuang; Chiou, Shih-Hwa; Li, Wen-Tai; Chen, Chiung-Tong; Chang, C. Allen; Chen, Jyh-Cheng; Lee, Yi-Jang</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3407-3415</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Background: N-Heterocyclic indolyl glyoxylamide compds. are derived from the antimicrotubule agent D-24851, which exhibits anticancer activity after oral administration.  The actions of these compds. on lung cancer cells are still unknown.  Here, we investigated the effects of two N-heterocyclic indolyl glyoxylamides, BPR0C259 and BPR0C123, on non-small human lung cancer cells.  Materials and Methods: 3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide (MTT) assay was used to det. the half maximal inhibitory concn. (IC50), cell viability and radiation response of A549 cells and H1299 cells.  Apoptosis was detd. by sub-G1 ratio, colony formation assay and caspase-3 activation.  Cell cycle distribution was detected using flow cytometry.  Results: Both compds. were able to inhibit the viability of human lung cancer cells, although the IC50 of BPR0C123 was lower than that of BPR0C259.  Both compds. induced significant sub-G1 and caspase-3 activation as low as 0.1 μM in both cell lines.  These effects were independent of p53 activation because the level of serine-15 phosphorylated p53 was not affected after drug treatment.  Furthermore, both compds. induced similar levels of G2/M phase arrest and radiosensitivity in these lung cancer cells.  Conclusion: Current data suggest that N-heterocyclic indolyl glyoxylamides can suppress the proliferation of and potentially increase radiosensitivity of human lung cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVYVjMd38qUbVg90H21EOLACvtfcHk0lgUyLZSVBNFrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2rsL7F&md5=f99020514e30ebdf21a113011562a487</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DT.-H.%26aulast%3DChiu%26aufirst%3DS.-J.%26aulast%3DChiang%26aufirst%3DP.-H.%26aulast%3DChiou%26aufirst%3DS.-H.%26aulast%3DLi%26aufirst%3DW.-T.%26aulast%3DChen%26aufirst%3DC.-T.%26aulast%3DChang%26aufirst%3DC.%2BA.%26aulast%3DChen%26aufirst%3DJ.-C.%26aulast%3DLee%26aufirst%3DY.-J.%26atitle%3DAntiproliferative%2520effects%2520of%2520N-heterocyclic%2520indole%2520glyoxylamide%2520derivatives%2520on%2520human%2520lung%2520cancer%2520cells%26jtitle%3DAnticancer%2520Res.%26date%3D2011%26volume%3D31%26spage%3D3407%26epage%3D3416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Li, W.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.-N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-T.</span><span> </span><span class="NLM_article-title">BPR0C305, and orally active microtubule-disrupting anticancer agent</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1047</span><span class="NLM_x">–</span> <span class="NLM_lpage">1057</span><span class="refDoi"> DOI: 10.1097/CAD.0000000000000014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1097%2FCAD.0000000000000014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=1047-1057&author=W.-T.+Liauthor=T.-K.+Yehauthor=J.-S.+Songauthor=Y.-N.+Yangauthor=T.-W.+Chenauthor=C.-H.+Linauthor=C.-P.+Chenauthor=C.-C.+Shenauthor=C.-C.+Hsiehauthor=H.-L.+Linauthor=Y.-S.+Chaoauthor=C.-T.+Chen&title=BPR0C305%2C+and+orally+active+microtubule-disrupting+anticancer+agent&doi=10.1097%2FCAD.0000000000000014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000014%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.-T.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DYang%26aufirst%3DY.-N.%26aulast%3DChen%26aufirst%3DT.-W.%26aulast%3DLin%26aufirst%3DC.-H.%26aulast%3DChen%26aufirst%3DC.-P.%26aulast%3DShen%26aufirst%3DC.-C.%26aulast%3DHsieh%26aufirst%3DC.-C.%26aulast%3DLin%26aufirst%3DH.-L.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DChen%26aufirst%3DC.-T.%26atitle%3DBPR0C305%252C%2520and%2520orally%2520active%2520microtubule-disrupting%2520anticancer%2520agent%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2013%26volume%3D24%26spage%3D1047%26epage%3D1057%26doi%3D10.1097%2FCAD.0000000000000014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Hu, C.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuu, J.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tung, F.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, K.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, D.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chern, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, L.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-T.</span><span> </span><span class="NLM_article-title">BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activities</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">182</span><span class="NLM_x">–</span> <span class="NLM_lpage">191</span><span class="refDoi"> DOI: 10.1111/j.1349-7006.2010.01744.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1111%2Fj.1349-7006.2010.01744.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=21040217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhslKnsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2011&pages=182-191&author=C.-B.+Huauthor=C.-P.+Chenauthor=T.-K.+Yehauthor=J.-S.+Songauthor=C.-Y.+Changauthor=J.-J.+Chuuauthor=F.-F.+Tungauthor=P.-Y.+Hoauthor=T.-W.+Chenauthor=C.-H.+Linauthor=M.-H.+Wangauthor=K.-Y.+Changauthor=C.-L.+Huangauthor=H.-L.+Linauthor=W.-T.+Liauthor=D.-R.+Hwangauthor=J.-H.+Chernauthor=L.-L.+Hwangauthor=J.-Y.+Changauthor=Y.-S.+Chaoauthor=C.-T.+Chen&title=BPR0C261+is+a+novel+orally+active+antitumor+agent+with+antimitotic+and+anti-angiogenic+activities&doi=10.1111%2Fj.1349-7006.2010.01744.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activities</span></div><div class="casAuthors">Hu, Chih-Bo; Chen, Ching-Ping; Yeh, Teng-Kuang; Song, Jen-Shin; Chang, Chi-Yen; Chuu, Jiunn-Jye; Tung, Fei-Feng; Ho, Pei-Yin; Chen, Tung-Wei; Lin, Chi-Hung; Wang, Min-Hsien; Chang, Kai-Yen; Huang, Chen-Lung; Lin, Heng-Liang; Li, Wen-Tai; Hwang, Der-Ren; Chern, Jyh-Haur; Hwang, Ling-Ling; Chang, Jang-Yang; Chao, Yu-Sheng; Chen, Chiung-Tong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">182-191</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BPR0C261 is a synthetic small mol. compd. cytotoxic against human cancer cells and active prolonging the lifespan of leukemia mice.  In the present study, we further investigated the mechanisms of its anticancer action and found that BPR0C261 inhibited microtubule polymn. through interacting with the colchicine binding sites on tubulins, disrupted microtubule arrangement and caused cell cycle arrest at G2/M phase in cancer cells.  BPR0C261 also inhibited the clonogenic growths of cancer cells and showed cytotoxicity against human cervical cancer cells of multidrug-resistant phenotype.  In addn., BPR0C261 concn.-dependently inhibited the proliferation and migration of HUVECs and disrupted the endothelial capillary-like tube formations in HUVEC and rat aorta ring cultures.  Given orally, BPR0C261 inhibited angiogenesis in s.c. implanted Matrigel plugs in mice.  Notably, its IC50 values against the endothelial cell growths were approx. 10-fold lower than those against the cancer cells.  It was found orally absorbable in mice and showed a good oral bioavailability (43%) in dogs.  BPR0C261 permeated through the human intestinal Caco-2 cell monolayer, suggesting oral availability in humans.  Orally absorbed BPR0C261 distributed readily into the s.c. xenografted tumors in nude mice in which the tumor tissue levels of BPR0C261 were found oral dose-dependent.  BPR0C261 showed in vivo activities against human colorectal, gastric, and nasopharyngeal tumors in nude mice.  Most interestingly, the combination of BPR0C261 plus cisplatin synergistically prolonged the lifespans of mice inoculated with murine leukemia cells.  Thus, BPR0C261 is a novel orally active tubulin-binding antitumor agent with antimitotic, apoptosis-inducing, and vasculature disrupting activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV5xsYzX3kxbVg90H21EOLACvtfcHk0lgUyLZSVBNFrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhslKnsb0%253D&md5=941a6cafbe07c1fddb88ac0fae9e4103</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2010.01744.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2010.01744.x%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DC.-B.%26aulast%3DChen%26aufirst%3DC.-P.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DChuu%26aufirst%3DJ.-J.%26aulast%3DTung%26aufirst%3DF.-F.%26aulast%3DHo%26aufirst%3DP.-Y.%26aulast%3DChen%26aufirst%3DT.-W.%26aulast%3DLin%26aufirst%3DC.-H.%26aulast%3DWang%26aufirst%3DM.-H.%26aulast%3DChang%26aufirst%3DK.-Y.%26aulast%3DHuang%26aufirst%3DC.-L.%26aulast%3DLin%26aufirst%3DH.-L.%26aulast%3DLi%26aufirst%3DW.-T.%26aulast%3DHwang%26aufirst%3DD.-R.%26aulast%3DChern%26aufirst%3DJ.-H.%26aulast%3DHwang%26aufirst%3DL.-L.%26aulast%3DChang%26aufirst%3DJ.-Y.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DChen%26aufirst%3DC.-T.%26atitle%3DBPR0C261%2520is%2520a%2520novel%2520orally%2520active%2520antitumor%2520agent%2520with%2520antimitotic%2520and%2520anti-angiogenic%2520activities%26jtitle%3DCancer%2520Sci.%26date%3D2011%26volume%3D102%26spage%3D182%26epage%3D191%26doi%3D10.1111%2Fj.1349-7006.2010.01744.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Li, W.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, D.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-T.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of <i>N</i>-heterocyclic indolyl glyoxylamides as orally active anticancer agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1706</span><span class="NLM_x">–</span> <span class="NLM_lpage">1715</span><span class="refDoi"> DOI: 10.1021/jm020471r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020471r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlGlurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1706-1715&author=W.-T.+Liauthor=D.-R.+Hwangauthor=C.-P.+Chenauthor=C.-W.+Shenauthor=C.-L.+Huangauthor=T.-W.+Chenauthor=C.-H.+Linauthor=Y.-L.+Changauthor=Y.-Y.+Changauthor=Y.-K.+Loauthor=H.-Y.+Tsengauthor=C.-C.+Linauthor=J.-S.+Songauthor=H.-C.+Chenauthor=S.-J.+Chenauthor=S.-H.+Wuauthor=C.-T.+Chen&title=Synthesis+and+biological+evaluation+of+N-heterocyclic+indolyl+glyoxylamides+as+orally+active+anticancer+agents&doi=10.1021%2Fjm020471r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of N-Heterocyclic Indolyl Glyoxylamides as Orally Active Anticancer Agents</span></div><div class="casAuthors">Li, Wen-Tai; Hwang, Der-Ren; Chen, Ching-Ping; Shen, Chien-Wei; Huang, Chen-Long; Chen, Tung-Wei; Lin, Chi-Hung; Chang, Yee-Ling; Chang, Ying-Ying; Lo, Yue-Kan; Tseng, Huan-Yi; Lin, Chu-Chung; Song, Jeng-Shin; Chen, Hua-Chien; Chen, Shu-Jen; Wu, Se-Hui; Chen, Chiung-Tong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1706-1715</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of N-heterocyclic indolyl glyoxylamides were synthesized and evaluated for in vitro and in vivo anticancer activities.  They exhibited a broad spectrum of anticancer activity not only in murine leukemic cancer cells but also in human gastric, breast, and uterus cancer cells as well as their multidrug resistant sublines with a wide range of IC50 values.  They also induced apoptosis and caused DNA fragmentation in human gastric cancer cells.  Among the compds. studied, N1-(3-Methyl-5-isothiazolyl)-2-1-[(3-methyl-5-isoxazolyl)methyl]-1H-3-indolyl-2-oxoacetamide (I) showed the most potent activity of growth inhibition (IC50 = 17-1711 nM) in several human cancer cells.  Given orally, compds. I and N1-(3-Methyl-5-isothiazolyl)-2-[1-(4-cyanobenzyl)-1H-3-indolyl]-2-oxoacetamide dose-dependently prolonged the survival of animals inoculated with P388 leukemic cancer cells.  N-Heterocyclic indolyl glyoxylamides may be useful as orally active chemotherapeutic agents against cancer and refractory cancerous diseases of multidrug resistance phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA1KRKnBPg9bVg90H21EOLACvtfcHk0lg0LtzFcRQhZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlGlurw%253D&md5=7f89777a57ec9bca8b710965195b5ad5</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjm020471r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020471r%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.-T.%26aulast%3DHwang%26aufirst%3DD.-R.%26aulast%3DChen%26aufirst%3DC.-P.%26aulast%3DShen%26aufirst%3DC.-W.%26aulast%3DHuang%26aufirst%3DC.-L.%26aulast%3DChen%26aufirst%3DT.-W.%26aulast%3DLin%26aufirst%3DC.-H.%26aulast%3DChang%26aufirst%3DY.-L.%26aulast%3DChang%26aufirst%3DY.-Y.%26aulast%3DLo%26aufirst%3DY.-K.%26aulast%3DTseng%26aufirst%3DH.-Y.%26aulast%3DLin%26aufirst%3DC.-C.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DChen%26aufirst%3DH.-C.%26aulast%3DChen%26aufirst%3DS.-J.%26aulast%3DWu%26aufirst%3DS.-H.%26aulast%3DChen%26aufirst%3DC.-T.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520N-heterocyclic%2520indolyl%2520glyoxylamides%2520as%2520orally%2520active%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1706%26epage%3D1715%26doi%3D10.1021%2Fjm020471r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Thompson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louth, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorrell, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irving, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cochrane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, A. J. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span> </span><span class="NLM_article-title">Structure–activity relationship refinement and further assessment of indole-3-glyoxylamides as a lead series against prion disease</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">–</span> <span class="NLM_lpage">130</span><span class="refDoi"> DOI: 10.1002/cmdc.201000383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1002%2Fcmdc.201000383" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=115-130&author=M.+J.+Thompsonauthor=J.+C.+Louthauthor=S.+Ferraraauthor=F.+J.+Sorrellauthor=B.+J.+Irvingauthor=E.+J.+Cochraneauthor=A.+J.+H.+M.+Meijerauthor=B.+Chen&title=Structure%E2%80%93activity+relationship+refinement+and+further+assessment+of+indole-3-glyoxylamides+as+a+lead+series+against+prion+disease&doi=10.1002%2Fcmdc.201000383"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000383%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DM.%2BJ.%26aulast%3DLouth%26aufirst%3DJ.%2BC.%26aulast%3DFerrara%26aufirst%3DS.%26aulast%3DSorrell%26aufirst%3DF.%2BJ.%26aulast%3DIrving%26aufirst%3DB.%2BJ.%26aulast%3DCochrane%26aufirst%3DE.%2BJ.%26aulast%3DMeijer%26aufirst%3DA.%2BJ.%2BH.%2BM.%26aulast%3DChen%26aufirst%3DB.%26atitle%3DStructure%25E2%2580%2593activity%2520relationship%2520refinement%2520and%2520further%2520assessment%2520of%2520indole-3-glyoxylamides%2520as%2520a%2520lead%2520series%2520against%2520prion%2520disease%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26spage%3D115%26epage%3D130%26doi%3D10.1002%2Fcmdc.201000383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Baell, J. B.</span><span> </span><span class="NLM_article-title">Screening-based translation of public research encounters painful problems</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00032</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00032" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisFyqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=229-234&author=J.+B.+Baell&title=Screening-based+translation+of+public+research+encounters+painful+problems&doi=10.1021%2Facsmedchemlett.5b00032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Screening-Based Translation of Public Research Encounters Painful Problems</span></div><div class="casAuthors">Baell, Jonathan B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">229-234</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Whether identified through high throughput screening or in silico screening, and whether target-based or phenotypic, sets of hits will contain chem. con artists.  Such pan-assay interference compds. (PAINS) and other subversive compds. continue to pollute the scientific literature.  There are several angles of attack to aid identification of such nonprogressable mols.  One of these rules above all, and this is a demonstration of genuine structure-activity relationships.  Recognition of this, which will require a greater effort in medicinal chem., will be of general benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotU7Zc6YDmhrVg90H21EOLACvtfcHk0lg0LtzFcRQhZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisFyqtLc%253D&md5=6307f394d9ed9d4859e8ec149914f064</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00032%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26atitle%3DScreening-based%2520translation%2520of%2520public%2520research%2520encounters%2520painful%2520problems%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D229%26epage%3D234%26doi%3D10.1021%2Facsmedchemlett.5b00032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Fitton, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jane, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millar, R.</span><span> </span><span class="NLM_article-title">Synthesis of simple oxetanes carrying reactive 2-sustituents</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">1987</span><span class="NLM_x">, </span> <span class="NLM_fpage">1140</span><span class="NLM_x">–</span> <span class="NLM_lpage">1142</span><span class="refDoi"> DOI: 10.1055/s-1987-28203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1055%2Fs-1987-28203" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1987&publication_year=1987&pages=1140-1142&author=A.+O.+Fittonauthor=J.+Hillauthor=D.+E.+Janeauthor=R.+Millar&title=Synthesis+of+simple+oxetanes+carrying+reactive+2-sustituents&doi=10.1055%2Fs-1987-28203"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1055%2Fs-1987-28203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1987-28203%26sid%3Dliteratum%253Aachs%26aulast%3DFitton%26aufirst%3DA.%2BO.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DJane%26aufirst%3DD.%2BE.%26aulast%3DMillar%26aufirst%3DR.%26atitle%3DSynthesis%2520of%2520simple%2520oxetanes%2520carrying%2520reactive%25202-sustituents%26jtitle%3DSynthesis%26date%3D1987%26volume%3D1987%26spage%3D1140%26epage%3D1142%26doi%3D10.1055%2Fs-1987-28203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42a','cit42b'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47a','cit47b'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57a','cit57b'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63a','cit63b'],'ref64':['cit64a','cit64b','cit64c'],'ref65':['cit65'],'ref66':['cit66a','cit66b','cit66c'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76a','cit76b'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83a','cit83b'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96a','cit96b'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 36 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Dehai Liu, Yaru Gao, Jie Huang, Zhenqian Fu, <span class="NLM_string-name hlFld-ContribAuthor">Wei Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Carbene-Catalyzed Construction of Carbazoles from Enals and 2-Methyl-3-oxoacetate Indoles. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (22)
                                     , 14210-14217. <a href="https://doi.org/10.1021/acs.joc.8b02532" title="DOI URL">https://doi.org/10.1021/acs.joc.8b02532</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b02532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b02532%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DCarbene-Catalyzed%252BConstruction%252Bof%252BCarbazoles%252Bfrom%252BEnals%252Band%252B2-Methyl-3-oxoacetate%252BIndoles%26aulast%3DLiu%26aufirst%3DDehai%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D01102018%26date%3D30102018%26date%3D23102018%26volume%3D83%26issue%3D22%26spage%3D14210%26epage%3D14217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Christian Kramer, Attilla Ting, Hao Zheng, Jérôme Hert, Torsten Schindler, Martin Stahl, Graeme Robb, James J. Crawford, Jeff Blaney, Shane Montague, Andrew G. Leach, Al G. Dossetter, <span class="NLM_string-name hlFld-ContribAuthor">Ed J. Griffen</span>. </span><span class="cited-content_cbyCitation_article-title">Learning Medicinal Chemistry Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) Rules from Cross-Company Matched Molecular Pairs Analysis (MMPA). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (8)
                                     , 3277-3292. <a href="https://doi.org/10.1021/acs.jmedchem.7b00935" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00935</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00935%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLearning%252BMedicinal%252BChemistry%252BAbsorption%25252C%252BDistribution%25252C%252BMetabolism%25252C%252BExcretion%25252C%252Band%252BToxicity%252B%252528ADMET%252529%252BRules%252Bfrom%252BCross-Company%252BMatched%252BMolecular%252BPairs%252BAnalysis%252B%252528MMPA%252529%26aulast%3DKramer%26aufirst%3DChristian%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D26062017%26date%3D28092017%26volume%3D61%26issue%3D8%26spage%3D3277%26epage%3D3292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tian-Jun  Gong</span>, <span class="hlFld-ContribAuthor ">Meng-Yu  Xu</span>, <span class="hlFld-ContribAuthor ">Shang-Hai  Yu</span>, <span class="hlFld-ContribAuthor ">Chu-Guo  Yu</span>, <span class="hlFld-ContribAuthor ">Wei  Su</span>, <span class="hlFld-ContribAuthor ">Xi  Lu</span>, <span class="hlFld-ContribAuthor ">Bin  Xiao</span>, and <span class="hlFld-ContribAuthor ">Yao  Fu</span>  . </span><span class="cited-content_cbyCitation_article-title">Rhodium(III)-Catalyzed Directed C–H Coupling with Methyl Trifluoroacrylate: Diverse Synthesis of Fluoroalkenes and Heterocycles. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (3)
                                     , 570-573. <a href="https://doi.org/10.1021/acs.orglett.7b03677" title="DOI URL">https://doi.org/10.1021/acs.orglett.7b03677</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.7b03677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.7b03677%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DRhodium%252528III%252529-Catalyzed%252BDirected%252BC%2525E2%252580%252593H%252BCoupling%252Bwith%252BMethyl%252BTrifluoroacrylate%25253A%252BDiverse%252BSynthesis%252Bof%252BFluoroalkenes%252Band%252BHeterocycles%26aulast%3DGong%26aufirst%3DTian-Jun%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D27112017%26date%3D19012018%26date%3D02022018%26volume%3D20%26issue%3D3%26spage%3D570%26epage%3D573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">María-Jesús  Pérez-Pérez</span>, <span class="hlFld-ContribAuthor ">Eva-María  Priego</span>, <span class="hlFld-ContribAuthor ">Oskía  Bueno</span>, <span class="hlFld-ContribAuthor ">Maria Solange  Martins</span>, <span class="hlFld-ContribAuthor ">María-Dolores  Canela</span>, and <span class="hlFld-ContribAuthor ">Sandra  Liekens</span>  . </span><span class="cited-content_cbyCitation_article-title">Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (19)
                                     , 8685-8711. <a href="https://doi.org/10.1021/acs.jmedchem.6b00463" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00463</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00463%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBlocking%252BBlood%252BFlow%252Bto%252BSolid%252BTumors%252Bby%252BDestabilizing%252BTubulin%25253A%252BAn%252BApproach%252Bto%252BTargeting%252BTumor%252BGrowth%26aulast%3DP%25C3%25A9rez-P%25C3%25A9rez%26aufirst%3DMar%25C3%25ADa-Jes%25C3%25BAs%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D29032016%26date%3D27062016%26date%3D13102016%26volume%3D59%26issue%3D19%26spage%3D8685%26epage%3D8711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xun  Chen</span>, <span class="hlFld-ContribAuthor ">Xinwei  Hu</span>, <span class="hlFld-ContribAuthor ">Yuanfu  Deng</span>, <span class="hlFld-ContribAuthor ">Huanfeng  Jiang</span>, and <span class="hlFld-ContribAuthor ">Wei  Zeng</span>  . </span><span class="cited-content_cbyCitation_article-title">A [4 + 1] Cyclative Capture Access to Indolizines via Cobalt(III)-Catalyzed Csp2–H Bond Functionalization. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2016,</strong> <em>18 </em>
                                    (18)
                                     , 4742-4745. <a href="https://doi.org/10.1021/acs.orglett.6b02421" title="DOI URL">https://doi.org/10.1021/acs.orglett.6b02421</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.6b02421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.6b02421%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DA%252B%25255B4%252B%25252B%252B1%25255D%252BCyclative%252BCapture%252BAccess%252Bto%252BIndolizines%252Bvia%252BCobalt%252528III%252529-Catalyzed%252BCsp2%2525E2%252580%252593H%252BBond%252BFunctionalization%26aulast%3DChen%26aufirst%3DXun%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D12082016%26date%3D01092016%26date%3D16092016%26volume%3D18%26issue%3D18%26spage%3D4742%26epage%3D4745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zulfahmi  Said</span>, <span class="hlFld-ContribAuthor ">Craig  Murdoch</span>, <span class="hlFld-ContribAuthor ">Jens  Hansen</span>, <span class="hlFld-ContribAuthor ">Lars  Siim Madsen</span>, <span class="hlFld-ContribAuthor ">Helen E.  Colley</span>. </span><span class="cited-content_cbyCitation_article-title">Corticosteroid delivery using oral mucosa equivalents for the treatment of inflammatory mucosal diseases. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Oral Sciences</span><span> <strong>2021,</strong> <em>129 </em>
                                    (2)
                                     <a href="https://doi.org/10.1111/eos.12761" title="DOI URL">https://doi.org/10.1111/eos.12761</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/eos.12761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Feos.12761%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Oral%2520Sciences%26atitle%3DCorticosteroid%252Bdelivery%252Busing%252Boral%252Bmucosa%252Bequivalents%252Bfor%252Bthe%252Btreatment%252Bof%252Binflammatory%252Bmucosal%252Bdiseases%26aulast%3DSaid%26aufirst%3DZulfahmi%26date%3D2021%26date%3D2021%26volume%3D129%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yilin  Fang</span>, <span class="hlFld-ContribAuthor ">Zhilin  Wu</span>, <span class="hlFld-ContribAuthor ">Mengwu  Xiao</span>, <span class="hlFld-ContribAuthor ">Li  Wei</span>, <span class="hlFld-ContribAuthor ">Kangming  Li</span>, <span class="hlFld-ContribAuthor ">Yuting  Tang</span>, <span class="hlFld-ContribAuthor ">Jiao  Ye</span>, <span class="hlFld-ContribAuthor ">Jiannan  Xiang</span>, <span class="hlFld-ContribAuthor ">Aixi  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and evaluation of new 2-oxoquinoline arylaminothiazole derivatives as potential anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>106 </em>, 104469. <a href="https://doi.org/10.1016/j.bioorg.2020.104469" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104469</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104469%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bevaluation%252Bof%252Bnew%252B2-oxoquinoline%252Barylaminothiazole%252Bderivatives%252Bas%252Bpotential%252Banticancer%252Bagents%26aulast%3DFang%26aufirst%3DYilin%26date%3D2021%26volume%3D106%26spage%3D104469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Valery K.  Brel</span>, <span class="hlFld-ContribAuthor ">Oleg I.  Artyushin</span>, <span class="hlFld-ContribAuthor ">Roman N.  Chuprov-Netochin</span>, <span class="hlFld-ContribAuthor ">Sergey V.  Leonov</span>, <span class="hlFld-ContribAuthor ">Marina N.  Semenova</span>, <span class="hlFld-ContribAuthor ">Victor V.  Semenov</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (23)
                                     , 127635. <a href="https://doi.org/10.1016/j.bmcl.2020.127635" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127635</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127635%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bindolylglyoxylamide%252Bbisphosphonates%25252C%252Bantimitotic%252Bmicrotubule-targeting%252Bderivatives%252Bof%252Bindibulin%252Bwith%252Bimproved%252Baqueous%252Bsolubility%26aulast%3DBrel%26aufirst%3DValery%2BK.%26date%3D2020%26volume%3D30%26issue%3D23%26spage%3D127635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nannan  Wu</span>, <span class="hlFld-ContribAuthor ">Guangyu  Lian</span>, <span class="hlFld-ContribAuthor ">Jingyi  Sheng</span>, <span class="hlFld-ContribAuthor ">Dan  Wu</span>, <span class="hlFld-ContribAuthor ">Xiyong  Yu</span>, <span class="hlFld-ContribAuthor ">Huiyao  Lan</span>, <span class="hlFld-ContribAuthor ">Wenhui  Hu</span>, <span class="hlFld-ContribAuthor ">Zhongjin  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a novel selective water-soluble SMAD3 inhibitor as an antitumor agent. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (17)
                                     , 127396. <a href="https://doi.org/10.1016/j.bmcl.2020.127396" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127396</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127396%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252Bnovel%252Bselective%252Bwater-soluble%252BSMAD3%252Binhibitor%252Bas%252Ban%252Bantitumor%252Bagent%26aulast%3DWu%26aufirst%3DNannan%26date%3D2020%26volume%3D30%26issue%3D17%26spage%3D127396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanshu  Jia</span>, <span class="hlFld-ContribAuthor ">Xiaoyue  Wen</span>, <span class="hlFld-ContribAuthor ">Yufeng  Gong</span>, <span class="hlFld-ContribAuthor ">Xuefeng  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Current scenario of indole derivatives with potential anti-drug-resistant cancer activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>200 </em>, 112359. <a href="https://doi.org/10.1016/j.ejmech.2020.112359" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112359</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112359%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252Bscenario%252Bof%252Bindole%252Bderivatives%252Bwith%252Bpotential%252Banti-drug-resistant%252Bcancer%252Bactivity%26aulast%3DJia%26aufirst%3DYanshu%26date%3D2020%26volume%3D200%26spage%3D112359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ebrahim S.  Moghadam</span>, <span class="hlFld-ContribAuthor ">Farhad  Saravani</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Zahra  Shahsavari</span>, <span class="hlFld-ContribAuthor ">Mohsen  Alipour</span>, <span class="hlFld-ContribAuthor ">Saman  Hosseinkhani</span>, <span class="hlFld-ContribAuthor ">Seyednasser  Ostad</span>, <span class="hlFld-ContribAuthor ">Mohsen  Amini</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and In Vitro Anti-Cancer Evaluation of Novel Derivatives of 2-(2-Methyl-1,5-diaryl-1H-pyrrol-3-yl)-2-oxo-N-(pyridin-3- yl)acetamide. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry</span><span> <strong>2020,</strong> <em>16 </em>
                                    (3)
                                     , 340-349. <a href="https://doi.org/10.2174/1573406415666190425153717" title="DOI URL">https://doi.org/10.2174/1573406415666190425153717</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1573406415666190425153717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1573406415666190425153717%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BIn%252BVitro%252BAnti-Cancer%252BEvaluation%252Bof%252BNovel%252BDerivatives%252Bof%252B2-%2525282-Methyl-1%25252C5-diaryl-1H-pyrrol-3-yl%252529-2-oxo-N-%252528pyridin-3-%252Byl%252529acetamide%26aulast%3DMoghadam%26aufirst%3DEbrahim%2BS.%26date%3D2020%26volume%3D16%26issue%3D3%26spage%3D340%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alberto  Brandi</span>, <span class="hlFld-ContribAuthor ">Stefano  Cicchi</span>, <span class="hlFld-ContribAuthor ">Franca M.  Cordero</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 5,6-membered With One Heteroatom N. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1016/B978-0-12-409547-2.14938-8" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.14938-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.14938-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.14938-8%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B5%25252C6-membered%252BWith%252BOne%252BHeteroatom%252BN%26aulast%3DBrandi%26aufirst%3DAlberto%26date%3D2020%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2020%26volume%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peng-Cheng  Diao</span>, <span class="hlFld-ContribAuthor ">Xie-Er  Jian</span>, <span class="hlFld-ContribAuthor ">Peng  Chen</span>, <span class="hlFld-ContribAuthor ">Chuan  Huang</span>, <span class="hlFld-ContribAuthor ">Jie  Yin</span>, <span class="hlFld-ContribAuthor ">Jie Chun  Huang</span>, <span class="hlFld-ContribAuthor ">Jun-Sheng  Li</span>, <span class="hlFld-ContribAuthor ">Pei-Liang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel indole-based oxalamide and aminoacetamide derivatives as tubulin polymerization inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (2)
                                     , 126816. <a href="https://doi.org/10.1016/j.bmcl.2019.126816" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126816</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126816%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bindole-based%252Boxalamide%252Band%252Baminoacetamide%252Bderivatives%252Bas%252Btubulin%252Bpolymerization%252Binhibitors%26aulast%3DDiao%26aufirst%3DPeng-Cheng%26date%3D2020%26volume%3D30%26issue%3D2%26spage%3D126816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yichao  Wan</span>, <span class="hlFld-ContribAuthor ">Yuanhua  Li</span>, <span class="hlFld-ContribAuthor ">Chunxing  Yan</span>, <span class="hlFld-ContribAuthor ">Mi  Yan</span>, <span class="hlFld-ContribAuthor ">Zilong  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Indole: A privileged scaffold for the design of anti-cancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>183 </em>, 111691. <a href="https://doi.org/10.1016/j.ejmech.2019.111691" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111691</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111691%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIndole%25253A%252BA%252Bprivileged%252Bscaffold%252Bfor%252Bthe%252Bdesign%252Bof%252Banti-cancer%252Bagents%26aulast%3DWan%26aufirst%3DYichao%26date%3D2019%26volume%3D183%26spage%3D111691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mintu Maan  Dutta</span>, <span class="hlFld-ContribAuthor ">Hrishikesh  Talukdar</span>, <span class="hlFld-ContribAuthor ">Prodeep  Phukan</span>. </span><span class="cited-content_cbyCitation_article-title">CuI incorporated cobalt ferrite nanoparticles as a magnetically separable catalyst for oxidative amidation reaction. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2019,</strong> <em>48 </em>
                                    (42)
                                     , 16041-16052. <a href="https://doi.org/10.1039/C9DT03440D" title="DOI URL">https://doi.org/10.1039/C9DT03440D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9DT03440D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9DT03440D%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DCuI%252Bincorporated%252Bcobalt%252Bferrite%252Bnanoparticles%252Bas%252Ba%252Bmagnetically%252Bseparable%252Bcatalyst%252Bfor%252Boxidative%252Bamidation%252Breaction%26aulast%3DDutta%26aufirst%3DMintu%2BMaan%26date%3D2019%26date%3D2019%26volume%3D48%26issue%3D42%26spage%3D16041%26epage%3D16052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ebrahim  Saeedian Moghadam</span>, <span class="hlFld-ContribAuthor ">Ernest  Hamel</span>, <span class="hlFld-ContribAuthor ">Zahra  Shahsavari</span>, <span class="hlFld-ContribAuthor ">Mohsen  Amini</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and anti-breast cancer activity of novel indibulin related diarylpyrrole derivatives. </span><span class="cited-content_cbyCitation_journal-name">DARU Journal of Pharmaceutical Sciences</span><span> <strong>2019,</strong> <em>27 </em>
                                    (1)
                                     , 179-189. <a href="https://doi.org/10.1007/s40199-019-00260-9" title="DOI URL">https://doi.org/10.1007/s40199-019-00260-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40199-019-00260-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40199-019-00260-9%26sid%3Dliteratum%253Aachs%26jtitle%3DDARU%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DSynthesis%252Band%252Banti-breast%252Bcancer%252Bactivity%252Bof%252Bnovel%252Bindibulin%252Brelated%252Bdiarylpyrrole%252Bderivatives%26aulast%3DSaeedian%2BMoghadam%26aufirst%3DEbrahim%26date%3D2019%26date%3D2019%26volume%3D27%26issue%3D1%26spage%3D179%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ebrahim S.  Moghadam</span>, <span class="hlFld-ContribAuthor ">Farhad  Saravani</span>, <span class="hlFld-ContribAuthor ">Seyednasser  Ostad</span>, <span class="hlFld-ContribAuthor ">Shohreh  Tavajohi</span>, <span class="hlFld-ContribAuthor ">Morteza P.  Hamedani</span>, <span class="hlFld-ContribAuthor ">Mohsen  Amini</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Anticancer Evaluation of Novel Series of Indibulin Analogues. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry</span><span> <strong>2019,</strong> <em>15 </em>
                                    (3)
                                     , 231-239. <a href="https://doi.org/10.2174/1573406414666181015145945" title="DOI URL">https://doi.org/10.2174/1573406414666181015145945</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1573406414666181015145945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1573406414666181015145945%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BAnticancer%252BEvaluation%252Bof%252BNovel%252BSeries%252Bof%252BIndibulin%252BAnalogues%26aulast%3DMoghadam%26aufirst%3DEbrahim%2BS.%26date%3D2019%26volume%3D15%26issue%3D3%26spage%3D231%26epage%3D239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jayanta  Ghorai</span>, <span class="hlFld-ContribAuthor ">Pazhamalai  Anbarasan</span>. </span><span class="cited-content_cbyCitation_article-title">Developments in Cp*Co
              III
              ‐Catalyzed C−H Bond Functionalizations. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>8 </em>
                                    (4)
                                     , 430-455. <a href="https://doi.org/10.1002/ajoc.201800452" title="DOI URL">https://doi.org/10.1002/ajoc.201800452</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.201800452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.201800452%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDevelopments%252Bin%252BCp%252ACo%252BIII%252B%2525E2%252580%252590Catalyzed%252BC%2525E2%252588%252592H%252BBond%252BFunctionalizations%26aulast%3DGhorai%26aufirst%3DJayanta%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D4%26spage%3D430%26epage%3D455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dehai  Liu</span>, <span class="hlFld-ContribAuthor ">Jie  Huang</span>, <span class="hlFld-ContribAuthor ">Zhenqian  Fu</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Direct construction of carbazoles from 2-methyl-indole-3-carbaldehydes and enals. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2019,</strong> <em>21 </em>
                                    (5)
                                     , 968-972. <a href="https://doi.org/10.1039/C9GC00064J" title="DOI URL">https://doi.org/10.1039/C9GC00064J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9GC00064J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9GC00064J%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DDirect%252Bconstruction%252Bof%252Bcarbazoles%252Bfrom%252B2-methyl-indole-3-carbaldehydes%252Band%252Benals%26aulast%3DLiu%26aufirst%3DDehai%26date%3D2019%26date%3D2019%26volume%3D21%26issue%3D5%26spage%3D968%26epage%3D972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pavel  Štarha</span>, <span class="hlFld-ContribAuthor ">Zdeněk  Trávníček</span>, <span class="hlFld-ContribAuthor ">Ján  Vančo</span>, <span class="hlFld-ContribAuthor ">Zdeněk  Dvořák</span>. </span><span class="cited-content_cbyCitation_article-title">In vitro anticancer active cis-Pt(II)-diiodido complexes containing 4-azaindoles. </span><span class="cited-content_cbyCitation_journal-name">JBIC Journal of Biological Inorganic Chemistry</span><span> <strong>2019,</strong> <em>24 </em>
                                    (2)
                                     , 257-269. <a href="https://doi.org/10.1007/s00775-019-01643-8" title="DOI URL">https://doi.org/10.1007/s00775-019-01643-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00775-019-01643-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00775-019-01643-8%26sid%3Dliteratum%253Aachs%26jtitle%3DJBIC%2520Journal%2520of%2520Biological%2520Inorganic%2520Chemistry%26atitle%3DIn%252Bvitro%252Banticancer%252Bactive%252Bcis-Pt%252528II%252529-diiodido%252Bcomplexes%252Bcontaining%252B4-azaindoles%26aulast%3D%25C5%25A0tarha%26aufirst%3DPavel%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D2%26spage%3D257%26epage%3D269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ya-Liang  Zhang</span>, <span class="hlFld-ContribAuthor ">Bo-Yan  Li</span>, <span class="hlFld-ContribAuthor ">Rong  Yang</span>, <span class="hlFld-ContribAuthor ">Lin-Ying  Xia</span>, <span class="hlFld-ContribAuthor ">A-Li  Fan</span>, <span class="hlFld-ContribAuthor ">Yi-Chun  Chu</span>, <span class="hlFld-ContribAuthor ">Lin-Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Zhong-Chang  Wang</span>, <span class="hlFld-ContribAuthor ">Ai-Qin  Jiang</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">A class of novel tubulin polymerization inhibitors exert effective anti-tumor activity via mitotic catastrophe. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>163 </em>, 896-910. <a href="https://doi.org/10.1016/j.ejmech.2018.12.030" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.12.030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.12.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.12.030%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bclass%252Bof%252Bnovel%252Btubulin%252Bpolymerization%252Binhibitors%252Bexert%252Beffective%252Banti-tumor%252Bactivity%252Bvia%252Bmitotic%252Bcatastrophe%26aulast%3DZhang%26aufirst%3DYa-Liang%26date%3D2019%26volume%3D163%26spage%3D896%26epage%3D910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarmad  Al-Sahaf</span>, <span class="hlFld-ContribAuthor ">Keith D.  Hunter</span>, <span class="hlFld-ContribAuthor ">Robert  Bolt</span>, <span class="hlFld-ContribAuthor ">Penelope D.  Ottewell</span>, <span class="hlFld-ContribAuthor ">Craig  Murdoch</span>. </span><span class="cited-content_cbyCitation_article-title">The IL-1/IL-1R axis induces greater fibroblast-derived chemokine release in human papillomavirus-negative compared to positive oropharyngeal cancer. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Cancer</span><span> <strong>2019,</strong> <em>144 </em>
                                    (2)
                                     , 334-344. <a href="https://doi.org/10.1002/ijc.31852" title="DOI URL">https://doi.org/10.1002/ijc.31852</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ijc.31852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fijc.31852%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Cancer%26atitle%3DThe%252BIL-1%25252FIL-1R%252Baxis%252Binduces%252Bgreater%252Bfibroblast-derived%252Bchemokine%252Brelease%252Bin%252Bhuman%252Bpapillomavirus-negative%252Bcompared%252Bto%252Bpositive%252Boropharyngeal%252Bcancer%26aulast%3DAl-Sahaf%26aufirst%3DSarmad%26date%3D2019%26date%3D2018%26volume%3D144%26issue%3D2%26spage%3D334%26epage%3D344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sonia  Kapoor</span>, <span class="hlFld-ContribAuthor ">Shalini  Srivastava</span>, <span class="hlFld-ContribAuthor ">Dulal  Panda</span>. </span><span class="cited-content_cbyCitation_article-title">Indibulin dampens microtubule dynamics and produces synergistic antiproliferative effect with vinblastine in MCF-7 cells: Implications in cancer chemotherapy. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2018,</strong> <em>8 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-018-30376-y" title="DOI URL">https://doi.org/10.1038/s41598-018-30376-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-018-30376-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-018-30376-y%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DIndibulin%252Bdampens%252Bmicrotubule%252Bdynamics%252Band%252Bproduces%252Bsynergistic%252Bantiproliferative%252Beffect%252Bwith%252Bvinblastine%252Bin%252BMCF-7%252Bcells%25253A%252BImplications%252Bin%252Bcancer%252Bchemotherapy%26aulast%3DKapoor%26aufirst%3DSonia%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ebrahim  Saeedian Moghadam</span>, <span class="hlFld-ContribAuthor ">Mohsen  Amini</span>. </span><span class="cited-content_cbyCitation_article-title">2-[2-Methyl-5-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-pyrrol-3-yl]-2-oxo-N-(pyridin-4-yl) acetamide. </span><span class="cited-content_cbyCitation_journal-name">Molbank</span><span> <strong>2018,</strong> <em>2018 </em>
                                    (3)
                                     , 1002. <a href="https://doi.org/10.3390/M1002" title="DOI URL">https://doi.org/10.3390/M1002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/M1002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2FM1002%26sid%3Dliteratum%253Aachs%26jtitle%3DMolbank%26atitle%3D2-%25255B2-Methyl-5-phenyl-1-%2525283%25252C4%25252C5-trimethoxyphenyl%252529-1H-pyrrol-3-yl%25255D-2-oxo-N-%252528pyridin-4-yl%252529%252Bacetamide%26aulast%3DSaeedian%2BMoghadam%26aufirst%3DEbrahim%26date%3D2018%26date%3D2018%26volume%3D2018%26issue%3D3%26spage%3D1002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ebrahim  Saeedian Moghadam</span>, <span class="hlFld-ContribAuthor ">Farhad  Saravani</span>, <span class="hlFld-ContribAuthor ">Seyednasser  Ostad</span>, <span class="hlFld-ContribAuthor ">Shohreh  Tavajohi</span>, <span class="hlFld-ContribAuthor ">Morteza  Pirali Hamedani</span>, <span class="hlFld-ContribAuthor ">Mohsen  Amini</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and cytotoxicity evaluation of indibulin analogs. </span><span class="cited-content_cbyCitation_journal-name">Heterocyclic Communications</span><span> <strong>2018,</strong> <em>24 </em>
                                    (4)
                                     , 211-217. <a href="https://doi.org/10.1515/hc-2018-0016" title="DOI URL">https://doi.org/10.1515/hc-2018-0016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1515/hc-2018-0016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1515%2Fhc-2018-0016%26sid%3Dliteratum%253Aachs%26jtitle%3DHeterocyclic%2520Communications%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bcytotoxicity%252Bevaluation%252Bof%252Bindibulin%252Banalogs%26aulast%3DSaeedian%2BMoghadam%26aufirst%3DEbrahim%26date%3D2018%26volume%3D24%26issue%3D4%26spage%3D211%26epage%3D217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kun  Chen</span>, <span class="hlFld-ContribAuthor ">Ya-Liang  Zhang</span>, <span class="hlFld-ContribAuthor ">Jing  Fan</span>, <span class="hlFld-ContribAuthor ">Xiang  Ma</span>, <span class="hlFld-ContribAuthor ">Ya-Juan  Qin</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Novel nicotinoyl pyrazoline derivates bearing N-methyl indole moiety as antitumor agents: Design, synthesis and evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>156 </em>, 722-737. <a href="https://doi.org/10.1016/j.ejmech.2018.07.044" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.07.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.07.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.07.044%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bnicotinoyl%252Bpyrazoline%252Bderivates%252Bbearing%252BN-methyl%252Bindole%252Bmoiety%252Bas%252Bantitumor%252Bagents%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bevaluation%26aulast%3DChen%26aufirst%3DKun%26date%3D2018%26volume%3D156%26spage%3D722%26epage%3D737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhimin  Yang</span>, <span class="hlFld-ContribAuthor ">Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Botao  Pan</span>, <span class="hlFld-ContribAuthor ">Fengli  He</span>, <span class="hlFld-ContribAuthor ">Zhengying  Pan</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of (aza)indolyl maleimide-based covalent inhibitors of glycogen synthase kinase 3β. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (22)
                                     , 4127-4140. <a href="https://doi.org/10.1039/C8OB00642C" title="DOI URL">https://doi.org/10.1039/C8OB00642C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB00642C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB00642C%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252B%252528aza%252529indolyl%252Bmaleimide-based%252Bcovalent%252Binhibitors%252Bof%252Bglycogen%252Bsynthase%252Bkinase%252B3%2525CE%2525B2%26aulast%3DYang%26aufirst%3DZhimin%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D22%26spage%3D4127%26epage%3D4140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuan  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoye  Jiang</span>, <span class="hlFld-ContribAuthor ">Shiyou  Sun</span>, <span class="hlFld-ContribAuthor ">Yongqiong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of novel quinolone derivatives dual targeting histone deacetylase and tubulin polymerization as antiproliferative agents. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2018,</strong> <em>8 </em>
                                    (30)
                                     , 16494-16502. <a href="https://doi.org/10.1039/C8RA02578A" title="DOI URL">https://doi.org/10.1039/C8RA02578A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8RA02578A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8RA02578A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bquinolone%252Bderivatives%252Bdual%252Btargeting%252Bhistone%252Bdeacetylase%252Band%252Btubulin%252Bpolymerization%252Bas%252Bantiproliferative%252Bagents%26aulast%3DWang%26aufirst%3DXuan%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D30%26spage%3D16494%26epage%3D16502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Barbara  Parrino</span>, <span class="hlFld-ContribAuthor ">Alessandro  Attanzio</span>, <span class="hlFld-ContribAuthor ">Virginia  Spanò</span>, <span class="hlFld-ContribAuthor ">Stella  Cascioferro</span>, <span class="hlFld-ContribAuthor ">Alessandra  Montalbano</span>, <span class="hlFld-ContribAuthor ">Paola  Barraja</span>, <span class="hlFld-ContribAuthor ">Luisa  Tesoriere</span>, <span class="hlFld-ContribAuthor ">Patrizia  Diana</span>, <span class="hlFld-ContribAuthor ">Girolamo  Cirrincione</span>, <span class="hlFld-ContribAuthor ">Anna  Carbone</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, antitumor activity and CDK1 inhibiton of new thiazole nortopsentin analogues. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>138 </em>, 371-383. <a href="https://doi.org/10.1016/j.ejmech.2017.06.052" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.06.052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.06.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.06.052%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%25252C%252Bantitumor%252Bactivity%252Band%252BCDK1%252Binhibiton%252Bof%252Bnew%252Bthiazole%252Bnortopsentin%252Banalogues%26aulast%3DParrino%26aufirst%3DBarbara%26date%3D2017%26volume%3D138%26spage%3D371%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pavlina  Marvanova</span>, <span class="hlFld-ContribAuthor ">Tereza  Padrtova</span>, <span class="hlFld-ContribAuthor ">Klara  Odehnalova</span>, <span class="hlFld-ContribAuthor ">Ondrej  Hosik</span>, <span class="hlFld-ContribAuthor ">Michal  Oravec</span>, <span class="hlFld-ContribAuthor ">Petr  Mokry</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Determination of Physicochemical Properties of New 3-(4-Arylpiperazin-1-yl)-2-hydroxypropyl 4-Alkoxyethoxybenzoates. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2016,</strong> <em>21 </em>
                                    (12)
                                     , 1682. <a href="https://doi.org/10.3390/molecules21121682" title="DOI URL">https://doi.org/10.3390/molecules21121682</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules21121682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules21121682%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DSynthesis%252Band%252BDetermination%252Bof%252BPhysicochemical%252BProperties%252Bof%252BNew%252B3-%2525284-Arylpiperazin-1-yl%252529-2-hydroxypropyl%252B4-Alkoxyethoxybenzoates%26aulast%3DMarvanova%26aufirst%3DPavlina%26date%3D2016%26date%3D2016%26volume%3D21%26issue%3D12%26spage%3D1682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mengqi  Dong</span>, <span class="hlFld-ContribAuthor ">Fang  Liu</span>, <span class="hlFld-ContribAuthor ">Hongyu  Zhou</span>, <span class="hlFld-ContribAuthor ">Shumei  Zhai</span>, <span class="hlFld-ContribAuthor ">Bing  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding Site. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2016,</strong> <em>21 </em>
                                    (10)
                                     , 1375. <a href="https://doi.org/10.3390/molecules21101375" title="DOI URL">https://doi.org/10.3390/molecules21101375</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules21101375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules21101375%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DNovel%252BNatural%252BProduct-%252Band%252BPrivileged%252BScaffold-Based%252BTubulin%252BInhibitors%252BTargeting%252Bthe%252BColchicine%252BBinding%252BSite%26aulast%3DDong%26aufirst%3DMengqi%26date%3D2016%26date%3D2016%26volume%3D21%26issue%3D10%26spage%3D1375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Margiani P.  Fortes</span>, <span class="hlFld-ContribAuthor ">Paulo B.N.  da Silva</span>, <span class="hlFld-ContribAuthor ">Teresinha G.  da Silva</span>, <span class="hlFld-ContribAuthor ">Teodoro S.  Kaufman</span>, <span class="hlFld-ContribAuthor ">Gardenia C.G.  Militão</span>, <span class="hlFld-ContribAuthor ">Claudio C.  Silveira</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and preliminary evaluation of 3-thiocyanato-1H-indoles as potential anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>118 </em>, 21-26. <a href="https://doi.org/10.1016/j.ejmech.2016.04.039" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.04.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.04.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.04.039%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bpreliminary%252Bevaluation%252Bof%252B3-thiocyanato-1H-indoles%252Bas%252Bpotential%252Banticancer%252Bagents%26aulast%3DFortes%26aufirst%3DMargiani%2BP.%26date%3D2016%26volume%3D118%26spage%3D21%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">N.K.  Terrett</span>. </span><span class="cited-content_cbyCitation_article-title">Combinatorial Chemistry Online Volume 18, Issue 2, February 2016. </span><span class="cited-content_cbyCitation_journal-name">Combinatorial Chemistry - an Online Journal</span><span> <strong>2016,</strong> <em>18 </em>
                                    (2)
                                     , 5-8. <a href="https://doi.org/10.1016/j.comche.2015.12.001" title="DOI URL">https://doi.org/10.1016/j.comche.2015.12.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.comche.2015.12.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.comche.2015.12.001%26sid%3Dliteratum%253Aachs%26jtitle%3DCombinatorial%2520Chemistry%2520-%2520an%2520Online%2520Journal%26atitle%3DCombinatorial%252BChemistry%252BOnline%252BVolume%252B18%25252C%252BIssue%252B2%25252C%252BFebruary%252B2016%26aulast%3DTerrett%26aufirst%3DN.K.%26date%3D2016%26volume%3D18%26issue%3D2%26spage%3D5%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianwei  Yan</span>, <span class="hlFld-ContribAuthor ">Guangjie  He</span>, <span class="hlFld-ContribAuthor ">Fulin  Yan</span>, <span class="hlFld-ContribAuthor ">Jixia  Zhang</span>, <span class="hlFld-ContribAuthor ">Guisheng  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">The dicarbonylation of indoles via Friedel–Crafts reaction with dicarbonyl nitrile generated in situ and retro-cyanohydrination. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2016,</strong> <em>6 </em>
                                    (50)
                                     , 44029-44033. <a href="https://doi.org/10.1039/C6RA04016K" title="DOI URL">https://doi.org/10.1039/C6RA04016K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6RA04016K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6RA04016K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DThe%252Bdicarbonylation%252Bof%252Bindoles%252Bvia%252BFriedel%2525E2%252580%252593Crafts%252Breaction%252Bwith%252Bdicarbonyl%252Bnitrile%252Bgenerated%252Bin%252Bsitu%252Band%252Bretro-cyanohydrination%26aulast%3DYan%26aufirst%3DJianwei%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D50%26spage%3D44029%26epage%3D44033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Renzhong  Fu</span>, <span class="hlFld-ContribAuthor ">Yang  Yang</span>, <span class="hlFld-ContribAuthor ">Weihua  Jin</span>, <span class="hlFld-ContribAuthor ">Hui  Gu</span>, <span class="hlFld-ContribAuthor ">Xiaojun  Zeng</span>, <span class="hlFld-ContribAuthor ">Wen  Chai</span>, <span class="hlFld-ContribAuthor ">Yunsheng  Ma</span>, <span class="hlFld-ContribAuthor ">Quan  Wang</span>, <span class="hlFld-ContribAuthor ">Jun  Yi</span>, <span class="hlFld-ContribAuthor ">Rongxin  Yuan</span>. </span><span class="cited-content_cbyCitation_article-title">Microwave-assisted heteropolyanion-based ionic liquid promoted sustainable protocol to N-heteroaryl amides via N-directing dual catalyzed oxidative amidation of aldehydes. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2016,</strong> <em>6 </em>
                                    (109)
                                     , 107699-107707. <a href="https://doi.org/10.1039/C6RA20961K" title="DOI URL">https://doi.org/10.1039/C6RA20961K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6RA20961K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6RA20961K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DMicrowave-assisted%252Bheteropolyanion-based%252Bionic%252Bliquid%252Bpromoted%252Bsustainable%252Bprotocol%252Bto%252BN-heteroaryl%252Bamides%252Bvia%252BN-directing%252Bdual%252Bcatalyzed%252Boxidative%252Bamidation%252Bof%252Baldehydes%26aulast%3DFu%26aufirst%3DRenzhong%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D109%26spage%3D107699%26epage%3D107707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexander V.  Aksenov</span>, <span class="hlFld-ContribAuthor ">Nicolai A.  Aksenov</span>, <span class="hlFld-ContribAuthor ">Zarema V.  Dzhandigova</span>, <span class="hlFld-ContribAuthor ">Dmitrii A.  Aksenov</span>, <span class="hlFld-ContribAuthor ">Leonid G.  Voskressensky</span>, <span class="hlFld-ContribAuthor ">Valentine G.  Nenajdenko</span>, <span class="hlFld-ContribAuthor ">Michael  Rubin</span>. </span><span class="cited-content_cbyCitation_article-title">Direct reductive coupling of indoles to nitrostyrenes en route to (indol-3-yl)acetamides. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2016,</strong> <em>6 </em>
                                    (96)
                                     , 93881-93886. <a href="https://doi.org/10.1039/C6RA21399E" title="DOI URL">https://doi.org/10.1039/C6RA21399E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6RA21399E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6RA21399E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DDirect%252Breductive%252Bcoupling%252Bof%252Bindoles%252Bto%252Bnitrostyrenes%252Ben%252Broute%252Bto%252B%252528indol-3-yl%252529acetamides%26aulast%3DAksenov%26aufirst%3DAlexander%2BV.%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D96%26spage%3D93881%26epage%3D93886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of glyoxylamide-based tubulin polymerization inhibitors that have progressed to clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0011.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Routes to the Indole-3-glyoxylamide Screening Libraries, Using Either (a) a One-Pot Procedure, or (b) a Two-Step Route Suitable for Modified Indoles<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaH, R<sup>1</sup>-X, DMF or THF, 6–83%; (b) (i) oxalyl chloride, THF, 3 h, (ii) R<sup>2</sup>-NH<sub>2</sub>, DIPEA, DMAP (catalytic), THF, 18 h, 20–78%; (c) methyl chlorooxoacetate, AlCl<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 7–86%; (d) R<sup>2</sup>-NH<sub>2</sub>, 30 mol % TBD, toluene, 85 °C, 18 h, 5–58%. For the sake of clarity, individual structures of <b>4a</b>–<b>i</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Table S8</a>) and modified indoles <b>66a</b>–<b>l</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Table S9</a>) and their <i>N</i>-alkylated derivatives <b>67a</b>–<b>o</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Table S10</a>) are provided in the Supporting Information.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0012.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of <i>N</i>-Substituted Indole Intermediates Accessed via Other Routes<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) cyclopentylboronic acid, NaHMDS, 10 mol % Cu(OAc)<sub>2</sub>, DMAP, toluene, 95 °C, 18 h, 34%; (b) isobutene oxide, NaH, DMF, 24 h, 74%; (c) MeI, NaH, THF, 24 h, 52%; (d) ethyl 2-bromopropionate, NaH, DMF, 40 °C, 18 h, 74%; (e) LDA, MeI, THF, −78 °C → rt, 18 h, 86%; (f) LiAlH<sub>4</sub>, THF, −78 °C → rt, 18 h, 78%; (g) MeI, NaH, THF, 3 h, 79% (<b>4l</b>) or ethyl bromoacetate, NaH, DMF, 20 h, 29% (<b>4m</b>); (h) methyl acrylate, 50 mol % DBU, MeCN, 50 °C, 12 h, 43%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0013.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of 5-Aminopyridines with Varied 2-Alkoxy Substituents<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) R<sup>5</sup>-OH, NaH, <sup><i>i</i></sup>PrOH or DMF or THF, 44–65%; (b) H<sub>2</sub>, Pd-C, MeOH, 62–95%.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0014.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Analogues Replacing the Indole System with an Indolizine Core<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) R<sup>1</sup>CH<sub>2</sub>C≡CH, 2 mol % PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, 4 mol % PPh<sub>3</sub>, 4 mol % CuI, TEA, 18 h, 63–78%; (b) MeI, NaH, DMF, 0 °C, 3.5 h, 27%; (c) CuCl, DMA/TEA (7:1), 130 °C, 31–55%; (d) (i) oxalyl chloride, THF, 0 °C, 3 h, (ii) R<sup>2</sup>-NH<sub>2</sub>, DIPEA, DMAP, THF, 18 h, 20–66%.</p></p></figure><figure data-id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Tubulin polymerization time-course plots following changes in OD<sub>340</sub> of reaction mixtures in the presence of increasing concentrations of <b>33</b> (blue lines) compared to vehicle control (red line). (b) Secondary plots of reaction end point data allow determination of IC<sub>50</sub> for inhibition of tubulin polymerization by <b>33</b> and other compounds as indicated. Data from multiple experiments was plotted as individual data points, as shown, and fit globally. (c) Competition for tubulin binding between [<sup>3</sup>H]-colchicine (at 0.1 μM) and vincristine, docetaxel, or podophyllotoxin shows only the latter competes with binding at the colchicine site, as expected. (d) The same six compounds listed in (b) above all compete for binding at the colchicine site with IC<sub>50</sub> values as shown, with representative results graphed for <b>32</b>, <b>51</b>, <b>57</b>, and podophyllotoxin (positive control).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Representative images of fixed FaDu cells stained for α-tubulin (green) and DNA (blue) after treatment as indicated for 24 h. Control cells (DMSO-treated) show a well-structured microtubule network and are dividing normally, with mitotic cells in anaphase (center) and prophase (left) clearly visible in the upper-left panel. In contrast, cells treated with active tubulin polymerization inhibitors showed multiple mitotic defects, most notably formation of multipolar spindles, and compound <b>59</b> appeared especially destructive to the microtubule network at high concentration. Images in all panels are to the same scale. An enlarged version of these images is provided in the Supporting Information for improved clarity (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S13</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Exposure of FaDu cells to increasing concentrations of the compounds indicated, for 24 h, caused dose-dependent cell cycle arrest in the G<sub>2</sub>/M phase; for comparisons, ns = <i>P</i> > 0.05, ** = <i>P</i> < 0.01, *** = <i>P</i> < 0.001. (b) Representative histograms for the three concentrations of <b>57</b> (cell count versus DNA staining intensity) showing the clear shift in cell cycle distribution upon compound treatment; DMSO control (not shown) was essentially identical to the 0.5 × LC<sub>50</sub> (green) plot. (c) A more detailed dose–response analysis for compounds <b>33</b> and <b>59</b> provided EC<sub>50</sub> values for the observed mitotic arrest.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0007.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Distribution of cytotoxicity LC<sub>50</sub> values for the compounds indicated across a range of cell lines representing different cancer types. (b) Ratio of LC<sub>50</sub> values for various compounds between the multidrug-resistant cell line MES-SA/Dx5 and its parent line, MES-SA. Varying degrees of resistance are seen to vinblastine, paclitaxel, and colchicine but not to <b>1</b> or a selection of members from the present series. The cytotoxicity data used in making both these graphs are tabulated in full (mean, SEM, n) in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Table S7a,b</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0008.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect of compounds <b>32</b>, <b>33</b>, and <b>59</b> on multicellular tumor spheroids (MCTS) formed from the FaDu cell line. (a) Images captured at 0, 2, 4, and 7 days postdosing demonstrate ongoing toxicity toward treated MCTS, whereas untreated controls show continued growth over the same time period; scale bar (lower left panel) 500 μm. (b) Images of MCTS treated with increasing concentrations of <b>59</b> captured 7 days postdosing, with enhanced brightness to emphasize the fragmentation of spheroids which is induced in a dose-dependent manner; scale bar (leftmost panel) 500 μm. (c) Time-course plots of average volume at selected concentrations of <b>59</b> again show dose-dependent toxicity toward FaDu MCTS. (d) Representative dose–response plots at end point (7 days postdosing) allow EC<sub>50</sub> determination for spheroid disruption; values derived from these data are 39 nM (<b>32</b>), 77 nM (<b>33</b>), and 113 nM (<b>59</b>). (e) Comparison of 3D cytotoxic potencies (mean ± SEM) with values from 2D (monolayer) screening reported earlier (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0009.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compounds <b>33</b> and <b>59</b> were administered by oral gavage at the doses indicated, once daily for 10 days (gray arrowheads), and produced a significant reduction in tumor growth relative to the control group. This effect was statistically significant (<i>P</i> < 0.05) in all treatment groups at days 3, 6, and 9, and significant at the <i>P</i> < 0.0001 level at day 6 in all cases. Only <b>33</b> exerted a sustained effect beyond the dosing period (<i>P</i> < 0.01 at days 13 and 15). Detailed plots of tumor volume, body weight, and survival for each treatment group, including results with vinblastine as a comparator/control drug, are presented in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf" class="ext-link">Figure S15</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/medium/jm-2015-01312h_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0010.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Some other indole-3-glyoxylamides with reported in vitro or in vivo antitumor activity. Note <b>88</b> is the indole analogue of <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01312/20151204/images/large/jm-2015-01312h_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01312&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i117">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56612" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56612" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 103 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Nitika, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapil, K.</span><span> </span><span class="NLM_article-title">Microtubule targeting agents: a benchmark in cancer therapy</span> <span class="citation_source-journal">Curr. Drug Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">189</span><span class="NLM_x">–</span> <span class="NLM_lpage">196</span><span class="refDoi"> DOI: 10.2174/15748855113086660011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.2174%2F15748855113086660011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=189-196&author=V.+Nitikaauthor=K.+Kapil&title=Microtubule+targeting+agents%3A+a+benchmark+in+cancer+therapy&doi=10.2174%2F15748855113086660011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2174%2F15748855113086660011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15748855113086660011%26sid%3Dliteratum%253Aachs%26aulast%3DNitika%26aufirst%3DV.%26aulast%3DKapil%26aufirst%3DK.%26atitle%3DMicrotubule%2520targeting%2520agents%253A%2520a%2520benchmark%2520in%2520cancer%2520therapy%26jtitle%3DCurr.%2520Drug%2520Ther.%26date%3D2014%26volume%3D8%26spage%3D189%26epage%3D196%26doi%3D10.2174%2F15748855113086660011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Risinger, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">Microtubule dynamics as a target in oncology</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span><span class="refDoi"> DOI: 10.1016/j.ctrv.2008.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.ctrv.2008.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=19117686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVantrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2009&pages=255-261&author=A.+L.+Risingerauthor=F.+J.+Gilesauthor=S.+L.+Mooberry&title=Microtubule+dynamics+as+a+target+in+oncology&doi=10.1016%2Fj.ctrv.2008.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule dynamics as a target in oncology</span></div><div class="casAuthors">Risinger, April L.; Giles, Francis J.; Mooberry, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-261</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Drugs that affect microtubule dynamics, including the taxanes and vinca alkaloids, have been a mainstay in the treatment of leukemias and solid tumors for decades.  New, more effective microtubule-targeting agents continue to enter into clin. trials and some, including the epothilone ixapebilone, have been approved for use.  In contrast, several other drugs of this class with promising preclin. data were later shown to be ineffective or intolerable in animal models or clin. trials.  In this review, we discuss the mol. mechanisms as well as preclin. and clin. results for a variety of microtubule-targeting agents in various stages of development.  We also offer a frank discussion of which microtubule-targeting agents are amenable to further development based on their availability, efficacy and toxic profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh2wR_5ls3DLVg90H21EOLACvtfcHk0lg-g7ZQ9gePBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVantrg%253D&md5=2d18cb599b5c35f1e0bc0292c183826f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2008.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2008.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DRisinger%26aufirst%3DA.%2BL.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DMicrotubule%2520dynamics%2520as%2520a%2520target%2520in%2520oncology%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2009%26volume%3D35%26spage%3D255%26epage%3D261%26doi%3D10.1016%2Fj.ctrv.2008.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Stanton, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gernert, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nettles, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aneja, R.</span><span> </span><span class="NLM_article-title">Drugs that target dynamic microtubules: a new molecular perspective</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">443</span><span class="NLM_x">–</span> <span class="NLM_lpage">481</span><span class="refDoi"> DOI: 10.1002/med.20242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1002%2Fmed.20242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=21381049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXksVKlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=443-481&author=R.+A.+Stantonauthor=K.+M.+Gernertauthor=J.+H.+Nettlesauthor=R.+Aneja&title=Drugs+that+target+dynamic+microtubules%3A+a+new+molecular+perspective&doi=10.1002%2Fmed.20242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs that target dynamic microtubules: A new molecular perspective</span></div><div class="casAuthors">Stanton, Richard A.; Gernert, Kim M.; Nettles, James H.; Aneja, Ritu</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">443-481</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Microtubules have long been considered an ideal target for anticancer drugs because of the essential role they play in mitosis, forming the dynamic spindle app.  As such, there is a wide variety of compds. currently in clin. use and in development that act as antimitotic agents by altering microtubule dynamics.  Although these diverse mols. are known to affect microtubule dynamics upon binding to one of the three established drug domains (taxane, vinca alkaloid, or colchicine site), the exact mechanism by which each drug works is still an area of intense speculation and research.  In this study, we review the effects of microtubule-binding chemotherapeutic agents from a new perspective, considering how their mode of binding induces conformational changes and alters biol. function relative to the mol. vectors of microtubule assembly or disassembly.  These "biol. vectors" can thus be used as a spatiotemporal context to describe mol. mechanisms by which microtubule-targeting drugs work. © 2011 Wiley Periodicals, Inc.  Med Res Rev, 31, No. 3, 443-481, 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpB6_lcUQbXYrVg90H21EOLACvtfcHk0lg-g7ZQ9gePBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXksVKlsLs%253D&md5=acce5b9cc89581a7dab0236072b68c72</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fmed.20242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20242%26sid%3Dliteratum%253Aachs%26aulast%3DStanton%26aufirst%3DR.%2BA.%26aulast%3DGernert%26aufirst%3DK.%2BM.%26aulast%3DNettles%26aufirst%3DJ.%2BH.%26aulast%3DAneja%26aufirst%3DR.%26atitle%3DDrugs%2520that%2520target%2520dynamic%2520microtubules%253A%2520a%2520new%2520molecular%2520perspective%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2011%26volume%3D31%26spage%3D443%26epage%3D481%26doi%3D10.1002%2Fmed.20242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Barbier, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsvetkov, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breuzard, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devred, F.</span><span> </span><span class="NLM_article-title">Deciphering the molecular mechanisms of anti-tubulin plant derived drugs</span> <span class="citation_source-journal">Phytochem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">157</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1007/s11101-013-9302-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1007%2Fs11101-013-9302-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislCksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=157-169&author=P.+Barbierauthor=P.+O.+Tsvetkovauthor=G.+Breuzardauthor=F.+Devred&title=Deciphering+the+molecular+mechanisms+of+anti-tubulin+plant+derived+drugs&doi=10.1007%2Fs11101-013-9302-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Deciphering the molecular mechanisms of anti-tubulin plant derived drugs</span></div><div class="casAuthors">Barbier, P.; Tsvetkov, P. O.; Breuzard, G.; Devred, F.</div><div class="citationInfo"><span class="NLM_cas:title">Phytochemistry Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">157-169</span>CODEN:
                <span class="NLM_cas:coden">PRHEBS</span>;
        ISSN:<span class="NLM_cas:issn">1568-7767</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Even though commercialized anticancer drugs are now produced by pharmaceutical companies, most of them were originally obtained from natural sources, and more particularly from plants.  Indeed, many structurally diverse compds. isolated from plants or marine flora have been purified and synthesized for their anticancer bioactivity.  Among these, several mols. belong to the class of anticancer drugs which target the microtubule cytoskeleton, either by stabilizing it or destabilizing it.  To characterize the activity of these drugs and to understand in which physiol. context they are more likely to be used as therapeutic agents, it is necessary to fully det. their interaction with tubulin.  Understanding the mol. basis of their effects on microtubule cytoskeleton is an important step in designing analogs with greater pharmacol. activity and with fewer side effects.  In addn., knowing the mol. mechanism of action of each drug that is already used in chemotherapy protocols will also help to find strategies to circumvent resistance.  By taking examples of known anti-tubulin plant derived drugs, we show how identification of microtubule targeting agents and further characterization of their activity can be achieved combining biophys. and biochem. approaches.  We also illustrate how continuing in depth study of mols. with already known primary mechanisms of action can lead to the discovery of new targets or biomarkers which can open new perspectives in anticancer strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi3RE25Y1WjLVg90H21EOLACvtfcHk0lg-g7ZQ9gePBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislCksb0%253D&md5=080159383138e7ed1f86783ed272d360</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs11101-013-9302-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11101-013-9302-8%26sid%3Dliteratum%253Aachs%26aulast%3DBarbier%26aufirst%3DP.%26aulast%3DTsvetkov%26aufirst%3DP.%2BO.%26aulast%3DBreuzard%26aufirst%3DG.%26aulast%3DDevred%26aufirst%3DF.%26atitle%3DDeciphering%2520the%2520molecular%2520mechanisms%2520of%2520anti-tubulin%2520plant%2520derived%2520drugs%26jtitle%3DPhytochem.%2520Rev.%26date%3D2014%26volume%3D13%26spage%3D157%26epage%3D169%26doi%3D10.1007%2Fs11101-013-9302-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Rohena, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mooberry, S. L.</span><span> </span><span class="NLM_article-title">Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities</span> <span class="citation_source-journal">Nat. Prod. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">355</span><span class="refDoi"> DOI: 10.1039/c3np70092e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1039%2Fc3np70092e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=24481420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVagsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=335-355&author=C.+C.+Rohenaauthor=S.+L.+Mooberry&title=Recent+progress+with+microtubule+stabilizers%3A+new+compounds%2C+binding+modes+and+cellular+activities&doi=10.1039%2Fc3np70092e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities</span></div><div class="casAuthors">Rohena, Cristina C.; Mooberry, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">335-355</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Covering: late 2008 to August 2013Nature has yielded numerous classes of chem. distinct microtubule stabilizers.  Several of these, including paclitaxel (Taxol) and docetaxel (Taxotere), are important drugs used in the treatment of cancer.  New microtubule stabilizers and novel formulations of these agents continue to provide advances in cancer therapy.  In this review we cover recent progress in the chem. and biol. of these diverse microtubule stabilizers focusing on the wide range of organisms that produce these compds., their mechanisms of inhibiting microtubule-dependent processes, mechanisms of drug resistance, and their interactions with tubulin including their distinct binding sites and modes.  A new potential role for microtubule stabilizers in neurodegenerative diseases is reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGbuNICZ6-bLVg90H21EOLACvtfcHk0linDqD1psj-7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVagsro%253D&md5=50febeef8c139e67374a92250e7e2a7a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1039%2Fc3np70092e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3np70092e%26sid%3Dliteratum%253Aachs%26aulast%3DRohena%26aufirst%3DC.%2BC.%26aulast%3DMooberry%26aufirst%3DS.%2BL.%26atitle%3DRecent%2520progress%2520with%2520microtubule%2520stabilizers%253A%2520new%2520compounds%252C%2520binding%2520modes%2520and%2520cellular%2520activities%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2014%26volume%3D31%26spage%3D335%26epage%3D355%26doi%3D10.1039%2Fc3np70092e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Jordan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horwitz, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correia, J. J.</span><span> </span><span class="NLM_article-title">Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">S6</span><span class="NLM_x">–</span> <span class="NLM_lpage">S12</span><span class="refDoi"> DOI: 10.1053/j.seminoncol.2008.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1053%2Fj.seminoncol.2008.01.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2008&pages=S6-S12&author=M.+A.+Jordanauthor=S.+B.+Horwitzauthor=S.+Lobertauthor=J.+J.+Correia&title=Exploring+the+mechanisms+of+action+of+the+novel+microtubule+inhibitor+vinflunine&doi=10.1053%2Fj.seminoncol.2008.01.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2008.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2008.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DHorwitz%26aufirst%3DS.%2BB.%26aulast%3DLobert%26aufirst%3DS.%26aulast%3DCorreia%26aufirst%3DJ.%2BJ.%26atitle%3DExploring%2520the%2520mechanisms%2520of%2520action%2520of%2520the%2520novel%2520microtubule%2520inhibitor%2520vinflunine%26jtitle%3DSemin.%2520Oncol.%26date%3D2008%26volume%3D35%26spage%3DS6%26epage%3DS12%26doi%3D10.1053%2Fj.seminoncol.2008.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Field, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanakkanthara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, J. H.</span><span> </span><span class="NLM_article-title">Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">5050</span><span class="NLM_x">–</span> <span class="NLM_lpage">5059</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.bmc.2014.02.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=24650703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksVWqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=5050-5059&author=J.+J.+Fieldauthor=A.+Kanakkantharaauthor=J.+H.+Miller&title=Microtubule-targeting+agents+are+clinically+successful+due+to+both+mitotic+and+interphase+impairment+of+microtubule+function&doi=10.1016%2Fj.bmc.2014.02.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function</span></div><div class="casAuthors">Field, Jessica J.; Kanakkanthara, Arun; Miller, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5050-5059</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Microtubules undergo continual dynamic changes in mitotic cells as the mitotic spindle forms and is broken down and in interphase cells where they play a central role in intracellular trafficking, cell signaling, cell migration, and angiogenesis.  Compds. that target the microtubule have been hugely successful in the clinic as chemotherapeutics, and this success is likely due to their ability to target cells regardless of their cell cycle stage.  Addnl., new generation antibody-conjugated microtubule-targeting agents are improving the targeting of these drugs to tumors.  Microtubule-targeting agents have been shown to have anti-angiogenic and vascular-disrupting properties as well as effects on cellular migration, intracellular trafficking, and cell secretion.  There are a no. of these compds. in development that target the vasculature, and different formulations of clin. used drugs are being developed to take advantage of these anti-angiogenic properties.  Microtubule-targeting agents have also been shown to have the potential to treat neurodegenerative diseases, such as Alzheimer's disease.  Thus, drugs that target the microtubule will continue to have a major impact in oncol. not only as anti-mitotics but also as potent inhibitors of interphase functions, and in future may also prove to be effective in reducing the consequences of neurodegenerative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2d-DR0ciixrVg90H21EOLACvtfcHk0linDqD1psj-7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksVWqsrw%253D&md5=e3ec8c5c15dfe25d1c527cecaec20d2f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.035%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DJ.%2BJ.%26aulast%3DKanakkanthara%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DJ.%2BH.%26atitle%3DMicrotubule-targeting%2520agents%2520are%2520clinically%2520successful%2520due%2520to%2520both%2520mitotic%2520and%2520interphase%2520impairment%2520of%2520microtubule%2520function%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D5050%26epage%3D5059%26doi%3D10.1016%2Fj.bmc.2014.02.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Zasadil, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersen, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeum, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocque, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilke, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tevaarwerk, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raines, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkard, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, B. A.</span><span> </span><span class="NLM_article-title">Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">229ra43</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3007965</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1126%2Fscitranslmed.3007965" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=24670687" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=229ra43&author=L.+M.+Zasadilauthor=K.+A.+Andersenauthor=D.+Yeumauthor=G.+B.+Rocqueauthor=L.+G.+Wilkeauthor=A.+J.+Tevaarwerkauthor=R.+T.+Rainesauthor=M.+E.+Burkardauthor=B.+A.+Weaver&title=Cytotoxicity+of+paclitaxel+in+breast+cancer+is+due+to+chromosome+missegregation+on+multipolar+spindles&doi=10.1126%2Fscitranslmed.3007965"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3007965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3007965%26sid%3Dliteratum%253Aachs%26aulast%3DZasadil%26aufirst%3DL.%2BM.%26aulast%3DAndersen%26aufirst%3DK.%2BA.%26aulast%3DYeum%26aufirst%3DD.%26aulast%3DRocque%26aufirst%3DG.%2BB.%26aulast%3DWilke%26aufirst%3DL.%2BG.%26aulast%3DTevaarwerk%26aufirst%3DA.%2BJ.%26aulast%3DRaines%26aufirst%3DR.%2BT.%26aulast%3DBurkard%26aufirst%3DM.%2BE.%26aulast%3DWeaver%26aufirst%3DB.%2BA.%26atitle%3DCytotoxicity%2520of%2520paclitaxel%2520in%2520breast%2520cancer%2520is%2520due%2520to%2520chromosome%2520missegregation%2520on%2520multipolar%2520spindles%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D229ra43%26doi%3D10.1126%2Fscitranslmed.3007965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Ogden, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rida, P. C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aneja, R.</span><span> </span><span class="NLM_article-title">Interphase microtubules: chief casualties in the war on cancer?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">824</span><span class="NLM_x">–</span> <span class="NLM_lpage">829</span><span class="refDoi"> DOI: 10.1016/j.drudis.2013.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.drudis.2013.10.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=24201225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvValtbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=824-829&author=A.+Ogdenauthor=P.+C.+G.+Ridaauthor=M.+D.+Reidauthor=R.+Aneja&title=Interphase+microtubules%3A+chief+casualties+in+the+war+on+cancer%3F&doi=10.1016%2Fj.drudis.2013.10.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Interphase microtubules: chief casualties in the war on cancer?</span></div><div class="casAuthors">Ogden, Angela; Rida, Padmashree C. G.; Reid, Michelle D.; Aneja, Ritu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">824-829</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Microtubule-targeting agents (MTAs) profoundly affect interphase cells, such as by disrupting axonal transport, transcription, translation, mitochondrial permeability, immune cell function, directional migration and centrosome clustering.  This finding is antithetical to the conventionally held notion that MTAs act on mitosis to trigger arrest-mediated apoptotic cell death.  Furthermore, the paucity of mitotic cells in patient tumors and lack of correlation of MTA efficacy with tumor proliferation rate provide strong impetus to re-examine the mechanistic basis of action of MTAs, with an eye toward interphase activities.  Whereas targeted antimitotics have unequivocally failed their promise across clin. studies, MTAs constitute a mainstay of chemotherapy.  This paradox necessitates the conclusion that MTAs exert mitosis-independent effects, spurring a dramatic paradigm shift in our understanding of the mode of action of MTAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ1qu2htK9XLVg90H21EOLACvtfcHk0linDqD1psj-7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvValtbjK&md5=adedd47ce4b6fdf0239e9d107c62c751</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DOgden%26aufirst%3DA.%26aulast%3DRida%26aufirst%3DP.%2BC.%2BG.%26aulast%3DReid%26aufirst%3DM.%2BD.%26aulast%3DAneja%26aufirst%3DR.%26atitle%3DInterphase%2520microtubules%253A%2520chief%2520casualties%2520in%2520the%2520war%2520on%2520cancer%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D824%26epage%3D829%26doi%3D10.1016%2Fj.drudis.2013.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Fürst, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vollmar, A. M.</span><span> </span><span class="NLM_article-title">A new perspective on old drugs: non-mitotic actions of tubulin-binding drugs play a major role in cancer treatment</span> <span class="citation_source-journal">Pharmazie</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">478</span><span class="NLM_x">–</span> <span class="NLM_lpage">483</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=478-483&author=R.+F%C3%BCrstauthor=A.+M.+Vollmar&title=A+new+perspective+on+old+drugs%3A+non-mitotic+actions+of+tubulin-binding+drugs+play+a+major+role+in+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DF%25C3%25BCrst%26aufirst%3DR.%26aulast%3DVollmar%26aufirst%3DA.%2BM.%26atitle%3DA%2520new%2520perspective%2520on%2520old%2520drugs%253A%2520non-mitotic%2520actions%2520of%2520tubulin-binding%2520drugs%2520play%2520a%2520major%2520role%2520in%2520cancer%2520treatment%26jtitle%3DPharmazie%26date%3D2013%26volume%3D68%26spage%3D478%26epage%3D483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Mitchison, T. J.</span><span> </span><span class="NLM_article-title">The proliferation rate paradox in antimitotic chemotherapy</span> <span class="citation_source-journal">Mol. Biol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1091/mbc.E10-04-0335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1091%2Fmbc.E10-04-0335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=22210845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVylsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=1-6&author=T.+J.+Mitchison&title=The+proliferation+rate+paradox+in+antimitotic+chemotherapy&doi=10.1091%2Fmbc.E10-04-0335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The proliferation rate paradox in antimitotic chemotherapy</span></div><div class="casAuthors">Mitchison, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Biology of the Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">MBCEEV</span>;
        ISSN:<span class="NLM_cas:issn">1939-4586</span>.
    
            (<span class="NLM_cas:orgname">American Society for Cell Biology</span>)
        </div><div class="casAbstract">A review.  Cytotoxic cancer chemotherapy drugs are believed to gain selectivity by targeting cells that proliferate rapidly.  However, the proliferation rate is low in many chemosensitive human cancers, and it is not clear how a drug that only kills dividing cells could promote tumor regression.  Four potential solns. to this "proliferation rate paradox" are discussed for the microtubule-stabilizing drug paclitaxel: drug retention in tumors, killing of quiescent cells, targeting of noncancer cells in the tumor, and bystander effects.  Testing these potential mechanisms of drug action will facilitate rational improvement of antimitotic chemotherapy and perhaps cytotoxic chemotherapy more generally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGostPy_gyyJCLVg90H21EOLACvtfcHk0lgR6spRmjgnMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVylsA%253D%253D&md5=32fea5a5b4d14d23feca77c5f5ab6823</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1091%2Fmbc.E10-04-0335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.E10-04-0335%26sid%3Dliteratum%253Aachs%26aulast%3DMitchison%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520proliferation%2520rate%2520paradox%2520in%2520antimitotic%2520chemotherapy%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2012%26volume%3D23%26spage%3D1%26epage%3D6%26doi%3D10.1091%2Fmbc.E10-04-0335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Seligmann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Twelves, C.</span><span> </span><span class="NLM_article-title">Tubulin: an example of targeted chemotherapy</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">339</span><span class="NLM_x">–</span> <span class="NLM_lpage">352</span><span class="refDoi"> DOI: 10.4155/fmc.12.217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.4155%2Ffmc.12.217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=23464522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsVKnurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=339-352&author=J.+Seligmannauthor=C.+Twelves&title=Tubulin%3A+an+example+of+targeted+chemotherapy&doi=10.4155%2Ffmc.12.217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin: an example of targeted chemotherapy</span></div><div class="casAuthors">Seligmann, Jenny; Twelves, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">339-352</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Anticancer drugs directed against the microtubule, including taxanes and vinca alkaloids, have been the backbone of many chemotherapy regimes for decades.  These drugs have, however, significant limitations, which have prompted the development of novel microtubule targeting agents (MTAs).  This article will discuss MTAs for anticancer therapies and recent debates regarding their mechanisms of action.  Furthermore, the limitations of taxanes, including hypersensitivity reactions, neurotoxicity, drug resistance and lack of validated biomarkers to guide therapy will be discussed, all of which have driven the development of novel agents.  The mechanisms of action and drug development of new generations of MTAs will also be outlined.  Agents demonstrating utility in Phase III clin. trials, including eribulin, ixabepilone, cabazitaxel and trastuzumab-DM1 will be highlighted, as well as novel agents currently in development and future directions for MTAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon5RB5hJ7vGbVg90H21EOLACvtfcHk0lgR6spRmjgnMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsVKnurg%253D&md5=2a2816f2805d063776f113aabdd3c28e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.217%26sid%3Dliteratum%253Aachs%26aulast%3DSeligmann%26aufirst%3DJ.%26aulast%3DTwelves%26aufirst%3DC.%26atitle%3DTubulin%253A%2520an%2520example%2520of%2520targeted%2520chemotherapy%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2013%26volume%3D5%26spage%3D339%26epage%3D352%26doi%3D10.4155%2Ffmc.12.217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Kavallaris, M.</span><span> </span><span class="NLM_article-title">Microtubules and resistance to tubulin-binding agents</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">194</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span><span class="refDoi"> DOI: 10.1038/nrc2803</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1038%2Fnrc2803" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=20147901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvVKrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=194-204&author=M.+Kavallaris&title=Microtubules+and+resistance+to+tubulin-binding+agents&doi=10.1038%2Fnrc2803"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules and resistance to tubulin-binding agents</span></div><div class="casAuthors">Kavallaris, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">194-204</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic structures composed of α-β-tubulin heterodimers that are essential in cell division and are important targets for cancer drugs.  Mutations in β-tubulin that affect microtubule polymer mass and/or drug binding are assocd. with resistance to tubulin-binding agents such as paclitaxel.  The aberrant expression of specific β-tubulin isotypes, in particular βIII-tubulin, or of microtubule-regulating proteins is important clin. in tumor aggressiveness and resistance to chemotherapy.  In addn., changes in actin regulation can also mediate resistance to tubulin-binding agents.  Understanding the mol. mechanisms that mediate resistance to tubulin-binding agents will be vital to improve the efficacy of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNkoVu03ikmrVg90H21EOLACvtfcHk0lgR6spRmjgnMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvVKrtbg%253D&md5=1ce71cc537091459d7ee6866c0950b33</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrc2803&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2803%26sid%3Dliteratum%253Aachs%26aulast%3DKavallaris%26aufirst%3DM.%26atitle%3DMicrotubules%2520and%2520resistance%2520to%2520tubulin-binding%2520agents%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D194%26epage%3D204%26doi%3D10.1038%2Fnrc2803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Katsetos, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Draber, P.</span><span> </span><span class="NLM_article-title">Tubulins as therapeutic targets in cancer: from bench to bedside</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2778</span><span class="NLM_x">–</span> <span class="NLM_lpage">2792</span><span class="refDoi"> DOI: 10.2174/138161212800626193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.2174%2F138161212800626193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=22390762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC38XoslCrs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2778-2792&author=C.+D.+Katsetosauthor=P.+Draber&title=Tubulins+as+therapeutic+targets+in+cancer%3A+from+bench+to+bedside&doi=10.2174%2F138161212800626193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulins as therapeutic targets in cancer: from bench to bedside</span></div><div class="casAuthors">Katsetos, Christos D.; Draber, Pavel</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2778-2792</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tubulin is the target of some of the most widely used and time-honored anticancer tubulin-binding agents (TBAs).  The clin. usefulness of many TBAs has been held back as a result of tumor cell drug-resistance.  The elucidation of the three-dimensional structure of αβ-tubulin dimer has provided an opportunity for rational drug design aimed at generating compds. that will target tubulin in therapeutically more efficacious ways compared to presently available drugs.  An issue to be addressed is which one(s) of the tubulin species, their isotypes, or their posttranslationally modified forms, should be specifically targeted in cancer chemotherapy.  This review offers a crit. appraisal of current knowledge on tubulins in cancer and an update on new anti-neoplastic microtubule-targeted treatment strategies.  Specifically, it examines, across disciplines, cellular/mol., biochem., clin./pathol., and pharmacol. aspects of β-tubulin isotypes, posttranslational modifications of tubulin dimers, γ-tubulin and microtubule nucleation, and microtubule regulatory proteins.  Emphasis is placed on the overexpression of (i) the βIII isotypes, which functions as a survival factor assocd. with dynamic instability of microtubules; (ii) γ-tubulin, a key microtubule nucleating protein; and (iii) the microtubule severing enzyme spastin, involved in cell motility and proliferation of glioblastoma cells.  The role of βIII-tubulin in resistance of cancer cells to taxanes is examd.  Attention is called to the novel concept that βIII-tubulin functions as a "gateway" for prosurvival signals in partnership with GTPases, such as GBP1.  Appraisal is also offered on epothilones and the concept of hypersensitization to TBAs as promising therapeutic strategies in taxane resistant epithelial cancers and in high-grade gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxdmReNG2Qw7Vg90H21EOLACvtfcHk0lj_aBQUNSr8Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XoslCrs7k%253D&md5=cc9638610d51334759aa081a624f7abe</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F138161212800626193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212800626193%26sid%3Dliteratum%253Aachs%26aulast%3DKatsetos%26aufirst%3DC.%2BD.%26aulast%3DDraber%26aufirst%3DP.%26atitle%3DTubulins%2520as%2520therapeutic%2520targets%2520in%2520cancer%253A%2520from%2520bench%2520to%2520bedside%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D2778%26epage%3D2792%26doi%3D10.2174%2F138161212800626193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Murray, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briasoulis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bafaloukos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadimitriou, C.</span><span> </span><span class="NLM_article-title">Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">890</span><span class="NLM_x">–</span> <span class="NLM_lpage">903</span><span class="refDoi"> DOI: 10.1016/j.ctrv.2012.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.ctrv.2012.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=22465195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVyrsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2012&pages=890-903&author=S.+Murrayauthor=E.+Briasoulisauthor=H.+Linardouauthor=D.+Bafaloukosauthor=C.+Papadimitriou&title=Taxane+resistance+in+breast+cancer%3A+mechanisms%2C+predictive+biomarkers+and+circumvention+strategies&doi=10.1016%2Fj.ctrv.2012.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies</span></div><div class="casAuthors">Murray, S.; Briasoulis, E.; Linardou, H.; Bafaloukos, D.; Papadimitriou, C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">890-903</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Taxanes are established in the treatment of metastatic breast cancer (MBC) and early breast cancer (EBC) as potent chemotherapy agents.  However, their therapeutic usefulness is limited by de-novo refractoriness or acquired resistance, which are common drawbacks to most anti-cancer cytotoxics.  Considering that the taxanes will remain principle chemotherapeutic agents for the treatment of breast cancer, we reviewed known mechanisms of resistance in with an outlook of optimizing their clin. use.We searched the PubMed and MEDLINE databases for articles (from inception through to 9th Jan. 2012; last search 10/01/2012) and journals known to publish information relevant to taxane chemotherapy.  We imposed no language restrictions.  Search terms included: cancer, breast cancer, response, resistance, taxane, paclitaxel, docetaxel, taxol.  Due to the possibility of alternative mechanisms of resistance all combination chemotherapy treated data sets were removed from our overview.Over-expression of the MDR-1 gene product Pgp was extensively studied in vitro in assocn. with taxane resistance, but data are conflicting.  Similarly, the target components microtubules, which are thought to mediate refractoriness through alterations of the expression pattern of tubulins or microtubule assocd. proteins and the expression of alternative tubulin isoforms, failed to confirm such assocns.  Little consensus has been generated for reported assocns. between taxane-sensitivity and mutated p53, or taxane-resistance and overexpression of Bcl-2, Bcl-xL or NFkB.  In contrary sufficient in vitro data support an assocn. of spindle assembly checkpoint (SAC) defects with resistance.  Clin. data have been limited and inconsistent, which relate to the variety of methods used, lack of standardization of cut-offs for quantitation, differences in clin. endpoints measured and in methods of tissue collection prepn. and storage, and study/patient heterogeneity.  The most prominent finding is that pharmaceutical down-regulation of HER-2 appears to reverse the taxane resistance.Currently no valid practical biomarkers exist that can predict resistance to the taxanes in breast cancer supporting the principle of individualized cancer therapy.  The incorporation of several biomarker analyses into prospectively designed studies in this setting are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUEZD9NN-37LVg90H21EOLACvtfcHk0lj_aBQUNSr8Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVyrsLo%253D&md5=62f84f64bb7f97bc4741ce4e5d435fd0</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2012.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2012.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DS.%26aulast%3DBriasoulis%26aufirst%3DE.%26aulast%3DLinardou%26aufirst%3DH.%26aulast%3DBafaloukos%26aufirst%3DD.%26aulast%3DPapadimitriou%26aufirst%3DC.%26atitle%3DTaxane%2520resistance%2520in%2520breast%2520cancer%253A%2520mechanisms%252C%2520predictive%2520biomarkers%2520and%2520circumvention%2520strategies%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2012%26volume%3D38%26spage%3D890%26epage%3D903%26doi%3D10.1016%2Fj.ctrv.2012.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Gan, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kavallaris, M.</span><span> </span><span class="NLM_article-title">Tubulin-targeted drug action: functional significance of class II and class IVb β-tubulin in <i>Vinca</i> alkaloid sensitivity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">9817</span><span class="NLM_x">–</span> <span class="NLM_lpage">9824</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-1501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1158%2F0008-5472.CAN-08-1501" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9817-9824&author=P.+P.+Ganauthor=M.+Kavallaris&title=Tubulin-targeted+drug+action%3A+functional+significance+of+class+II+and+class+IVb+%CE%B2-tubulin+in+Vinca+alkaloid+sensitivity&doi=10.1158%2F0008-5472.CAN-08-1501"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1501%26sid%3Dliteratum%253Aachs%26aulast%3DGan%26aufirst%3DP.%2BP.%26aulast%3DKavallaris%26aufirst%3DM.%26atitle%3DTubulin-targeted%2520drug%2520action%253A%2520functional%2520significance%2520of%2520class%2520II%2520and%2520class%2520IVb%2520%25CE%25B2-tubulin%2520in%2520Vinca%2520alkaloid%2520sensitivity%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9817%26epage%3D9824%26doi%3D10.1158%2F0008-5472.CAN-08-1501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Carlson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ocean, A. J.</span><span> </span><span class="NLM_article-title">Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach</span> <span class="citation_source-journal">Clin. Breast Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span><span class="refDoi"> DOI: 10.1016/j.clbc.2011.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.clbc.2011.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=21569993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKisrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=73-81&author=K.+Carlsonauthor=A.+J.+Ocean&title=Peripheral+neuropathy+with+microtubule-targeting+agents%3A+occurrence+and+management+approach&doi=10.1016%2Fj.clbc.2011.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral neuropathy with micortubule-targeting agents: occurrence and management approach</span></div><div class="casAuthors">Carlson, Karen; Ocean, Allyson J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">73-81</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Microtubule-targeting agents (MTAs), which include vinca alkaloids, taxanes, and the recently introduced epothilone, ixabepilone, are widely used chemotherapeutic agents for treatment of patients with cancer.  MTAs interfere with the normal structure and function of microtubules, leading to cell-cycle arrest and tumor cell death.  Microtubule function is crit. to normal neuronal function, thus MTA therapy is commonly assocd. with some form of neuropathy.  There is poor agreement between tools for clin. assessment of MTA-assocd. peripheral neuropathy, and standardization of grading scales is needed to reduce variability.  For a majority of patients, MTA-assocd. neuropathy is mild to moderate in intensity and reversible, but it can be severe and resolve incompletely.  The incidence and severity of MTA-assocd. neuropathy is drug, dose, and schedule dependent.  The first-generation vinca alkaloids (eg, vincristine) are assocd. with severe mixed sensory and motor neuropathy, whereas the newer vinca alkaloids (eg, vinorelbine, vinflunine) induce a milder sensory neuropathy.  Taxane-assocd. sensory neuropathy occurs more often with std. (polyoxyethylated castor oil-based) and albumin-bound paclitaxel than with docetaxel.  The incidence and presentation of peripheral neuropathy with ixabepilone, alone or in combination with capecitabine, are similar to that with taxanes.  Management of neuropathy may involve reducing or delaying the MTA dose, or in severe persistent or disabling cases discontinuing treatment.  Reversal of neuropathy after dosage intervention appears to be more rapid with ixabepilone than with other MTAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVEwY7MtdfdbVg90H21EOLACvtfcHk0lj_aBQUNSr8Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKisrnN&md5=36df2eda9b12ae15fa5de5b79e335b62</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2011.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2011.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DCarlson%26aufirst%3DK.%26aulast%3DOcean%26aufirst%3DA.%2BJ.%26atitle%3DPeripheral%2520neuropathy%2520with%2520microtubule-targeting%2520agents%253A%2520occurrence%2520and%2520management%2520approach%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D73%26epage%3D81%26doi%3D10.1016%2Fj.clbc.2011.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Canta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiorazzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavaletti, G.</span><span> </span><span class="NLM_article-title">Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1315</span><span class="NLM_x">–</span> <span class="NLM_lpage">1324</span><span class="refDoi"> DOI: 10.2174/092986709787846488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.2174%2F092986709787846488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=19355888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltVeqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=1315-1324&author=A.+Cantaauthor=A.+Chiorazziauthor=G.+Cavaletti&title=Tubulin%3A+a+target+for+antineoplastic+drugs+into+the+cancer+cells+but+also+in+the+peripheral+nervous+system&doi=10.2174%2F092986709787846488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin as a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system</span></div><div class="casAuthors">Canta, Annalisa; Chiorazzi, Alessia; Cavaletti, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1315-1324</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the introduction into clin. practice of vinca alkaloids, tubulin has become a key and well-established target of modern antineoplastic chemotherapy.  When taxanes became available their broad spectrum of activity was striking and opened up new horizons for cancer patients' treatment.  However, taxanes' susceptibility to drug resistance caused by the drug efflux pump protein, P-glycoprotein, is not infrequent and their use may be limited by poor soly., synthetic problems and toxicity.  The epothilones are a new class of chemotherapeutic agents with a mechanism of action similar to that of taxanes, but different enough to escape, for example, the multidrug resistance caused by P-glycoprotein.  Moreover, the epothilones (that are strong promoters of tubulin polymn.) have significant antitumor activity against human cancer cells that are taxane-resistant, express the multidrug resistance gene MDR-1, and have acquired tubulin mutations.  Finally, starting from the natural mols., several synthetic analogs have been developed.  Besides their antineoplastic efficacy, all the antitubulin drugs share a common toxicity on the peripheral nervous system and peripheral neurotoxicity is a major, potentially dose-limiting side effect also of the epothilones.  The current knowledge regarding the features of epothilones' peripheral neurotoxicity and their comparison with taxanes will be reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrud9z8vnFGFLVg90H21EOLACvtfcHk0lgwd1k6nTnZWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltVeqsbo%253D&md5=88fe8b8400cb3ec5be160439503c914f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F092986709787846488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986709787846488%26sid%3Dliteratum%253Aachs%26aulast%3DCanta%26aufirst%3DA.%26aulast%3DChiorazzi%26aufirst%3DA.%26aulast%3DCavaletti%26aufirst%3DG.%26atitle%3DTubulin%253A%2520a%2520target%2520for%2520antineoplastic%2520drugs%2520into%2520the%2520cancer%2520cells%2520but%2520also%2520in%2520the%2520peripheral%2520nervous%2520system%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2009%26volume%3D16%26spage%3D1315%26epage%3D1324%26doi%3D10.2174%2F092986709787846488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Dumontet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, M. A.</span><span> </span><span class="NLM_article-title">Microtubule-binding agents: a dynamic field of cancer therapeutics</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">790</span><span class="NLM_x">–</span> <span class="NLM_lpage">803</span><span class="refDoi"> DOI: 10.1038/nrd3253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1038%2Fnrd3253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=20885410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=790-803&author=C.+Dumontetauthor=M.+A.+Jordan&title=Microtubule-binding+agents%3A+a+dynamic+field+of+cancer+therapeutics&doi=10.1038%2Fnrd3253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-binding agents: a dynamic field of cancer therapeutics</span></div><div class="casAuthors">Dumontet, Charles; Jordan, Mary Ann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">790-803</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic filamentous cytoskeletal proteins composed of tubulin and are an important therapeutic target in tumor cells.  Agents that bind to microtubules have been part of the pharmacopoeia of anticancer therapy for decades and until the advent of targeted therapy, microtubules were the only alternative to DNA as a therapeutic target in cancer.  The screening of a range of botanical species and marine organisms has yielded promising new antitubulin agents with novel properties.  In the current search for novel microtubule-binding agents, enhanced tumor specificity, reduced neurotoxicity and insensitivity to chemoresistance mechanisms are the three main objectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ43DyXjdN7rVg90H21EOLACvtfcHk0lgwd1k6nTnZWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI&md5=9fc6fd966859785605936ecbe6dca44e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrd3253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3253%26sid%3Dliteratum%253Aachs%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DM.%2BA.%26atitle%3DMicrotubule-binding%2520agents%253A%2520a%2520dynamic%2520field%2520of%2520cancer%2520therapeutics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D790%26epage%3D803%26doi%3D10.1038%2Fnrd3253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Kingston, D. G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, J. P.</span><span> </span><span class="NLM_article-title">The quest for a simple bioactive analog of paclitaxel as a potential anticancer agent</span> <span class="citation_source-journal">Acc. Chem. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2682</span><span class="NLM_x">–</span> <span class="NLM_lpage">2691</span><span class="refDoi"> DOI: 10.1021/ar500203h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar500203h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyqsL3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2014&pages=2682-2691&author=D.+G.+I.+Kingstonauthor=J.+P.+Snyder&title=The+quest+for+a+simple+bioactive+analog+of+paclitaxel+as+a+potential+anticancer+agent&doi=10.1021%2Far500203h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The Quest for a Simple Bioactive Analog of Paclitaxel as a Potential Anticancer Agent</span></div><div class="casAuthors">Kingston, David G. I.; Snyder, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2682-2691</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Paclitaxel (PTX), introduced into the clinic in 1991, has revealed itself as an effective antimicrotubule drug for treatment of a range of otherwise intractable cancers.  Along with docetaxel (DTX) and in combination with other agents such as cisplatin, it has proven to be a first-line therapy.  Unfortunately, PTX and DTX carry severe liabilities such as debilitating side effects, rapid onset of resistance, and rather complex mol. structures offering substantial challenges to ease of synthetic manipulation.  Consequently, the past 15 years has witnessed many efforts to synthesize and test highly modified analogs based on intuitive structural similarity relationships with the PTX mol. skeleton, as well as efforts to mimic the conformational profile of the ligand obsd. in the macromol. tubulin-PTX complex.  Highly successful improvements in potency, up to 50-fold increases in IC50, have been achieved by constructing bridges between distal centers in PTX that imitate the conformer of the electron crystallog. binding pose.  Much less successful have been numerous attempts to truncate PTX by replacing the baccatin core with simpler moieties to achieve PTX-like potencies and applying a wide range of flexible synthesis-based chemistries.  Reported efforts, characterized by a fascinating array of baccatin substitutes, have failed to surpass the bioactivities of PTX in both microtubule disassembly assays and cytotoxicity measurements against a range of cell types.  Most of the structures retain the main elements of the PTX C13 side chain, while seeking a smaller rigid bicycle as a baccatin replacement adorned with substituents to mimic the C2 benzoyl moiety and the oxetane ring.  We surmise that past studies have been handicapped by soly. and membrane permeability issues, but primarily by the existence of an expansive taxane binding pocket and the discrepancy in mol. size between PTX and the pruned analogs.  A no. of these mols. offer mol. vols. 50-60% that of PTX, fewer contacts with the tubulin protein, severe mismatches with the PTX pharmacophore, lessened capacity to dispel binding site waters contributing to ΔGbind, and unanticipated binding poses.  The latter is a crit. drawback if mol. designs of simpler PTX structures are based on a perceived or known PTX binding conformation.  We conclude that design and synthesis of a highly cytotoxic tubulin-assembly agent based on the paclitaxel pharmacophore remains an unsolved challenge, but one that can be overcome by focus on the architecture of the taxane binding site independent of the effective, but not unique, hand-in-glove match represented by the PTX-tubulin complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ5O3QzLeCZLVg90H21EOLACvtfcHk0ljglHAzAd-Nkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyqsL3O&md5=6d9271e63a706174a82bd62247507031</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Far500203h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far500203h%26sid%3Dliteratum%253Aachs%26aulast%3DKingston%26aufirst%3DD.%2BG.%2BI.%26aulast%3DSnyder%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520quest%2520for%2520a%2520simple%2520bioactive%2520analog%2520of%2520paclitaxel%2520as%2520a%2520potential%2520anticancer%2520agent%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2014%26volume%3D47%26spage%3D2682%26epage%3D2691%26doi%3D10.1021%2Far500203h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Gerullis, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ecke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eimer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishahi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, T.</span><span> </span><span class="NLM_article-title">Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span><span class="refDoi"> DOI: 10.1097/CAD.0b013e3283404db0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1097%2FCAD.0b013e3283404db0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=9-17&author=H.+Gerullisauthor=T.+Eckeauthor=C.+Eimerauthor=M.+Wishahiauthor=T.+Otto&title=Vinflunine+as+second-line+treatment+in+platin-resistant+metastatic+urothelial+carcinoma%3A+a+review&doi=10.1097%2FCAD.0b013e3283404db0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1097%2FCAD.0b013e3283404db0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0b013e3283404db0%26sid%3Dliteratum%253Aachs%26aulast%3DGerullis%26aufirst%3DH.%26aulast%3DEcke%26aufirst%3DT.%26aulast%3DEimer%26aufirst%3DC.%26aulast%3DWishahi%26aufirst%3DM.%26aulast%3DOtto%26aufirst%3DT.%26atitle%3DVinflunine%2520as%2520second-line%2520treatment%2520in%2520platin-resistant%2520metastatic%2520urothelial%2520carcinoma%253A%2520a%2520review%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2011%26volume%3D22%26spage%3D9%26epage%3D17%26doi%3D10.1097%2FCAD.0b013e3283404db0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Gourmelon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frenel, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campone, M.</span><span> </span><span class="NLM_article-title">Eribulin mesylate for the treatment of late-stage breast cancer</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2883</span><span class="NLM_x">–</span> <span class="NLM_lpage">2890</span><span class="refDoi"> DOI: 10.1517/14656566.2011.637490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1517%2F14656566.2011.637490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=22087618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsV2ju7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=2883-2890&author=C.+Gourmelonauthor=J.+S.+Frenelauthor=M.+Campone&title=Eribulin+mesylate+for+the+treatment+of+late-stage+breast+cancer&doi=10.1517%2F14656566.2011.637490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Eribulin mesylate for the treatment of late-stage breast cancer</span></div><div class="casAuthors">Gourmelon, Carole; Frenel, Jean Sebastien; Campone, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2883-2890</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Chemotherapy agents, particularly anthracycline and taxane, have demonstrated their significance in metastatic breast cancer.  However, improving overall survival in late-stage breast cancer remains a challenge.  Eribulin mesylate, a new chemotherapy agent, has a proven significance in this setting.  Eribulin mesylate is a synthetic analog of a macrolide isolated from a marine sponge.  It inhibits microtubule polymn., inducing mitosis arrest and apoptosis, and aggregates sol. tubulin in nonproductive form.  In Phase II studies, this drug has shown a partial and stable response.  The Phase III EMBRACE study showed that eribulin mesylate improved overall survival, compared with the physician's choice of treatment, in women who had received two to five prior chemotherapy regimens, including anthracycline and taxane for advanced breast cancer (median overall survival: 13.1 vs. 10.6 mo HR 0.81, p == 0.041).  This compd. is well tolerated.  The most common adverse event is neutropenia.  This paper provides an introduction to the drug, eribulin mesylate, along with an overview of the current drug market for late-stage breast cancer; it also reviews its pharmacodynamics, pharmacokinetics and clin. efficacy.  Currently, eribulin mesylate is only the third single-agent chemotherapy that has improved overall survival (after anthracycline and taxane) in advanced breast cancer.  These results, particularly in heavily pretreated breast cancer, suggest that this drug could become a new std. in the treatment of metastatic breast cancer, and should, therefore, be further developed in its earlier stages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-4HFg_jLJIbVg90H21EOLACvtfcHk0ljglHAzAd-Nkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsV2ju7jO&md5=af96bd55472db449e26d5791421b1e97</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1517%2F14656566.2011.637490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2011.637490%26sid%3Dliteratum%253Aachs%26aulast%3DGourmelon%26aufirst%3DC.%26aulast%3DFrenel%26aufirst%3DJ.%2BS.%26aulast%3DCampone%26aufirst%3DM.%26atitle%3DEribulin%2520mesylate%2520for%2520the%2520treatment%2520of%2520late-stage%2520breast%2520cancer%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2011%26volume%3D12%26spage%3D2883%26epage%3D2890%26doi%3D10.1517%2F14656566.2011.637490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Preston, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trivedi, M. V.</span><span> </span><span class="NLM_article-title">Eribulin: a novel cytotoxic chemotherapy agent</span> <span class="citation_source-journal">Ann. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">802</span><span class="NLM_x">–</span> <span class="NLM_lpage">811</span><span class="refDoi"> DOI: 10.1345/aph.1Q636</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1345%2Faph.1Q636" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2012&pages=802-811&author=J.+N.+Prestonauthor=M.+V.+Trivedi&title=Eribulin%3A+a+novel+cytotoxic+chemotherapy+agent&doi=10.1345%2Faph.1Q636"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1345%2Faph.1Q636&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1345%252Faph.1Q636%26sid%3Dliteratum%253Aachs%26aulast%3DPreston%26aufirst%3DJ.%2BN.%26aulast%3DTrivedi%26aufirst%3DM.%2BV.%26atitle%3DEribulin%253A%2520a%2520novel%2520cytotoxic%2520chemotherapy%2520agent%26jtitle%3DAnn.%2520Pharmacother.%26date%3D2012%26volume%3D46%26spage%3D802%26epage%3D811%26doi%3D10.1345%2Faph.1Q636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montero, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glück, S.</span><span> </span><span class="NLM_article-title">Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span><span class="refDoi"> DOI: 10.1016/j.ctrv.2011.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.ctrv.2011.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=21550727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVaitLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2012&pages=143-151&author=J.+Cortesauthor=A.+J.+Monteroauthor=S.+Gl%C3%BCck&title=Eribulin+mesylate%2C+a+novel+microtubule+inhibitor+in+the+treatment+of+breast+cancer&doi=10.1016%2Fj.ctrv.2011.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer</span></div><div class="casAuthors">Cortes, Javier; Montero, Alberto J.; Glueck, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-151</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Background: Microtubule-targeted agents are one of the most common classes of chemotherapeutic drug for the treatment of breast cancer.  Limitations of current microtubule-targeted agents such as primary or secondary resistance of cancer cells and side effects like neuropathy prompted the discovery and introduction of newer more effective drugs.  This review aims to provide a summary of the novel halichondrin B analog eribulin mesylate (E7389) and illustrate where it is placed in the treatment arena vs. other agents that are approved or are currently in various stages of clin. development.  Methods: Preclin. and clin. trial (phases I-III) data for eribulin were obtained from scientific journals and meeting abstrs., posters, and oral presentations.  The use of current and other emerging microtubule inhibiting agents in breast cancer was also surveyed and briefly reviewed.  Results: Eribulin mesylate at a dose of 1.4 mg/m2 given on days 1 and 8 of a 21-day cycle increased overall survival in patients with metastatic breast cancer (MBC).  Neutropenia, fatigue, alopecia, nausea and anemia were common adverse events (AEs) assocd. with eribulin in clin. studies.  A low incidence of peripheral neuropathy was also assocd. with eribulin in clin. studies (21-26%).  Other emerging microtubule targeted agents, such as vinflunine and larotaxel, also reported efficacy in patients with MBC who had received prior chemotherapy, with grade 3/4 neutropenia being the most common AEs for both agents.  Conclusions: Eribulin mesylate offers clin. activity in advanced breast cancer through improved overall survival, its favorable side-effect profile and convenience of prepn. and administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5f0GUSxcP1rVg90H21EOLACvtfcHk0ljglHAzAd-Nkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVaitLc%253D&md5=3c5f83244f6b3fe79104d05503c9fce9</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2011.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2011.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DMontero%26aufirst%3DA.%2BJ.%26aulast%3DGl%25C3%25BCck%26aufirst%3DS.%26atitle%3DEribulin%2520mesylate%252C%2520a%2520novel%2520microtubule%2520inhibitor%2520in%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2012%26volume%3D38%26spage%3D143%26epage%3D151%26doi%3D10.1016%2Fj.ctrv.2011.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Brogdon, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canetta, R. M.</span><span> </span><span class="NLM_article-title">Development of other microtubule-stabilizer families: the epothilones and their derivatives</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">599</span><span class="NLM_x">–</span> <span class="NLM_lpage">609</span><span class="refDoi"> DOI: 10.1097/CAD.0000000000000071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1097%2FCAD.0000000000000071" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=599-609&author=C.+F.+Brogdonauthor=F.+Y.+Leeauthor=R.+M.+Canetta&title=Development+of+other+microtubule-stabilizer+families%3A+the+epothilones+and+their+derivatives&doi=10.1097%2FCAD.0000000000000071"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000071%26sid%3Dliteratum%253Aachs%26aulast%3DBrogdon%26aufirst%3DC.%2BF.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DCanetta%26aufirst%3DR.%2BM.%26atitle%3DDevelopment%2520of%2520other%2520microtubule-stabilizer%2520families%253A%2520the%2520epothilones%2520and%2520their%2520derivatives%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2014%26volume%3D25%26spage%3D599%26epage%3D609%26doi%3D10.1097%2FCAD.0000000000000071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Edelman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shvartsbeyn, M.</span><span> </span><span class="NLM_article-title">Epothilones in development for non-small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance</span> <span class="citation_source-journal">Clin. Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.1016/j.cllc.2011.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.cllc.2011.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=22133291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVSmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=171-180&author=M.+J.+Edelmanauthor=M.+Shvartsbeyn&title=Epothilones+in+development+for+non-small-cell+lung+cancer%3A+novel+anti-tubulin+agents+with+the+potential+to+overcome+taxane+resistance&doi=10.1016%2Fj.cllc.2011.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Epothilones in Development for Non-Small-Cell Lung Cancer: Novel Anti-Tubulin Agents With the Potential to Overcome Taxane Resistance</span></div><div class="casAuthors">Edelman, Martin J.; Shvartsbeyn, Marianna</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lung Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-180</span>CODEN:
                <span class="NLM_cas:coden">CLCLCA</span>;
        ISSN:<span class="NLM_cas:issn">1525-7304</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Progress in the treatment of non-small-cell lung cancer (NSCLC) will require the introduction of new agents as well as better use of existing therapies.  Targeted therapies are likely to have a profound effect on the treatment of NSCLC after identification of patients who are most likely to benefit.  The epothilones are novel anti-tubulin agents derived from Sorangium cellulosum. β III tubulin overexpression has been implicated as a mechanism of anti-tubulin resistance that can be overcome by epothilones.  Several epothilones have advanced to clin. trials; ixabepilone (BMS247550, aza-epothilone B, Bristol-Myers Squibb, New York, NY), patupilone (EPO906, Novartis, Basel, Switzerland) and sagopilone (ZK-EPO, ZK-219477, Schering AG, Berlin-Wedding, Germany) are currently in active development.  Several of the epothilones, most notably ixabepilone, have demonstrated activity in lung cancer in phase I and II trials, including taxane-resistant patients.  Although a phase II study failed to show superior outcome in patients with β III tubulin overexpression, other aspects of the epothilones argue for their continued development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOd1ey7FnY17Vg90H21EOLACvtfcHk0lj2IX9HRWwngw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVSmsrY%253D&md5=97e1a9c969690719ef30bfd0bd513a66</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.cllc.2011.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cllc.2011.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DEdelman%26aufirst%3DM.%2BJ.%26aulast%3DShvartsbeyn%26aufirst%3DM.%26atitle%3DEpothilones%2520in%2520development%2520for%2520non-small-cell%2520lung%2520cancer%253A%2520novel%2520anti-tubulin%2520agents%2520with%2520the%2520potential%2520to%2520overcome%2520taxane%2520resistance%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2012%26volume%3D13%26spage%3D171%26epage%3D180%26doi%3D10.1016%2Fj.cllc.2011.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Sadeghi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olevsky, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurvitz, S. A.</span><span> </span><span class="NLM_article-title">Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine</span> <span class="citation_source-journal">Pharmacogenomics Pers. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">338</span><span class="refDoi"> DOI: 10.2147/PGPM.S47524</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.2147%2FPGPM.S47524" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=25378946" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=329-338&author=S.+Sadeghiauthor=O.+Olevskyauthor=S.+A.+Hurvitz&title=Profiling+and+targeting+HER2-positive+breast+cancer+using+trastuzumab+emtansine&doi=10.2147%2FPGPM.S47524"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2147%2FPGPM.S47524&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FPGPM.S47524%26sid%3Dliteratum%253Aachs%26aulast%3DSadeghi%26aufirst%3DS.%26aulast%3DOlevsky%26aufirst%3DO.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26atitle%3DProfiling%2520and%2520targeting%2520HER2-positive%2520breast%2520cancer%2520using%2520trastuzumab%2520emtansine%26jtitle%3DPharmacogenomics%2520Pers.%2520Med.%26date%3D2014%26volume%3D7%26spage%3D329%26epage%3D338%26doi%3D10.2147%2FPGPM.S47524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Coen van Hasselt, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussein, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijnen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huitema, A. D. R.</span><span> </span><span class="NLM_article-title">Population pharmacokinetic–pharmacodynamic analysis for eribulin mesylate-associated neutropenia</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">412</span><span class="NLM_x">–</span> <span class="NLM_lpage">424</span><span class="refDoi"> DOI: 10.1111/bcp.12143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1111%2Fbcp.12143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=23601153" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2013&pages=412-424&author=J.+G.+Coen+van+Hasseltauthor=A.+Guptaauthor=Z.+Husseinauthor=J.+H.+Beijnenauthor=J.+H.+M.+Schellensauthor=A.+D.+R.+Huitema&title=Population+pharmacokinetic%E2%80%93pharmacodynamic+analysis+for+eribulin+mesylate-associated+neutropenia&doi=10.1111%2Fbcp.12143"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12143%26sid%3Dliteratum%253Aachs%26aulast%3DCoen%2Bvan%2BHasselt%26aufirst%3DJ.%2BG.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DHussein%26aufirst%3DZ.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DHuitema%26aufirst%3DA.%2BD.%2BR.%26atitle%3DPopulation%2520pharmacokinetic%25E2%2580%2593pharmacodynamic%2520analysis%2520for%2520eribulin%2520mesylate-associated%2520neutropenia%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D76%26spage%3D412%26epage%3D424%26doi%3D10.1111%2Fbcp.12143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Valero, V.</span><span> </span><span class="NLM_article-title">Managing ixabepilone adverse events with dose reduction</span> <span class="citation_source-journal">Clin. Breast Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1016/j.clbc.2012.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.clbc.2012.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=23098573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnslyquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1-6&author=V.+Valero&title=Managing+ixabepilone+adverse+events+with+dose+reduction&doi=10.1016%2Fj.clbc.2012.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Managing Ixabepilone Adverse Events With Dose Reduction</span></div><div class="casAuthors">Valero, Vicente</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Ixabepilone is a synthetic analog of epothilone B approved for the treatment of patients with metastatic or locally advanced breast cancer in combination with capecitabine for cancer resistant to an anthracycline and a taxane, and as monotherapy for cancer resistant or refractory to anthracyclines, taxanes, and capecitabine.  The principal dose-limiting adverse events (AEs) of ixabepilone's std. dose (40 mg/m2 administered by 3-h infusion once every 3 wk) are peripheral neuropathy, neutropenia, and fatigue.  An effective strategy to manage ixabepilone-related AEs is dose redn. by 20% (from 40 to 32 to 25 mg/m2); this does not appear to affect treatment efficacy and enables continuation of treatment after recovery (grade 1 or resolved).  When appropriate, treatment can be restarted with a 20% dose redn. (to 32 mg/m2).  For heavily pretreated patients, esp. those with a low performance status, 32 mg/m2 is an appropriate initial dose; the dose of capecitabine should also be lowered by 20%.  Weekly ixabepilone (15-20 mg/m2 on days 1, 8, and 15 every 28 days) may have an improved tolerability profile, but prospective studies with a large no. of patients are required to det. whether it has therapeutic benefit comparable with the current approved regimen.  More information is required on dosage and scheduling of ixabepilone in combination with other agents, including novel targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDnYGjenLYcbVg90H21EOLACvtfcHk0lj1OcO0vdGYPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnslyquw%253D%253D&md5=b0857bc68e040bcc7421d424d88ab217</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2012.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2012.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DValero%26aufirst%3DV.%26atitle%3DManaging%2520ixabepilone%2520adverse%2520events%2520with%2520dose%2520reduction%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D1%26epage%3D6%26doi%3D10.1016%2Fj.clbc.2012.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Ebenezer, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donovan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cobham, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cigler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramnarain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vahdat, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polydefkis, M.</span><span> </span><span class="NLM_article-title">Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients</span> <span class="citation_source-journal">Ann. Clin. Transl. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">639</span><span class="NLM_x">–</span> <span class="NLM_lpage">649</span><span class="refDoi"> DOI: 10.1002/acn3.90</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1002%2Facn3.90" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=25493278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yisLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2014&pages=639-649&author=G.+J.+Ebenezerauthor=K.+Carlsonauthor=D.+Donovanauthor=M.+Cobhamauthor=E.+Chuangauthor=A.+Mooreauthor=T.+Ciglerauthor=M.+Wardauthor=M.+E.+Laneauthor=A.+Ramnarainauthor=L.+T.+Vahdatauthor=M.+Polydefkis&title=Ixabepilone-induced+mitochondria+and+sensory+axon+loss+in+breast+cancer+patients&doi=10.1002%2Facn3.90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients</span></div><div class="casAuthors">Ebenezer, Gigi J.; Carlson, Karen; Donovan, Diana; Cobham, Marta; Chuang, Ellen; Moore, Anne; Cigler, Tessa; Ward, Maureen; Lane, Maureen E.; Ramnarain, Anita; Vahdat, Linda T.; Polydefkis, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Clinical and Translational Neurology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">639-649</span>CODEN:
                <span class="NLM_cas:coden">ACTNCG</span>;
        ISSN:<span class="NLM_cas:issn">2328-9503</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Background : We sought to define the clin. and ultrastructure effects of ixabepilone (Ix), a microtubule-stabilizing chemotherapy agent on cutaneous sensory nerves and to investigate a potential mitochondrial toxicity mechanism.  Methods : Ten breast cancer patients receiving Ix underwent total neuropathy score clin. (TNSc) assessment, distal leg skin biopsies at cycle (Cy) 3 (80-90 mg/m2), Cy5 (160-190 mg/m2), and Cy7 (>200 mg/m2) and were compared to 5 controls.  Skin blocks were processed for EM and ultrastructural morphometry of Remak axons done.  Results : At baseline, Ix-treated subjects had higher TNSc values (4.5 ± 0.8 vs. 0.0 ± 0.0), greater percentage of empty (denervated) Schwann cells (29% vs. 12%), altered axonal diam. (422.9 ± 17 vs. 354.9 ± 14.8 nm, P = 0.01), and axon profiles without mitochondria tended to increase compared to control subjects (71% vs. 70%).  With increasing cumulative Ix exposure, an increase in TNSc values (Cy3: 5.4 ± 1.2, Cy7: 10 ± 4, P < 0.001), empty Schwann cells (39% by Cy7), and dilated axons (in nm, Cy3: 506.3 ± 22.1, Cy5: 534.8 ± 33, Cy7: 527.8 ± 24.4; P < 0.001) was obsd.  In addn., axon profiles without mitochondria (Cy3:74%, Cy7:78%) and mitochondria with abnormal morphol. (grade 3 or 4) increased from 24% to 79%.  Schwann cells with atypical mitochondria and perineuronal macrophage infiltration in dermis were noted.  Interpretation : This study provides functional and structural evidence that Ix exposure induces a dose-dependent toxicity on small sensory fibers with an increase in TNSc scores and progressive axonal loss.  Mitochondria appear to bear the cumulative toxic effect and chemotherapy-induced toxicity can be monitored through serial skin biopsy-based anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx6GF4qIrHyrVg90H21EOLACvtfcHk0lj1OcO0vdGYPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yisLzL&md5=ed2873b30eb7638c3a8d62479b4815ff</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Facn3.90&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Facn3.90%26sid%3Dliteratum%253Aachs%26aulast%3DEbenezer%26aufirst%3DG.%2BJ.%26aulast%3DCarlson%26aufirst%3DK.%26aulast%3DDonovan%26aufirst%3DD.%26aulast%3DCobham%26aufirst%3DM.%26aulast%3DChuang%26aufirst%3DE.%26aulast%3DMoore%26aufirst%3DA.%26aulast%3DCigler%26aufirst%3DT.%26aulast%3DWard%26aufirst%3DM.%26aulast%3DLane%26aufirst%3DM.%2BE.%26aulast%3DRamnarain%26aufirst%3DA.%26aulast%3DVahdat%26aufirst%3DL.%2BT.%26aulast%3DPolydefkis%26aufirst%3DM.%26atitle%3DIxabepilone-induced%2520mitochondria%2520and%2520sensory%2520axon%2520loss%2520in%2520breast%2520cancer%2520patients%26jtitle%3DAnn.%2520Clin.%2520Transl.%2520Neurol.%26date%3D2014%26volume%3D1%26spage%3D639%26epage%3D649%26doi%3D10.1002%2Facn3.90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Vahdat, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellegrino, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindquist, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iannotti, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopalakrishna, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sparano, J. A.</span><span> </span><span class="NLM_article-title">Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized phase II study comparing the incidence of peripheral neuropathy</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">140</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">351</span><span class="refDoi"> DOI: 10.1007/s10549-013-2574-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1007%2Fs10549-013-2574-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=23877339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOktrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2013&pages=341-351&author=L.+T.+Vahdatauthor=A.+A.+Garciaauthor=C.+Vogelauthor=C.+Pellegrinoauthor=D.+L.+Lindquistauthor=N.+Iannottiauthor=P.+Gopalakrishnaauthor=J.+A.+Sparano&title=Eribulin+mesylate+versus+ixabepilone+in+patients+with+metastatic+breast+cancer%3A+a+randomized+phase+II+study+comparing+the+incidence+of+peripheral+neuropathy&doi=10.1007%2Fs10549-013-2574-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy</span></div><div class="casAuthors">Vahdat, Linda T.; Garcia, Agustin A.; Vogel, Charles; Pellegrino, Christine; Lindquist, Deborah L.; Iannotti, Nicholas; Gopalakrishna, Prashanth; Sparano, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">341-351</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Peripheral neuropathy is a common toxicity assocd. with tubulin-targeted chemotherapeutic agents.  This Phase II study compares the incidence and severity of neuropathy assocd. with eribulin mesylate or ixabepilone in metastatic breast cancer (MBC).  The primary objective was to assess the incidence of neuropathy; the study was designed to detect a difference in neuropathy rate of 35 % for eribulin vs. 63 % for ixabepilone (odds ratio 0.316, 80 % power, 0.05 two-sided significance level).  Eligibility criteria included: MBC; prior taxane therapy; at least one chemotherapy for advanced disease; no or minimal pre-existing neuropathy (Grade 0 or 1).  The intent-to-treat population comprised 104 patients randomized (1:1) to eribulin mesylate (1.4 mg/m2, 2-5 min i.v. on days 1 and 8) or ixabepilone (40 mg/m2, 3 h i.v. on day 1) on a 21-day cycle. 101 patients in the safety population received a median of 5.0 eribulin and 3.5 ixabepilone cycles.  Incidence of neuropathy (any grade) was 33.3 and 48.0 %, and peripheral neuropathy was 31.4 and 44.0 % for eribulin and ixabepilone, resp.  After controlling for pre-existing neuropathy and no. of prior chemotherapies, these differences were not significant.  Compared with ixabepilone, fewer patients receiving eribulin discontinued treatment due to neuropathy (3.9 vs. 18.0 %) or adverse events (AEs) in general (11.8 vs. 32.0 %).  Time to onset of neuropathy was 35.9 wk for eribulin and 11.6 wk for ixabepilone, and time to resoln. was 48 vs. 10 wk, resp.; other AEs were comparable.  Objective responses were 15.4 vs. 5.8 % and clin. benefit rates were 26.9 vs. 19.2 %.  In conclusion, after controlling for pre-existing neuropathy and no. of prior chemotherapies, the differences in the incidence of neuropathy with eribulin and ixabepilone were not statistically significant.  Onset of neuropathy tended to occur later with eribulin and resolve later.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP_yjKO0ZQ0bVg90H21EOLACvtfcHk0lj1OcO0vdGYPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOktrzP&md5=2a4b931926deb65e362b92e54a08be0f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1007%2Fs10549-013-2574-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-013-2574-2%26sid%3Dliteratum%253Aachs%26aulast%3DVahdat%26aufirst%3DL.%2BT.%26aulast%3DGarcia%26aufirst%3DA.%2BA.%26aulast%3DVogel%26aufirst%3DC.%26aulast%3DPellegrino%26aufirst%3DC.%26aulast%3DLindquist%26aufirst%3DD.%2BL.%26aulast%3DIannotti%26aufirst%3DN.%26aulast%3DGopalakrishna%26aufirst%3DP.%26aulast%3DSparano%26aufirst%3DJ.%2BA.%26atitle%3DEribulin%2520mesylate%2520versus%2520ixabepilone%2520in%2520patients%2520with%2520metastatic%2520breast%2520cancer%253A%2520a%2520randomized%2520phase%2520II%2520study%2520comparing%2520the%2520incidence%2520of%2520peripheral%2520neuropathy%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2013%26volume%3D140%26spage%3D341%26epage%3D351%26doi%3D10.1007%2Fs10549-013-2574-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Wozniak, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomoto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapidus, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carozzi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavaletti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayakawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosokawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Towle, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littlefield, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slusher, B. S.</span><span> </span><span class="NLM_article-title">Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel and ixabepilone in mice</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">3952</span><span class="NLM_x">–</span> <span class="NLM_lpage">3962</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-4184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1158%2F0008-5472.CAN-10-4184" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=3952-3962&author=K.+M.+Wozniakauthor=K.+Nomotoauthor=R.+G.+Lapidusauthor=Y.+Wuauthor=V.+Carozziauthor=G.+Cavalettiauthor=K.+Hayakawaauthor=S.+Hosokawaauthor=M.+J.+Towleauthor=B.+A.+Littlefieldauthor=B.+S.+Slusher&title=Comparison+of+neuropathy-inducing+effects+of+eribulin+mesylate%2C+paclitaxel+and+ixabepilone+in+mice&doi=10.1158%2F0008-5472.CAN-10-4184"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4184%26sid%3Dliteratum%253Aachs%26aulast%3DWozniak%26aufirst%3DK.%2BM.%26aulast%3DNomoto%26aufirst%3DK.%26aulast%3DLapidus%26aufirst%3DR.%2BG.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DCarozzi%26aufirst%3DV.%26aulast%3DCavaletti%26aufirst%3DG.%26aulast%3DHayakawa%26aufirst%3DK.%26aulast%3DHosokawa%26aufirst%3DS.%26aulast%3DTowle%26aufirst%3DM.%2BJ.%26aulast%3DLittlefield%26aufirst%3DB.%2BA.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26atitle%3DComparison%2520of%2520neuropathy-inducing%2520effects%2520of%2520eribulin%2520mesylate%252C%2520paclitaxel%2520and%2520ixabepilone%2520in%2520mice%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D3952%26epage%3D3962%26doi%3D10.1158%2F0008-5472.CAN-10-4184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">LaPointe, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morfini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brady, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feinstein, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, M. A.</span><span> </span><span class="NLM_article-title">Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy</span> <span class="citation_source-journal">NeuroToxicology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="NLM_x">–</span> <span class="NLM_lpage">239</span><span class="refDoi"> DOI: 10.1016/j.neuro.2013.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.neuro.2013.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=23711742" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSmurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2013&pages=231-239&author=N.+E.+LaPointeauthor=G.+Morfiniauthor=S.+T.+Bradyauthor=S.+C.+Feinsteinauthor=L.+Wilsonauthor=M.+A.+Jordan&title=Effects+of+eribulin%2C+vincristine%2C+paclitaxel+and+ixabepilone+on+fast+axonal+transport+and+kinesin-1+driven+microtubule+gliding%3A+implications+for+chemotherapy-induced+peripheral+neuropathy&doi=10.1016%2Fj.neuro.2013.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: Implications for chemotherapy-induced peripheral neuropathy</span></div><div class="casAuthors">LaPointe, Nichole E.; Morfini, Gerardo; Brady, Scott T.; Feinstein, Stuart C.; Wilson, Leslie; Jordan, Mary Ann</div><div class="citationInfo"><span class="NLM_cas:title">NeuroToxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">231-239</span>CODEN:
                <span class="NLM_cas:coden">NRTXDN</span>;
        ISSN:<span class="NLM_cas:issn">0161-813X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Chemotherapy-induced peripheral neuropathy (CIPN) is a serious, painful and dose-limiting side effect of cancer drugs that target microtubules.  The mechanisms underlying the neuronal damage are unknown, but may include disruption of fast axonal transport, an essential microtubule-based process that moves cellular components over long distances between neuronal cell bodies and nerve terminals.  This idea is supported by the "dying back" pattern of degeneration obsd. in CIPN, and by the selective vulnerability of sensory neurons bearing the longest axonal projections.  In this study, we test the hypothesis that microtubule-targeting drugs disrupt fast axonal transport using vesicle motility assays in isolated squid axoplasm and a cell-free microtubule gliding assay with defined components.  We compare four clin.-used drugs, eribulin, vincristine, paclitaxel and ixabepilone.  Of these, eribulin is assocd. with a relatively low incidence of severe neuropathy, while vincristine has a relatively high incidence.  In vesicle motility assays, we found that all four drugs inhibited anterograde (conventional kinesin-dependent) fast axonal transport, with the potency being vincristine = ixabepilone > paclitaxel = eribulin.  Interestingly, eribulin and paclitaxel did not inhibit retrograde (cytoplasmic dynein-dependent) fast axonal transport, in contrast to vincristine and ixabepilone.  Similarly, vincristine and ixabepilone both exerted significant inhibitory effects in an in vitro microtubule gliding assay consisting of recombinant kinesin (kinesin-1) and microtubules composed of purified bovine brain tubulin, whereas paclitaxel and eribulin had negligible effects.  Our results suggest that (i) inhibition of microtubule-based fast axonal transport may be a significant contributor to neurotoxicity induced by microtubule-targeting drugs, and (ii) that individual microtubule-targeting drugs affect fast axonal transport through different mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxrFqowG6Y2rVg90H21EOLACvtfcHk0liwvS7QVNbjeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSmurvI&md5=afe584faafb51bd439dfc89cf9e9ccc7</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.neuro.2013.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuro.2013.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DLaPointe%26aufirst%3DN.%2BE.%26aulast%3DMorfini%26aufirst%3DG.%26aulast%3DBrady%26aufirst%3DS.%2BT.%26aulast%3DFeinstein%26aufirst%3DS.%2BC.%26aulast%3DWilson%26aufirst%3DL.%26aulast%3DJordan%26aufirst%3DM.%2BA.%26atitle%3DEffects%2520of%2520eribulin%252C%2520vincristine%252C%2520paclitaxel%2520and%2520ixabepilone%2520on%2520fast%2520axonal%2520transport%2520and%2520kinesin-1%2520driven%2520microtubule%2520gliding%253A%2520implications%2520for%2520chemotherapy-induced%2520peripheral%2520neuropathy%26jtitle%3DNeuroToxicology%26date%3D2013%26volume%3D37%26spage%3D231%26epage%3D239%26doi%3D10.1016%2Fj.neuro.2013.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Polastro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aftimos, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awada, A.</span><span> </span><span class="NLM_article-title">Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">649</span><span class="NLM_x">–</span> <span class="NLM_lpage">665</span><span class="refDoi"> DOI: 10.1586/14737140.2014.920693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1586%2F14737140.2014.920693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=24852360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVWitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=649-665&author=L.+Polastroauthor=P.+G.+Aftimosauthor=A.+Awada&title=Eribulin+mesylate+in+the+management+of+metastatic+breast+cancer+and+other+solid+cancers%3A+a+drug+review&doi=10.1586%2F14737140.2014.920693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: a drug review</span></div><div class="casAuthors">Polastro, Laura; Aftimos, Philippe G.; Awada, Ahmad</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">649-665</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  In the new era of 'precision' cancer medicine, new drug development has shifted from cytotoxic chemotherapy to molecularly targeted agents.  Eribulin mesylate, a microtubule-destabilizing agent, is the only 'classical' cytotoxic agent approved for the treatment of breast cancer in the last 7 years.  This synthetic analog of halichondrin B, isolated from the marine sponge 'Halicondria Okaida', was responsible for prolonging overall survival of heavily pretreated metastatic breast cancer patients in a large Phase III trial.  Eribulin is now under clin. development in earlier settings such as the neo-adjuvant and adjuvant settings.  Furthermore, its unique mechanism of action and the absence of cross-resistance with taxanes have led to the design of clin. trials in multiple indications: bladder cancer, lung cancer, prostate cancer...  The main adverse events are neutropenia, fatigue and peripheral neuropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEFzLnmwuRM7Vg90H21EOLACvtfcHk0liwvS7QVNbjeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVWitLk%253D&md5=65618013db9faa8001320d9e58016224</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1586%2F14737140.2014.920693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.2014.920693%26sid%3Dliteratum%253Aachs%26aulast%3DPolastro%26aufirst%3DL.%26aulast%3DAftimos%26aufirst%3DP.%2BG.%26aulast%3DAwada%26aufirst%3DA.%26atitle%3DEribulin%2520mesylate%2520in%2520the%2520management%2520of%2520metastatic%2520breast%2520cancer%2520and%2520other%2520solid%2520cancers%253A%2520a%2520drug%2520review%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2014%26volume%3D14%26spage%3D649%26epage%3D665%26doi%3D10.1586%2F14737140.2014.920693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Laughney, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprachman, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohler, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orth, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchison, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissleder, R.</span><span> </span><span class="NLM_article-title">Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">261ra152</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3009318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1126%2Fscitranslmed.3009318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=25378644" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=261ra152&author=A.+M.+Laughneyauthor=E.+Kimauthor=M.+M.+Sprachmanauthor=M.+A.+Millerauthor=R.+H.+Kohlerauthor=K.+S.+Yangauthor=J.+D.+Orthauthor=T.+J.+Mitchisonauthor=R.+Weissleder&title=Single-cell+pharmacokinetic+imaging+reveals+a+therapeutic+strategy+to+overcome+drug+resistance+to+the+microtubule+inhibitor+eribulin&doi=10.1126%2Fscitranslmed.3009318"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3009318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3009318%26sid%3Dliteratum%253Aachs%26aulast%3DLaughney%26aufirst%3DA.%2BM.%26aulast%3DKim%26aufirst%3DE.%26aulast%3DSprachman%26aufirst%3DM.%2BM.%26aulast%3DMiller%26aufirst%3DM.%2BA.%26aulast%3DKohler%26aufirst%3DR.%2BH.%26aulast%3DYang%26aufirst%3DK.%2BS.%26aulast%3DOrth%26aufirst%3DJ.%2BD.%26aulast%3DMitchison%26aufirst%3DT.%2BJ.%26aulast%3DWeissleder%26aufirst%3DR.%26atitle%3DSingle-cell%2520pharmacokinetic%2520imaging%2520reveals%2520a%2520therapeutic%2520strategy%2520to%2520overcome%2520drug%2520resistance%2520to%2520the%2520microtubule%2520inhibitor%2520eribulin%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2014%26volume%3D6%26spage%3D261ra152%26doi%3D10.1126%2Fscitranslmed.3009318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. D.</span><span> </span><span class="NLM_article-title">An overview of tubulin inhibitors that interact with the colchicine binding site</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">2943</span><span class="NLM_x">–</span> <span class="NLM_lpage">2971</span><span class="refDoi"> DOI: 10.1007/s11095-012-0828-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1007%2Fs11095-012-0828-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=22814904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVOis7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=2943-2971&author=Y.+Luauthor=J.+Chenauthor=M.+Xiaoauthor=W.+Liauthor=D.+D.+Miller&title=An+overview+of+tubulin+inhibitors+that+interact+with+the+colchicine+binding+site&doi=10.1007%2Fs11095-012-0828-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site</span></div><div class="casAuthors">Lu, Yan; Chen, Jianjun; Xiao, Min; Li, Wei; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2943-2971</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Tubulin dynamics is a promising target for new chemotherapeutic agents.  The colchicine binding site is one of the most important pockets for potential tubulin polymn. destabilizers.  Colchicine binding site inhibitors (CBSI) exert their biol. effects by inhibiting tubulin assembly and suppressing microtubule formation.  A large no. of mols. interacting with the colchicine binding site have been designed and synthesized with significant structural diversity.  CBSIs have been modified as to chem. structure as well as pharmacokinetic properties, and tested in order to find a highly potent, low toxicity agent for treatment of cancers.  CBSIs are believed to act by a common mechanism via binding to the colchicine site on tubulin.  The present review is a synopsis of compds. that have been reported in the past decade that have provided an increase in our understanding of the actions of CBSIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFrFQVgeCbBbVg90H21EOLACvtfcHk0lig7Gjt70WAtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVOis7vN&md5=dfe42e8eb1f0ff22b256641aaa8c17ab</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs11095-012-0828-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-012-0828-z%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DAn%2520overview%2520of%2520tubulin%2520inhibitors%2520that%2520interact%2520with%2520the%2520colchicine%2520binding%2520site%26jtitle%3DPharm.%2520Res.%26date%3D2012%26volume%3D29%26spage%3D2943%26epage%3D2971%26doi%3D10.1007%2Fs11095-012-0828-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Patil, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. D.</span><span> </span><span class="NLM_article-title">Indole molecules as inhibitors of tubulin polymerization: potential new anticancer agents</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">2085</span><span class="NLM_x">–</span> <span class="NLM_lpage">2115</span><span class="refDoi"> DOI: 10.4155/fmc.12.141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.4155%2Ffmc.12.141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=23157240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1ynsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=2085-2115&author=S.+A.+Patilauthor=R.+Patilauthor=D.+D.+Miller&title=Indole+molecules+as+inhibitors+of+tubulin+polymerization%3A+potential+new+anticancer+agents&doi=10.4155%2Ffmc.12.141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Indole molecules as inhibitors of tubulin polymerization: potential new anticancer agents</span></div><div class="casAuthors">Patil, Shivaputra A.; Patil, Renukadevi; Miller, Duane D.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2085-2115</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Agents that interfere with tubulin function have a broad anti-tumor spectrum and they represent one of the most significant classes of anticancer agents.  In the past few years, several small synthetic mols. that have an indole nucleus as a core structure have been identified as tubulin inhibitors.  Among these, several aroylindoles, arylthioindoles, diarylindoles and indolylglyoxyamides have shown good inhibition towards the tubulin polymn.  This article reviews the synthesis, biol. activities and SARs of these main classes of indoles.  Brief mention has also been made about the fused indole analogs as tubulin inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-6yFCbyEmnrVg90H21EOLACvtfcHk0lig7Gjt70WAtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1ynsbjP&md5=341d510a2a4fe59892af97fe3d40fbb7</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.141%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DS.%2BA.%26aulast%3DPatil%26aufirst%3DR.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26atitle%3DIndole%2520molecules%2520as%2520inhibitors%2520of%2520tubulin%2520polymerization%253A%2520potential%2520new%2520anticancer%2520agents%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D2085%26epage%3D2115%26doi%3D10.4155%2Ffmc.12.141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Kaur, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bariwal, J.</span><span> </span><span class="NLM_article-title">Recent developments in tubulin polymerization inhibitors: an overview</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.09.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.ejmech.2014.09.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=25240869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFOltbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2014&pages=89-124&author=R.+Kaurauthor=G.+Kaurauthor=R.+K.+Gillauthor=R.+Soniauthor=J.+Bariwal&title=Recent+developments+in+tubulin+polymerization+inhibitors%3A+an+overview&doi=10.1016%2Fj.ejmech.2014.09.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in tubulin polymerization inhibitors: An overview</span></div><div class="casAuthors">Kaur, Ramandeep; Kaur, Gurneet; Gill, Rupinder Kaur; Soni, Richard; Bariwal, Jitender</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-124</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Microtubules are protein biopolymers formed through polymn. of heterodimers of α- and β-tubulins.  Disruption of microtubules can induce cell cycle arrest in G2-M phase and formation of abnormal mitotic spindles.  Their importance in mitosis and cell division makes microtubules an attractive target for anticancer drug discovery.  A no. of naturally occurring compds. such as paclitaxel, epothilones, vinblastine, combretastatin, and colchicines exert their effect by changing dynamics of tubulin such as polymn. and depolymn.  During past few years, rapid development of the novel tubulin polymn. inhibitors has been witnessed.  Diverse classes of chem. compds. from the natural as well as from the synthetic origin have been extensively studied.  This review highlights the various classes of synthetically derived chem. compds. those have been reported in last few years as potential tubulin polymn. inhibitors.  A brief synthetic methodol. to access these compds. has been highlighted along with the brief SAR studies.  We strongly believe that this review will provide a platform to the synthetic chemists and biologists to design and synthesize new and potent compds. to inhibit the tubulin polymn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV6nQysY8nvbVg90H21EOLACvtfcHk0lig7Gjt70WAtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFOltbzE&md5=2ffd2f9bb073a7830f4aae7c29f070d9</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.09.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.09.051%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DR.%26aulast%3DKaur%26aufirst%3DG.%26aulast%3DGill%26aufirst%3DR.%2BK.%26aulast%3DSoni%26aufirst%3DR.%26aulast%3DBariwal%26aufirst%3DJ.%26atitle%3DRecent%2520developments%2520in%2520tubulin%2520polymerization%2520inhibitors%253A%2520an%2520overview%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D87%26spage%3D89%26epage%3D124%26doi%3D10.1016%2Fj.ejmech.2014.09.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Liu, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, J.-P.</span><span> </span><span class="NLM_article-title">Tubulin inhibitors: a patent review</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">69</span><span class="NLM_x">–</span> <span class="NLM_lpage">88</span><span class="refDoi"> DOI: 10.1517/13543776.2014.859247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1517%2F13543776.2014.859247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=24313741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFSlurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=69-88&author=Y.-M.+Liuauthor=H.-L.+Chenauthor=H.-Y.+Leeauthor=J.-P.+Liou&title=Tubulin+inhibitors%3A+a+patent+review&doi=10.1517%2F13543776.2014.859247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Tubulin inhibitors: a patent review</span></div><div class="casAuthors">Liu, Yi-Min; Chen, Hsiao-Ling; Lee, Hsueh-Yun; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-88</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Microtubules play an important role in several cellular processes, particularly in the formation of the mitotic spindle during the process of mitosis.  These highly dynamic mitotic-spindle microtubules have become a successful target of cancer therapy.  Microtubule-targeting agents, such as vinca alkaloids and taxanes, were used in clinic over 50 years.  In past decades, development of new antimicrotubule agents that possess different structure and binding sites of tubulin has shown potent activity against the proliferation of various cancer cells, as well as in multidrug-resistant cancers.  Interestingly, many of these agents represent an attractive ability that targeting the tumor blood vessels results in tumor vascular disruption.  Therefore, exploring new agents and strategies may provide more effective therapeutic options in the related treatment of cancer.  Areas covered: In past few years, there are many chem. compds. that successfully interferes the microtubules and display antitumor effect.  In these, published compds. supply the fresh minds in modification of present drugs and new insights into the development of tubulin inhibitors.  Expert opinion: This article arranges the microtubule-targeting agents that have published in patent in recent years.  It may help in the investigation of new tubulin binding site and development of novel drug candidate in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtnvpvVK8NmrVg90H21EOLACvtfcHk0lig7Gjt70WAtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFSlurvP&md5=e17a15b0f0538911f2a80035edbf89b7</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.859247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.859247%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.-M.%26aulast%3DChen%26aufirst%3DH.-L.%26aulast%3DLee%26aufirst%3DH.-Y.%26aulast%3DLiou%26aufirst%3DJ.-P.%26atitle%3DTubulin%2520inhibitors%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26spage%3D69%26epage%3D88%26doi%3D10.1517%2F13543776.2014.859247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Wienecke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bacher, G.</span><span> </span><span class="NLM_article-title">Indibulin, a novel microtubule inhibitor, discriminates between mature neuronal and nonneuronal tubulin</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">177</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-1342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1158%2F0008-5472.CAN-08-1342" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=171-177&author=A.+Wieneckeauthor=G.+Bacher&title=Indibulin%2C+a+novel+microtubule+inhibitor%2C+discriminates+between+mature+neuronal+and+nonneuronal+tubulin&doi=10.1158%2F0008-5472.CAN-08-1342"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1342%26sid%3Dliteratum%253Aachs%26aulast%3DWienecke%26aufirst%3DA.%26aulast%3DBacher%26aufirst%3DG.%26atitle%3DIndibulin%252C%2520a%2520novel%2520microtubule%2520inhibitor%252C%2520discriminates%2520between%2520mature%2520neuronal%2520and%2520nonneuronal%2520tubulin%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D171%26epage%3D177%26doi%3D10.1158%2F0008-5472.CAN-08-1342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Desai, A.; Ratain, M. J.; Moshier, K.; Tipton, M.; Dooley, W.; Hocknell, K.; Dahl, T.; Sherman, M.; Limentani, S.</span><span> </span><span class="NLM_article-title">A phase I, dose-escalation trial of STA-5312, a microtubule inhibitor with a novel binding site, in advanced or metastatic solid malignancies</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">13040</span>, <div class="note"><p class="first last">2006 ASCO Annual Meeting Proceedings Part I</p></div>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=13040&author=A.+Desai&author=M.+J.+Ratain&author=K.+Moshier&author=M.+Tipton&author=W.+Dooley&author=K.+Hocknell&author=T.+Dahl&author=M.+Sherman&author=S.+Limentani&title=A+phase+I%2C+dose-escalation+trial+of+STA-5312%2C+a+microtubule+inhibitor+with+a+novel+binding+site%2C+in+advanced+or+metastatic+solid+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDesai%26aufirst%3DA.%26atitle%3DA%2520phase%2520I%252C%2520dose-escalation%2520trial%2520of%2520STA-5312%252C%2520a%2520microtubule%2520inhibitor%2520with%2520a%2520novel%2520binding%2520site%252C%2520in%2520advanced%2520or%2520metastatic%2520solid%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D13040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42a"><span><span class="NLM_label">(a) </span><span> </span><span class="NLM_article-title">STA-5312 administered on alternate weekdays every two weeks to patients with hematologic malignancies and patients with solid tumors, NCT00088101</span>. <a href="http://www.clinicaltrials.gov" class="extLink">www.clinicaltrials.gov</a> (accessed December 30, 2014).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+STA-5312+administered+on+alternate+weekdays+every+two+weeks+to+patients+with+hematologic+malignancies+and+patients+with+solid+tumors%2C+NCT00088101.+www.clinicaltrials.gov+%28accessed+December+30%2C+2014%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DSTA-5312%2520administered%2520on%2520alternate%2520weekdays%2520every%2520two%2520weeks%2520to%2520patients%2520with%2520hematologic%2520malignancies%2520and%2520patients%2520with%2520solid%2520tumors%252C%2520NCT00088101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit42b"><span><span class="NLM_label">(b) </span><span> </span><span class="NLM_article-title">A phase I study of STA-5312 in subjects with advanced or metastatic solid tumors, NCT00276913</span>. <a href="http://www.clinicaltrials.gov" class="extLink">www.clinicaltrials.gov</a> (accessed December 30, 2014).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+A+phase+I+study+of+STA-5312+in+subjects+with+advanced+or+metastatic+solid+tumors%2C+NCT00276913.+www.clinicaltrials.gov+%28accessed+December+30%2C+2014%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DA%2520phase%2520I%2520study%2520of%2520STA-5312%2520in%2520subjects%2520with%2520advanced%2520or%2520metastatic%2520solid%2520tumors%252C%2520NCT00276913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Bacher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emig, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanhoefer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shandra, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klenner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckers, T.</span><span> </span><span class="NLM_article-title">D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">392</span><span class="NLM_x">–</span> <span class="NLM_lpage">399</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=392-399&author=G.+Bacherauthor=B.+Nickelauthor=P.+Emigauthor=U.+Vanhoeferauthor=S.+Seeberauthor=A.+Shandraauthor=T.+Klennerauthor=T.+Beckers&title=D-24851%2C+a+novel+synthetic+microtubule+inhibitor%2C+exerts+curative+antitumoral+activity+in+vivo%2C+shows+efficacy+toward+multidrug-resistant+tumor+cells%2C+and+lacks+neurotoxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBacher%26aufirst%3DG.%26aulast%3DNickel%26aufirst%3DB.%26aulast%3DEmig%26aufirst%3DP.%26aulast%3DVanhoefer%26aufirst%3DU.%26aulast%3DSeeber%26aufirst%3DS.%26aulast%3DShandra%26aufirst%3DA.%26aulast%3DKlenner%26aufirst%3DT.%26aulast%3DBeckers%26aufirst%3DT.%26atitle%3DD-24851%252C%2520a%2520novel%2520synthetic%2520microtubule%2520inhibitor%252C%2520exerts%2520curative%2520antitumoral%2520activity%2520in%2520vivo%252C%2520shows%2520efficacy%2520toward%2520multidrug-resistant%2520tumor%2520cells%252C%2520and%2520lacks%2520neurotoxicity%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D392%26epage%3D399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Kuppens, I. E. L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witteveen, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuessler, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daehling, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijnen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voest, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H. M.</span><span> </span><span class="NLM_article-title">Phase I dose-finding and pharmacokinetic trial of orally administered Indibulin (D-24851) to patients with solid tumors</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">235</span><span class="refDoi"> DOI: 10.1007/s10637-006-9027-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1007%2Fs10637-006-9027-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=227-235&author=I.+E.+L.+M.+Kuppensauthor=P.+O.+Witteveenauthor=M.+Schotauthor=V.+M.+Schuesslerauthor=A.+Daehlingauthor=J.+H.+Beijnenauthor=E.+E.+Voestauthor=J.+H.+M.+Schellens&title=Phase+I+dose-finding+and+pharmacokinetic+trial+of+orally+administered+Indibulin+%28D-24851%29+to+patients+with+solid+tumors&doi=10.1007%2Fs10637-006-9027-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs10637-006-9027-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-006-9027-2%26sid%3Dliteratum%253Aachs%26aulast%3DKuppens%26aufirst%3DI.%2BE.%2BL.%2BM.%26aulast%3DWitteveen%26aufirst%3DP.%2BO.%26aulast%3DSchot%26aufirst%3DM.%26aulast%3DSchuessler%26aufirst%3DV.%2BM.%26aulast%3DDaehling%26aufirst%3DA.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DVoest%26aufirst%3DE.%2BE.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DPhase%2520I%2520dose-finding%2520and%2520pharmacokinetic%2520trial%2520of%2520orally%2520administered%2520Indibulin%2520%2528D-24851%2529%2520to%2520patients%2520with%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2007%26volume%3D25%26spage%3D227%26epage%3D235%26doi%3D10.1007%2Fs10637-006-9027-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Oostendorp, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witteveen, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vainchtein, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nol, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosing, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijnen, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voest, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H. M.</span><span> </span><span class="NLM_article-title">Dose-finding and pharmacokinetic study of orally administered Indibulin (D-24851) to patients with advanced solid tumors</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">–</span> <span class="NLM_lpage">170</span><span class="refDoi"> DOI: 10.1007/s10637-009-9244-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1007%2Fs10637-009-9244-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=163-170&author=R.+L.+Oostendorpauthor=P.+O.+Witteveenauthor=B.+Schwartzauthor=L.+D.+Vainchteinauthor=M.+Schotauthor=A.+Nolauthor=H.+Rosingauthor=B.+H.+Beijnenauthor=E.+E.+Voestauthor=J.+H.+M.+Schellens&title=Dose-finding+and+pharmacokinetic+study+of+orally+administered+Indibulin+%28D-24851%29+to+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-009-9244-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1007%2Fs10637-009-9244-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-009-9244-6%26sid%3Dliteratum%253Aachs%26aulast%3DOostendorp%26aufirst%3DR.%2BL.%26aulast%3DWitteveen%26aufirst%3DP.%2BO.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DVainchtein%26aufirst%3DL.%2BD.%26aulast%3DSchot%26aufirst%3DM.%26aulast%3DNol%26aufirst%3DA.%26aulast%3DRosing%26aufirst%3DH.%26aulast%3DBeijnen%26aufirst%3DB.%2BH.%26aulast%3DVoest%26aufirst%3DE.%2BE.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DDose-finding%2520and%2520pharmacokinetic%2520study%2520of%2520orally%2520administered%2520Indibulin%2520%2528D-24851%2529%2520to%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2010%26volume%3D28%26spage%3D163%26epage%3D170%26doi%3D10.1007%2Fs10637-009-9244-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Semenova, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiselyov, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Titov, I. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raihstat, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molodtsov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grishchuk, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spiridonov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Semenov, V. V.</span><span> </span><span class="NLM_article-title"><i>In vivo</i> evaluation of indolyl glyoxylamides in the phenotypic sea urchin embryo assay</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">–</span> <span class="NLM_lpage">490</span><span class="refDoi"> DOI: 10.1111/j.1747-0285.2007.00591.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1111%2Fj.1747-0285.2007.00591.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=17991295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=485-490&author=M.+N.+Semenovaauthor=A.+S.+Kiselyovauthor=I.+Y.+Titovauthor=M.+M.+Raihstatauthor=M.+Molodtsovauthor=E.+Grishchukauthor=I.+Spiridonovauthor=V.+V.+Semenov&title=In+vivo+evaluation+of+indolyl+glyoxylamides+in+the+phenotypic+sea+urchin+embryo+assay&doi=10.1111%2Fj.1747-0285.2007.00591.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo evaluation of indolyl glyoxamides in the phenotypic sea urchin embryo assay</span></div><div class="casAuthors">Semenova, Marina N.; Kiselyov, Alex S.; Titov, Ilia Y.; Raihstat, Mikhail M.; Molodtsov, Maxim; Grishchuk, Ekaterina; Spiridonov, Ilia; Semenov, Victor V.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">485-490</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The authors have devised a 'one-pot' phenotypic in vivo assay for the rapid evaluation of potential tubulin inhibitors using the sea urchin embryo model.  An effect of a small mol. on two specific developmental stages of sea urchin embryo, namely: (i) fertilized egg test for antimitotic activity and (ii) behavioral monitoring of a free-swimming blastulae for changes in the embryo swimming pattern could be quantified by a threshold concn. resulting in resp. abnormalities.  Derivs. of the clin. candidate D-24851 featured good correlation between activity in tubulin polymn. assay and the in vivo data.  Importantly, the authors demonstrated that in these series, the N-substitution of indole is nonessential to attain profound in vitro and cellular effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhFSq68fWM97Vg90H21EOLACvtfcHk0lhU8AotCsbqWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGhsb3F&md5=ab32c91067df926c7943b1c221f94d2c</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00591.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00591.x%26sid%3Dliteratum%253Aachs%26aulast%3DSemenova%26aufirst%3DM.%2BN.%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DTitov%26aufirst%3DI.%2BY.%26aulast%3DRaihstat%26aufirst%3DM.%2BM.%26aulast%3DMolodtsov%26aufirst%3DM.%26aulast%3DGrishchuk%26aufirst%3DE.%26aulast%3DSpiridonov%26aufirst%3DI.%26aulast%3DSemenov%26aufirst%3DV.%2BV.%26atitle%3DIn%2520vivo%2520evaluation%2520of%2520indolyl%2520glyoxylamides%2520in%2520the%2520phenotypic%2520sea%2520urchin%2520embryo%2520assay%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D70%26spage%3D485%26epage%3D490%26doi%3D10.1111%2Fj.1747-0285.2007.00591.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J. F.</span><span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability – are too many aromatic rings a liability in drug design?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1011</span><span class="NLM_x">–</span> <span class="NLM_lpage">1020</span><span class="refDoi"> DOI: 10.1016/j.drudis.2009.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.drudis.2009.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=19729075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1011-1020&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonald&title=The+impact+of+aromatic+ring+count+on+compound+developability+%E2%80%93+are+too+many+aromatic+rings+a+liability+in+drug+design%3F&doi=10.1016%2Fj.drudis.2009.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47aR"><div class="casContent"><span class="casTitleNuber">47a</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: Are too many aromatic rings a liability in drug design?</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">21/22</span>),
    <span class="NLM_cas:pages">1011-1020</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of arom. ring count (the no. of arom. and heteroarom. rings) in mols. has been analyzed against various developability parameters, aq. soly., lipophilicity, serum albumin binding, CyP450 inhibition and hERG inhibition.  On the basis of this anal., it was concluded that the fewer arom. rings contained in an oral drug candidate, the more developable that candidate is probably to be; in addn., more than three arom. rings in a mol. correlates with poorer compd. developability and, thus, an increased risk of attrition in development.  Data are also presented that demonstrate that even within a defined lipophilicity range, increased arom. ring count leads to decreased aq. soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hOeD6TNGUbVg90H21EOLACvtfcHk0lhU8AotCsbqWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP&md5=48454c9809e8225b4336ea76aad3f3ba</span></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%2520%25E2%2580%2593%2520are%2520too%2520many%2520aromatic%2520rings%2520a%2520liability%2520in%2520drug%2520design%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D1011%26epage%3D1020%26doi%3D10.1016%2Fj.drudis.2009.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit47b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, S. D.</span><span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">164</span><span class="NLM_x">–</span> <span class="NLM_lpage">171</span><span class="refDoi"> DOI: 10.1016/j.drudis.2010.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.drudis.2010.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=21129497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=164-171&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=R.+J.+Youngauthor=S.+D.+Pickett&title=The+impact+of+aromatic+ring+count+on+compound+developability%3A+further+insights+by+examining+carbo-+and+hetero-aromatic+and+-aliphatic+ring+types&doi=10.1016%2Fj.drudis.2010.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47bR"><div class="casContent"><span class="casTitleNuber">47b</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Young, Robert J.; Pickett, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3/4</span>),
    <span class="NLM_cas:pages">164-171</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of carboarom., heteroarom., carboaliph. and heteroaliph. ring counts and fused arom. ring count on several developability measures (soly., lipophilicity, protein binding, P 450 inhibition and hERG binding) is the topic for this review article.  Recent results indicate that increasing ring counts have detrimental effects on developability in the order carboaroms. » heteroaroms. > carboaliphatics > heteroaliphatics, with heteroaliphatics exerting a beneficial effect in many cases.  Increasing arom. ring count exerts effects on several developability parameters that are lipophilicity- and size-independent, and fused arom. systems have a beneficial effect relative to their nonfused counterparts.  Increasing arom. ring count has a detrimental effect on human bioavailability parameters, and heteroarom. ring count (but not other ring counts) has increased over time in marketed oral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJYPC7hkoyv7Vg90H21EOLACvtfcHk0lhU8AotCsbqWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D&md5=8e2d0e4e499d2f07d66ca2f385defb2d</span></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%253A%2520further%2520insights%2520by%2520examining%2520carbo-%2520and%2520hetero-aromatic%2520and%2520-aliphatic%2520ring%2520types%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.drudis.2010.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Lovering, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bikker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humblet, C.</span><span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6752</span><span class="NLM_x">–</span> <span class="NLM_lpage">6756</span><span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lhJami5YJlxGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Ishikawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashimoto, Y.</span><span> </span><span class="NLM_article-title">Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1539</span><span class="NLM_x">–</span> <span class="NLM_lpage">1554</span><span class="refDoi"> DOI: 10.1021/jm101356p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101356p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1539-1554&author=M.+Ishikawaauthor=Y.+Hashimoto&title=Improvement+in+aqueous+solubility+in+small+molecule+drug+discovery+programs+by+disruption+of+molecular+planarity+and+symmetry&doi=10.1021%2Fjm101356p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry</span></div><div class="casAuthors">Ishikawa, Minoru; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1539-1554</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKbtbfvqKZjrVg90H21EOLACvtfcHk0lhJami5YJlxGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D&md5=a88804b3850625ef9c3f7424366acb91</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm101356p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101356p%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DImprovement%2520in%2520aqueous%2520solubility%2520in%2520small%2520molecule%2520drug%2520discovery%2520programs%2520by%2520disruption%2520of%2520molecular%2520planarity%2520and%2520symmetry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1539%26epage%3D1554%26doi%3D10.1021%2Fjm101356p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Mok, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenk, R.</span><span> </span><span class="NLM_article-title">Locating sweet spots for screening hits and evaluating pan-assay interference filters from the performance analysis of two lead-like libraries</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">534</span><span class="NLM_x">–</span> <span class="NLM_lpage">544</span><span class="refDoi"> DOI: 10.1021/ci300382f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci300382f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtlGhtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=534-544&author=N.+Y.+Mokauthor=S.+Maxeauthor=R.+Brenk&title=Locating+sweet+spots+for+screening+hits+and+evaluating+pan-assay+interference+filters+from+the+performance+analysis+of+two+lead-like+libraries&doi=10.1021%2Fci300382f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Locating Sweet Spots for Screening Hits and Evaluating Pan-Assay Interference Filters from the Performance Analysis of Two Lead-like Libraries</span></div><div class="casAuthors">Mok, N. Yi; Maxe, Sara; Brenk, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">534-544</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The efficiency of automated compd. screening is heavily influenced by the design and the quality of the screening libraries used.  We recently reported on the assembly of one diverse and one target-focused lead-like screening library.  Using data from 15 enzyme-based screenings conducted using these libraries, their performance was investigated.  Both libraries delivered screening hits across a range of targets, with the hits distributed across the entire chem. space represented by both libraries.  On closer inspection, however, hit distribution was uneven across the chem. space, with enrichments obsd. in octants characterized by compds. at the higher end of the mol. wt. and lipophilicity spectrum for lead-like compds., while polar and sp3-carbon atom rich compds. were underrepresented among the screening hits.  Based on these observations, we propose that screening libraries should not be evenly distributed in lead-like chem. space but be enriched in polar, aliph. compds.  In conjunction with variable concn. screening, this could lead to more balanced hit rates across the chem. space and screening hits of higher ligand efficiency will be captured.  Apart from chem. diversity, both screening libraries were shown to be clean from any pan-assay interference (PAINS) behavior.  Even though some compds. were flagged to contain PAINS structural motifs, some of these motifs were demonstrated to be less problematic than previously suggested.  To maximize the diversity of the chem. space sampled in a screening campaign, we therefore consider it justifiable to retain compds. contg. PAINS structural motifs that were apparently clean in this anal. when assembling screening libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp51XFLjlCNULVg90H21EOLACvtfcHk0lhJami5YJlxGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtlGhtbg%253D&md5=3662f26e446cb8166adf6edabdc71482</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fci300382f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci300382f%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DN.%2BY.%26aulast%3DMaxe%26aufirst%3DS.%26aulast%3DBrenk%26aufirst%3DR.%26atitle%3DLocating%2520sweet%2520spots%2520for%2520screening%2520hits%2520and%2520evaluating%2520pan-assay%2520interference%2520filters%2520from%2520the%2520performance%2520analysis%2520of%2520two%2520lead-like%2520libraries%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D534%26epage%3D544%26doi%3D10.1021%2Fci300382f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Hennemann, B.</span><span> </span><span class="NLM_article-title">Palliative chemotherapy of head and neck cancer: present status and future development</span> <span class="citation_source-journal">Laryngorhinootologie</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">172</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1055/s-2005-921107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1055%2Fs-2005-921107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=16547892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A280%3ADC%252BD287lslOntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2006&pages=172-178&author=B.+Hennemann&title=Palliative+chemotherapy+of+head+and+neck+cancer%3A+present+status+and+future+development&doi=10.1055%2Fs-2005-921107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Palliative chemotherapy of head and neck cancer: present status and future development</span></div><div class="casAuthors">Hennemann B</div><div class="citationInfo"><span class="NLM_cas:title">Laryngo- rhino- otologie</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">172-8</span>
        ISSN:<span class="NLM_cas:issn">0935-8943</span>.
    </div><div class="casAbstract">BACKGROUND:  Patients with head and neck tumors are treated with palliative chemotherapy in case of the detection of distant metastases or local recurrence without the option of surgical therapy or radiation.  Alongside 5-fluorouracil (5-FU) in combination with cisplatin or carboplatin, taxanes, gemcitabine and vinorelbine as well as monoclonal antibodies or small molecule tyrosine kinase inhibitors have been used.  METHODS:  This review analyses the published literature of the past 15 years, including selected abstracts with view to response rate, overall survival and adverse effects.  RESULTS:  5-FU plus cisplatin or carboplatin can still be considered as standard treatment, achieving response rates of 20-30 %.  The addition of taxanes increases the objective response rate but adds remarkable toxicity to the treatment protocol.  Phase III studies demonstrate higher response rates but fail to demonstrate a significant increase of the overall survival after polychemotherapy as compared to monotherapy protocols.  Thus, patients with a reduced performance can be treated with monotherapy.  In case of disease progression after cisplatin-containing chemotherapy further treatment should only be offered to selected patients.  For this situation, platin-free chemotherapy protocols containing taxanes, gemcitabine or vinorelbine seem promising.  Recent studies with monoclonal antibodies or small molecule tyrosine kinase inhibitors report on a response rate of 10-20 %.  CONCLUSION:  The use of new drugs increases the response rate and amends the side effects of the chemotherapy.  However, phase III studies documenting an improved overall survival are lacking.  Targeted therapies broaden the therapeutic armament, and possibly, EGFR inhibition will help to overcome chemotherapy resistance in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9gCiZ2w69GzAEfvC7EH1LfW6udTcc2eYkt_FV09juA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287lslOntA%253D%253D&md5=8c0dd62ee6f0e44791f8680844747c23</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1055%2Fs-2005-921107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2005-921107%26sid%3Dliteratum%253Aachs%26aulast%3DHennemann%26aufirst%3DB.%26atitle%3DPalliative%2520chemotherapy%2520of%2520head%2520and%2520neck%2520cancer%253A%2520present%2520status%2520and%2520future%2520development%26jtitle%3DLaryngorhinootologie%26date%3D2006%26volume%3D85%26spage%3D172%26epage%3D178%26doi%3D10.1055%2Fs-2005-921107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Cullen, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schumaker, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikitakis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goloubeva, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarlis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haddad, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posner, M. R.</span><span> </span><span class="NLM_article-title">β-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">6222</span><span class="NLM_x">–</span> <span class="NLM_lpage">6228</span><span class="refDoi"> DOI: 10.1200/JCO.2009.23.0953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1200%2FJCO.2009.23.0953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=19917838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1agsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=6222-6228&author=K.+J.+Cullenauthor=L.+Schumakerauthor=N.+Nikitakisauthor=O.+Goloubevaauthor=M.+Tanauthor=M.+J.+Sarlisauthor=R.+I.+Haddadauthor=M.+R.+Posner&title=%CE%B2-Tubulin-II+expression+strongly+predicts+outcome+in+patients+receiving+induction+chemotherapy+for+locally+advanced+squamous+carcinoma+of+the+head+and+neck%3A+a+companion+analysis+of+the+TAX+324+trial&doi=10.1200%2FJCO.2009.23.0953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">β-tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial</span></div><div class="casAuthors">Cullen, Kevin J.; Schumaker, Lisa; Nikitakis, Nikolaos; Goloubeva, Olga; Tan, Ming; Sarlis, Nicholas J.; Haddad, Robert I.; Posner, Marshall R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">6222-6228</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose TAX 324 was a phase III trial comparing induction chemotherapy (IC) with docetaxel, cisplatin, and fluorouracil (TPF) with cisplatin and fluorouracil (PF) followed by concomitant chemoradiotherapy in locally advanced squamous cell cancer of the head and neck (LASCCHN).  This study evaluates a series of tumor markers in pretreatment biopsies from that trial TAX 324 and correlates expression with survival.  Methods Pretherapy biopsy specimens were available for 265 of 501 participants.  Expression of a series of six markers (p53, thymidylate synthase, glutathione s-transferase pi [GST-π], Bcl 2, beta tubulin II [βT-2], and HER2 neu) was evaluated by immunohistochem.  Results For patients with low βT-II expression, median overall survival (OS) was 58.6 mo (95% CI, not reached [NR]), compared with 18.2 mo for patients with high βT-II expression (95% CI, 13.11 to 30.06: hazard ratio [HR], 2.39; 95% CI, 1.67 to 3.72; P < .0001).  Progression-free survival in patients with low βT-II expression was 43.2 mo (95% CI, 24.4 to NR) vs. 9.8 mo (95% CI, 7.06 to 18.53) for high βT-II expression, with a HR of 1.9 (95% CI, 1.43 to 2.77; P < .0001).  The predictive value of βT-II expression was greater in the TPF vs. PF arm than in the PF arm.  Conclusion Increased tumor expression of βT-II is strongly assocd. with adverse outcome in LASCCHN patients treated with IC, and our data suggest low expression of βT-II may predict patients most likely to benefit from induction TPF therapy.  Further, simple models which combine expression of βT-II with a carefully defined set of addnl. immunohistochem. markers may have significant prognostic impact for patients with LASCCHN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEHq9fHSMDPbVg90H21EOLACvtfcHk0lgk8H9O1fPOAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1agsbw%253D&md5=e183d97af6833796fb97c02987c53ae0</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.23.0953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.23.0953%26sid%3Dliteratum%253Aachs%26aulast%3DCullen%26aufirst%3DK.%2BJ.%26aulast%3DSchumaker%26aufirst%3DL.%26aulast%3DNikitakis%26aufirst%3DN.%26aulast%3DGoloubeva%26aufirst%3DO.%26aulast%3DTan%26aufirst%3DM.%26aulast%3DSarlis%26aufirst%3DM.%2BJ.%26aulast%3DHaddad%26aufirst%3DR.%2BI.%26aulast%3DPosner%26aufirst%3DM.%2BR.%26atitle%3D%25CE%25B2-Tubulin-II%2520expression%2520strongly%2520predicts%2520outcome%2520in%2520patients%2520receiving%2520induction%2520chemotherapy%2520for%2520locally%2520advanced%2520squamous%2520carcinoma%2520of%2520the%2520head%2520and%2520neck%253A%2520a%2520companion%2520analysis%2520of%2520the%2520TAX%2520324%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D6222%26epage%3D6228%26doi%3D10.1200%2FJCO.2009.23.0953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Schena, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barone, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birocco, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dongiovanni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Numico, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colantonio, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertetto, O.</span><span> </span><span class="NLM_article-title">Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">276</span><span class="refDoi"> DOI: 10.1007/s00280-004-0875-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1007%2Fs00280-004-0875-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=15592837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVCnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2005&pages=271-276&author=M.+Schenaauthor=C.+Baroneauthor=N.+Biroccoauthor=D.+Dongiovanniauthor=G.+Numicoauthor=I.+Colantonioauthor=O.+Bertetto&title=Weekly+cisplatin+paclitaxel+and+continuous+infusion+fluorouracil+in+patients+with+recurrent+and%2For+metastatic+head+and+neck+squamous+cell+carcinoma%3A+a+phase+II+study&doi=10.1007%2Fs00280-004-0875-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study</span></div><div class="casAuthors">Schena, M.; Barone, C.; Birocco, N.; Dongiovanni, D.; Numico, G.; Colantonio, I.; Bertetto, O.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">271-276</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">Background: Cisplatin, paclitaxel and 5-fluorouracil (5-FU) have demonstrated significant activity in patients with advanced squamous head and neck cancer (HNSCC) despite relevant toxicity.  A weekly administration of cisplatin and paclitaxel with continuous infusion of 5-FU could offer a better toxicity profile without affecting dose intensity or treatment outcome.  We evaluated the toxicity and the activity of weekly cisplatin/paclitaxel with continuous infusion 5-FU in patients with recurrent and/or metastatic HNSCC.  Methods: A total of 44 patients were studied.  Treatment consisted of two 6-wk cycles with weekly cisplatin 20 mg/m2 and paclitaxel 60 mg/m2 and daily continuous infusion 5-FU 200 mg/m2 from day 1 to 42.  Patients were evaluated for toxicity and response.  Results: 40 out of 44 patients were evaluable for response.  After two cycles we obsd. seven complete responses (16) and 12 partial responses (27), with a 43 (95 CI 28-58) overall response rate.  Stable disease was seen in 13 patients (29) and progressive disease in 12 patients (27).  Toxicity was mild in treated patients: we obsd. less than 10 of grade 3/4 hematol. and gastroenteric toxicity.  Conclusions: A weekly schedule of cisplatin and paclitaxel assocd. with continuous infusion 5-FU showed low toxicity in the treatment of advanced HNSCC while significant activity was conserved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU80o4H-qxE7Vg90H21EOLACvtfcHk0lgpSeDDD8mYNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVCnsg%253D%253D&md5=1caa5634a2555153fb4bf436b28f8a2d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2Fs00280-004-0875-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-004-0875-1%26sid%3Dliteratum%253Aachs%26aulast%3DSchena%26aufirst%3DM.%26aulast%3DBarone%26aufirst%3DC.%26aulast%3DBirocco%26aufirst%3DN.%26aulast%3DDongiovanni%26aufirst%3DD.%26aulast%3DNumico%26aufirst%3DG.%26aulast%3DColantonio%26aufirst%3DI.%26aulast%3DBertetto%26aufirst%3DO.%26atitle%3DWeekly%2520cisplatin%2520paclitaxel%2520and%2520continuous%2520infusion%2520fluorouracil%2520in%2520patients%2520with%2520recurrent%2520and%252For%2520metastatic%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%253A%2520a%2520phase%2520II%2520study%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2005%26volume%3D55%26spage%3D271%26epage%3D276%26doi%3D10.1007%2Fs00280-004-0875-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Pointreau, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garaud, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sire, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuchais, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tortochaux, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faivre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrif, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfonsi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calais, G.</span><span> </span><span class="NLM_article-title">Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">498</span><span class="NLM_x">–</span> <span class="NLM_lpage">506</span><span class="refDoi"> DOI: 10.1093/jnci/djp007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1093%2Fjnci%2Fdjp007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=19318632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFWrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2009&pages=498-506&author=Y.+Pointreauauthor=P.+Garaudauthor=S.+Chapetauthor=C.+Sireauthor=C.+Tuchaisauthor=J.+Tortochauxauthor=S.+Faivreauthor=S.+Guerrifauthor=M.+Alfonsiauthor=G.+Calais&title=Randomized+trial+of+induction+chemotherapy+with+cisplatin+and+5-fluorouracil+with+or+without+docetaxel+for+larynx+preservation&doi=10.1093%2Fjnci%2Fdjp007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Larynx Preservation</span></div><div class="casAuthors">Pointreau, Yoann; Garaud, Pascal; Chapet, Sophie; Sire, Christian; Tuchais, Claude; Tortochaux, Jacques; Faivre, Sandrine; Guerrif, Stephane; Alfonsi, Marc; Calais, Gilles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">498-506</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: Chemotherapy with cisplatin (P) and 5-fluorouracil (F) followed by radiotherapy in patients who respond to chemotherapy is an alternative to total laryngectomy for patients with locally advanced larynx and hypopharynx cancer.  Data suggest that docetaxel (T) may add to the efficacy of PF.  The objective of this trial was to det. whether adding T to PF could increase the larynx preservation rate.  Methods: Patients who had larynx and hypopharynx cancer that required total laryngectomy were randomly assigned to receive three cycles of TPF or PF.  Patients who responded to chemotherapy received radiotherapy with or without addnl. chemotherapy.  Patients who did not respond to chemotherapy underwent total laryngectomy followed by radiotherapy with or without addnl. chemotherapy.  The primary endpoint was 3-yr larynx preservation rate.  Secondary endpoints included acute toxicities and overall response.  All statistical tests were two-sided.  Results: Baseline patient and tumor characteristics were well balanced between the TPF (n = 110) and PF (n = 103) groups.  With a median follow-up of 36 mo, the 3-yr actuarial larynx preservation rate was 70.3% with TPF vs 57.5% with PF (difference = 12.8%; P = .03).  Patients in the TPF group had more grade 2 alopecia, grade 4 neutropenia, and febrile neutropenia, whereas patients in the PF group had more grade 3 and 4 stomatitis, thrombocytopenia, and grade 4 creatinine elevation.  The overall response was 80.0% in the TPF group vs 59.2% in the PF group (difference = 20.8%; P = .002).  Conclusions: In patients with advanced larynx and hypopharynx carcinomas, TPF induction chemotherapy was superior to the PF regimen in terms of overall response rate.  These results suggest that larynx preservation could be achieved for a higher proportion of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBs1fGBsp_-LVg90H21EOLACvtfcHk0lgpSeDDD8mYNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFWrtbc%253D&md5=059750feb70a2c7f11cb3c5258e27034</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjp007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjp007%26sid%3Dliteratum%253Aachs%26aulast%3DPointreau%26aufirst%3DY.%26aulast%3DGaraud%26aufirst%3DP.%26aulast%3DChapet%26aufirst%3DS.%26aulast%3DSire%26aufirst%3DC.%26aulast%3DTuchais%26aufirst%3DC.%26aulast%3DTortochaux%26aufirst%3DJ.%26aulast%3DFaivre%26aufirst%3DS.%26aulast%3DGuerrif%26aufirst%3DS.%26aulast%3DAlfonsi%26aufirst%3DM.%26aulast%3DCalais%26aufirst%3DG.%26atitle%3DRandomized%2520trial%2520of%2520induction%2520chemotherapy%2520with%2520cisplatin%2520and%25205-fluorouracil%2520with%2520or%2520without%2520docetaxel%2520for%2520larynx%2520preservation%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2009%26volume%3D101%26spage%3D498%26epage%3D506%26doi%3D10.1093%2Fjnci%2Fdjp007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Paccagnella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghi, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loreggian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buffoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koussis, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mione, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campostrini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardizzoia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dondi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guaraldi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavallo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gava, A.</span><span> </span><span class="NLM_article-title">Concomintant chemoradiotherapy versus induction docetaxel, cisplatin and 5-fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1515</span><span class="NLM_x">–</span> <span class="NLM_lpage">1522</span><span class="refDoi"> DOI: 10.1093/annonc/mdp573</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1093%2Fannonc%2Fmdp573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=20032123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A280%3ADC%252BC3crovVGksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=1515-1522&author=A.+Paccagnellaauthor=M.+G.+Ghiauthor=L.+Loreggianauthor=A.+Buffoliauthor=H.+Koussisauthor=C.+A.+Mioneauthor=A.+Bonettiauthor=F.+Campostriniauthor=G.+Gardaniauthor=A.+Ardizzoiaauthor=D.+Dondiauthor=M.+Guaraldiauthor=R.+Cavalloauthor=L.+Tomioauthor=A.+Gava&title=Concomintant+chemoradiotherapy+versus+induction+docetaxel%2C+cisplatin+and+5-fluorouracil+%28TPF%29+followed+by+concomitant+chemoradiotherapy+in+locally+advanced+head+and+neck+cancer%3A+a+phase+II+randomized+study&doi=10.1093%2Fannonc%2Fmdp573"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study</span></div><div class="casAuthors">Paccagnella A; Ghi M G; Loreggian L; Buffoli A; Koussis H; Mione C A; Bonetti A; Campostrini F; Gardani G; Ardizzoia A; Dondi D; Guaraldi M; Cavallo R; Tomio L; Gava A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1515-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Concomitant chemoradiotherapy (CT/RT) is the standard treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN).  We evaluated the efficacy of induction docetaxel (Taxotere), cisplatin, and 5-fluorouracil (TPF) before CT/RT versus CT/RT alone.  PATIENTS AND METHODS:  Patients with stage III-IVM0 SCCHN, Eastern Cooperative Oncology Group performance status of zero to one, were randomly assigned to receive CT/RT alone (arm A: two cycles of cisplatin 20 mg/m(2), days1-4, plus 5-fluorouracil 800 mg/m(2)/day 96 h continuous infusion, during weeks 1 and 6 of radiotherapy) or three cycles of TPF (arm B: docetaxel 75 mg/m(2) and cisplatin 80 mg/m(2), day 1, and 5-fluorouracil 800 mg/m(2)/day 96 h continuous infusion, every 3 weeks) followed by the same CT/RT.  The primary end point was the rate of radiologic complete response (CR) at 6-8 weeks after the end of CT/RT.  RESULTS:  A total of 101 patients were randomly allocated to the study (51 arm A; 50 arm B).  CR rates were 21.2% (arm A) versus 50% (arm B).  Median progression-free survival and overall survival were, respectively, 19.7 and 33.3 months (arm A) and 30.4 and 39.6 months (arm B).  Hematologic and non-hematologic toxic effects during CT/RT were similar in the two arms.  CONCLUSION:  Induction TPF followed by CT/RT was associated with higher radiologic CR in patients with locally advanced SCCHN with no negative impact on CT/RT feasibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlH16FjxFCdc25P7XSLhESfW6udTcc2eYeB6wRFYdlqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3crovVGksQ%253D%253D&md5=2ceb3f018ab8a5a8eb152101690e1861</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdp573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdp573%26sid%3Dliteratum%253Aachs%26aulast%3DPaccagnella%26aufirst%3DA.%26aulast%3DGhi%26aufirst%3DM.%2BG.%26aulast%3DLoreggian%26aufirst%3DL.%26aulast%3DBuffoli%26aufirst%3DA.%26aulast%3DKoussis%26aufirst%3DH.%26aulast%3DMione%26aufirst%3DC.%2BA.%26aulast%3DBonetti%26aufirst%3DA.%26aulast%3DCampostrini%26aufirst%3DF.%26aulast%3DGardani%26aufirst%3DG.%26aulast%3DArdizzoia%26aufirst%3DA.%26aulast%3DDondi%26aufirst%3DD.%26aulast%3DGuaraldi%26aufirst%3DM.%26aulast%3DCavallo%26aufirst%3DR.%26aulast%3DTomio%26aufirst%3DL.%26aulast%3DGava%26aufirst%3DA.%26atitle%3DConcomintant%2520chemoradiotherapy%2520versus%2520induction%2520docetaxel%252C%2520cisplatin%2520and%25205-fluorouracil%2520%2528TPF%2529%2520followed%2520by%2520concomitant%2520chemoradiotherapy%2520in%2520locally%2520advanced%2520head%2520and%2520neck%2520cancer%253A%2520a%2520phase%2520II%2520randomized%2520study%26jtitle%3DAnn.%2520Oncol.%26date%3D2010%26volume%3D21%26spage%3D1515%26epage%3D1522%26doi%3D10.1093%2Fannonc%2Fmdp573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Theile, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketabi-Kiyanvash, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herold-Mende, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyckhoff, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efferth, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertholet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haefeli, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span> </span><span class="NLM_article-title">Evaluation of drug transporters’ significance in for multidrug resistance in head and neck squamous cell carcinoma</span> <span class="citation_source-journal">Head Neck</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">959</span><span class="NLM_x">–</span> <span class="NLM_lpage">968</span><span class="refDoi"> DOI: 10.1002/hed.21559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1002%2Fhed.21559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=20737486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A280%3ADC%252BC3MngtlWltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2011&pages=959-968&author=D.+Theileauthor=N.+Ketabi-Kiyanvashauthor=C.+Herold-Mendeauthor=G.+Dyckhoffauthor=T.+Efferthauthor=V.+Bertholetauthor=W.+E.+Haefeliauthor=J.+Weiss&title=Evaluation+of+drug+transporters%E2%80%99+significance+in+for+multidrug+resistance+in+head+and+neck+squamous+cell+carcinoma&doi=10.1002%2Fhed.21559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma</span></div><div class="casAuthors">Theile Dirk; Ketabi-Kiyanvash Nahal; Herold-Mende Christel; Dyckhoff Gerhardt; Efferth Thomas; Bertholet Vincent; Haefeli Walter Emil; Weiss Johanna</div><div class="citationInfo"><span class="NLM_cas:title">Head & neck</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">959-68</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Multidrug resistance (MDR) hampers chemotherapy in head and neck squamous cell carcinoma (HNSCC).  There is little information about MDR mediating drug transporters in HNSCC.  METHODS:  Nine HNSCC cell lines were characterized concerning drug transporter expression and susceptibility to cisplatin, paclitaxel, and 5-fluorouracil (5-FU) using a DNA microarray and proliferation assays.  Three cells lines were precisely investigated for transporter expression using reverse transcriptase-polymerase chain reaction (RT-PCR) and drug resistance before and after simulated chemotherapies.  RESULTS:  The cell lines differed in drug resistance and transporter expression.  Cisplatin and paclitaxel resistances were inversely associated.  Drugs rendered HNSCC cells resistant, cross-resistant, or cross-sensitive.  Sensitivity changes were accompanied by transporter mRNA expression changes.  CONCLUSION:  Paclitaxel was identified as a potent inducer of numerous drug transporters and phenotypic MDR in HNSCC.  Thus, cytostatic susceptibility of HNSCC cannot exclusively be deduced from the expression of single transporters but more likely of the entire transportome and non-transporter modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRGdLhGwPYWrFU0A1HOshhfW6udTcc2eaDBB9qbPkjyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MngtlWltg%253D%253D&md5=27d8ca174adeb58d6f2d2b679cfc2a74</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2Fhed.21559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhed.21559%26sid%3Dliteratum%253Aachs%26aulast%3DTheile%26aufirst%3DD.%26aulast%3DKetabi-Kiyanvash%26aufirst%3DN.%26aulast%3DHerold-Mende%26aufirst%3DC.%26aulast%3DDyckhoff%26aufirst%3DG.%26aulast%3DEfferth%26aufirst%3DT.%26aulast%3DBertholet%26aufirst%3DV.%26aulast%3DHaefeli%26aufirst%3DW.%2BE.%26aulast%3DWeiss%26aufirst%3DJ.%26atitle%3DEvaluation%2520of%2520drug%2520transporters%25E2%2580%2599%2520significance%2520in%2520for%2520multidrug%2520resistance%2520in%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%26jtitle%3DHead%2520Neck%26date%3D2011%26volume%3D33%26spage%3D959%26epage%3D968%26doi%3D10.1002%2Fhed.21559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jacobs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velez-Garcia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhar, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochster, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodnough, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortimer, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einhorn, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schacter, L.</span><span> </span><span class="NLM_article-title">A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">257</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1732427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A280%3ADyaK387itF2gtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1992&pages=257-263&author=C.+Jacobsauthor=G.+Lymanauthor=E.+Velez-Garciaauthor=K.+S.+Sridharauthor=W.+Knightauthor=H.+Hochsterauthor=L.+T.+Goodnoughauthor=J.+E.+Mortimerauthor=L.+H.+Einhornauthor=L.+Schacter&title=A+phase+III+randomized+study+comparing+cisplatin+and+fluorouracil+as+single+agents+and+in+combination+for+advanced+squamous+cell+carcinoma+of+the+head+and+neck"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57aR"><div class="casContent"><span class="casTitleNuber">57a</span><div class="casTitle"><span class="NLM_cas:atitle">A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck</span></div><div class="casAuthors">Jacobs C; Lyman G; Velez-Garcia E; Sridhar K S; Knight W; Hochster H; Goodnough L T; Mortimer J E; Einhorn L H; Schacter L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-63</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">PURPOSE:  To determine whether combination chemotherapy is superior to single agents for recurrent/metastatic head and neck cancer, we compared the efficacy and toxicity of cisplatin (CP) and fluorouracil (5-FU), alone and in combination in a phase III trial.  PATIENTS AND METHODS:  Two hundred forty-nine patients with recurrent head and neck cancer were randomized to one of three treatments: CP (100 mg/m2) and 5-FU (1 g/m2 x 4), CP, or 5-FU every 3 weeks.  RESULTS:  The overall response rate to the combination (32%) was superior to that of CP (17%) or 5-FU (13%) (P = .035).  Response was associated with good performance status (PS) but not with primary site, site of recurrence, histology, prior irradiation, or relative dose intensity.  Median time to progression was less than 2.5 months, and there was no significant difference in median survival (5.7 months) among the groups.  By multivariate analysis, patients with better PS and poorly differentiated tumors had superior survival.  Hematologic toxicity and alopecia were worse in the combination arm.  CONCLUSION:  Although the response rate to the combination of CP plus 5-FU was superior to that achieved with single agents, survival did not improve.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTf8lbNGCbaB75oR8RchjrrfW6udTcc2eaDBB9qbPkjyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK387itF2gtA%253D%253D&md5=3d5f4f4b74b0eef2f61d140033e0e196</span></div><a href="/servlet/linkout?suffix=cit57a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DC.%26aulast%3DLyman%26aufirst%3DG.%26aulast%3DVelez-Garcia%26aufirst%3DE.%26aulast%3DSridhar%26aufirst%3DK.%2BS.%26aulast%3DKnight%26aufirst%3DW.%26aulast%3DHochster%26aufirst%3DH.%26aulast%3DGoodnough%26aufirst%3DL.%2BT.%26aulast%3DMortimer%26aufirst%3DJ.%2BE.%26aulast%3DEinhorn%26aufirst%3DL.%2BH.%26aulast%3DSchacter%26aufirst%3DL.%26atitle%3DA%2520phase%2520III%2520randomized%2520study%2520comparing%2520cisplatin%2520and%2520fluorouracil%2520as%2520single%2520agents%2520and%2520in%2520combination%2520for%2520advanced%2520squamous%2520cell%2520carcinoma%2520of%2520the%2520head%2520and%2520neck%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1992%26volume%3D10%26spage%3D257%26epage%3D263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit57b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Forastiere, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metch, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuller, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ensley, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutchins, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Triozzi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClure, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VonFeldt, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williamson, S. K.</span><span> </span><span class="NLM_article-title">Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1245</span><span class="NLM_x">–</span> <span class="NLM_lpage">1251</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1634913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A280%3ADyaK38zktFWguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1992&pages=1245-1251&author=A.+A.+Forastiereauthor=B.+Metchauthor=D.+E.+Schullerauthor=J.+F.+Ensleyauthor=L.+F.+Hutchinsauthor=P.+Triozziauthor=J.+A.+Kishauthor=S.+McClureauthor=E.+VonFeldtauthor=S.+K.+Williamson&title=Randomized+comparison+of+cisplatin+plus+fluorouracil+and+carboplatin+plus+fluorouracil+versus+methotrexate+in+advanced+squamous-cell+carcinoma+of+the+head+and+neck%3A+a+Southwest+Oncology+Group+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57bR"><div class="casContent"><span class="casTitleNuber">57b</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study</span></div><div class="casAuthors">Forastiere A A; Metch B; Schuller D E; Ensley J F; Hutchins L F; Triozzi P; Kish J A; McClure S; VonFeldt E; Williamson S K</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1245-51</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">PURPOSE:  The Southwest Oncology Group (SWOG) conducted a randomized comparison of cisplatin plus fluorouracil (5-FU) and carboplatin plus 5-FU versus single-agent methotrexate (MTX) in patients with recurrent and metastatic squamous-cell carcinoma (SCC) of the head and neck.  The primary objective was to compare separately the response rates of each combination regimen to standard weekly MTX.  PATIENTS AND METHODS:  Two hundred seventy-seven patients diagnosed with SCC of the head and neck were randomized to one of three treatments: (1) cisplatin 100 mg/m2 intravenously (IV) on day 1 and 5-FU 1,000 mg/m2 per day for a 96-hour continuous infusion repeated every 21 days; (2) carboplatin 300 mg/m2 IV on day 1 and 5-FU 1,000 mg/m2 per day for a 96-hour continuous infusion repeated every 28 days; and (3) MTX 40 mg/m2 IV given weekly.  RESULTS:  All three treatment regimens were well tolerated.  However, both hematologic and nonhematologic toxicities were significantly greater with cisplatin plus 5-FU compared with MTX (P = .001).  Toxicity from carboplatin plus 5-FU was intermediate compared with the other regimens.  The complete and partial response rates were 32% for cisplatin plus 5-FU, 21% for carboplatin plus 5-FU, and 10% for MTX.  The comparison of cisplatin plus 5-FU to MTX was statistically significant (P less than .001), and the comparison of carboplatin plus 5-FU to MTX was of borderline statistical significance (P = .05).  Median response durations and median survival times were similar for all three treatment groups.  Logistic regression models showed that only treatment assigned was associated significantly with response (P = .001).  Cox proportional hazards models indicated that only performance status was associated significantly with survival (P less than .01).  CONCLUSIONS:  We conclude that combination chemotherapy resulted in improved response rates but was associated with an increased toxicity and no improvement in overall survival.  Therefore, new treatments that may alter the course of disease in recurrent head and neck cancer patients still need to be identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQP_hlUnrjdhIFEOhA_Im3cfW6udTcc2eaD0A3F95T91Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38zktFWguw%253D%253D&md5=b9f04fd3109000f6e490c1c174d1a300</span></div><a href="/servlet/linkout?suffix=cit57b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DForastiere%26aufirst%3DA.%2BA.%26aulast%3DMetch%26aufirst%3DB.%26aulast%3DSchuller%26aufirst%3DD.%2BE.%26aulast%3DEnsley%26aufirst%3DJ.%2BF.%26aulast%3DHutchins%26aufirst%3DL.%2BF.%26aulast%3DTriozzi%26aufirst%3DP.%26aulast%3DKish%26aufirst%3DJ.%2BA.%26aulast%3DMcClure%26aufirst%3DS.%26aulast%3DVonFeldt%26aufirst%3DE.%26aulast%3DWilliamson%26aufirst%3DS.%2BK.%26atitle%3DRandomized%2520comparison%2520of%2520cisplatin%2520plus%2520fluorouracil%2520and%2520carboplatin%2520plus%2520fluorouracil%2520versus%2520methotrexate%2520in%2520advanced%2520squamous-cell%2520carcinoma%2520of%2520the%2520head%2520and%2520neck%253A%2520a%2520Southwest%2520Oncology%2520Group%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1992%26volume%3D10%26spage%3D1245%26epage%3D1251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, C.</span><span> </span><span class="NLM_article-title">Current status of experimental therapeutics for head and neck cancer</span> <span class="citation_source-journal">Exp. Biol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">236</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">–</span> <span class="NLM_lpage">389</span><span class="refDoi"> DOI: 10.1258/ebm.2010.010354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1258%2Febm.2010.010354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXms1ahs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=236&publication_year=2011&pages=375-389&author=J.+Leeauthor=C.+Moon&title=Current+status+of+experimental+therapeutics+for+head+and+neck+cancer&doi=10.1258%2Febm.2010.010354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Current status of experimental therapeutics for head and neck cancer</span></div><div class="casAuthors">Lee, Juna; Moon, Chulso</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Biology and Medicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">236</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">375-389</span>CODEN:
                <span class="NLM_cas:coden">EBMMBE</span>;
        ISSN:<span class="NLM_cas:issn">1535-3702</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Medicine Press Ltd.</span>)
        </div><div class="casAbstract">A review.  As with many cancers, early detection of head and neck cancer increases a patient's survival rate.  If diagnosed early, its five-year survival nears 90% with std. therapy alone.  Unfortunately, the av. survival rate for head and neck cancer is low due to the difficulty in early detection and achieving a sustainable response.  Conventional treatments are not adequate for the majority of advanced or recurrent head and neck cancer patients because of the remarkable resistance of tumors to chemotherapy and radiation, and the situation is esp. devastating for the first time treatment failure.  The major limitations of these treatments are the lack of specificity for the tumor cell and unacceptable toxicity to the patient.  As a result, current research in therapeutics for advanced, chemotherapy-resistant or recurrent head and neck cancer patients has focused on new treatment modalities that exploit biol. differences between tumor and normal cells.  These therapies include monoclonal antibodies, mol. inhibitors, gene therapy and photodynamic therapy.  This article reviews the current preclin. and clin. evidence of these exptl. therapeutics as they relate to head and neck cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjv1Q3E-v2g7Vg90H21EOLACvtfcHk0ljuO3ynvkSd-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXms1ahs70%253D&md5=f983309484e5aedb0e4d3f543f8f9257</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1258%2Febm.2010.010354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1258%252Febm.2010.010354%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMoon%26aufirst%3DC.%26atitle%3DCurrent%2520status%2520of%2520experimental%2520therapeutics%2520for%2520head%2520and%2520neck%2520cancer%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D2011%26volume%3D236%26spage%3D375%26epage%3D389%26doi%3D10.1258%2Febm.2010.010354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Machiels, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitz, S.</span><span> </span><span class="NLM_article-title">New advances in targeted therapies for squamous cell carcinoma of the head and neck</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">626</span><span class="NLM_x">–</span> <span class="NLM_lpage">633</span><span class="refDoi"> DOI: 10.1097/CAD.0b013e328341071e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1097%2FCAD.0b013e328341071e" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=626-633&author=J.+P.+Machielsauthor=S.+Schmitz&title=New+advances+in+targeted+therapies+for+squamous+cell+carcinoma+of+the+head+and+neck&doi=10.1097%2FCAD.0b013e328341071e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1097%2FCAD.0b013e328341071e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0b013e328341071e%26sid%3Dliteratum%253Aachs%26aulast%3DMachiels%26aufirst%3DJ.%2BP.%26aulast%3DSchmitz%26aufirst%3DS.%26atitle%3DNew%2520advances%2520in%2520targeted%2520therapies%2520for%2520squamous%2520cell%2520carcinoma%2520of%2520the%2520head%2520and%2520neck%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2011%26volume%3D22%26spage%3D626%26epage%3D633%26doi%3D10.1097%2FCAD.0b013e328341071e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Matta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ralhan, R.</span><span> </span><span class="NLM_article-title">Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma</span> <span class="citation_source-journal">Head Neck Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">6</span><span class="refDoi"> DOI: 10.1186/1758-3284-1-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1186%2F1758-3284-1-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=19284526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A280%3ADC%252BD1M3jtVagtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=6&author=A.+Mattaauthor=R.+Ralhan&title=Overview+of+current+and+future+biologically+based+targeted+therapies+in+head+and+neck+squamous+cell+carcinoma&doi=10.1186%2F1758-3284-1-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma</span></div><div class="casAuthors">Matta Ajay; Ralhan Ranju</div><div class="citationInfo"><span class="NLM_cas:title">Head & neck oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recent advances in genomics, proteomics, bioinformatics and systems biology have unraveled the complex aberrant signaling networks in cancer.  The knowledge accrued has dramatically increased the opportunities for discovery of novel molecular targets for drug development.  Major emphasis is being laid on designing new therapeutic strategies targeting multiple signaling pathways for more effective disease management.  However, the translation of in vitro findings to patient management often poses major challenges that limit their clinical efficacy.  Here we will discuss how understanding the dysregulated signaling networks can explain the pitfalls in translating the laboratory findings from the bench-to-bedside and suggest novel approaches to overcome these problems using head and neck cancer as a prototype.  The five year survival rates of HNSCC patients (about 50% at 5 years) have not improved significantly despite advancements in multimodality therapy including surgery, radiation and chemotherapy.  Molecular targeted therapies with inhibitors of EGFR and VEGF either alone, or in combination with conventional treatments have shown limited improved efficacy.  The key deregulated signaling pathways in head and neck squamous cell carcinoma (HNSCC) include EGFR, Ras, TGFbeta, NFkappaB, Stat, Wnt/beta-catenin and PI3-K/AKT/mTOR.  The aberrant activities of these interrelated signaling pathways contribute to HNSCC development.  In depth understanding of the cross-talks between these pathways and networks will form the basis of developing novel strategies for targeting multiple molecular components for more effective prevention and treatment of HNSCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDlBeNme77Bs25P7XSLhESfW6udTcc2eZ4_SP9_XoFrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3jtVagtQ%253D%253D&md5=d95688c22b5b568d48cabbfa411f5002</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1186%2F1758-3284-1-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1758-3284-1-6%26sid%3Dliteratum%253Aachs%26aulast%3DMatta%26aufirst%3DA.%26aulast%3DRalhan%26aufirst%3DR.%26atitle%3DOverview%2520of%2520current%2520and%2520future%2520biologically%2520based%2520targeted%2520therapies%2520in%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%26jtitle%3DHead%2520Neck%2520Oncol.%26date%3D2009%26volume%3D1%26spage%3D6%26doi%3D10.1186%2F1758-3284-1-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Raza, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornblum, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kancharla, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baig, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kavalar, M.</span><span> </span><span class="NLM_article-title">Emerging therapies in the treatment of locally advanced squamous cell carcinomas of the head and neck</span> <span class="citation_source-journal">Recent Pat. Anti-Cancer Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">246</span><span class="NLM_x">–</span> <span class="NLM_lpage">257</span><span class="refDoi"> DOI: 10.2174/157489211795328477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.2174%2F157489211795328477" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=246-257&author=S.+Razaauthor=N.+Kornblumauthor=V.+P.+Kancharlaauthor=M.+A.+Baigauthor=A.+B.+Singhauthor=M.+Kavalar&title=Emerging+therapies+in+the+treatment+of+locally+advanced+squamous+cell+carcinomas+of+the+head+and+neck&doi=10.2174%2F157489211795328477"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.2174%2F157489211795328477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157489211795328477%26sid%3Dliteratum%253Aachs%26aulast%3DRaza%26aufirst%3DS.%26aulast%3DKornblum%26aufirst%3DN.%26aulast%3DKancharla%26aufirst%3DV.%2BP.%26aulast%3DBaig%26aufirst%3DM.%2BA.%26aulast%3DSingh%26aufirst%3DA.%2BB.%26aulast%3DKavalar%26aufirst%3DM.%26atitle%3DEmerging%2520therapies%2520in%2520the%2520treatment%2520of%2520locally%2520advanced%2520squamous%2520cell%2520carcinomas%2520of%2520the%2520head%2520and%2520neck%26jtitle%3DRecent%2520Pat.%2520Anti-Cancer%2520Drug%2520Discovery%26date%3D2011%26volume%3D6%26spage%3D246%26epage%3D257%26doi%3D10.2174%2F157489211795328477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Denaro, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russi, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colantonio, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merlano, M. C.</span><span> </span><span class="NLM_article-title">The role of antiangiogenic agents in the treatment of head and neck cancer</span> <span class="citation_source-journal">Oncology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1159/000339542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1159%2F000339542" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2012&pages=108-116&author=N.+Denaroauthor=E.+G.+Russiauthor=I.+Colantonioauthor=V.+Adamoauthor=M.+C.+Merlano&title=The+role+of+antiangiogenic+agents+in+the+treatment+of+head+and+neck+cancer&doi=10.1159%2F000339542"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1159%2F000339542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000339542%26sid%3Dliteratum%253Aachs%26aulast%3DDenaro%26aufirst%3DN.%26aulast%3DRussi%26aufirst%3DE.%2BG.%26aulast%3DColantonio%26aufirst%3DI.%26aulast%3DAdamo%26aufirst%3DV.%26aulast%3DMerlano%26aufirst%3DM.%2BC.%26atitle%3DThe%2520role%2520of%2520antiangiogenic%2520agents%2520in%2520the%2520treatment%2520of%2520head%2520and%2520neck%2520cancer%26jtitle%3DOncology%26date%3D2012%26volume%3D83%26spage%3D108%26epage%3D116%26doi%3D10.1159%2F000339542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Faller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ertl, P.</span><span> </span><span class="NLM_article-title">Computational approaches to determine drug solubility</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">533</span><span class="NLM_x">–</span> <span class="NLM_lpage">545</span><span class="refDoi"> DOI: 10.1016/j.addr.2007.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.addr.2007.05.005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2007&pages=533-545&author=B.+Fallerauthor=P.+Ertl&title=Computational+approaches+to+determine+drug+solubility&doi=10.1016%2Fj.addr.2007.05.005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63a&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2007.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2007.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DFaller%26aufirst%3DB.%26aulast%3DErtl%26aufirst%3DP.%26atitle%3DComputational%2520approaches%2520to%2520determine%2520drug%2520solubility%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2007%26volume%3D59%26spage%3D533%26epage%3D545%26doi%3D10.1016%2Fj.addr.2007.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit63b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Delaney, J. S.</span><span> </span><span class="NLM_article-title">Predicting aqueous solubility from structure</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span><span class="refDoi"> DOI: 10.1016/S1359-6446(04)03365-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2FS1359-6446%2804%2903365-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=15708748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlajsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=289-295&author=J.+S.+Delaney&title=Predicting+aqueous+solubility+from+structure&doi=10.1016%2FS1359-6446%2804%2903365-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63bR"><div class="casContent"><span class="casTitleNuber">63b</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting aqueous solubility from structure</span></div><div class="casAuthors">Delaney, John S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">289-295</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The aq. soly. of a drug is one of the key phys. properties that affect both its ADME profile and 'screenability' in HTS.  This review critically surveys a range of methods that can be used to predict the soly. of a compd. in water and presents some of the main issues that affect the applicability of different techniques.  As ever, there are trade-offs to be made between the speed, accuracy and transparency of methods, but current programs can provide ests. to well within an order of magnitude in favorable cases.  The need for new ways to predict soly. in more challenging systems (e.g solvents such as DMSO and charged solutes) is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjIB-nQrVm0rVg90H21EOLACvtfcHk0lg8-erT6svMJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlajsbs%253D&md5=efdd8087ce60bc613501b00420b22d6d</span></div><a href="/servlet/linkout?suffix=cit63b&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903365-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903365-3%26sid%3Dliteratum%253Aachs%26aulast%3DDelaney%26aufirst%3DJ.%2BS.%26atitle%3DPredicting%2520aqueous%2520solubility%2520from%2520structure%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D289%26epage%3D295%26doi%3D10.1016%2FS1359-6446%2804%2903365-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tetko, I. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanchuk, V. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasheva, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, A. E.</span><span> </span><span class="NLM_article-title">Estimation of aqueous solubility of chemical compounds using E-state indices</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1488</span><span class="NLM_x">–</span> <span class="NLM_lpage">1493</span><span class="refDoi"> DOI: 10.1021/ci000392t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci000392t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=1488-1493&author=I.+V.+Tetkoauthor=V.+Y.+Tanchukauthor=T.+N.+Kashevaauthor=A.+E.+Villa&title=Estimation+of+aqueous+solubility+of+chemical+compounds+using+E-state+indices&doi=10.1021%2Fci000392t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64a&amp;dbid=16384&amp;doi=10.1021%2Fci000392t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci000392t%26sid%3Dliteratum%253Aachs%26aulast%3DTetko%26aufirst%3DI.%2BV.%26aulast%3DTanchuk%26aufirst%3DV.%2BY.%26aulast%3DKasheva%26aufirst%3DT.%2BN.%26aulast%3DVilla%26aufirst%3DA.%2BE.%26atitle%3DEstimation%2520of%2520aqueous%2520solubility%2520of%2520chemical%2520compounds%2520using%2520E-state%2520indices%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2001%26volume%3D41%26spage%3D1488%26epage%3D1493%26doi%3D10.1021%2Fci000392t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit64b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tetko, I. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gasteiger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todeschini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livingstone, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ertl, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palyulin, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radchenko, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zefirov, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makarenko, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanchuk, V. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prokopenko, V. V.</span><span> </span><span class="NLM_article-title">Virtual computational chemistry laboratory – design and description</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">453</span><span class="NLM_x">–</span> <span class="NLM_lpage">463</span><span class="refDoi"> DOI: 10.1007/s10822-005-8694-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1007%2Fs10822-005-8694-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=16231203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFaht77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2005&pages=453-463&author=I.+V.+Tetkoauthor=J.+Gasteigerauthor=R.+Todeschiniauthor=A.+Mauriauthor=D.+Livingstoneauthor=P.+Ertlauthor=V.+A.+Palyulinauthor=E.+V.+Radchenkoauthor=N.+S.+Zefirovauthor=A.+S.+Makarenkoauthor=V.+Y.+Tanchukauthor=V.+V.+Prokopenko&title=Virtual+computational+chemistry+laboratory+%E2%80%93+design+and+description&doi=10.1007%2Fs10822-005-8694-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64bR"><div class="casContent"><span class="casTitleNuber">64b</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual computational chemistry laboratory - design and description</span></div><div class="casAuthors">Tetko, Igor V.; Gasteiger, Johann; Todeschini, Roberto; Mauri, Andrea; Livingstone, David; Ertl, Peter; Palyulin, Vladimir A.; Radchenko, Eugene V.; Zefirov, Nikolay S.; Makarenko, Alexander S.; Tanchuk, Vsevolod Yu.; Prokopenko, Volodymyr V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">453-463</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Internet technol. offers an excellent opportunity for the development of tools by the cooperative effort of various groups and institutions.  We have developed a multi-platform software system, Virtual Computational Chem. Lab., http://www.vcclab.org, allowing the computational chemist to perform a comprehensive series of mol. indexes/properties calcns. and data anal.  The implemented software is based on a three-tier architecture that is one of the std. technologies to provide client-server services on the Internet.  The developed software includes several popular programs, including the indexes generation program, DRAGON, a 3D structure generator, CORINA, a program to predict lipophilicity and aq. soly. of chems., ALOGPS and others.  All these programs are running at the host institutes located in five countries over Europe.  In this article we review the main features and statistics of the developed system that can be used as a prototype for academic and industry models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHcQMybC6rRrVg90H21EOLACvtfcHk0liR5RQ2o_srqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFaht77F&md5=6e48f916c58c1e772ade43fa8e4b4b1a</span></div><a href="/servlet/linkout?suffix=cit64b&amp;dbid=16384&amp;doi=10.1007%2Fs10822-005-8694-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-005-8694-y%26sid%3Dliteratum%253Aachs%26aulast%3DTetko%26aufirst%3DI.%2BV.%26aulast%3DGasteiger%26aufirst%3DJ.%26aulast%3DTodeschini%26aufirst%3DR.%26aulast%3DMauri%26aufirst%3DA.%26aulast%3DLivingstone%26aufirst%3DD.%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DPalyulin%26aufirst%3DV.%2BA.%26aulast%3DRadchenko%26aufirst%3DE.%2BV.%26aulast%3DZefirov%26aufirst%3DN.%2BS.%26aulast%3DMakarenko%26aufirst%3DA.%2BS.%26aulast%3DTanchuk%26aufirst%3DV.%2BY.%26aulast%3DProkopenko%26aufirst%3DV.%2BV.%26atitle%3DVirtual%2520computational%2520chemistry%2520laboratory%2520%25E2%2580%2593%2520design%2520and%2520description%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2005%26volume%3D19%26spage%3D453%26epage%3D463%26doi%3D10.1007%2Fs10822-005-8694-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit64c"><span><span class="NLM_label">(c) </span>VCCLAB; <span class="NLM_publisher-name">Virtual Computational Chemistry Laboratory</span>; <a href="http://www.vcclab.org" class="extLink">http://www.vcclab.org</a>, (accessed October 17, 2015).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=VCCLAB%3B+Virtual+Computational+Chemistry+Laboratory%3B+http%3A%2F%2Fwww.vcclab.org%2C+%28accessed+October+17%2C+2015%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DVCCLAB%26pub%3DVirtual%2520Computational%2520Chemistry%2520Laboratory" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Tetko, I. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanchuk, V. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasheva, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villa, A. E. P.</span><span> </span><span class="NLM_article-title">Internet software for the calculation of the lipophilicity and aqeuous solubility of chemical compounds</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">246</span><span class="NLM_x">–</span> <span class="NLM_lpage">252</span><span class="refDoi"> DOI: 10.1021/ci000393l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci000393l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2001&pages=246-252&author=I.+V.+Tetkoauthor=V.+Y.+Tanchukauthor=T.+N.+Kashevaauthor=A.+E.+P.+Villa&title=Internet+software+for+the+calculation+of+the+lipophilicity+and+aqeuous+solubility+of+chemical+compounds&doi=10.1021%2Fci000393l"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fci000393l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci000393l%26sid%3Dliteratum%253Aachs%26aulast%3DTetko%26aufirst%3DI.%2BV.%26aulast%3DTanchuk%26aufirst%3DV.%2BY.%26aulast%3DKasheva%26aufirst%3DT.%2BN.%26aulast%3DVilla%26aufirst%3DA.%2BE.%2BP.%26atitle%3DInternet%2520software%2520for%2520the%2520calculation%2520of%2520the%2520lipophilicity%2520and%2520aqeuous%2520solubility%2520of%2520chemical%2520compounds%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2001%26volume%3D41%26spage%3D246%26epage%3D252%26doi%3D10.1021%2Fci000393l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Leach, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosgrove, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruston, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacFaul, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, B.</span><span> </span><span class="NLM_article-title">Matched molecular pairs as a guide in the optimization of pharmaceutical properties: a study of aqueous solubility, plasma protein binding and oral exposure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6672</span><span class="NLM_x">–</span> <span class="NLM_lpage">6682</span><span class="refDoi"> DOI: 10.1021/jm0605233</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0605233" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6672-6682&author=A.+G.+Leachauthor=H.+D.+Jonesauthor=D.+A.+Cosgroveauthor=P.+W.+Kennyauthor=L.+Rustonauthor=P.+MacFaulauthor=J.+M.+Woodauthor=N.+Colcloughauthor=B.+Law&title=Matched+molecular+pairs+as+a+guide+in+the+optimization+of+pharmaceutical+properties%3A+a+study+of+aqueous+solubility%2C+plasma+protein+binding+and+oral+exposure&doi=10.1021%2Fjm0605233"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66a&amp;dbid=16384&amp;doi=10.1021%2Fjm0605233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0605233%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DJones%26aufirst%3DH.%2BD.%26aulast%3DCosgrove%26aufirst%3DD.%2BA.%26aulast%3DKenny%26aufirst%3DP.%2BW.%26aulast%3DRuston%26aufirst%3DL.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DLaw%26aufirst%3DB.%26atitle%3DMatched%2520molecular%2520pairs%2520as%2520a%2520guide%2520in%2520the%2520optimization%2520of%2520pharmaceutical%2520properties%253A%2520a%2520study%2520of%2520aqueous%2520solubility%252C%2520plasma%2520protein%2520binding%2520and%2520oral%2520exposure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6672%26epage%3D6682%26doi%3D10.1021%2Fjm0605233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit66b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gleeson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowe, D.</span><span> </span><span class="NLM_article-title">ADMET rules of thumb II: a comparison of the effects of common substituents on a range of ADMET parameters</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5906</span><span class="NLM_x">–</span> <span class="NLM_lpage">5919</span><span class="refDoi"> DOI: 10.1016/j.bmc.2009.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.bmc.2009.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=19632124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps1Crs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=5906-5919&author=P.+Gleesonauthor=G.+Braviauthor=S.+Modiauthor=D.+Lowe&title=ADMET+rules+of+thumb+II%3A+a+comparison+of+the+effects+of+common+substituents+on+a+range+of+ADMET+parameters&doi=10.1016%2Fj.bmc.2009.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66bR"><div class="casContent"><span class="casTitleNuber">66b</span><div class="casTitle"><span class="NLM_cas:atitle">ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters</span></div><div class="casAuthors">Gleeson, Paul; Bravi, Gianpaolo; Modi, Sandeep; Lowe, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5906-5919</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A systematic anal. of data generated in key in vitro assays within GSK has been undertaken to identify what impact a range of common substituents have on a range of ADMET parameters.  These include; P 450 1A2, 2C9, 2C19, 2D6 and 3A4 inhibition, hERG inhibition, phosphate buffer soly. and artificial membrane permeability.  We do this by identifying all matched mol. pairs, differing by the replacement of a hydrogen atom with a list of predefined substituents.  For each substituent we calc. the mean difference in the ADMET parameter for all the matched mol. pairs identified, making a statistical assessment of the difference, as well as assessing the diversity for each example to ensure that the results can be generalized.  We also relate the change in activity obsd. for each substituent to differences in their mol. properties in an effort to identify any structural alerts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk7HA_bqdilrVg90H21EOLACvtfcHk0ljj3OAJkQxumQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps1Crs7o%253D&md5=fce672cbaadb66c4d7212aa1b92bd7d2</span></div><a href="/servlet/linkout?suffix=cit66b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DGleeson%26aufirst%3DP.%26aulast%3DBravi%26aufirst%3DG.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DLowe%26aufirst%3DD.%26atitle%3DADMET%2520rules%2520of%2520thumb%2520II%253A%2520a%2520comparison%2520of%2520the%2520effects%2520of%2520common%2520substituents%2520on%2520a%2520range%2520of%2520ADMET%2520parameters%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D5906%26epage%3D5919%26doi%3D10.1016%2Fj.bmc.2009.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit66c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Griffen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robb, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, D. J.</span><span> </span><span class="NLM_article-title">Matched molecular pairs as a medicinal chemistry tool</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7739</span><span class="NLM_x">–</span> <span class="NLM_lpage">7750</span><span class="refDoi"> DOI: 10.1021/jm200452d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200452d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Wks7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7739-7750&author=E.+Griffenauthor=A.+G.+Leachauthor=G.+R.+Robbauthor=D.+J.+Warner&title=Matched+molecular+pairs+as+a+medicinal+chemistry+tool&doi=10.1021%2Fjm200452d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66cR"><div class="casContent"><span class="casTitleNuber">66c</span><div class="casTitle"><span class="NLM_cas:atitle">Matched Molecular Pairs as a Medicinal Chemistry Tool</span></div><div class="casAuthors">Griffen, Ed; Leach, Andrew G.; Robb, Graeme R.; Warner, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7739-7750</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">At the very heart of the role of a medicinal chemist or drug designer is the ability to link chem. structure to mol. properties.  This is the structure-activity relationship(SAR) or structure-property relationship(SPR).  Drug discovery projects often discover that a particular structural change causes a change to a property of interest.  The authors of this paper have been involved in developing and implementing some variations on the original theme of MMPA (matched mol. pairs anal.) and felt this to be the time to highlight some of these and to point toward future developments.  All of them are involved in the process of drug design, and it is within this context that they will set their comments.  In outline, they introduce matched mol. pair anal. and highlight why it fits so well with the kind of problem solving that is required in the process of drug design.  This will be followed by some comments concerning when the application of the methodol. is appropriate.  Then in a section intended for those with more computational interests, the authors describe the various ways that have been devised for identifying such matched pairs.  Throughout the paper, the authors have elected to use a publicly available data set to illustrate some of the comments: the ChEMBL database of inhibitors of the epidermal growth factor receptor tyrosine kinase (EGFR).  This consists of 2899 measurements of an IC50 annotated as a binding measurement on 2348 unique compds.  These measurements are drawn from a no. of sources, having been abstracted from the scientific literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMGFfO8Flm5bVg90H21EOLACvtfcHk0ljj3OAJkQxumQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Wks7jK&md5=fab3344d790d1c0ae688ec65830d9143</span></div><a href="/servlet/linkout?suffix=cit66c&amp;dbid=16384&amp;doi=10.1021%2Fjm200452d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200452d%26sid%3Dliteratum%253Aachs%26aulast%3DGriffen%26aufirst%3DE.%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DRobb%26aufirst%3DG.%2BR.%26aulast%3DWarner%26aufirst%3DD.%2BJ.%26atitle%3DMatched%2520molecular%2520pairs%2520as%2520a%2520medicinal%2520chemistry%2520tool%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7739%26epage%3D7750%26doi%3D10.1021%2Fjm200452d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Fishburn, C. S.</span><span> </span><span class="NLM_article-title">Attenuating attrition</span>.  <span class="citation_source-journal">SciBX</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">26</span>), doi:<span class="refDoi"> DOI: 10.1038/scibx.2013.647</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1038%2Fscibx.2013.647" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&issue=26&author=C.+S.+Fishburn&title=Attenuating+attrition&doi=10.1038%2Fscibx.2013.647"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fscibx.2013.647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fscibx.2013.647%26sid%3Dliteratum%253Aachs%26aulast%3DFishburn%26aufirst%3DC.%2BS.%26atitle%3DAttenuating%2520attrition%26jtitle%3DSciBX%26date%3D2013%26volume%3D6%26issue%3D26%26doi%3D10.1038%2Fscibx.2013.647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Hussain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rea, C.</span><span> </span><span class="NLM_article-title">Computationally efficient algorithm to identify matched molecular pairs (MMPs) in large data sets</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">339</span><span class="NLM_x">–</span> <span class="NLM_lpage">348</span><span class="refDoi"> DOI: 10.1021/ci900450m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci900450m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=339-348&author=J.+Hussainauthor=C.+Rea&title=Computationally+efficient+algorithm+to+identify+matched+molecular+pairs+%28MMPs%29+in+large+data+sets&doi=10.1021%2Fci900450m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Computationally Efficient Algorithm to Identify Matched Molecular Pairs (MMPs) in Large Data Sets</span></div><div class="casAuthors">Hussain, Jameed; Rea, Ceara</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">339-348</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Modern drug discovery organizations generate large vols. of SAR data.  A promising methodol. that can be used to mine this chem. data to identify novel structure-activity relationships is the matched mol. pair (MMP) methodol.  However, before the full potential of the MMP methodol. can be utilized, a MMP identification method that is capable of identifying all MMPs in large chem. data sets on modest computational hardware is required.  In this paper we report an algorithm that is capable of systematically generating all MMPs in chem. data sets.  Addnl., the algorithm is computationally efficient enough to be applied on large data sets.  As an example the algorithm was used to identify the MMPs in the ∼300k NIH MLSMR set.  The algorithm identified ∼5.3 million matched mol. pairs in the set.  These pairs cover ∼2.6 million unique mol. transformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF0rN8jaKSjrVg90H21EOLACvtfcHk0ljj3OAJkQxumQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWltr4%253D&md5=23964abebc23274f5c36c319bee52bab</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fci900450m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci900450m%26sid%3Dliteratum%253Aachs%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DRea%26aufirst%3DC.%26atitle%3DComputationally%2520efficient%2520algorithm%2520to%2520identify%2520matched%2520molecular%2520pairs%2520%2528MMPs%2529%2520in%2520large%2520data%2520sets%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26spage%3D339%26epage%3D348%26doi%3D10.1021%2Fci900450m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Warner, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St-Gallay, S. A.</span><span> </span><span class="NLM_article-title">WizePairZ: a novel algorithm to identify, encode, and exploit matched molecular pairs with unspecified cores in medicinal chemistry</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1350</span><span class="NLM_x">–</span> <span class="NLM_lpage">1357</span><span class="refDoi"> DOI: 10.1021/ci100084s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci100084s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVSgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=1350-1357&author=D.+J.+Warnerauthor=E.+Griffenauthor=S.+A.+St-Gallay&title=WizePairZ%3A+a+novel+algorithm+to+identify%2C+encode%2C+and+exploit+matched+molecular+pairs+with+unspecified+cores+in+medicinal+chemistry&doi=10.1021%2Fci100084s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">WizePairZ: A Novel Algorithm to Identify, Encode, and Exploit Matched Molecular Pairs with Unspecified Cores in Medicinal Chemistry</span></div><div class="casAuthors">Warner, Daniel J.; Griffen, Edward J.; St-Gallay, Stephen A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1350-1357</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An algorithm to automatically identify and ext. matched mol. pairs from a collection of compds. has been developed, allowing the learning assocd. with each mol. transformation to be readily exploited in drug discovery projects.  Here, we present the application to an example data set of 11 histone deacetylase inhibitors.  The matched pairs were identified, and corresponding differences in activity and lipophilicity were recorded.  These property differences were assocd. with the chem. transformations encoded in the SMIRKS reaction notation.  The transformations identified a subseries with the optimal balance of these two parameters.  Enumeration of a virtual library of compds. using the extd. transformations identified two addnl. compds. initially excluded from the anal. with an accurate estn. of their biol. activity.  We describe how the WizePairZ system can be used to archive and apply medicinal chem. knowledge from one drug discovery project to another as well as identify common bioisosteres.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSWafs2qQ4UbVg90H21EOLACvtfcHk0ljHk2TnB7g7pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVSgs7c%253D&md5=9d83eb14cdb56079429761e79beeb292</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fci100084s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci100084s%26sid%3Dliteratum%253Aachs%26aulast%3DWarner%26aufirst%3DD.%2BJ.%26aulast%3DGriffen%26aufirst%3DE.%26aulast%3DSt-Gallay%26aufirst%3DS.%2BA.%26atitle%3DWizePairZ%253A%2520a%2520novel%2520algorithm%2520to%2520identify%252C%2520encode%252C%2520and%2520exploit%2520matched%2520molecular%2520pairs%2520with%2520unspecified%2520cores%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26spage%3D1350%26epage%3D1357%26doi%3D10.1021%2Fci100084s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Papadatos, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alkarouri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillet, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willett, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadirkamanathan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luscombe, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, A. W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J. F.</span><span> </span><span class="NLM_article-title">Lead optimization using matched molecular pairs: inclusion of contextual information for enchanced prediction of hERG inhibition, solubility and lipophilicity</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1872</span><span class="NLM_x">–</span> <span class="NLM_lpage">1886</span><span class="refDoi"> DOI: 10.1021/ci100258p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci100258p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Whs7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2010&pages=1872-1886&author=G.+Papadatosauthor=M.+Alkarouriauthor=V.+J.+Gilletauthor=P.+Willettauthor=V.+Kadirkamanathanauthor=C.+N.+Luscombeauthor=G.+Braviauthor=N.+J.+Richmondauthor=S.+D.+Pickettauthor=J.+Hussainauthor=J.+M.+Pritchardauthor=A.+W.+J.+Cooperauthor=S.+J.+F.+Macdonald&title=Lead+optimization+using+matched+molecular+pairs%3A+inclusion+of+contextual+information+for+enchanced+prediction+of+hERG+inhibition%2C+solubility+and+lipophilicity&doi=10.1021%2Fci100258p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Lead Optimization Using Matched Molecular Pairs: Inclusion of Contextual Information for Enhanced Prediction of hERG Inhibition, Solubility, and Lipophilicity</span></div><div class="casAuthors">Papadatos, George; Alkarouri, Muhammad; Gillet, Valerie J.; Willett, Peter; Kadirkamanathan, Visakan; Luscombe, Christopher N.; Bravi, Gianpaolo; Richmond, Nicola J.; Pickett, Stephen D.; Hussain, Jameed; Pritchard, John M.; Cooper, Anthony W. J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1872-1886</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Previous studies of the anal. of mol. matched pairs (MMPs) have often assumed that the effect of a substructural transformation on a mol. property is independent of the context (i.e., the local structural environment in which that transformation occurs).  Expts. with large sets of hERG, soly., and lipophilicity data demonstrate that the inclusion of contextual information can enhance the predictive power of MMP analyses, with significant trends (both pos. and neg.) being identified that are not apparent when using conventional, context-independent approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLZfW5E3jgX7Vg90H21EOLACvtfcHk0ljHk2TnB7g7pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Whs7jJ&md5=464dff86e047cf1b0273571f82786994</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Fci100258p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci100258p%26sid%3Dliteratum%253Aachs%26aulast%3DPapadatos%26aufirst%3DG.%26aulast%3DAlkarouri%26aufirst%3DM.%26aulast%3DGillet%26aufirst%3DV.%2BJ.%26aulast%3DWillett%26aufirst%3DP.%26aulast%3DKadirkamanathan%26aufirst%3DV.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DBravi%26aufirst%3DG.%26aulast%3DRichmond%26aufirst%3DN.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DPritchard%26aufirst%3DJ.%2BM.%26aulast%3DCooper%26aufirst%3DA.%2BW.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DLead%2520optimization%2520using%2520matched%2520molecular%2520pairs%253A%2520inclusion%2520of%2520contextual%2520information%2520for%2520enchanced%2520prediction%2520of%2520hERG%2520inhibition%252C%2520solubility%2520and%2520lipophilicity%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2010%26volume%3D50%26spage%3D1872%26epage%3D1886%26doi%3D10.1021%2Fci100258p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Thompson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louth, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorrell, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cochrane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gever, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxendale, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silber, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roehl, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span> </span><span class="NLM_article-title">Discovery of 6-substituted indole-3-glyoxylamides as lead antiprion agents with enhanced cell line activity, improved microsomal stability and low toxicity</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4125</span><span class="NLM_x">–</span> <span class="NLM_lpage">4132</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2011.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.ejmech.2011.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=21726921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2rt7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=4125-4132&author=M.+J.+Thompsonauthor=J.+C.+Louthauthor=S.+Ferraraauthor=M.+P.+Jacksonauthor=F.+J.+Sorrellauthor=E.+J.+Cochraneauthor=J.+Geverauthor=S.+Baxendaleauthor=M.+B.+Silberauthor=H.+H.+Roehlauthor=B.+Chen&title=Discovery+of+6-substituted+indole-3-glyoxylamides+as+lead+antiprion+agents+with+enhanced+cell+line+activity%2C+improved+microsomal+stability+and+low+toxicity&doi=10.1016%2Fj.ejmech.2011.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-substituted indole-3-glyoxylamides as lead antiprion agents with enhanced cell line activity, improved microsomal stability and low toxicity</span></div><div class="casAuthors">Thompson, Mark J.; Louth, Jennifer C.; Ferrara, Steven; Jackson, Matthew P.; Sorrell, Fiona J.; Cochrane, Edward J.; Gever, Joel; Baxendale, Sarah; Silber, B. Michael; Roehl, Henry H.; Chen, Beining</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4125-4132</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of highly potent indole-3-glyoxylamide based antiprion agents was previously characterized, focusing on optimization of structure-activity relationship (SAR) at positions 1-3 of the indole system.  New libraries interrogating the SAR at indole C-4 to C-7 now demonstrate that introducing electron-withdrawing substituents at C-6 may improve biol. activity by up to an order of magnitude, and addnl. confer higher metabolic stability.  For the present screening libraries, both the degree of potency and trends in SAR were consistent across two cell line models of prion disease, and the large majority of compds. showed no evidence of toxic effects in zebrafish.  The foregoing observations thus make the indole-3-glyoxylamides an attractive lead series for continuing development as potential therapeutic agents against prion disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwDFVhW3qW9bVg90H21EOLACvtfcHk0ljHk2TnB7g7pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2rt7fF&md5=fa78e940d0023a888c4e0f2f5878fb04</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DM.%2BJ.%26aulast%3DLouth%26aufirst%3DJ.%2BC.%26aulast%3DFerrara%26aufirst%3DS.%26aulast%3DJackson%26aufirst%3DM.%2BP.%26aulast%3DSorrell%26aufirst%3DF.%2BJ.%26aulast%3DCochrane%26aufirst%3DE.%2BJ.%26aulast%3DGever%26aufirst%3DJ.%26aulast%3DBaxendale%26aufirst%3DS.%26aulast%3DSilber%26aufirst%3DM.%2BB.%26aulast%3DRoehl%26aufirst%3DH.%2BH.%26aulast%3DChen%26aufirst%3DB.%26atitle%3DDiscovery%2520of%25206-substituted%2520indole-3-glyoxylamides%2520as%2520lead%2520antiprion%2520agents%2520with%2520enhanced%2520cell%2520line%2520activity%252C%2520improved%2520microsomal%2520stability%2520and%2520low%2520toxicity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D4125%26epage%3D4132%26doi%3D10.1016%2Fj.ejmech.2011.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meanwell, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kadow, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span> </span><span class="NLM_article-title">An effective procedure for the acylation of azaindoles at C-3</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">6226</span><span class="NLM_x">–</span> <span class="NLM_lpage">6227</span><span class="refDoi"> DOI: 10.1021/jo020135i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo020135i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2002&pages=6226-6227&author=Z.+Zhangauthor=Z.+Yangauthor=H.+Wongauthor=J.+Zhuauthor=N.+A.+Meanwellauthor=J.+F.+Kadowauthor=T.+Wang&title=An+effective+procedure+for+the+acylation+of+azaindoles+at+C-3&doi=10.1021%2Fjo020135i"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjo020135i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo020135i%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DWang%26aufirst%3DT.%26atitle%3DAn%2520effective%2520procedure%2520for%2520the%2520acylation%2520of%2520azaindoles%2520at%2520C-3%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2002%26volume%3D67%26spage%3D6226%26epage%3D6227%26doi%3D10.1021%2Fjo020135i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Sabot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meunier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mioskowski, C.</span><span> </span><span class="NLM_article-title">A convenient aminolysis of esters catalyzed by 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) under solvent-free conditions</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">3863</span><span class="NLM_x">–</span> <span class="NLM_lpage">3866</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2007.03.146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.tetlet.2007.03.146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvFyqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=3863-3866&author=C.+Sabotauthor=K.+A.+Kumarauthor=S.+Meunierauthor=C.+Mioskowski&title=A+convenient+aminolysis+of+esters+catalyzed+by+1%2C5%2C7-triazabicyclo%5B4.4.0%5Ddec-5-ene+%28TBD%29+under+solvent-free+conditions&doi=10.1016%2Fj.tetlet.2007.03.146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">A convenient aminolysis of esters catalyzed by 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) under solvent-free conditions</span></div><div class="casAuthors">Sabot, Cyrille; Kumar, Kanduluru Ananda; Meunier, Stephane; Mioskowski, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3863-3866</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Aminolysis of esters by using the organocatalyst 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) is reported.  Secondary and tertiary amides were synthesized from alkyl or aryl esters with a variety of primary and secondary amines in good to excellent yields (60-94%) under solvent-free conditions (SFC).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpWg2wOwFmFLVg90H21EOLACvtfcHk0liulJyAvX_A8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvFyqs70%253D&md5=3d668f04b0b3a294db6822d467a04876</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2007.03.146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2007.03.146%26sid%3Dliteratum%253Aachs%26aulast%3DSabot%26aufirst%3DC.%26aulast%3DKumar%26aufirst%3DK.%2BA.%26aulast%3DMeunier%26aufirst%3DS.%26aulast%3DMioskowski%26aufirst%3DC.%26atitle%3DA%2520convenient%2520aminolysis%2520of%2520esters%2520catalyzed%2520by%25201%252C5%252C7-triazabicyclo%255B4.4.0%255Ddec-5-ene%2520%2528TBD%2529%2520under%2520solvent-free%2520conditions%26jtitle%3DTetrahedron%2520Lett.%26date%3D2007%26volume%3D48%26spage%3D3863%26epage%3D3866%26doi%3D10.1016%2Fj.tetlet.2007.03.146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Tsuritani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strotman, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasuda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mase, T.</span><span> </span><span class="NLM_article-title"><i>N</i>-Cyclopropylation of indoles and cyclic amides with copper(II) reagent</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1653</span><span class="NLM_x">–</span> <span class="NLM_lpage">1655</span><span class="refDoi"> DOI: 10.1021/ol800376f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol800376f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsVOmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=1653-1655&author=T.+Tsuritaniauthor=N.+A.+Strotmanauthor=Y.+Yamamotoauthor=M.+Kawasakiauthor=N.+Yasudaauthor=T.+Mase&title=N-Cyclopropylation+of+indoles+and+cyclic+amides+with+copper%28II%29+reagent&doi=10.1021%2Fol800376f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">N-Cyclopropylation of Indoles and Cyclic Amides with Copper(II) Reagent</span></div><div class="casAuthors">Tsuritani, Takayuki; Strotman, Neil A.; Yamamoto, Yuhei; Kawasaki, Masashi; Yasuda, Nobuyoshi; Mase, Toshiaki</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1653-1655</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Copper-mediated coupling reactions of cyclopropylboronic acid with indoles and cyclic amides are described.  The process utilizes catalytic or stoichiometric amts. of copper(II) acetate, DMAP, and NaHMDS at 95 °C under an atm. contg. oxygen.  A variety of functional groups remain intact throughout the reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeYQQwBWe-k7Vg90H21EOLACvtfcHk0liulJyAvX_A8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsVOmsLs%253D&md5=85663665b757993739702914df92f335</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Fol800376f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol800376f%26sid%3Dliteratum%253Aachs%26aulast%3DTsuritani%26aufirst%3DT.%26aulast%3DStrotman%26aufirst%3DN.%2BA.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKawasaki%26aufirst%3DM.%26aulast%3DYasuda%26aufirst%3DN.%26aulast%3DMase%26aufirst%3DT.%26atitle%3DN-Cyclopropylation%2520of%2520indoles%2520and%2520cyclic%2520amides%2520with%2520copper%2528II%2529%2520reagent%26jtitle%3DOrg.%2520Lett.%26date%3D2008%26volume%3D10%26spage%3D1653%26epage%3D1655%26doi%3D10.1021%2Fol800376f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Nguyen, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duong, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard, J.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johannes, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pincheng, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, D. K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuying, E. L.</span><span> </span><span class="NLM_article-title">Cascade fluorofunctionalisatdon of 2,3-unsubstituted indoles by means of electrophilic fluorination</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">10602</span><span class="NLM_x">–</span> <span class="NLM_lpage">10604</span><span class="refDoi"> DOI: 10.1039/c3cc46564k</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1039%2Fc3cc46564k" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=10602-10604&author=T.+M.+Nguyenauthor=H.+A.+Duongauthor=J.-A.+Richardauthor=C.+W.+Johannesauthor=F.+Pinchengauthor=D.+K.+J.+Yeauthor=E.+L.+Shuying&title=Cascade+fluorofunctionalisatdon+of+2%2C3-unsubstituted+indoles+by+means+of+electrophilic+fluorination&doi=10.1039%2Fc3cc46564k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1039%2Fc3cc46564k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3cc46564k%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DT.%2BM.%26aulast%3DDuong%26aufirst%3DH.%2BA.%26aulast%3DRichard%26aufirst%3DJ.-A.%26aulast%3DJohannes%26aufirst%3DC.%2BW.%26aulast%3DPincheng%26aufirst%3DF.%26aulast%3DYe%26aufirst%3DD.%2BK.%2BJ.%26aulast%3DShuying%26aufirst%3DE.%2BL.%26atitle%3DCascade%2520fluorofunctionalisatdon%2520of%25202%252C3-unsubstituted%2520indoles%2520by%2520means%2520of%2520electrophilic%2520fluorination%26jtitle%3DChem.%2520Commun.%26date%3D2013%26volume%3D49%26spage%3D10602%26epage%3D10604%26doi%3D10.1039%2Fc3cc46564k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Conner, S. E.; Gossett, L. S.; Green, J. E.; Jones, W. D.,  Jr.; Mantlo, N. B.; Matthews, D. P.; Mayhugh, D. R.; Smith, D. L.; Vance, J. A.; Wang, X.; Warshawsky, A. M.; Winneroski, L. L.,  Jr.; Xu, Y.; Zhu, G.</span><span> </span><span class="NLM_article-title">Preparation of sulfonamide derivatives, in particular <i>N</i>,<i>N</i>-benzo[<i>b</i>]thiophene sulfonamides, as PPAR modulators, especially PPAR agonists</span>. (Eli Lilly & Co., USA) WO 2004073606 A2, <span class="NLM_month">September</span><span class="NLM_day">2</span>,<span class="NLM_x"> </span><span class="NLM_year">2004</span><span class="NLM_x">; </span>SciFinder Scholar AN 2004:718289;.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=S.+E.+Conner&author=L.+S.+Gossett&author=J.+E.+Green&author=W.+D.+Jones&author=N.+B.+Mantlo&author=D.+P.+Matthews&author=D.+R.+Mayhugh&author=D.+L.+Smith&author=J.+A.+Vance&author=X.+Wang&author=A.+M.+Warshawsky&author=L.+L.+Winneroski&author=Y.+Xu&author=G.+Zhu&title=Preparation+of+sulfonamide+derivatives%2C+in+particular+N%2CN-benzo%5Bb%5Dthiophene+sulfonamides%2C+as+PPAR+modulators%2C+especially+PPAR+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DConner%26aufirst%3DS.%2BE.%26atitle%3DPreparation%2520of%2520sulfonamide%2520derivatives%252C%2520in%2520particular%2520N%252CN-benzo%255Bb%255Dthiophene%2520sulfonamides%252C%2520as%2520PPAR%2520modulators%252C%2520especially%2520PPAR%2520agonists%26date%3D2004%26jtitle%3DSciFinder%2520Scholar" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit76b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Wilson, D.; Fanning, L. T. D.; Sheth, U.; Martinborough, E.; Termin, A.; Neubert, T.; Zimmermann, N.; Knoll, T.; Whitney, T.; Kawatkar, A.; Lehsten, D.; Stamos, D.; Zhou, J.; Arumugam, V.; Gutierrez, C.</span><span> </span><span class="NLM_article-title">Heterocyclic derivatives as modulators of ion channels and their preparation, pharmaceutical compositions and use in the treatment of diseases</span>. (Vertex Pharmaceuticals Inc., USA) WO 2007075892 A2, <span class="NLM_month">July</span><span class="NLM_day">5</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span>SciFinder Scholar AN 2007:730896.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=D.+Wilson&author=L.+T.+D.+Fanning&author=U.+Sheth&author=E.+Martinborough&author=A.+Termin&author=T.+Neubert&author=N.+Zimmermann&author=T.+Knoll&author=T.+Whitney&author=A.+Kawatkar&author=D.+Lehsten&author=D.+Stamos&author=J.+Zhou&author=V.+Arumugam&author=C.+Gutierrez&title=Heterocyclic+derivatives+as+modulators+of+ion+channels+and+their+preparation%2C+pharmaceutical+compositions+and+use+in+the+treatment+of+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DD.%26atitle%3DHeterocyclic%2520derivatives%2520as%2520modulators%2520of%2520ion%2520channels%2520and%2520their%2520preparation%252C%2520pharmaceutical%2520compositions%2520and%2520use%2520in%2520the%2520treatment%2520of%2520diseases%26date%3D2007%26jtitle%3DSciFinder%2520Scholar" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Yeom, C.-E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B. M.</span><span> </span><span class="NLM_article-title">1,8-Diazabycyclo[5.4.0]undec-7-ene (DBU)-promoted efficient and versatile aza-Michael reaction</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">904</span><span class="NLM_x">–</span> <span class="NLM_lpage">909</span><span class="refDoi"> DOI: 10.1016/j.tet.2006.11.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.tet.2006.11.037" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2007&pages=904-909&author=C.-E.+Yeomauthor=M.+J.+Kimauthor=B.+M.+Kim&title=1%2C8-Diazabycyclo%5B5.4.0%5Dundec-7-ene+%28DBU%29-promoted+efficient+and+versatile+aza-Michael+reaction&doi=10.1016%2Fj.tet.2006.11.037"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2006.11.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2006.11.037%26sid%3Dliteratum%253Aachs%26aulast%3DYeom%26aufirst%3DC.-E.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DKim%26aufirst%3DB.%2BM.%26atitle%3D1%252C8-Diazabycyclo%255B5.4.0%255Dundec-7-ene%2520%2528DBU%2529-promoted%2520efficient%2520and%2520versatile%2520aza-Michael%2520reaction%26jtitle%3DTetrahedron%26date%3D2007%26volume%3D63%26spage%3D904%26epage%3D909%26doi%3D10.1016%2Fj.tet.2006.11.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Amato, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roeloffs, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigdon, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonio, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mersch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNaughton-Smith, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickenden, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suto, M. J.</span><span> </span><span class="NLM_article-title"><i>N</i>-Pyridyl and pyrimidine benzamides as KCNQ2/Q3 potassium channel openers for the treatment of epilepsy</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">481</span><span class="NLM_x">–</span> <span class="NLM_lpage">484</span><span class="refDoi"> DOI: 10.1021/ml200053x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200053x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=481-484&author=G.+Amatoauthor=R.+Roeloffsauthor=G.+C.+Rigdonauthor=B.+Antonioauthor=T.+Merschauthor=G.+McNaughton-Smithauthor=A.+G.+Wickendenauthor=P.+Fritchauthor=M.+J.+Suto&title=N-Pyridyl+and+pyrimidine+benzamides+as+KCNQ2%2FQ3+potassium+channel+openers+for+the+treatment+of+epilepsy&doi=10.1021%2Fml200053x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fml200053x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200053x%26sid%3Dliteratum%253Aachs%26aulast%3DAmato%26aufirst%3DG.%26aulast%3DRoeloffs%26aufirst%3DR.%26aulast%3DRigdon%26aufirst%3DG.%2BC.%26aulast%3DAntonio%26aufirst%3DB.%26aulast%3DMersch%26aufirst%3DT.%26aulast%3DMcNaughton-Smith%26aufirst%3DG.%26aulast%3DWickenden%26aufirst%3DA.%2BG.%26aulast%3DFritch%26aufirst%3DP.%26aulast%3DSuto%26aufirst%3DM.%2BJ.%26atitle%3DN-Pyridyl%2520and%2520pyrimidine%2520benzamides%2520as%2520KCNQ2%252FQ3%2520potassium%2520channel%2520openers%2520for%2520the%2520treatment%2520of%2520epilepsy%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D481%26epage%3D484%26doi%3D10.1021%2Fml200053x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Kel'in, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sromek, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gevorgyan, V.</span><span> </span><span class="NLM_article-title">A novel Cu-assisted cycloisomerization of alkynyl imines: efficient synthesis of pyrroles and pyrrole-containing heterocycles</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">2074</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span><span class="refDoi"> DOI: 10.1021/ja0058684</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0058684" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2001&pages=2074-2075&author=A.+V.+Kel%27inauthor=A.+W.+Sromekauthor=V.+Gevorgyan&title=A+novel+Cu-assisted+cycloisomerization+of+alkynyl+imines%3A+efficient+synthesis+of+pyrroles+and+pyrrole-containing+heterocycles&doi=10.1021%2Fja0058684"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fja0058684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0058684%26sid%3Dliteratum%253Aachs%26aulast%3DKel%2527in%26aufirst%3DA.%2BV.%26aulast%3DSromek%26aufirst%3DA.%2BW.%26aulast%3DGevorgyan%26aufirst%3DV.%26atitle%3DA%2520novel%2520Cu-assisted%2520cycloisomerization%2520of%2520alkynyl%2520imines%253A%2520efficient%2520synthesis%2520of%2520pyrroles%2520and%2520pyrrole-containing%2520heterocycles%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2001%26volume%3D123%26spage%3D2074%26epage%3D2075%26doi%3D10.1021%2Fja0058684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span> </span><span class="NLM_article-title">Development of a practical synthesis of STA-5312, a novel indolizine oxalylamide microtubule inhibitor</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">246</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span><span class="refDoi"> DOI: 10.1021/op6002852</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op6002852" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVyitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=246-250&author=H.+Liauthor=Z.+Xiaauthor=S.+Chenauthor=K.+Koyaauthor=M.+Onoauthor=L.+Sun&title=Development+of+a+practical+synthesis+of+STA-5312%2C+a+novel+indolizine+oxalylamide+microtubule+inhibitor&doi=10.1021%2Fop6002852"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a practical synthesis of STA-5312, a novel indolizine oxalylamide microtubule inhibitor</span></div><div class="casAuthors">Li, Hao; Xia, Zhiqiang; Chen, Shoujun; Koya, Keizo; Ono, Mitsunori; Sun, Lijun</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-250</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An efficient synthesis of the novel microtubule inhibitor STA-5312 (3-[(4-cyanophenyl)methyl]-N-(3-methyl-5-isothiazolyl)-α-oxo-1-indolizineacetamide) was developed.  A novel DMF/Me2SO4 directed regioselective synthesis of the 3-(4-cyanobenzoyl)-indolizine (4) was a crit. transformation within the four-step process.  Alternatively, a CuCl mediated synthesis of 3-(4-cyanobenzyl)indolizine (5) was also developed.  All intermediates were obtained in high quality and were used directly for the next step without extensive purifn.  The drug substance itself was purified by recrystn. from a mixt. of THF and water, resulting in a high purity product (HPLC >98%).  The process was applied successfully in the manufg. of kilograms of GMP API.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEfERaIRQgoLVg90H21EOLACvtfcHk0liJQ355QBNd0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVyitb4%253D&md5=4bb3dbe5cca1398bef973cef1bb83920</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fop6002852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop6002852%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DH.%26aulast%3DXia%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DKoya%26aufirst%3DK.%26aulast%3DOno%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DL.%26atitle%3DDevelopment%2520of%2520a%2520practical%2520synthesis%2520of%2520STA-5312%252C%2520a%2520novel%2520indolizine%2520oxalylamide%2520microtubule%2520inhibitor%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2007%26volume%3D11%26spage%3D246%26epage%3D250%26doi%3D10.1021%2Fop6002852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Debnar, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreisigacker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menche, D.</span><span> </span><span class="NLM_article-title">Highly regioselective opening of zirconacyclopentadienes by remote coordination: concise synthesis of the furan core of the leupyrrins</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">725</span><span class="NLM_x">–</span> <span class="NLM_lpage">727</span><span class="refDoi"> DOI: 10.1039/C2CC37678D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1039%2FC2CC37678D" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=725-727&author=T.+Debnarauthor=S.+Dreisigackerauthor=D.+Menche&title=Highly+regioselective+opening+of+zirconacyclopentadienes+by+remote+coordination%3A+concise+synthesis+of+the+furan+core+of+the+leupyrrins&doi=10.1039%2FC2CC37678D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1039%2FC2CC37678D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2CC37678D%26sid%3Dliteratum%253Aachs%26aulast%3DDebnar%26aufirst%3DT.%26aulast%3DDreisigacker%26aufirst%3DS.%26aulast%3DMenche%26aufirst%3DD.%26atitle%3DHighly%2520regioselective%2520opening%2520of%2520zirconacyclopentadienes%2520by%2520remote%2520coordination%253A%2520concise%2520synthesis%2520of%2520the%2520furan%2520core%2520of%2520the%2520leupyrrins%26jtitle%3DChem.%2520Commun.%26date%3D2013%26volume%3D49%26spage%3D725%26epage%3D727%26doi%3D10.1039%2FC2CC37678D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Chen, Y.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, S.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wistuba, I. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, C.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, K.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, T.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, C.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M.-C.</span><span> </span><span class="NLM_article-title">Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e21428</span><span class="refDoi"> DOI: 10.1371/journal.pone.0021428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1371%2Fjournal.pone.0021428" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e21428&author=Y.-J.+Chenauthor=W.-C.+Huangauthor=Y.-L.+Weiauthor=S.-C.+Hsuauthor=P.+Yuanauthor=H.+Y.+Linauthor=I.+I.+Wistubaauthor=J.+J.+Leeauthor=C.-J.+Yenauthor=W.-C.+Suauthor=K.-Y.+Changauthor=W.-C.+Changauthor=T.-C.+Chouauthor=C.-K.+Chouauthor=C.-H.+Tsaiauthor=M.-C.+Hung&title=Elevated+BCRP%2FABCG2+expression+confers+acquired+resistance+to+gefitinib+in+wild-type+EGFR-expressing+cells&doi=10.1371%2Fjournal.pone.0021428"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0021428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0021428%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.-J.%26aulast%3DHuang%26aufirst%3DW.-C.%26aulast%3DWei%26aufirst%3DY.-L.%26aulast%3DHsu%26aufirst%3DS.-C.%26aulast%3DYuan%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DH.%2BY.%26aulast%3DWistuba%26aufirst%3DI.%2BI.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DYen%26aufirst%3DC.-J.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DChang%26aufirst%3DK.-Y.%26aulast%3DChang%26aufirst%3DW.-C.%26aulast%3DChou%26aufirst%3DT.-C.%26aulast%3DChou%26aufirst%3DC.-K.%26aulast%3DTsai%26aufirst%3DC.-H.%26aulast%3DHung%26aufirst%3DM.-C.%26atitle%3DElevated%2520BCRP%252FABCG2%2520expression%2520confers%2520acquired%2520resistance%2520to%2520gefitinib%2520in%2520wild-type%2520EGFR-expressing%2520cells%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De21428%26doi%3D10.1371%2Fjournal.pone.0021428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shelanski, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaskin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantor, C. R.</span><span> </span><span class="NLM_article-title">Microtubule assembly in the absence of added nucleotides</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">765</span><span class="NLM_x">–</span> <span class="NLM_lpage">768</span><span class="refDoi"> DOI: 10.1073/pnas.70.3.765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1073%2Fpnas.70.3.765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=4514990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADyaE3sXhsVCgtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1973&pages=765-768&author=M.+L.+Shelanskiauthor=F.+Gaskinauthor=C.+R.+Cantor&title=Microtubule+assembly+in+the+absence+of+added+nucleotides&doi=10.1073%2Fpnas.70.3.765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83aR"><div class="casContent"><span class="casTitleNuber">83a</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule assembly in the absence of added nucleotides</span></div><div class="casAuthors">Shelanski, Michael L.; Gaskin, Felicia; Cantor, Charles R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">765-8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Microtubule assembly was enhanced by the addn. of M sucrose or 4 M glycerol to the reassembly mixt.  Tubulin was purified from guinea pig brain readily and in good yield by tycles of assembly in glycerol-contg. solns  The tubules assembled in glycerol and sucrose were more stable than tubules formed in the absence of these compds.  Assembly occurred in glycerol or sucrose in he absence of ATP or GT but was greatly accelerated by their presence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVpPUVyzxhcbVg90H21EOLACvtfcHk0lgACDN_wE6ZlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXhsVCgtrs%253D&md5=c0eb0f728884f0a0eba421d633c9031b</span></div><a href="/servlet/linkout?suffix=cit83a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.70.3.765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.70.3.765%26sid%3Dliteratum%253Aachs%26aulast%3DShelanski%26aufirst%3DM.%2BL.%26aulast%3DGaskin%26aufirst%3DF.%26aulast%3DCantor%26aufirst%3DC.%2BR.%26atitle%3DMicrotubule%2520assembly%2520in%2520the%2520absence%2520of%2520added%2520nucleotides%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1973%26volume%3D70%26spage%3D765%26epage%3D768%26doi%3D10.1073%2Fpnas.70.3.765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit83b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timasheff, S. N.</span><span> </span><span class="NLM_article-title">In vitro reconstitution of calf brain microtubules: effects of solution variables</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1754</span><span class="NLM_x">–</span> <span class="NLM_lpage">1764</span><span class="refDoi"> DOI: 10.1021/bi00627a037</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00627a037" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADyaE2sXhvVCkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1977&pages=1754-1764&author=J.+C.+Leeauthor=S.+N.+Timasheff&title=In+vitro+reconstitution+of+calf+brain+microtubules%3A+effects+of+solution+variables&doi=10.1021%2Fbi00627a037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83bR"><div class="casContent"><span class="casTitleNuber">83b</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro reconstitution of calf brain microtubules:  effects of solution variables</span></div><div class="casAuthors">Lee, James C.; Timasheff, Serge N.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1754-64</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">The effects of soln. variables on the in vitro reconstitution of calf brain tubulin were investigated at pH 7.0.  Reconstitution of microtubules was successful in a variety of buffer systems.  Microtubule formation was promoted by Mg2+ and GTP, but inhibited by Ca2+.  The dependence of the apparent assocn. const. for microtubule formation on ligand concn. was analyzed.  The formation of a tubulin-tubulin contact involves the binding of 1 addnl. Mg2+/tubulin dimer.  Microtubule formation is also accompanied by the apparent binding of 1 addnl. proton and the release of H2O mols., as suggested by thermodyn. parameters.  The reaction is entropy driven with an apparent heat capacity change, ΔCp, of -1500 cal/degree-mol.  The enhancement of tubulin reassembly by glycerol is most likely due to nonspecific protein-solvent general thermodyn. interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMRSO63LMZTrVg90H21EOLACvtfcHk0lgACDN_wE6ZlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXhvVCkuro%253D&md5=0764be20538284d0834b08ca054e751e</span></div><a href="/servlet/linkout?suffix=cit83b&amp;dbid=16384&amp;doi=10.1021%2Fbi00627a037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00627a037%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTimasheff%26aufirst%3DS.%2BN.%26atitle%3DIn%2520vitro%2520reconstitution%2520of%2520calf%2520brain%2520microtubules%253A%2520effects%2520of%2520solution%2520variables%26jtitle%3DBiochemistry%26date%3D1977%26volume%3D16%26spage%3D1754%26epage%3D1764%26doi%3D10.1021%2Fbi00627a037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Bonne, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heusèle, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantaloni, D.</span><span> </span><span class="NLM_article-title">4′,6-Diamidino-2-phenylindole, a fluorescent probe for tubulin and microtubules</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">260</span><span class="NLM_x">, </span> <span class="NLM_fpage">2819</span><span class="NLM_x">–</span> <span class="NLM_lpage">2825</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=260&publication_year=1985&pages=2819-2825&author=D.+Bonneauthor=C.+Heus%C3%A8leauthor=C.+Simonauthor=D.+Pantaloni&title=4%E2%80%B2%2C6-Diamidino-2-phenylindole%2C+a+fluorescent+probe+for+tubulin+and+microtubules"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBonne%26aufirst%3DD.%26aulast%3DHeus%25C3%25A8le%26aufirst%3DC.%26aulast%3DSimon%26aufirst%3DC.%26aulast%3DPantaloni%26aufirst%3DD.%26atitle%3D4%25E2%2580%25B2%252C6-Diamidino-2-phenylindole%252C%2520a%2520fluorescent%2520probe%2520for%2520tubulin%2520and%2520microtubules%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1985%26volume%3D260%26spage%3D2819%26epage%3D2825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Cortese, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhattacharyya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolff, J.</span><span> </span><span class="NLM_article-title">Podophyllotoxin as a probe for the colchicine binding site of tubulin</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">252</span><span class="NLM_x">, </span> <span class="NLM_fpage">1134</span><span class="NLM_x">–</span> <span class="NLM_lpage">1140</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=252&publication_year=1977&pages=1134-1140&author=F.+Corteseauthor=B.+Bhattacharyyaauthor=J.+Wolff&title=Podophyllotoxin+as+a+probe+for+the+colchicine+binding+site+of+tubulin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCortese%26aufirst%3DF.%26aulast%3DBhattacharyya%26aufirst%3DB.%26aulast%3DWolff%26aufirst%3DJ.%26atitle%3DPodophyllotoxin%2520as%2520a%2520probe%2520for%2520the%2520colchicine%2520binding%2520site%2520of%2520tubulin%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1977%26volume%3D252%26spage%3D1134%26epage%3D1140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Wallner, B. P.; Schwartz, B. E.; Komarnitsky, P. B.; Bacher, G.; Kutscher, B.; Raab, G.</span><span> </span><span class="NLM_article-title">Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer</span>. (Ziopharm Oncology Inc., USA) WO 2008066807 A1, <span class="NLM_month">Jun</span><span class="NLM_day">5</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>SciFinder Scholar AN 2008:673085.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=B.+P.+Wallner&author=B.+E.+Schwartz&author=P.+B.+Komarnitsky&author=G.+Bacher&author=B.+Kutscher&author=G.+Raab&title=Use+of+indolyl-3-glyoxylic+acid+derivatives+including+indibulin%2C+alone+or+in+combination+with+further+agents+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWallner%26aufirst%3DB.%2BP.%26atitle%3DUse%2520of%2520indolyl-3-glyoxylic%2520acid%2520derivatives%2520including%2520indibulin%252C%2520alone%2520or%2520in%2520combination%2520with%2520further%2520agents%2520for%2520treating%2520cancer%26date%3D2008%26jtitle%3DSciFinder%2520Scholar" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Yamada, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorbsky, G. J.</span><span> </span><span class="NLM_article-title">Spindle checkpoint function and cellular sensitivity to antimitotic drugs</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">2963</span><span class="NLM_x">–</span> <span class="NLM_lpage">2969</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1158%2F1535-7163.MCT-06-0319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=17172401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtlagsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=2963-2969&author=H.+Y.+Yamadaauthor=G.+J.+Gorbsky&title=Spindle+checkpoint+function+and+cellular+sensitivity+to+antimitotic+drugs&doi=10.1158%2F1535-7163.MCT-06-0319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Spindle checkpoint function and cellular sensitivity to antimitotic drugs</span></div><div class="casAuthors">Yamada, Hiroshi Y.; Gorbsky, Gary J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2963-2969</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review which discusses the mitotic/postmitotic events and mol. signaling involved in cancer treatments with antimitotic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaGJPPHTlIL7Vg90H21EOLACvtfcHk0lhFkl9ihj4nqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtlagsb3O&md5=38e31d7e1983aa5400fa6d5896effaa6</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0319%26sid%3Dliteratum%253Aachs%26aulast%3DYamada%26aufirst%3DH.%2BY.%26aulast%3DGorbsky%26aufirst%3DG.%2BJ.%26atitle%3DSpindle%2520checkpoint%2520function%2520and%2520cellular%2520sensitivity%2520to%2520antimitotic%2520drugs%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D2963%26epage%3D2969%26doi%3D10.1158%2F1535-7163.MCT-06-0319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Harker, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sikic, B. I.</span><span> </span><span class="NLM_article-title">Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4091</span><span class="NLM_x">–</span> <span class="NLM_lpage">4096</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=4028002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADyaL2MXlslWmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1985&pages=4091-4096&author=W.+G.+Harkerauthor=B.+I.+Sikic&title=Multidrug+%28pleiotropic%29+resistance+in+doxorubicin-selected+variants+of+the+human+sarcoma+cell+line+MES-SA"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA</span></div><div class="casAuthors">Harker, W. Graydon; Sikic, Branimir Ivan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4091-6</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Doxorubicin (DOX)  [23214-92-8]-resistant sublines of the human sarcoma cell line MES-SA were selected by continuous in vitro exposure to DOX; stepwise increases in DOX concn. produced variants which were 25- and 100-fold resistant to DOX.  These sublines displayed marked cross-resistant to daunorubicin  [20830-81-3], dactinomycin  [50-76-0], mitoxantrone  [65271-80-9], colchicine  [64-86-8], vincristine  [57-22-7], vinblastine  [865-21-4], and etoposide  [33419-42-0] and moderate resistance to mitomycin C  [50-07-7] and melphalan  [148-82-3].  Cross-resistance was not obsd., however, to methotrexate  [59-05-2], 5-fluorouracil  [51-21-8], bleomycin  [11056-06-7], carmustine  [154-93-8], or cisplatin  [15663-27-1].  DOX resistance in these cell lines appeared to be stable despite long periods of growth in drug-free medium.  Two addnl. marker chromosomes were identified in the 100-fold resistant variant, which indicated clonal selection during drug exposure, but no double minute chromosomes or homogeneously staining regions were noted.  Doxorubicin accumulation in the DOX-resistant cells was reduced by approx. 50% compared to that of the sensitive MES-SA cells, as a result of enhanced efflux of DOX from the resistant cells.  There was no evidence of appreciable DOX metab. by either the sensitive or resistant cells.  These studies demonstrate marked DOX resistance and multidrug resistance arising in a human sarcoma line during exposure to DOX.  The pleiotropic nature of this resistance is similar to that described in other models.  Decreased drug accumulation due to enhanced drug efflux is identified as a major mechanism of resistance in these cells, although other factors may also be involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJX9_zdf-RX7Vg90H21EOLACvtfcHk0lhFkl9ihj4nqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXlslWmtLY%253D&md5=d08d715f84eccd8fa0a3638a5c0e4a9a</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHarker%26aufirst%3DW.%2BG.%26aulast%3DSikic%26aufirst%3DB.%2BI.%26atitle%3DMultidrug%2520%2528pleiotropic%2529%2520resistance%2520in%2520doxorubicin-selected%2520variants%2520of%2520the%2520human%2520sarcoma%2520cell%2520line%2520MES-SA%26jtitle%3DCancer%2520Res.%26date%3D1985%26volume%3D45%26spage%3D4091%26epage%3D4096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffrézou, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durán, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sikic, B. I.</span><span> </span><span class="NLM_article-title">Prevalence of multidrug resistance related to activation of the <i>Mdr1</i> gene in human sarcoma mutants derived by single-step doxorubicin selection</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4980</span><span class="NLM_x">–</span> <span class="NLM_lpage">4987</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1994&pages=4980-4987&author=G.+Chenauthor=J.-P.+Jaffr%C3%A9zouauthor=W.+H.+Flemingauthor=G.+E.+Dur%C3%A1nauthor=B.+I.+Sikic&title=Prevalence+of+multidrug+resistance+related+to+activation+of+the+Mdr1+gene+in+human+sarcoma+mutants+derived+by+single-step+doxorubicin+selection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%26aulast%3DJaffr%25C3%25A9zou%26aufirst%3DJ.-P.%26aulast%3DFleming%26aufirst%3DW.%2BH.%26aulast%3DDur%25C3%25A1n%26aufirst%3DG.%2BE.%26aulast%3DSikic%26aufirst%3DB.%2BI.%26atitle%3DPrevalence%2520of%2520multidrug%2520resistance%2520related%2520to%2520activation%2520of%2520the%2520Mdr1%2520gene%2520in%2520human%2520sarcoma%2520mutants%2520derived%2520by%2520single-step%2520doxorubicin%2520selection%26jtitle%3DCancer%2520Res.%26date%3D1994%26volume%3D54%26spage%3D4980%26epage%3D4987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakaeda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohmoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirakawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuroda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasuga, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okumura, K.</span><span> </span><span class="NLM_article-title">Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2 and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1124/dmd.30.1.4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1124%2Fdmd.30.1.4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2002&pages=4-6&author=T.+Nakamuraauthor=T.+Sakaedaauthor=N.+Ohmotoauthor=T.+Tamuraauthor=N.+Aoyamaauthor=T.+Shirakawaauthor=T.+Nakamuraauthor=K.+I.+Kimauthor=S.+R.+Kimauthor=Y.+Kurodaauthor=M.+Matsuoauthor=M.+Kasugaauthor=K.+Okumura&title=Real-time+quantitative+polymerase+chain+reaction+for+MDR1%2C+MRP1%2C+MRP2+and+CYP3A-mRNA+levels+in+Caco-2+cell+lines%2C+human+duodenal+enterocytes%2C+normal+colorectal+tissues%2C+and+colorectal+adenocarcinomas&doi=10.1124%2Fdmd.30.1.4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1124%2Fdmd.30.1.4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.30.1.4%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DSakaeda%26aufirst%3DT.%26aulast%3DOhmoto%26aufirst%3DN.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DAoyama%26aufirst%3DN.%26aulast%3DShirakawa%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DK.%2BI.%26aulast%3DKim%26aufirst%3DS.%2BR.%26aulast%3DKuroda%26aufirst%3DY.%26aulast%3DMatsuo%26aufirst%3DM.%26aulast%3DKasuga%26aufirst%3DM.%26aulast%3DOkumura%26aufirst%3DK.%26atitle%3DReal-time%2520quantitative%2520polymerase%2520chain%2520reaction%2520for%2520MDR1%252C%2520MRP1%252C%2520MRP2%2520and%2520CYP3A-mRNA%2520levels%2520in%2520Caco-2%2520cell%2520lines%252C%2520human%2520duodenal%2520enterocytes%252C%2520normal%2520colorectal%2520tissues%252C%2520and%2520colorectal%2520adenocarcinomas%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2002%26volume%3D30%26spage%3D4%26epage%3D6%26doi%3D10.1124%2Fdmd.30.1.4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Gutmann, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fricker, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Török, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michael, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beglinger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewe, J.</span><span> </span><span class="NLM_article-title">Evidence for different ABC-transporters in Caco-2 cells modulating drug uptake</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">402</span><span class="NLM_x">–</span> <span class="NLM_lpage">407</span><span class="refDoi"> DOI: 10.1023/A:1018825819249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1023%2FA%3A1018825819249" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1999&pages=402-407&author=H.+Gutmannauthor=G.+Frickerauthor=M.+T%C3%B6r%C3%B6kauthor=S.+Michaelauthor=C.+Beglingerauthor=J.+Drewe&title=Evidence+for+different+ABC-transporters+in+Caco-2+cells+modulating+drug+uptake&doi=10.1023%2FA%3A1018825819249"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1023%2FA%3A1018825819249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1018825819249%26sid%3Dliteratum%253Aachs%26aulast%3DGutmann%26aufirst%3DH.%26aulast%3DFricker%26aufirst%3DG.%26aulast%3DT%25C3%25B6r%25C3%25B6k%26aufirst%3DM.%26aulast%3DMichael%26aufirst%3DS.%26aulast%3DBeglinger%26aufirst%3DC.%26aulast%3DDrewe%26aufirst%3DJ.%26atitle%3DEvidence%2520for%2520different%2520ABC-transporters%2520in%2520Caco-2%2520cells%2520modulating%2520drug%2520uptake%26jtitle%3DPharm.%2520Res.%26date%3D1999%26volume%3D16%26spage%3D402%26epage%3D407%26doi%3D10.1023%2FA%3A1018825819249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Xia, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miwa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, L.-S.</span><span> </span><span class="NLM_article-title">Expression, localization and functional characteristics of breast cancer resistance protein in Caco-2 cells</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">637</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span><span class="refDoi"> DOI: 10.1124/dmd.104.003442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1124%2Fdmd.104.003442" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=637-643&author=C.+Q.+Xiaauthor=N.+Liuauthor=D.+Yangauthor=G.+Miwaauthor=L.-S.+Gan&title=Expression%2C+localization+and+functional+characteristics+of+breast+cancer+resistance+protein+in+Caco-2+cells&doi=10.1124%2Fdmd.104.003442"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1124%2Fdmd.104.003442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.104.003442%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DC.%2BQ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DMiwa%26aufirst%3DG.%26aulast%3DGan%26aufirst%3DL.-S.%26atitle%3DExpression%252C%2520localization%2520and%2520functional%2520characteristics%2520of%2520breast%2520cancer%2520resistance%2520protein%2520in%2520Caco-2%2520cells%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D637%26epage%3D643%26doi%3D10.1124%2Fdmd.104.003442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Breslin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Driscoll, L.</span><span> </span><span class="NLM_article-title">Three-dimensional cell culture: the missing link in drug discovery</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span><span class="refDoi"> DOI: 10.1016/j.drudis.2012.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.drudis.2012.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=23073387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1aqs7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=240-249&author=S.+Breslinauthor=L.+O%E2%80%99Driscoll&title=Three-dimensional+cell+culture%3A+the+missing+link+in+drug+discovery&doi=10.1016%2Fj.drudis.2012.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Three-dimensional cell culture: the missing link in drug discovery</span></div><div class="casAuthors">Breslin, Susan; O'Driscoll, Lorraine</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">240-249</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cells, grown as monolayers (2D models), are routinely used as initial model systems for evaluating the effectiveness and safety of libraries of mols. with potential as therapeutic drugs.  While this initial screening precedes preclin. animal studies before advancing to human clin. trials, cultured cells frequently det. the initial, yet crucial, 'stop/go' decisions on the progressing of the development of a drug.  Growing cells as three-dimensional (3D) models more analogous to their existence in vivo, for example, akin to a tumor, and possibly co-cultured with other cells and cellular components that naturally occur in their microenvironment may be more clin. relevant.  Here, in the context of anti-cancer drug screening, we review 2D and 3D culture approaches, consider the strengths and relevance of each method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6L1vxblLJJbVg90H21EOLACvtfcHk0lht9ME3pM96Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1aqs7%252FN&md5=caec0a115779d0204fea9e083963487f</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2012.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2012.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DBreslin%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Driscoll%26aufirst%3DL.%26atitle%3DThree-dimensional%2520cell%2520culture%253A%2520the%2520missing%2520link%2520in%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D240%26epage%3D249%26doi%3D10.1016%2Fj.drudis.2012.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Hirschhaeuser, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menne, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dittfeld, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller-Klieser, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunz-Schughart, L. A.</span><span> </span><span class="NLM_article-title">Multicellular tumor spheroids: an underestimated tool is catching up again</span> <span class="citation_source-journal">J. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">148</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span><span class="refDoi"> DOI: 10.1016/j.jbiotec.2010.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1016%2Fj.jbiotec.2010.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=20097238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvVOqtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2010&pages=3-15&author=F.+Hirschhaeuserauthor=H.+Menneauthor=C.+Dittfeldauthor=J.+Westauthor=W.+Mueller-Klieserauthor=L.+A.+Kunz-Schughart&title=Multicellular+tumor+spheroids%3A+an+underestimated+tool+is+catching+up+again&doi=10.1016%2Fj.jbiotec.2010.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Multicellular tumor spheroids: An underestimated tool is catching up again</span></div><div class="casAuthors">Hirschhaeuser, Franziska; Menne, Heike; Dittfeld, Claudia; West, Jonathan; Mueller-Klieser, Wolfgang; Kunz-Schughart, Leoni A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-15</span>CODEN:
                <span class="NLM_cas:coden">JBITD4</span>;
        ISSN:<span class="NLM_cas:issn">0168-1656</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The present article highlights the rationale, potential and flexibility of tumor spheroid mono- and cocultures for implementation into state of the art anti-cancer therapy test platforms.  Unlike classical monolayer-based models, spheroids strikingly mirror the 3D cellular context and therapeutically relevant pathophysiol. gradients of in vivo tumors.  Some concepts for standardization and automation of spheroid culturing, monitoring and anal. are discussed, and the challenges to define the most convenient anal. endpoints for therapy testing are outlined.  The potential of spheroids to contribute to either the elimination of poor drug candidates at the pre-animal and pre-clin. state or the identification of promising drugs that would fail in classical 2D cell assays is emphasized.  Microtechnologies, in the form of micropatterning and microfluidics, are also discussed and offer the exciting prospect of standardized spheroid mass prodn. to tackle high-throughput screening applications within the context of traditional lab. settings.  The extension towards more sophisticated spheroid coculture models which more closely reflect heterologous tumor tissues composed of tumor and various stromal cell types is also covered.  Examples are given with particular emphasis on tumor-immune cell cocultures and their usefulness for testing novel immunotherapeutic treatment strategies.  Finally, tumor cell heterogeneity and the extraordinary possibilities of putative cancer stem/tumor-initiating cell populations that can be maintained and expanded in sphere-forming assays are introduced.  The relevance of the cancer stem cell hypothesis for cancer cure is highlighted, with the resp. sphere cultures being envisioned as an integral tool for next generation drug development offensives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqdopugkTjz7Vg90H21EOLACvtfcHk0lht9ME3pM96Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvVOqtbc%253D&md5=a35667ebcc7c36348b9400a2239e6ae7</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.jbiotec.2010.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbiotec.2010.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DHirschhaeuser%26aufirst%3DF.%26aulast%3DMenne%26aufirst%3DH.%26aulast%3DDittfeld%26aufirst%3DC.%26aulast%3DWest%26aufirst%3DJ.%26aulast%3DMueller-Klieser%26aufirst%3DW.%26aulast%3DKunz-Schughart%26aufirst%3DL.%2BA.%26atitle%3DMulticellular%2520tumor%2520spheroids%253A%2520an%2520underestimated%2520tool%2520is%2520catching%2520up%2520again%26jtitle%3DJ.%2520Biotechnol.%26date%3D2010%26volume%3D148%26spage%3D3%26epage%3D15%26doi%3D10.1016%2Fj.jbiotec.2010.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Colley, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hearnden, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avila-Olias, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cecchin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canton, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacNeil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warren, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeating, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armes, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murdoch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornhill, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battaglia, G.</span><span> </span><span class="NLM_article-title">Polymersome-mediated delivery of combination anticancer therapy to head and neck cancer cells: 2D and 3D <i>in vitro</i> evaluation</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1176</span><span class="NLM_x">–</span> <span class="NLM_lpage">1188</span><span class="refDoi"> DOI: 10.1021/mp400610b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp400610b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC2cXis1ejt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=1176-1188&author=H.+E.+Colleyauthor=V.+Hearndenauthor=M.+Avila-Oliasauthor=D.+Cecchinauthor=I.+Cantonauthor=J.+Madsenauthor=S.+MacNeilauthor=N.+Warrenauthor=K.+Huauthor=J.+A.+McKeatingauthor=S.+P.+Armesauthor=C.+Murdochauthor=M.+H.+Thornhillauthor=G.+Battaglia&title=Polymersome-mediated+delivery+of+combination+anticancer+therapy+to+head+and+neck+cancer+cells%3A+2D+and+3D+in+vitro+evaluation&doi=10.1021%2Fmp400610b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Polymersome-Mediated Delivery of Combination Anticancer Therapy to Head and Neck Cancer Cells: 2D and 3D in Vitro Evaluation</span></div><div class="casAuthors">Colley, Helen E.; Hearnden, Vanessa; Avila-Olias, Milagros; Cecchin, Denis; Canton, Irene; Madsen, Jeppe; MacNeil, Sheila; Warren, Nicholas; Hu, Ke; McKeating, Jane A.; Armes, Steven P.; Murdoch, Craig; Thornhill, Martin H.; Battaglia, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1176-1188</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polymersomes have the potential to encapsulate and deliver chemotherapeutic drugs into tumor cells, reducing off-target toxicity that often compromises anticancer treatment.  Here, we assess the ability of the pH-sensitive poly 2-(methacryloyloxy)ethyl phosphorylcholine (PMPC)- poly 2-(diisopropylamino)ethyl methacrylate (PDPA) polymersomes to encapsulate chemotherapeutic agents for effective combinational anticancer therapy.  Polymersome uptake and ability to deliver encapsulated drugs into healthy normal oral cells and oral head and neck squamous cell carcinoma (HNSCC) cells was measured in two and three-dimensional culture systems.  PMPC-PDPA polymersomes were more rapidly internalized by HNSCC cells compared to normal oral cells.  Polymersome cellular uptake was found to be mediated by class B scavenger receptors.  We also obsd. that these receptors are more highly expressed by cancer cells compared to normal oral cells, enabling polymersome-mediated targeting.  Doxorubicin and paclitaxel were encapsulated into pH-sensitive PMPC-PDPA polymersomes with high efficiencies either in isolation or as a dual-load for both singular and combinational delivery.  In monolayer culture, only a short exposure to drug-loaded polymersomes was required to elicit a strong cytotoxic effect.  When delivered to three-dimensional tumor models, PMPC-PDPA polymersomes were able to penetrate deep into the center of the spheroid resulting in extensive cell damage when loaded with both singular and dual-loaded chemotherapeutics.  PMPC-PDPA polymersomes offer a novel system for the effective delivery of chemotherapeutics for the treatment of HNSCC.  Moreover, the preferential internalization of PMPC polymersomes by exploiting elevated scavenger receptor expression on cancer cells opens up the opportunity to target polymersomes to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFYzFKKeUtR7Vg90H21EOLACvtfcHk0lisdUCrY3pbfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXis1ejt7w%253D&md5=2497815bbd4096beea08d6423d5496d7</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fmp400610b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp400610b%26sid%3Dliteratum%253Aachs%26aulast%3DColley%26aufirst%3DH.%2BE.%26aulast%3DHearnden%26aufirst%3DV.%26aulast%3DAvila-Olias%26aufirst%3DM.%26aulast%3DCecchin%26aufirst%3DD.%26aulast%3DCanton%26aufirst%3DI.%26aulast%3DMadsen%26aufirst%3DJ.%26aulast%3DMacNeil%26aufirst%3DS.%26aulast%3DWarren%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DK.%26aulast%3DMcKeating%26aufirst%3DJ.%2BA.%26aulast%3DArmes%26aufirst%3DS.%2BP.%26aulast%3DMurdoch%26aufirst%3DC.%26aulast%3DThornhill%26aufirst%3DM.%2BH.%26aulast%3DBattaglia%26aufirst%3DG.%26atitle%3DPolymersome-mediated%2520delivery%2520of%2520combination%2520anticancer%2520therapy%2520to%2520head%2520and%2520neck%2520cancer%2520cells%253A%25202D%2520and%25203D%2520in%2520vitro%2520evaluation%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2014%26volume%3D11%26spage%3D1176%26epage%3D1188%26doi%3D10.1021%2Fmp400610b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kadletz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heiduschka, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domayer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Enzenhofer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurnher, D.</span><span> </span><span class="NLM_article-title">Evaluation of spheroid head and neck squamous cell carcinoma cell models in comparison to monolayer cultures</span> <span class="citation_source-journal">Oncol. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">–</span> <span class="NLM_lpage">1286</span><span class="refDoi"> DOI: 10.3892/ol.2015.3487</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.3892%2Fol.2015.3487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=26622664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsFOjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1281-1286&author=L.+Kadletzauthor=G.+Heiduschkaauthor=J.+Domayerauthor=R.+Schmidauthor=E.+Enzenhoferauthor=D.+Thurnher&title=Evaluation+of+spheroid+head+and+neck+squamous+cell+carcinoma+cell+models+in+comparison+to+monolayer+cultures&doi=10.3892%2Fol.2015.3487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96aR"><div class="casContent"><span class="casTitleNuber">96a</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of spheroid head and neck squamous cell carcinoma cell models in comparison to monolayer cultures</span></div><div class="casAuthors">Kadletz, Lorenz; Heiduschka, Gregor; Domayer, Julian; Schmid, Rainer; Enzenhofer, Elisabeth; Thurnher, Dietmar</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1281-1286</span>CODEN:
                <span class="NLM_cas:coden">OLNEB5</span>;
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Two-dimensional (2D) monolayer cell culture models are the most common method used to investigate tumor cells in vitro.  In the few last decades, a multicellular spheroid model has gained attention due to its adjacency to tumors in vivo.  The aim of the present study was to investigate immunohistochem. differences between these two cell culture systems.  The FaDu, CAL27 and SCC25 head and neck squamous cell carcinoma (HNSCC) cell lines were seeded out in monolayer and multicellular spheroids.  The FaDu and SCC25 cells were treated with increasing doses of cisplatin and irradn.  CAL27 cells were not used in theproliferation expts., since the spheroids of CAL27 cells were not able to process the reagent in CCK-8 assays.  Furthermore, they were stained to present alterations of the following antigens: Ki-67, vascular endothelial growth factor receptor, epithelial growth factor and survivin.  Differences in growth rates and expression patterns were detected in certain HNSCC cell lines.  The proliferation rates showed a significant divergence of cells grown in the three-dimensional model compared with cells grown in the 2D model.  Overall, multicellular spheroids are a promising method to reproduce the immunohistochem. aspects and characteristics of tumor cells, and may show different response rates to therapeutic options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQWw4Zv3SiGrVg90H21EOLACvtfcHk0lisdUCrY3pbfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsFOjs7s%253D&md5=ef475dde6298c46843244125b5aa4551</span></div><a href="/servlet/linkout?suffix=cit96a&amp;dbid=16384&amp;doi=10.3892%2Fol.2015.3487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2015.3487%26sid%3Dliteratum%253Aachs%26aulast%3DKadletz%26aufirst%3DL.%26aulast%3DHeiduschka%26aufirst%3DG.%26aulast%3DDomayer%26aufirst%3DJ.%26aulast%3DSchmid%26aufirst%3DR.%26aulast%3DEnzenhofer%26aufirst%3DE.%26aulast%3DThurnher%26aufirst%3DD.%26atitle%3DEvaluation%2520of%2520spheroid%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinoma%2520cell%2520models%2520in%2520comparison%2520to%2520monolayer%2520cultures%26jtitle%3DOncol.%2520Lett.%26date%3D2015%26volume%3D10%26spage%3D1281%26epage%3D1286%26doi%3D10.3892%2Fol.2015.3487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit96b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tupper, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greco, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dachs, G. U.</span><span> </span><span class="NLM_article-title">Analysis of the horseradish peroxidase/indole-3-acetic acid combination in a three-dimensional tumor model</span> <span class="citation_source-journal">Cancer Gene Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">508</span><span class="NLM_x">–</span> <span class="NLM_lpage">513</span><span class="refDoi"> DOI: 10.1038/sj.cgt.7700713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1038%2Fsj.cgt.7700713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=15143345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlt1Crsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=508-513&author=J.+Tupperauthor=O.+Grecoauthor=G.+M.+Tozerauthor=G.+U.+Dachs&title=Analysis+of+the+horseradish+peroxidase%2Findole-3-acetic+acid+combination+in+a+three-dimensional+tumor+model&doi=10.1038%2Fsj.cgt.7700713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96bR"><div class="casContent"><span class="casTitleNuber">96b</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the horseradish peroxidase/indole-3-acetic acid combination in a three-dimensional tumor model</span></div><div class="casAuthors">Tupper, Joanna; Greco, Olga; Tozer, Gillian M.; Dachs, Gabi U.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Gene Therapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">508-513</span>CODEN:
                <span class="NLM_cas:coden">CGTHEG</span>;
        ISSN:<span class="NLM_cas:issn">0929-1903</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Horseradish peroxidase has previously been shown to catalyze the conversion of indole-3-acetic acid (IAA) to a potent cytotoxin in a gene therapy setting.  A three-dimensional spheroid model composed of a human head and neck carcinoma cell line, has been used to mimic the tumor microenvironment, such as regions of hypoxia.  Exposure of intact spheroids to 0.05-5 mM concns. of IAA and the halogenated indole, 5-bromoindole-3-acetic acid (5Br-IAA), resulted in decreased cell survival, and demonstrates that this combination is effective under tumor-simulated conditions.  In addn., 5Br-IAA, displayed selectivity for spheroids with a large hypoxic fraction following short exposure times.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8asu7z_mxnbVg90H21EOLACvtfcHk0lisdUCrY3pbfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlt1Crsro%253D&md5=21db487304fbe11d2725491e75f245b5</span></div><a href="/servlet/linkout?suffix=cit96b&amp;dbid=16384&amp;doi=10.1038%2Fsj.cgt.7700713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cgt.7700713%26sid%3Dliteratum%253Aachs%26aulast%3DTupper%26aufirst%3DJ.%26aulast%3DGreco%26aufirst%3DO.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26aulast%3DDachs%26aufirst%3DG.%2BU.%26atitle%3DAnalysis%2520of%2520the%2520horseradish%2520peroxidase%252Findole-3-acetic%2520acid%2520combination%2520in%2520a%2520three-dimensional%2520tumor%2520model%26jtitle%3DCancer%2520Gene%2520Ther.%26date%3D2004%26volume%3D11%26spage%3D508%26epage%3D513%26doi%3D10.1038%2Fsj.cgt.7700713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Huang, T.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, S.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiang, P.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiou, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, Y.-J.</span><span> </span><span class="NLM_article-title">Antiproliferative effects of <i>N</i>-heterocyclic indole glyoxylamide derivatives on human lung cancer cells</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">3407</span><span class="NLM_x">–</span> <span class="NLM_lpage">3416</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=21965754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2rsL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=3407-3416&author=T.-H.+Huangauthor=S.-J.+Chiuauthor=P.-H.+Chiangauthor=S.-H.+Chiouauthor=W.-T.+Liauthor=C.-T.+Chenauthor=C.+A.+Changauthor=J.-C.+Chenauthor=Y.-J.+Lee&title=Antiproliferative+effects+of+N-heterocyclic+indole+glyoxylamide+derivatives+on+human+lung+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Antiproliferative effects of N-heterocyclic indolyl glyoxylamide derivatives on human lung cancer cells</span></div><div class="casAuthors">Huang, Tien-Heng; Chiu, Shu-Jun; Chiang, Pei-Hsiuang; Chiou, Shih-Hwa; Li, Wen-Tai; Chen, Chiung-Tong; Chang, C. Allen; Chen, Jyh-Cheng; Lee, Yi-Jang</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3407-3415</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Background: N-Heterocyclic indolyl glyoxylamide compds. are derived from the antimicrotubule agent D-24851, which exhibits anticancer activity after oral administration.  The actions of these compds. on lung cancer cells are still unknown.  Here, we investigated the effects of two N-heterocyclic indolyl glyoxylamides, BPR0C259 and BPR0C123, on non-small human lung cancer cells.  Materials and Methods: 3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide (MTT) assay was used to det. the half maximal inhibitory concn. (IC50), cell viability and radiation response of A549 cells and H1299 cells.  Apoptosis was detd. by sub-G1 ratio, colony formation assay and caspase-3 activation.  Cell cycle distribution was detected using flow cytometry.  Results: Both compds. were able to inhibit the viability of human lung cancer cells, although the IC50 of BPR0C123 was lower than that of BPR0C259.  Both compds. induced significant sub-G1 and caspase-3 activation as low as 0.1 μM in both cell lines.  These effects were independent of p53 activation because the level of serine-15 phosphorylated p53 was not affected after drug treatment.  Furthermore, both compds. induced similar levels of G2/M phase arrest and radiosensitivity in these lung cancer cells.  Conclusion: Current data suggest that N-heterocyclic indolyl glyoxylamides can suppress the proliferation of and potentially increase radiosensitivity of human lung cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVYVjMd38qUbVg90H21EOLACvtfcHk0liQMR7yUOJnLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2rsL7F&md5=f99020514e30ebdf21a113011562a487</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DT.-H.%26aulast%3DChiu%26aufirst%3DS.-J.%26aulast%3DChiang%26aufirst%3DP.-H.%26aulast%3DChiou%26aufirst%3DS.-H.%26aulast%3DLi%26aufirst%3DW.-T.%26aulast%3DChen%26aufirst%3DC.-T.%26aulast%3DChang%26aufirst%3DC.%2BA.%26aulast%3DChen%26aufirst%3DJ.-C.%26aulast%3DLee%26aufirst%3DY.-J.%26atitle%3DAntiproliferative%2520effects%2520of%2520N-heterocyclic%2520indole%2520glyoxylamide%2520derivatives%2520on%2520human%2520lung%2520cancer%2520cells%26jtitle%3DAnticancer%2520Res.%26date%3D2011%26volume%3D31%26spage%3D3407%26epage%3D3416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Li, W.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.-N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-T.</span><span> </span><span class="NLM_article-title">BPR0C305, and orally active microtubule-disrupting anticancer agent</span> <span class="citation_source-journal">Anti-Cancer Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1047</span><span class="NLM_x">–</span> <span class="NLM_lpage">1057</span><span class="refDoi"> DOI: 10.1097/CAD.0000000000000014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1097%2FCAD.0000000000000014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=1047-1057&author=W.-T.+Liauthor=T.-K.+Yehauthor=J.-S.+Songauthor=Y.-N.+Yangauthor=T.-W.+Chenauthor=C.-H.+Linauthor=C.-P.+Chenauthor=C.-C.+Shenauthor=C.-C.+Hsiehauthor=H.-L.+Linauthor=Y.-S.+Chaoauthor=C.-T.+Chen&title=BPR0C305%2C+and+orally+active+microtubule-disrupting+anticancer+agent&doi=10.1097%2FCAD.0000000000000014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000014%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.-T.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DYang%26aufirst%3DY.-N.%26aulast%3DChen%26aufirst%3DT.-W.%26aulast%3DLin%26aufirst%3DC.-H.%26aulast%3DChen%26aufirst%3DC.-P.%26aulast%3DShen%26aufirst%3DC.-C.%26aulast%3DHsieh%26aufirst%3DC.-C.%26aulast%3DLin%26aufirst%3DH.-L.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DChen%26aufirst%3DC.-T.%26atitle%3DBPR0C305%252C%2520and%2520orally%2520active%2520microtubule-disrupting%2520anticancer%2520agent%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2013%26volume%3D24%26spage%3D1047%26epage%3D1057%26doi%3D10.1097%2FCAD.0000000000000014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Hu, C.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuu, J.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tung, F.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, K.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, H.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, D.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chern, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, L.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-T.</span><span> </span><span class="NLM_article-title">BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activities</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">182</span><span class="NLM_x">–</span> <span class="NLM_lpage">191</span><span class="refDoi"> DOI: 10.1111/j.1349-7006.2010.01744.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1111%2Fj.1349-7006.2010.01744.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=21040217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhslKnsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2011&pages=182-191&author=C.-B.+Huauthor=C.-P.+Chenauthor=T.-K.+Yehauthor=J.-S.+Songauthor=C.-Y.+Changauthor=J.-J.+Chuuauthor=F.-F.+Tungauthor=P.-Y.+Hoauthor=T.-W.+Chenauthor=C.-H.+Linauthor=M.-H.+Wangauthor=K.-Y.+Changauthor=C.-L.+Huangauthor=H.-L.+Linauthor=W.-T.+Liauthor=D.-R.+Hwangauthor=J.-H.+Chernauthor=L.-L.+Hwangauthor=J.-Y.+Changauthor=Y.-S.+Chaoauthor=C.-T.+Chen&title=BPR0C261+is+a+novel+orally+active+antitumor+agent+with+antimitotic+and+anti-angiogenic+activities&doi=10.1111%2Fj.1349-7006.2010.01744.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activities</span></div><div class="casAuthors">Hu, Chih-Bo; Chen, Ching-Ping; Yeh, Teng-Kuang; Song, Jen-Shin; Chang, Chi-Yen; Chuu, Jiunn-Jye; Tung, Fei-Feng; Ho, Pei-Yin; Chen, Tung-Wei; Lin, Chi-Hung; Wang, Min-Hsien; Chang, Kai-Yen; Huang, Chen-Lung; Lin, Heng-Liang; Li, Wen-Tai; Hwang, Der-Ren; Chern, Jyh-Haur; Hwang, Ling-Ling; Chang, Jang-Yang; Chao, Yu-Sheng; Chen, Chiung-Tong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">182-191</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BPR0C261 is a synthetic small mol. compd. cytotoxic against human cancer cells and active prolonging the lifespan of leukemia mice.  In the present study, we further investigated the mechanisms of its anticancer action and found that BPR0C261 inhibited microtubule polymn. through interacting with the colchicine binding sites on tubulins, disrupted microtubule arrangement and caused cell cycle arrest at G2/M phase in cancer cells.  BPR0C261 also inhibited the clonogenic growths of cancer cells and showed cytotoxicity against human cervical cancer cells of multidrug-resistant phenotype.  In addn., BPR0C261 concn.-dependently inhibited the proliferation and migration of HUVECs and disrupted the endothelial capillary-like tube formations in HUVEC and rat aorta ring cultures.  Given orally, BPR0C261 inhibited angiogenesis in s.c. implanted Matrigel plugs in mice.  Notably, its IC50 values against the endothelial cell growths were approx. 10-fold lower than those against the cancer cells.  It was found orally absorbable in mice and showed a good oral bioavailability (43%) in dogs.  BPR0C261 permeated through the human intestinal Caco-2 cell monolayer, suggesting oral availability in humans.  Orally absorbed BPR0C261 distributed readily into the s.c. xenografted tumors in nude mice in which the tumor tissue levels of BPR0C261 were found oral dose-dependent.  BPR0C261 showed in vivo activities against human colorectal, gastric, and nasopharyngeal tumors in nude mice.  Most interestingly, the combination of BPR0C261 plus cisplatin synergistically prolonged the lifespans of mice inoculated with murine leukemia cells.  Thus, BPR0C261 is a novel orally active tubulin-binding antitumor agent with antimitotic, apoptosis-inducing, and vasculature disrupting activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV5xsYzX3kxbVg90H21EOLACvtfcHk0liQMR7yUOJnLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhslKnsb0%253D&md5=941a6cafbe07c1fddb88ac0fae9e4103</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2010.01744.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2010.01744.x%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DC.-B.%26aulast%3DChen%26aufirst%3DC.-P.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DChuu%26aufirst%3DJ.-J.%26aulast%3DTung%26aufirst%3DF.-F.%26aulast%3DHo%26aufirst%3DP.-Y.%26aulast%3DChen%26aufirst%3DT.-W.%26aulast%3DLin%26aufirst%3DC.-H.%26aulast%3DWang%26aufirst%3DM.-H.%26aulast%3DChang%26aufirst%3DK.-Y.%26aulast%3DHuang%26aufirst%3DC.-L.%26aulast%3DLin%26aufirst%3DH.-L.%26aulast%3DLi%26aufirst%3DW.-T.%26aulast%3DHwang%26aufirst%3DD.-R.%26aulast%3DChern%26aufirst%3DJ.-H.%26aulast%3DHwang%26aufirst%3DL.-L.%26aulast%3DChang%26aufirst%3DJ.-Y.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DChen%26aufirst%3DC.-T.%26atitle%3DBPR0C261%2520is%2520a%2520novel%2520orally%2520active%2520antitumor%2520agent%2520with%2520antimitotic%2520and%2520anti-angiogenic%2520activities%26jtitle%3DCancer%2520Sci.%26date%3D2011%26volume%3D102%26spage%3D182%26epage%3D191%26doi%3D10.1111%2Fj.1349-7006.2010.01744.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Li, W.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, D.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tseng, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-T.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of <i>N</i>-heterocyclic indolyl glyoxylamides as orally active anticancer agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1706</span><span class="NLM_x">–</span> <span class="NLM_lpage">1715</span><span class="refDoi"> DOI: 10.1021/jm020471r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020471r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlGlurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1706-1715&author=W.-T.+Liauthor=D.-R.+Hwangauthor=C.-P.+Chenauthor=C.-W.+Shenauthor=C.-L.+Huangauthor=T.-W.+Chenauthor=C.-H.+Linauthor=Y.-L.+Changauthor=Y.-Y.+Changauthor=Y.-K.+Loauthor=H.-Y.+Tsengauthor=C.-C.+Linauthor=J.-S.+Songauthor=H.-C.+Chenauthor=S.-J.+Chenauthor=S.-H.+Wuauthor=C.-T.+Chen&title=Synthesis+and+biological+evaluation+of+N-heterocyclic+indolyl+glyoxylamides+as+orally+active+anticancer+agents&doi=10.1021%2Fjm020471r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of N-Heterocyclic Indolyl Glyoxylamides as Orally Active Anticancer Agents</span></div><div class="casAuthors">Li, Wen-Tai; Hwang, Der-Ren; Chen, Ching-Ping; Shen, Chien-Wei; Huang, Chen-Long; Chen, Tung-Wei; Lin, Chi-Hung; Chang, Yee-Ling; Chang, Ying-Ying; Lo, Yue-Kan; Tseng, Huan-Yi; Lin, Chu-Chung; Song, Jeng-Shin; Chen, Hua-Chien; Chen, Shu-Jen; Wu, Se-Hui; Chen, Chiung-Tong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1706-1715</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of N-heterocyclic indolyl glyoxylamides were synthesized and evaluated for in vitro and in vivo anticancer activities.  They exhibited a broad spectrum of anticancer activity not only in murine leukemic cancer cells but also in human gastric, breast, and uterus cancer cells as well as their multidrug resistant sublines with a wide range of IC50 values.  They also induced apoptosis and caused DNA fragmentation in human gastric cancer cells.  Among the compds. studied, N1-(3-Methyl-5-isothiazolyl)-2-1-[(3-methyl-5-isoxazolyl)methyl]-1H-3-indolyl-2-oxoacetamide (I) showed the most potent activity of growth inhibition (IC50 = 17-1711 nM) in several human cancer cells.  Given orally, compds. I and N1-(3-Methyl-5-isothiazolyl)-2-[1-(4-cyanobenzyl)-1H-3-indolyl]-2-oxoacetamide dose-dependently prolonged the survival of animals inoculated with P388 leukemic cancer cells.  N-Heterocyclic indolyl glyoxylamides may be useful as orally active chemotherapeutic agents against cancer and refractory cancerous diseases of multidrug resistance phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA1KRKnBPg9bVg90H21EOLACvtfcHk0ljFUhnOTOR4eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlGlurw%253D&md5=7f89777a57ec9bca8b710965195b5ad5</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjm020471r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020471r%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.-T.%26aulast%3DHwang%26aufirst%3DD.-R.%26aulast%3DChen%26aufirst%3DC.-P.%26aulast%3DShen%26aufirst%3DC.-W.%26aulast%3DHuang%26aufirst%3DC.-L.%26aulast%3DChen%26aufirst%3DT.-W.%26aulast%3DLin%26aufirst%3DC.-H.%26aulast%3DChang%26aufirst%3DY.-L.%26aulast%3DChang%26aufirst%3DY.-Y.%26aulast%3DLo%26aufirst%3DY.-K.%26aulast%3DTseng%26aufirst%3DH.-Y.%26aulast%3DLin%26aufirst%3DC.-C.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DChen%26aufirst%3DH.-C.%26aulast%3DChen%26aufirst%3DS.-J.%26aulast%3DWu%26aufirst%3DS.-H.%26aulast%3DChen%26aufirst%3DC.-T.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520N-heterocyclic%2520indolyl%2520glyoxylamides%2520as%2520orally%2520active%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1706%26epage%3D1715%26doi%3D10.1021%2Fjm020471r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Thompson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louth, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorrell, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irving, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cochrane, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, A. J. H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span> </span><span class="NLM_article-title">Structure–activity relationship refinement and further assessment of indole-3-glyoxylamides as a lead series against prion disease</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">115</span><span class="NLM_x">–</span> <span class="NLM_lpage">130</span><span class="refDoi"> DOI: 10.1002/cmdc.201000383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1002%2Fcmdc.201000383" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=115-130&author=M.+J.+Thompsonauthor=J.+C.+Louthauthor=S.+Ferraraauthor=F.+J.+Sorrellauthor=B.+J.+Irvingauthor=E.+J.+Cochraneauthor=A.+J.+H.+M.+Meijerauthor=B.+Chen&title=Structure%E2%80%93activity+relationship+refinement+and+further+assessment+of+indole-3-glyoxylamides+as+a+lead+series+against+prion+disease&doi=10.1002%2Fcmdc.201000383"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000383%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DM.%2BJ.%26aulast%3DLouth%26aufirst%3DJ.%2BC.%26aulast%3DFerrara%26aufirst%3DS.%26aulast%3DSorrell%26aufirst%3DF.%2BJ.%26aulast%3DIrving%26aufirst%3DB.%2BJ.%26aulast%3DCochrane%26aufirst%3DE.%2BJ.%26aulast%3DMeijer%26aufirst%3DA.%2BJ.%2BH.%2BM.%26aulast%3DChen%26aufirst%3DB.%26atitle%3DStructure%25E2%2580%2593activity%2520relationship%2520refinement%2520and%2520further%2520assessment%2520of%2520indole-3-glyoxylamides%2520as%2520a%2520lead%2520series%2520against%2520prion%2520disease%26jtitle%3DChemMedChem%26date%3D2011%26volume%3D6%26spage%3D115%26epage%3D130%26doi%3D10.1002%2Fcmdc.201000383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Baell, J. B.</span><span> </span><span class="NLM_article-title">Screening-based translation of public research encounters painful problems</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00032</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00032" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisFyqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=229-234&author=J.+B.+Baell&title=Screening-based+translation+of+public+research+encounters+painful+problems&doi=10.1021%2Facsmedchemlett.5b00032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Screening-Based Translation of Public Research Encounters Painful Problems</span></div><div class="casAuthors">Baell, Jonathan B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">229-234</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Whether identified through high throughput screening or in silico screening, and whether target-based or phenotypic, sets of hits will contain chem. con artists.  Such pan-assay interference compds. (PAINS) and other subversive compds. continue to pollute the scientific literature.  There are several angles of attack to aid identification of such nonprogressable mols.  One of these rules above all, and this is a demonstration of genuine structure-activity relationships.  Recognition of this, which will require a greater effort in medicinal chem., will be of general benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotU7Zc6YDmhrVg90H21EOLACvtfcHk0ljFUhnOTOR4eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisFyqtLc%253D&md5=6307f394d9ed9d4859e8ec149914f064</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00032%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26atitle%3DScreening-based%2520translation%2520of%2520public%2520research%2520encounters%2520painful%2520problems%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D229%26epage%3D234%26doi%3D10.1021%2Facsmedchemlett.5b00032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Fitton, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jane, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millar, R.</span><span> </span><span class="NLM_article-title">Synthesis of simple oxetanes carrying reactive 2-sustituents</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">1987</span><span class="NLM_x">, </span> <span class="NLM_fpage">1140</span><span class="NLM_x">–</span> <span class="NLM_lpage">1142</span><span class="refDoi"> DOI: 10.1055/s-1987-28203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;key=10.1055%2Fs-1987-28203" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1987&publication_year=1987&pages=1140-1142&author=A.+O.+Fittonauthor=J.+Hillauthor=D.+E.+Janeauthor=R.+Millar&title=Synthesis+of+simple+oxetanes+carrying+reactive+2-sustituents&doi=10.1055%2Fs-1987-28203"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1055%2Fs-1987-28203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1987-28203%26sid%3Dliteratum%253Aachs%26aulast%3DFitton%26aufirst%3DA.%2BO.%26aulast%3DHill%26aufirst%3DJ.%26aulast%3DJane%26aufirst%3DD.%2BE.%26aulast%3DMillar%26aufirst%3DR.%26atitle%3DSynthesis%2520of%2520simple%2520oxetanes%2520carrying%2520reactive%25202-sustituents%26jtitle%3DSynthesis%26date%3D1987%26volume%3D1987%26spage%3D1140%26epage%3D1142%26doi%3D10.1055%2Fs-1987-28203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i112"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01312">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_15681"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01312">10.1021/acs.jmedchem.5b01312</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Characterization data, purification details, and HPLC purity for all screening compounds; NMR spectra for all screening compounds and synthetic intermediates (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_001.pdf">jm5b01312_si_001.pdf (9.65 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01312/suppl_file/jm5b01312_si_002.csv">jm5b01312_si_002.csv (8.68 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01312&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01312%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-23%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01312" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b12d3fdf124fd","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
